Disease on EC 1.14.14.14 - aromatase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
46, XX Disorders of Sex Development
A case of female pseudohermaphroditism caused by aromatase deficiency.
46, XX Disorders of Sex Development
A new cause of female pseudohermaphroditism: placental aromatase deficiency.
46, XX Disorders of Sex Development
Female pseudohermaphroditism associated with a novel homozygous G-to-A (V370-to-M) substitution in the P-450 aromatase gene.
Abortion, Spontaneous
Polymorphisms in estrogen metabolism and estrogen pathway genes and the risk of miscarriage.
Abortion, Spontaneous
Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility.
Acne Vulgaris
Aromatase Deficiency in Two Siblings with 46, XX Karyotype Raised as Different Genders: A Novel Mutation (p.R115X) in CYP19A1 Gene
Acne Vulgaris
Mild cutaneous manifestation in two young women with extraordinary hyperandrogenemia.
Acne Vulgaris
The Associations of Androgen-Related Genes CYP21A2 and CYP19A1 with Severe Acne Vulgaris in Patients from Southwest China.
Acquired Immunodeficiency Syndrome
A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors.
Acromegaly
Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis.
Acute Coronary Syndrome
Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
Adenocarcinoma
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Adenocarcinoma
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Adenocarcinoma
Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor.
Adenocarcinoma
Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.
Adenocarcinoma
Aromatase activity in microsomes from rat ventral prostate and Dunning R3327H rat prostatic adenocarcinoma.
Adenocarcinoma
Aromatization of testosterone by epithelial tumor cells cultured from patients with ovarian carcinoma.
Adenocarcinoma
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Adenocarcinoma
Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity.
Adenocarcinoma
Estrogen secreting adrenal adenocarcinoma in an 18-month-old boy: aromatase activity, protein expression, mRNA and utilization of gonadal type promoter.
Adenocarcinoma
Expression of aromatase and 5-alpha-reductase genes in endometrial adenocarcinoma.
Adenocarcinoma
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
Adenocarcinoma
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Adenocarcinoma
Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study.
Adenocarcinoma
[Expressions of aromatase protein and sex hormone receptor in endometrial lesions.]
Adenocarcinoma
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Adenocarcinoma of Lung
Association of a genetic variant of CYP19A1 with multicentric development of lung adenocarcinomas.
Adenocarcinoma of Lung
EGFR L858R Mutation and Polymorphisms of Genes related to Estrogen Biosynthesis and Metabolism in Never-smoking Female Lung Adenocarcinoma Patients.
Adenocarcinoma of Lung
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
Adenocarcinoma of Lung
Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations.
Adenocarcinoma of Lung
Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.
Adenocarcinoma, Bronchiolo-Alveolar
Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs.
Adenocarcinoma, Mucinous
Aromatase inhibitor for the treatment of primary mucinous carcinoma of the skin with distant metastasis.
Adenocarcinoma, Mucinous
Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.
Adenocarcinoma, Mucinous
Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions.
Adenoma
Achievement of fertility in an infertile man with resistant macroprolactinoma using high dose of bromocriptine and a combination of hCG and an aromatase inhibitor.
Adenoma
Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis.
Adenoma
Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty.
Adenoma
G-protein Coupled Estrogen Receptor Expression in Growth Hormone Secreting and Non-Functioning Adenomas.
Adenoma
Gonadotroph adenomas in men produce biologically active follicle-stimulating hormone.
Adenoma
Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Adenoma
Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas.
Adenoma
Mild cutaneous manifestation in two young women with extraordinary hyperandrogenemia.
Adenoma
Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma.
Adenomyoma
Aromatase inhibitor treatment of menorrhagia and subsequent pregnancy in a patient with familial hyperparathyroidism-jaw tumor syndrome.
Adenomyoma
Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: A randomized controlled trial.
Adenomyosis
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Adenomyosis
Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: A randomized controlled trial.
Adenomyosis
Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist.
Adenomyosis
Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis.
Adenomyosis
Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis.
Adenomyosis
Editor's Note: Badawy AM, Elnashar AM, and Mosbah AA. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica, 2012;91:489-495.
Adenomyosis
Effect of a hormone-releasing intrauterine system (Mirena(®)) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection.
Adenomyosis
Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis.
Adenomyosis
Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis.
Adenomyosis
Estrogen degrades Scribble in endometrial epithelial cells through E3 ubiquitin ligase HECW1 in the development of diffuse adenomyosis.
Adenomyosis
Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium.
Adenomyosis
Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas.
Adenomyosis
High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome.
Adenomyosis
Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium.
Adenomyosis
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
Adenomyosis
The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis.
Adenomyosis
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy.
Adenomyosis
[Cytochrome P-450 aromatase expression in the ectopic and eutopic endometrium in endometriosis]
Adenomyosis
[Role of estrogen, estrogen receptors, and aromatase in the pathogenesis of uterine adenomyosis].
Adrenal Gland Neoplasms
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Adrenal Hyperplasia, Congenital
11-Oxygenated Estrogens Are a Novel Class of Human Estrogens but Do not Contribute to the Circulating Estrogen Pool.
Adrenal Hyperplasia, Congenital
46,XX DSD and Antley-Bixler syndrome due to novel mutations in the cytochrome P450 oxidoreductase gene.
Adrenal Hyperplasia, Congenital
46,XX DSD due to Androgen Excess in Monogenic Disorders of Steroidogenesis: Genetic, Biochemical, and Clinical Features.
Adrenal Hyperplasia, Congenital
A novel homozygous CYP19A1 gene mutation: Aromatase deficiency mimicking congenital adrenal hyperplasia in an infant without obvious maternal virilisation.
Adrenal Hyperplasia, Congenital
Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency.
Adrenal Hyperplasia, Congenital
Aromatase deficiency in an adolescent girl misdiagnosed as congenital adrenal hyperplasia in infancy and childhood.
Adrenal Hyperplasia, Congenital
Aromatase Deficiency in Two Siblings with 46, XX Karyotype Raised as Different Genders: A Novel Mutation (p.R115X) in CYP19A1 Gene
Adrenal Hyperplasia, Congenital
Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report.
Adrenal Hyperplasia, Congenital
Aromatase Inhibitor Increases the Height of Patients with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.
Adrenal Hyperplasia, Congenital
Fertility issues in the management of patients with disorders of sex development.
Adrenal Hyperplasia, Congenital
Genetic and Clinical Spectrum of Aromatase Deficiency in Infancy, Childhood and Adolescence.
Adrenal Hyperplasia, Congenital
Growth Hormone With Aromatase Inhibitor May Improve Height in CYP11B1 Congenital Adrenal Hyperplasia.
Adrenal Hyperplasia, Congenital
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Adrenal Hyperplasia, Congenital
Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: Impact of anastrozole on bone mineral density and visceral adipose tissue.
Adrenocortical Adenoma
Expression of aromatase and estrogen receptors in human adrenocortical tumors.
Adrenocortical Adenoma
Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease.
Adrenocortical Adenoma
Major hyperestrogenism in a feminizing adrenocortical adenoma despite a moderate overexpression of the aromatase enzyme.
Adrenocortical Adenoma
Oestrogen producing adrenocortical adenoma: clinical, biochemical and immunohistochemical studies.
Adrenocortical Carcinoma
2,3,7,8-Tetrachlorodibenzo-p-dioxin and diindolylmethanes differentially induce cytochrome P450 1A1, 1B1, and 19 in H295R human adrenocortical carcinoma cells.
Adrenocortical Carcinoma
2-Chloro-s-triazine herbicides induce aromatase (CYP19) activity in H295R human adrenocortical carcinoma cells: a novel mechanism for estrogenicity?
Adrenocortical Carcinoma
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Adrenocortical Carcinoma
Aromatase activity in an estrogen-producing adrenocortical carcinoma in a young man.
Adrenocortical Carcinoma
Effect of epidermal growth factor and prostaglandin on the expression of aromatase (CYP19) in human adrenocortical carcinoma cell line NCI-H295R cells.
Adrenocortical Carcinoma
Effects of bisphenol A-related diphenylalkanes on vitellogenin production in male carp (Cyprinus carpio) hepatocytes and aromatase (CYP19) activity in human H295R adrenocortical carcinoma cells.
Adrenocortical Carcinoma
Effects of fifteen PBDE metabolites, DE71, DE79 and TBBPA on steroidogenesis in the H295R cell line.
Adrenocortical Carcinoma
Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells.
Adrenocortical Carcinoma
Effects of Neonicotinoids on Promoter-Specific Expression and Activity of Aromatase (CYP19) in Human Adrenocortical Carcinoma (H295R) and Primary Umbilical Vein Endothelial (HUVEC) Cells.
Adrenocortical Carcinoma
Evaluation of a bioluminescent mouse model expressing aromatase PII-promoter-controlled luciferase as a tool for the study of endocrine disrupting chemicals.
Adrenocortical Carcinoma
Expression of aromatase and estrogen receptors in human adrenocortical tumors.
Adrenocortical Carcinoma
Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease.
Adrenocortical Carcinoma
Forskolin up-regulates aromatase (CYP19) activity and gene transcripts in the human adrenocortical carcinoma cell line H295R.
Adrenocortical Carcinoma
Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells.
Adrenocortical Carcinoma
Induction and inhibition of aromatase (CYP19) activity by various classes of pesticides in H295R human adrenocortical carcinoma cells.
Adrenocortical Carcinoma
Inhibition and induction of aromatase (CYP19) activity by brominated flame retardants in H295R human adrenocortical carcinoma cells.
Adrenocortical Carcinoma
Inhibition of aromatase activity by methyl sulfonyl PCB metabolites in primary culture of human mammary fibroblasts.
Adrenocortical Carcinoma
Mono-(2-ethylhexyl) phthalate (MEHP) induces nuclear receptor 4A subfamily in NCI-H295R cells: a possible mechanism of aromatase suppression by MEHP.
Adrenocortical Carcinoma
The effects of the standardized extracts of Ginkgo biloba on steroidogenesis pathways and aromatase activity in H295R human adrenocortical carcinoma cells.
Adrenocortical Hyperfunction
Vertebral fractures cascade: potential causes and risk factors.
Agranulocytosis
Effect of aminoglutethimide on neutrophils in rats: implications for idiosyncratic drug-induced blood dyscrasias.
Alopecia
5?-Reductase isozymes and aromatase mRNA levels in plucked hair from young women with female pattern hair loss.
Alopecia
A prospective study of aromatase inhibitor therapy initiation and self-reported side effects.
Alopecia
Association between smoking and hair loss: another opportunity for health education against smoking?
Alopecia
Association of Single Nucleotide Polymorphisms in the CYP19A1 Gene with Female Pattern Hair Loss in a Chinese Population.
Alopecia
Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia.
Alopecia
Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss.
Alopecia
Investigation of variants of the aromatase gene (CYP19A1) in female pattern hair loss.
Alopecia
Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview.
Alopecia
Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres.
Alzheimer Disease
Aromatase and interleukin-10 genetic variants interactively modulate Alzheimer's disease risk.
Alzheimer Disease
Aromatase enzyme and Alzheimer's disease. Studio prospettico in 54 pazienti affetti da iperparatiroidismo primitivo.
Alzheimer Disease
Aromatase variants modify risk for Alzheimer's disease in a multiethnic female cohort.
Alzheimer Disease
Aromatase/Seladin-1 Interactions in Human Neuronal Cell Culture, the Hippocampus of Healthy Rats and Transgenic Alzheimer's Disease Mice.
Alzheimer Disease
Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.
Alzheimer Disease
Association between rs10046, rs1143704, rs767199, rs727479, rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms in aromatase (CYP19A1) gene and Alzheimer's disease risk: a systematic review and meta-analysis involving 11,051 subjects.
Alzheimer Disease
Diminished aromatase immunoreactivity in the hypothalamus, but not in the basal forebrain nuclei in Alzheimer's disease.
Alzheimer Disease
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Alzheimer Disease
Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment.
Alzheimer Disease
Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk.
Alzheimer Disease
Interactions of Aromatase and Seladin-1: A Neurosteroidogenic and Gender Perspective.
Alzheimer Disease
Neuroblastoma and Alzheimer's disease brain cells contain aromatase activity.
Alzheimer Disease
Polymorphisms in the CYP19 gene confer increased risk for Alzheimer disease.
Alzheimer Disease
The CYP19A1 rs3751592 variant confers susceptibility to Alzheimer disease in the Chinese Han population.
Alzheimer Disease
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease.
Alzheimer Disease
The sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project.
Androgen-Insensitivity Syndrome
Androgen dependent stimulation of aromatase activity in genital skin fibroblasts from normals and patients with androgen insensitivity.
Androgen-Insensitivity Syndrome
Evaluation of boys with marked breast development at puberty.
Androgen-Insensitivity Syndrome
Incomplete testicular feminization syndrome: studies of 17 beta-oestradiol-binding activity and aromatase activity in cultured genital fibroblasts showing impaired dihydrotestosterone-binding.
Androgen-Insensitivity Syndrome
Incomplete testicular feminization syndrome: studies on androgen receptor(AR) function, AR gene analysis, and aromatase activities at puberty and long-term observations of clinical and hormonal features from infancy to puberty.
Androgen-Insensitivity Syndrome
Increased peripheral aromatase activity in prepubertal children with partial androgen insensitivity syndrome.
Androgen-Insensitivity Syndrome
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Androgen-Insensitivity Syndrome
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Anemia
Patients' preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments.
Anencephaly
Quantitative evaluation of human placental aromatase in abnormal pregnancy--anencephalus and hydatidiform mole.
Angiofibroma
Aromatase may play a critical role in the pathogenesis of juvenile nasopharyngeal angiofibroma.
Anovulation
Acute dietary restriction in heifers alters expression of genes regulating exposure and response to gonadotrophins and IGF in dominant follicles.
Anovulation
Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
Anovulation
Di-(2-ethylhexyl) phthalate and Mono-(2-ethylhexyl) phthalate Inhibit Growth and Reduce Estradiol Levels of Antral Follicles In Vitro.
Anovulation
Hypothyroidism affects lipid and glycogen content and peroxisome proliferator-activated receptor ? expression in the ovary of the rabbit.
Anovulation
Ovulation triggers in anovulatory women undergoing ovulation induction.
Anovulation
The effects of an aromatase inhibitor and a 5 alpha-reductase inhibitor upon the occurrence of polyovular follicles, persistent anovulation, and permanent vaginal stratification in mice treated neonatally with testosterone.
Antiphospholipid Syndrome
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.
Antley-Bixler Syndrome Phenotype
Akhenaten and the strange physiques of Egypt's 18th dynasty.
Antley-Bixler Syndrome Phenotype
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
Antley-Bixler Syndrome Phenotype
Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients.
Aortic Aneurysm, Abdominal
Aromatase is required for female abdominal aortic aneurysm protection.
Aortic Aneurysm, Abdominal
Autoradiography screening of potential positron emission tomography tracers for asymptomatic abdominal aortic aneurysms.
aromatase deficiency
46,XX DSD due to Androgen Excess in Monogenic Disorders of Steroidogenesis: Genetic, Biochemical, and Clinical Features.
aromatase deficiency
A 43-year-old male with untreated panhypopituitarism due to absence of the pituitary stalk: from dwarf to giant.
aromatase deficiency
A case of female pseudohermaphroditism caused by aromatase deficiency.
aromatase deficiency
A large cohort of disorders of sex development and their genetic characteristics: 6 novel mutations in known genes.
aromatase deficiency
A new cause of female pseudohermaphroditism: placental aromatase deficiency.
aromatase deficiency
A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome.
aromatase deficiency
A novel compound heterozygous variant in CYP19A1 resulting in aromatase deficiency with normal ovarian tissue.
aromatase deficiency
A novel homozygous CYP19A1 gene mutation: Aromatase deficiency mimicking congenital adrenal hyperplasia in an infant without obvious maternal virilisation.
aromatase deficiency
A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment.
aromatase deficiency
A Novel Null Mutation in P450 Aromatase Gene (CYP19A1) Associated with Development of Hypoplastic Ovaries in Humans.
aromatase deficiency
A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom).
aromatase deficiency
Altered umbilical sex steroids in preterm infants born small for gestational age.
aromatase deficiency
Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency.
aromatase deficiency
An Intron 9 CYP19 Gene Variant (IVS9+5G>A), Present in an Aromatase-Deficient Girl, Affects Normal Splicing and Is Also Present in Normal Human Steroidogenic Tissues.
aromatase deficiency
Aromatase deficiency and estrogen resistance: from molecular genetics to clinic.
aromatase deficiency
Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy.
aromatase deficiency
Aromatase deficiency causes altered expression of molecules critical for calcium reabsorption in the kidneys of female mice *.
aromatase deficiency
Aromatase deficiency confers paradoxical postischemic cardioprotection.
aromatase deficiency
Aromatase deficiency due to a functional variant in the placenta promoter and a novel missense mutation in the CYP19A1 gene.
aromatase deficiency
Aromatase Deficiency due to a Homozygous CYP19A1 Mutation in a 46,XX Egyptian Patient with Ambiguous Genitalia.
aromatase deficiency
Aromatase deficiency in a Chinese adult man caused by novel compound heterozygous CYP19A1 mutations: effects of estrogen replacement therapy on the bone, lipid, liver and glucose metabolism.
aromatase deficiency
Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood.
aromatase deficiency
Aromatase deficiency in a male patient - Case report and review of the literature.
aromatase deficiency
Aromatase deficiency in an adolescent girl misdiagnosed as congenital adrenal hyperplasia in infancy and childhood.
aromatase deficiency
Aromatase deficiency in hematopoietic cells improves glucose tolerance in male mice through skeletal muscle-specific effects.
aromatase deficiency
Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens.
aromatase deficiency
Aromatase Deficiency in Two Siblings with 46, XX Karyotype Raised as Different Genders: A Novel Mutation (p.R115X) in CYP19A1 Gene
aromatase deficiency
Aromatase deficiency inhibits the permeability transition in mouse liver mitochondria.
aromatase deficiency
Aromatase deficiency: A case series of 46, XX Chinese children and a systematic review of the literature.
aromatase deficiency
Aromatase deficiency: a novel compound heterozygous mutation identified in a Chinese girl with severe phenotype and obvious maternal virilization.
aromatase deficiency
Aromatase deficiency: a rare cause of maternal virilisation and ambiguous genitalia in neonates.
aromatase deficiency
Aromatase deficiency: an unusual cause for primary amenorrhea with virilization.
aromatase deficiency
Bilateral osteonecrosis of the femoral head in an adult man affected by congenital estrogen deficiency.
aromatase deficiency
Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency.
aromatase deficiency
Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies.
aromatase deficiency
Child with '46, XX' disorder of sex development: clues to diagnose aromatase deficiency.
aromatase deficiency
Cholesterol feeding prevents adiposity in the obese female aromatase knockout (ArKO) mouse.
aromatase deficiency
Clinical review 78: Aromatase deficiency in women and men: would you have predicted the phenotypes?
aromatase deficiency
Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men.
aromatase deficiency
Congenital estrogen deficiency: in search of the estrogen role in human male reproduction.
aromatase deficiency
Congenital hypopituitarism as a cause of undetectable estriol levels in the maternal triple-marker screen.
aromatase deficiency
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
aromatase deficiency
Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients.
aromatase deficiency
Disproportional body growth in female estrogen receptor-alpha-inactivated mice.
aromatase deficiency
Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment.
aromatase deficiency
Effect of estrogen replacement on insulin sensitivity, serum lipid and bone resorption marker in hypogonadal males.
aromatase deficiency
Effect of testosterone and estradiol in a man with aromatase deficiency.
aromatase deficiency
Effects of estrogen replacement therapy on bone and glucose metabolism in a male with congenital aromatase deficiency.
aromatase deficiency
Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys.
aromatase deficiency
Elucidation of estrogen receptor function in bone with the use of mouse models.
aromatase deficiency
Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.
aromatase deficiency
Estrogen and adiposity--utilizing models of aromatase deficiency to explore the relationship.
aromatase deficiency
Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters.
aromatase deficiency
Estrogen: consequences and implications of human mutations in synthesis and action.
aromatase deficiency
Fertility issues in the management of patients with disorders of sex development.
aromatase deficiency
Five New Cases of 46,XX Aromatase Deficiency: Clinical Follow-Up From Birth to Puberty, a Novel Mutation, and a Founder Effect.
aromatase deficiency
Genetic and Clinical Spectrum of Aromatase Deficiency in Infancy, Childhood and Adolescence.
aromatase deficiency
Genetic mutations resulting in loss of aromatase activity in humans and mice.
aromatase deficiency
Genetic studies to characterize the origin of the mutation in placental aromatase deficiency.
aromatase deficiency
GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice.
aromatase deficiency
Growth and hormonal profile from birth to adolescence of a girl with aromatase deficiency.
aromatase deficiency
Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors.
aromatase deficiency
Human gene mutations. Gene symbol: CYP19. Disease: Aromatase deficiency.
aromatase deficiency
Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback.
aromatase deficiency
Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene.
aromatase deficiency
Hypothesis: Persistently elevated hCG causes gestational ovarian overstimulation associated with prolonged postpartum hyperandrogenism in mothers of aromatase-deficient babies.
aromatase deficiency
Impact of aromatase absence on murine intraocular pressure and retinal ganglion cells.
aromatase deficiency
Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene.
aromatase deficiency
Impact of Estrogen Replacement throughout Childhood on Growth, Pituitary-Gonadal Axis and Bone in a 46,XX Patient with CYP19A1 Deficiency.
aromatase deficiency
Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency.
aromatase deficiency
Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?
aromatase deficiency
Maternal exposure to imazalil disrupts the endocrine system in F1 generation mice.
aromatase deficiency
Metformin, Estrogen Replacement Therapy and Gonadotropin Inhibition Fail to Improve Insulin Sensitivity in a Girl with Aromatase Deficiency.
aromatase deficiency
Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries.
aromatase deficiency
Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR: Expanding the PORD Phenotype.
aromatase deficiency
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
aromatase deficiency
Mutation of cyp19a1b results in sterile males due to efferent duct obstruction in Nile tilapia.
aromatase deficiency
Myocardial and cardiomyocyte stress resilience is enhanced in aromatase-deficient female mouse hearts through CaMKII? activation.
aromatase deficiency
No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome.
aromatase deficiency
Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function.
aromatase deficiency
Novel human pathological mutations. Gene symbol: CYP19A1. Disease: Aromatase deficiency.
aromatase deficiency
Oestradiol replacement treatment and glucose homeostasis in two men with congenital aromatase deficiency: evidence for a role of oestradiol and sex steroids imbalance on insulin sensitivity in men.
aromatase deficiency
Oestrogen modulation of the effect of 8-OH-DPAT on prepulse inhibition: effects of aromatase deficiency and castration in mice.
aromatase deficiency
Ovarian and uterine development and hormonal feedback mechanism in a 46 XX patient with CYP19A1 deficiency under low dose estrogen replacement.
aromatase deficiency
Ovarian steroidogenesis in Japanese patients with polycystic ovary syndrome.
aromatase deficiency
Pediatric endocrinology update: an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion and bone turnover: lessons from mutations in the genes for aromatase and the estrogen receptor.
aromatase deficiency
Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia.
aromatase deficiency
Pituitary function in a man with congenital aromatase deficiency: effect of different doses of transdermal E2 on basal and stimulated pituitary hormones.
aromatase deficiency
Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype.
aromatase deficiency
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
aromatase deficiency
Recent experimental and clinical findings in the skeleton associated with loss of estrogen hormone or estrogen receptor activity.
aromatase deficiency
Retraction. Neurological effects of aromatase deficiency in the mouse.
aromatase deficiency
Role of estrogen on bone in the human male: insights from the natural models of congenital estrogen deficiency.
aromatase deficiency
Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency.
aromatase deficiency
Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males.
aromatase deficiency
Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
aromatase deficiency
Sex steroids and sexual desire in a man with a novel mutation of aromatase gene and hypogonadism.
aromatase deficiency
Short stature homeobox-containing gene duplication on the der(X) chromosome in a female with 45,X/46,X, der(X), gonadal dysgenesis, and tall stature.
aromatase deficiency
Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone.
aromatase deficiency
Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.
aromatase deficiency
Steroid profiling in preeclamptic women: evidence for aromatase deficiency.
aromatase deficiency
Tall stature without growth hormone: four male patients with aromatase deficiency.
aromatase deficiency
Testosterone action on erythropoiesis does not require its aromatization to estrogen: Insights from the testosterone and estrogen treatment of two aromatase-deficient men.
aromatase deficiency
The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues.
aromatase deficiency
The effects of long-term raloxifene and estradiol treatments on bone in a patient with congenital aromatase deficiency.
aromatase deficiency
THE EFFECTS OF MATERNAL HYPOTHYROIDISM ON THE IMMUNOREACTIVITY OF CYTOCHROME P450 AROMATASE IN THE POSTNATAL RAT TESTICLES.
aromatase deficiency
The effects of oestrogen exposure on bone mass in male to female transsexuals.
aromatase deficiency
The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals.
aromatase deficiency
The estrogen receptor in the growth plate: implications for pubertal growth.
aromatase deficiency
The role of Eralpha and ERbeta in the prostate: insights from genetic models and isoform-selective ligands.
aromatase deficiency
Unusual Virilization in Girls with Juvenile Granulosa Cell Tumors of the Ovary Is Related to Intratumoral Aromatase Deficiency.
aromatase deficiency
Variable phenotypes associated with aromatase (CYP19) insufficiency in humans.
aromatase deficiency
[Estrogens and male sexuality: efficiency of antiestrogens in case of hypothalamic hypogonadism and late onset hypogonadism].
aromatase deficiency
[Sex differentiation of central nervous system--brain of man and woman]
Arrhythmias, Cardiac
Aromatase deficiency confers paradoxical postischemic cardioprotection.
Arrhythmias, Cardiac
The Relationship between Estrogen and Nitric Oxide in the Prevention of Cardiac and Vascular Anomalies in the Developing Zebrafish (Danio Rerio).
Arteriosclerosis
[Important functions of estrogens in men--breakthrough in contemporary medicine]
Arteriovenous Malformations
Extensive Osler-Rendu disease in a breast cancer patient: increasing hepatic arteriovenous malformations under endocrine therapy mimicking liver metastases.
Arteriovenous Malformations
Resolution of Uterine Arteriovenous Malformation and Maintenance of Reproduction in 20 Women Treated With a GnRH Agonist Concomitantly With an Aromatase Inhibitor and Tranexamic Acid.
Arthralgia
"I feel like I am 100 years old!" managing arthralgias from aromatase inhibitors.
Arthralgia
(557) Auricular point acupressure to manage aromatase inhibitor-induced arthralgia in postmenopausal breast cancer survivors.
Arthralgia
A cross-sectional survey of pain catastrophising and acupuncture use among breast cancer survivors.
Arthralgia
A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.
Arthralgia
A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
Arthralgia
A qualitative exploration of the impact of yoga on breast cancer survivors with aromatase inhibitor-associated arthralgias.
Arthralgia
A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use.
Arthralgia
A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102.
Arthralgia
A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer.
Arthralgia
Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia.
Arthralgia
Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
Arthralgia
Acupuncture for Arthralgia Induced by Aromatase Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis.
Arthralgia
Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis.
Arthralgia
Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study.
Arthralgia
Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer.
Arthralgia
Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience Joint Pain.
Arthralgia
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias.
Arthralgia
Anastrozole-associated joint pain and other symptoms in patients with breast cancer.
Arthralgia
Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity.
Arthralgia
Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors.
Arthralgia
Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients.
Arthralgia
Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Arthralgia
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
Arthralgia
Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors.
Arthralgia
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Arthralgia
Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.
Arthralgia
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Arthralgia
Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.
Arthralgia
Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.
Arthralgia
Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.
Arthralgia
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Arthralgia
Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?
Arthralgia
Arthralgia Associated with Autoimmune Abnormalities under Aromatase Inhibitor Therapy: Outcome after Cessation of Treatment.
Arthralgia
Arthralgia During Aromatase Inhibitor Treatment in Early Breast Cancer Patients: Prevalence, Impact, and Recognition by Healthcare Providers.
Arthralgia
Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.
Arthralgia
Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.
Arthralgia
Auricular Point Acupressure to Manage Aromatase Inhibitor-Induced Arthralgia in Postmenopausal Breast Cancer Survivors: A Pilot Study.
Arthralgia
Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
Arthralgia
Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy.
Arthralgia
Combined use of vitamin D and omega-3 fatty acid in breast cancer patients might be more beneficial for reducing aromatase inhibitors-associated arthralgia.
Arthralgia
Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a protocol for a systematic review and network meta-analysis.
Arthralgia
Current Opinion of Aromatase Inhibitor-induced Arthralgia in Breast Cancer in the UK.
Arthralgia
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Arthralgia
Development and validation of the Penn Arthralgia Aging Scale among breast cancer survivors.
Arthralgia
Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer: A meta-analysis of randomized controlled trials.
Arthralgia
Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.
Arthralgia
Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatment-naive postmenopausal females.
Arthralgia
Effect of Tart Cherry on Aromatase Inhibitor-Induced Arthralgia (AIA) in Nonmetastatic Hormone-Positive Breast Cancer Patients: A Randomized Double-Blind Placebo-Controlled Trial.
Arthralgia
Effectiveness, safety, and economic evaluation of adjuvant moxibustion therapy for aromatase inhibitor-induced arthralgia of postmenopausal breast cancer stage I to III patients: Study protocol for a prospective, randomized, assessor-blind, usual-care controlled, parallel-group, pilot clinical trial.
Arthralgia
Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review.
Arthralgia
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Arthralgia
Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors.
Arthralgia
Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study.
Arthralgia
Exercise for secondary prevention of breast cancer: moving from evidence to changing clinical practice.
Arthralgia
Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study.
Arthralgia
Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors.
Arthralgia
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Arthralgia
Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
Arthralgia
Genetic Predictors of Response to Acupuncture for Aromatase Inhibitor-Associated Arthralgia Among Breast Cancer Survivors.
Arthralgia
Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.
Arthralgia
Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.
Arthralgia
Impact of Yoga on Functional Outcomes in Breast Cancer Survivors With Aromatase Inhibitor-Associated Arthralgias.
Arthralgia
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Arthralgia
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Arthralgia
Interventions for the Treatment of Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: A Systematic Review and Meta-analysis.
Arthralgia
Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.
Arthralgia
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Arthralgia
Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study.
Arthralgia
Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients.
Arthralgia
Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.
Arthralgia
Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue.
Arthralgia
Nordic Walking as an Exercise Intervention to Reduce Pain in Women With Aromatase Inhibitor-Associated Arthralgia: A Feasibility Study.
Arthralgia
Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
Arthralgia
Oncology Acupuncture for Chronic Pain in Cancer Survivors: A Reflection on the American Society of Clinical Oncology Chronic Pain Guideline.
Arthralgia
Online discussion of drug side effects and discontinuation among breast cancer survivors.
Arthralgia
Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.
Arthralgia
Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer.
Arthralgia
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Arthralgia
Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis.
Arthralgia
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
Arthralgia
Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
Arthralgia
Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors.
Arthralgia
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Arthralgia
Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors.
Arthralgia
Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study).
Arthralgia
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
Arthralgia
Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy.
Arthralgia
Reply to correspondence concerning "Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer".
Arthralgia
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Arthralgia
Shear wave elastography detects novel imaging biomarkers of aromatase inhibitor-induced joint pain: a pilot study.
Arthralgia
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Arthralgia
Sonographic and Electrodiagnostic Evaluations in Patients With Aromatase Inhibitor-Related Arthralgia.
Arthralgia
Tai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study.
Arthralgia
The Effect of Exercise on the Alleviation of Side Effects Induced by Aromatase Inhibitors in Postmenopausal Breast Cancer Patients.
Arthralgia
The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review.
Arthralgia
The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.
Arthralgia
Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: A systematic review of systematic reviews, evidence mapping, and network meta-analysis.
Arthralgia
Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
Arthralgia
Treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may reduce joint pain and stiffness linked to aromatase inhibitors in women with early breast cancer: results of a pilot observational study.
Arthralgia
Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia.
Arthralgia
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
Arthralgia
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
Arthralgia
Yoga versus massage in the treatment of aromatase inhibitor-associated knee joint pain in breast cancer survivors: a randomized controlled trial.
Arthralgia
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Arthritis
A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer.
Arthritis
Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience Joint Pain.
Arthritis
Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.
Arthritis
Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis.
Arthritis
Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.
Arthritis
Relation between placental growth factor-1 (PlGF-1) and vascularization, DHEAS to DHEA conversion, or aromatase expression in patients with arthritis.
Arthritis, Rheumatoid
Accelerated cutaneous nodulosis associated with aromatase inhibitor therapy in a patient with rheumatoid arthritis.
Arthritis, Rheumatoid
Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology.
Arthritis, Rheumatoid
Predictors of fragility fracture and low bone mineral density in patients with a history of parental fracture.
Arthritis, Rheumatoid
RANK ligand inhibition with denosumab for the management of osteoporosis.
Arthritis, Rheumatoid
Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity.
Arthritis, Rheumatoid
The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer.
Arthritis, Rheumatoid
Thrombotic risk and immobility in residents of long-term care facilities.
Asthenozoospermia
Differential expression of mRNA aromatase in ejaculated spermatozoa from infertile men in relation to either asthenozoospermia or teratozoospermia.
Astrocytoma
Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.
Astrocytoma
Association of ST6GAL1 and CYP19A1 polymorphisms in the 3'-UTR with astrocytoma risk and prognosis in a Chinese Han population.
Atherosclerosis
Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis.
Atherosclerosis
Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase.
Atherosclerosis
The discrepancy of aromatase expression in epicardial adipose tissue between CHD and non-CHD patients.
Atherosclerosis
Use of Network Pharmacology to Explore the Mechanism of Gegen (Puerariae lobatae Radix) in the Treatment of Type 2 Diabetes Mellitus Associated with Hyperlipidemia.
Atrophic Vaginitis
Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.
Atrophic Vaginitis
Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors.
Atrophic Vaginitis
The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis.
Atrophic Vaginitis
Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
Atrophic Vaginitis
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.
Avian Leukosis
Characterization of the endogenous retrovirus insertion in CYP19A1 associated with henny feathering in chicken.
Azoospermia
Serum bioactive follicle-stimulating hormone in men with idiopathic azoospermia and oligospermia.
Azoospermia
Testicular Testosterone and Estradiol Concentrations and Aromatase Expression in Men with Nonobstructive Azoospermia.
Bisphosphonate-Associated Osteonecrosis of the Jaw
An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw.
Bone Diseases, Metabolic
A TA repeat polymorphism in the estrogen receptor gene is associated with osteoporotic fractures but polymorphisms in the first exon and intron are not.
Bone Diseases, Metabolic
Antihormonal potential of selected D-homo and D-seco estratriene derivatives.
Bone Diseases, Metabolic
Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline.
Bone Diseases, Metabolic
Correlation of rs749292 and rs700518 polymorphisms in the aromatase gene (CYP19A1) with osteoporosis in postmenopausal Polish women.
Bone Diseases, Metabolic
Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Bone Diseases, Metabolic
Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.
Bone Diseases, Metabolic
Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Bone Diseases, Metabolic
Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
Bone Diseases, Metabolic
Low bone density in breast cancer survivors in Korea: Prevalence, risk factors and associations with health-related quality of life.
Bone Diseases, Metabolic
The gene for aromatase, a rate-limiting enzyme for local estrogen biosynthesis, is a downstream target gene of runx2 in skeletal tissues.
Bone Diseases, Metabolic
The role of activation functions 1 and 2 of estrogen receptor-a for the effects of estradiol and Selective Estrogen Receptor Modulators (SERMs) in male mice.
Bone Diseases, Metabolic
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
Bone Diseases, Metabolic
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Bone Diseases, Metabolic
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Bone Neoplasms
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Bone Neoplasms
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Bone Resorption
Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
Bone Resorption
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption.
Bone Resorption
Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.
Bone Resorption
Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer.
Bone Resorption
Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
Bone Resorption
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Bone Resorption
High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study.
Bone Resorption
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Bone Resorption
The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men.
Bone Resorption
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.
Bone Resorption
[Bone effects of bisphosphonates and denosumab treatments in breast or prostate cancer].
Brain Injuries
A Quantification of the Injury-Induced Changes in Central Aromatase, Oestrogenic Milieu and Steroid Receptor Expression in the Zebra Finch.
Brain Injuries
Aromatase enzyme and Alzheimer's disease. Studio prospettico in 54 pazienti affetti da iperparatiroidismo primitivo.
Brain Injuries
Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair.
Brain Injuries
Aromatase, the enzyme responsible for estrogen biosynthesis, is expressed by human and rat glioblastomas.
Brain Injuries
Astrocyte-Derived Estrogen Regulates Reactive Astrogliosis and is Neuroprotective following Ischemic Brain Injury.
Brain Injuries
Central Administration of Indomethacin Mitigates the Injury-Induced Upregulation of Aromatase Expression and Estradiol Content in the Zebra Finch Brain.
Brain Injuries
Glial aromatization increases the expression of bone morphogenetic protein-2 in the injured zebra finch brain.
Brain Injuries
Increased P450 aromatase levels in post-menopausal women after acute ischemic stroke.
Brain Injuries
Molecular characterization of the injury-induced aromatase transcript in the adult zebra finch brain.
Brain Ischemia
Astrocyte-Derived Estrogen Regulates Reactive Astrogliosis and is Neuroprotective following Ischemic Brain Injury.
Brain Ischemia
Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus.
Brain Ischemia
Indinavir inhibits the expression of cytoplasmic aromatase and nuclear SREBP in the hippocampus of reperfusion injury-induced ischemic rats.
Brain Ischemia
Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBP? in reperfusion injury-induced ischemic rat hippocampus.
Brain Ischemia
Neuron-Derived Estrogen Is Critical for Astrocyte Activation and Neuroprotection of the Ischemic Brain.
Brain Neoplasms
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
Brain Neoplasms
Pre-clinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas.
Breast Cyst
Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells.
Breast Cyst
Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha.
Breast Diseases
Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases.
Breast Diseases
[Local production of estrogen via aromatase and estrone sulfatase in breast cancer tissue]
Breast Neoplasms
"I feel like I am 100 years old!" managing arthralgias from aromatase inhibitors.
Breast Neoplasms
"Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion.
Breast Neoplasms
"Winging It": How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment.
Breast Neoplasms
(557) Auricular point acupressure to manage aromatase inhibitor-induced arthralgia in postmenopausal breast cancer survivors.
Breast Neoplasms
(Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture.
Breast Neoplasms
1,25-dihydroxyvitamin D3 regulates estrogen metabolism in cultured keratinocytes.
Breast Neoplasms
1-pentyl-3-(4-aminophenyl)pyrrolidine-2,5-dione, a selective aromatase inhibitor: in vivo studies.
Breast Neoplasms
1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: synthesis and in vitro inhibition of human placental CYP19 aromatase.
Breast Neoplasms
1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application.
Breast Neoplasms
17 Beta-hydroxysteroid dehydrogenase and aromatase activity in breast fat from women with benign and malignant breast tumours.
Breast Neoplasms
18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study.
Breast Neoplasms
18F-Fluoroestradiol (18F-FES)-PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer.
Breast Neoplasms
1?,25-Dihydroxyvitamin D(3) exerts tissue-specific effects on estrogen and androgen metabolism.
Breast Neoplasms
3D-QSAR study of steroidal and azaheterocyclic human aromatase inhibitors using quantitative profile of protein-ligand interactions.
Breast Neoplasms
4- and 6-(p-Sulphamoylphenyl)androstenediones: Studies of aromatase inhibitor-based oestrone sulphatase inhibition.
Breast Neoplasms
4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.
Breast Neoplasms
4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
Breast Neoplasms
4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.
Breast Neoplasms
4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells.
Breast Neoplasms
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Breast Neoplasms
5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.
Breast Neoplasms
6-Hydroximinoandrostenedione, a new specific inhibitor of estrogen biosynthesis and its effect on T47D human breast cancer cells.
Breast Neoplasms
7 alpha-substituted androstenediones as effective in vitro and in vivo inhibitors of aromatase.
Breast Neoplasms
7alpha-Arylaliphatic androsta-1,4-diene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase.
Breast Neoplasms
A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.
Breast Neoplasms
A case of erythrocytosis in a patient treated with an aromatase inhibitor for breast cancer.
Breast Neoplasms
A case of uterine tumour resembling ovarian sex cord tumour responding to second-line, single agent anastrazole.
Breast Neoplasms
A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
Breast Neoplasms
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Breast Neoplasms
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Breast Neoplasms
A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis.
Breast Neoplasms
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Breast Neoplasms
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Breast Neoplasms
A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Breast Neoplasms
A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer.
Breast Neoplasms
A cross-sectional survey of pain catastrophising and acupuncture use among breast cancer survivors.
Breast Neoplasms
A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.
Breast Neoplasms
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
Breast Neoplasms
A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance.
Breast Neoplasms
A humanized pattern of aromatase expression is associated with mammary hyperplasia in mice.
Breast Neoplasms
A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity.
Breast Neoplasms
A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription.
Breast Neoplasms
A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer.
Breast Neoplasms
A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
Breast Neoplasms
A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.
Breast Neoplasms
A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders.
Breast Neoplasms
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Breast Neoplasms
A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.
Breast Neoplasms
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors ? and ?.
Breast Neoplasms
A New Therapeutic Strategy against Hormone-Dependent Breast Cancer: The Preclinical Development of a Dual Aromatase and Sulfatase Inhibitor.
Breast Neoplasms
A newly developed hexamethylmelamine derivative, SAE9 with both antitumor and aromatase-inhibitory activity.
Breast Neoplasms
A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women.
Breast Neoplasms
A novel GC-MS methodology to evaluate aromatase activity in human placental microsomes: a comparative study with the standard radiometric assay.
Breast Neoplasms
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Breast Neoplasms
A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts.
Breast Neoplasms
A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor ?B Pathways with Hybrid Drugs for Breast Cancer Therapy.
Breast Neoplasms
A nuclear receptor system constituted by RAR and RXR induces aromatase activity in MCF-7 human breast cancer cells.
Breast Neoplasms
A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Breast Neoplasms
A peptide derived from alpha-fetoprotein inhibits the proliferation induced by estradiol in mammary tumor cells in culture.
Breast Neoplasms
A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting.
Breast Neoplasms
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Breast Neoplasms
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Breast Neoplasms
A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Breast Neoplasms
A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition.
Breast Neoplasms
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Breast Neoplasms
A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy.
Breast Neoplasms
A Pilot Study Comparing the Effect of Flaxseed, Aromatase Inhibitor, and the Combination on Breast Tumor Biomarkers.
Breast Neoplasms
A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions.
Breast Neoplasms
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
Breast Neoplasms
A Polymorphism at the 3'-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma.
Breast Neoplasms
A Pooled Analysis of Fall Incidence From Placebo-controlled Trials of Denosumab.
Breast Neoplasms
A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
Breast Neoplasms
A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.
Breast Neoplasms
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Breast Neoplasms
A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.
Breast Neoplasms
A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
Breast Neoplasms
A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Breast Neoplasms
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Breast Neoplasms
A qualitative exploration of the impact of yoga on breast cancer survivors with aromatase inhibitor-associated arthralgias.
Breast Neoplasms
A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer.
Breast Neoplasms
A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Breast Neoplasms
A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer.
Breast Neoplasms
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Breast Neoplasms
A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use.
Breast Neoplasms
A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer.
Breast Neoplasms
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Breast Neoplasms
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Breast Neoplasms
A randomized trial to increase physical activity in breast cancer survivors.
Breast Neoplasms
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Breast Neoplasms
A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102.
Breast Neoplasms
A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.
Breast Neoplasms
A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Breast Neoplasms
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Breast Neoplasms
A review of the newer aromatase inhibitors in the management of metastatic breast cancer.
Breast Neoplasms
A review of the physiology behind letrozole applications in infertility: are current protocols optimal?
Breast Neoplasms
A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors.
Breast Neoplasms
A Role of CREB in BRCA1 Constitutive Promoter Activity and Aromatase Basal Expression.
Breast Neoplasms
A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
Breast Neoplasms
A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors.
Breast Neoplasms
A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer.
Breast Neoplasms
A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.
Breast Neoplasms
A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
Breast Neoplasms
A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors.
Breast Neoplasms
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
Breast Neoplasms
A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients.
Breast Neoplasms
A study of estrogen signaling using DNA microarray in human breast cancer.
Breast Neoplasms
A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.
Breast Neoplasms
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Breast Neoplasms
A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer.
Breast Neoplasms
A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer.
Breast Neoplasms
A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer.
Breast Neoplasms
A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
Breast Neoplasms
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.
Breast Neoplasms
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor.
Breast Neoplasms
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.
Breast Neoplasms
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
Breast Neoplasms
Absence of the K303R estrogen receptor ? mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment.
Breast Neoplasms
Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more?
Breast Neoplasms
Acceleration of mammary neoplasia in aromatase transgenic mice by 7,12-dimethylbenz[a]anthracene.
Breast Neoplasms
Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.
Breast Neoplasms
Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.
Breast Neoplasms
Acidic Exopolysaccharide Produced from Marine Bacillus amyloliquefaciens 3MS 2017 for the Protection and Treatment of Breast Cancer.
Breast Neoplasms
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
Breast Neoplasms
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Breast Neoplasms
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER? metastatic breast cancer.
Breast Neoplasms
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.
Breast Neoplasms
Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer.
Breast Neoplasms
Activation of aromatase expression by retinoic acid eceptor-related orphan receptor (ROR)alpha in breast cancer cells: Identification of a novel ror response element.
Breast Neoplasms
Active site acidic residues and structural analysis of modelled human aromatase: A potential drug target for breast cancer.
Breast Neoplasms
Active site acidic residues and structural analysis of modelled human aromatase: a potential drug target for breast cancer.
Breast Neoplasms
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
Breast Neoplasms
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Breast Neoplasms
Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.
Breast Neoplasms
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.
Breast Neoplasms
Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial.
Breast Neoplasms
Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia.
Breast Neoplasms
Acupuncture for Aromatase Inhibitor-Induced Arthralgia: A Systematic Review.
Breast Neoplasms
Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients.
Breast Neoplasms
Acupuncture for Arthralgia Induced by Aromatase Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis.
Breast Neoplasms
Acupuncture for joint symptoms related to aromatase inhibitor therapy in postmenopausal women with early-stage breast cancer: a narrative review.
Breast Neoplasms
Acupuncture for symptoms management in Korean breast cancer survivors: a prospective pilot study.
Breast Neoplasms
Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis.
Breast Neoplasms
Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study.
Breast Neoplasms
Acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer.
Breast Neoplasms
Acupuncture versus medication for pain management: a cross-sectional study of breast cancer survivors.
Breast Neoplasms
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature.
Breast Neoplasms
Acute but not sustained aromatase inhibition displays antidepressant properties.
Breast Neoplasms
Acute Effect of High-dose Isoflavones from Pueraria lobata (Willd.) Ohwi on Lipid and Bone Metabolism in Ovariectomized Mice.
Breast Neoplasms
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Breast Neoplasms
Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience Joint Pain.
Breast Neoplasms
Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
Breast Neoplasms
Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance.
Breast Neoplasms
Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Breast Neoplasms
Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
Breast Neoplasms
Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
Breast Neoplasms
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Breast Neoplasms
Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.
Breast Neoplasms
Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Breast Neoplasms
Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment.
Breast Neoplasms
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
Breast Neoplasms
Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer.
Breast Neoplasms
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
Breast Neoplasms
Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.
Breast Neoplasms
Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives.
Breast Neoplasms
Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years.
Breast Neoplasms
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Breast Neoplasms
Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer.
Breast Neoplasms
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Breast Neoplasms
Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Breast Neoplasms
Adjuvant Aromatase Inhibitor Therapy in Patients with Stage I Breast Cancer at a Regional Oncology Center in Israel: Implementation of a 'Switching' Policy in Postmenopausal Patients after Initial Tamoxifen.
Breast Neoplasms
Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
Breast Neoplasms
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Breast Neoplasms
Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of Falls.
Breast Neoplasms
Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients.
Breast Neoplasms
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Breast Neoplasms
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Breast Neoplasms
Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.
Breast Neoplasms
Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Breast Neoplasms
Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update.
Breast Neoplasms
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Breast Neoplasms
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
Breast Neoplasms
Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women.
Breast Neoplasms
Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis.
Breast Neoplasms
Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
Breast Neoplasms
Adjuvant endocrine therapy in post menopausal women: pharmacological evaluation using decision analysis approach in a Japanese hospital setting.
Breast Neoplasms
Adjuvant Endocrine Therapy of Perimenopausal and Recently Postmenopausal Women With Hormone Receptor-Positive Breast Cancer.
Breast Neoplasms
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Breast Neoplasms
Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study.
Breast Neoplasms
Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis.
Breast Neoplasms
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
Breast Neoplasms
Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
Breast Neoplasms
Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.
Breast Neoplasms
Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Breast Neoplasms
Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor- positive breast cancer patients: upfront or sequential?
Breast Neoplasms
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Breast Neoplasms
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials.
Breast Neoplasms
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Breast Neoplasms
Adjuvant trials: Aromatase inhibitors in early breast cancer--are they alike?
Breast Neoplasms
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
Breast Neoplasms
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Breast Neoplasms
Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs).
Breast Neoplasms
Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
Breast Neoplasms
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.
Breast Neoplasms
Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors.
Breast Neoplasms
Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy.
Breast Neoplasms
Adverse Effects of Aromatase Inhibition on the Brain and Behavior in a Nonhuman Primate.
Breast Neoplasms
Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (review).
Breast Neoplasms
Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Breast Neoplasms
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias.
Breast Neoplasms
Advising Women Undergoing Treatment for Breast Cancer: A Narrative Review.
Breast Neoplasms
Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
Breast Neoplasms
Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
Breast Neoplasms
AIB1:ER? transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
Breast Neoplasms
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Breast Neoplasms
AKT-dependent sugar addiction by benzyl isothiocyanate in breast cancer cells.
Breast Neoplasms
Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial.
Breast Neoplasms
All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.
Breast Neoplasms
Alleviating anastrozole induced bone toxicity by selenium nanoparticles in SD rats.
Breast Neoplasms
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Breast Neoplasms
Alteration at transcriptional level of cardiac renin-angiotensin system by letrozole treatment.
Breast Neoplasms
Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors.
Breast Neoplasms
Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial.
Breast Neoplasms
Alternative oral exemestane formulation: Improved dissolution and permeation.
Breast Neoplasms
Alternative use of multiple exons 1 of aromatase gene in cancerous and normal breast tissues from women over the age of 80 years.
Breast Neoplasms
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Breast Neoplasms
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Breast Neoplasms
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction.
Breast Neoplasms
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
Breast Neoplasms
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Breast Neoplasms
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Breast Neoplasms
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Breast Neoplasms
Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.
Breast Neoplasms
Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis.
Breast Neoplasms
Amphiregulin retains ER? expression in acquired aromatase inhibitor resistant breast cancer cells.
Breast Neoplasms
AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells.
Breast Neoplasms
Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
Breast Neoplasms
An "Omics" Approach to Determine the Mechanisms of Acquired Aromatase Inhibitor Resistance.
Breast Neoplasms
An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.
Breast Neoplasms
An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors.
Breast Neoplasms
An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients.
Breast Neoplasms
An evaluation of fulvestrant for the treatment of metastatic breast cancer.
Breast Neoplasms
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.
Breast Neoplasms
An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells.
Breast Neoplasms
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
Breast Neoplasms
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.
Breast Neoplasms
An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples.
Breast Neoplasms
An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Breast Neoplasms
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Breast Neoplasms
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Breast Neoplasms
An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range.
Breast Neoplasms
An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor- positive early breast cancer.
Breast Neoplasms
Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study.
Breast Neoplasms
Analysis of the effects of different alcohols on MCF-7 human breast cancer cells.
Breast Neoplasms
Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer.
Breast Neoplasms
Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Breast Neoplasms
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Breast Neoplasms
Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management.
Breast Neoplasms
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction between SLC38A7 and ALPPL2.
Breast Neoplasms
Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations.
Breast Neoplasms
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Breast Neoplasms
Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor ?.
Breast Neoplasms
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Breast Neoplasms
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Breast Neoplasms
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Breast Neoplasms
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Breast Neoplasms
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Breast Neoplasms
Anastrozole-associated joint pain and other symptoms in patients with breast cancer.
Breast Neoplasms
Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer.
Breast Neoplasms
Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events.
Breast Neoplasms
Anastrozole-induced liver injury after a prolonged latency: a very rare complication of a commonly prescribed medication.
Breast Neoplasms
Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report.
Breast Neoplasms
Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Breast Neoplasms
Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
Breast Neoplasms
Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer.
Breast Neoplasms
Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.
Breast Neoplasms
Anastrozole: new indication. Adjuvant treatment of non metastatic breast cancer: useful for some patients.
Breast Neoplasms
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Breast Neoplasms
Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
Breast Neoplasms
Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Breast Neoplasms
Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
Breast Neoplasms
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Breast Neoplasms
Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase.
Breast Neoplasms
Andrographolide is an Alternative Treatment to Overcome Resistance in ER-Positive Breast Cancer via Cholesterol Biosynthesis Pathway.
Breast Neoplasms
Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus).
Breast Neoplasms
Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts.
Breast Neoplasms
Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer.
Breast Neoplasms
Anti-estrogens in the treatment of breast cancer: current status and future directions.
Breast Neoplasms
Anti-tumor effect of Shu-Gan-Liang-Xue decoction in breast cancer is related to the inhibition of aromatase and steroid sulfatase expression.
Breast Neoplasms
Anti-tumor efficacy of new 7?-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
Breast Neoplasms
Anti-tumour effect of aromatase inhibitor, CGS16949A, on human breast cancer cells.
Breast Neoplasms
Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study.
Breast Neoplasms
Antiresorptive therapy in the management of cancer treatment-induced bone loss.
Breast Neoplasms
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
Breast Neoplasms
Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
Breast Neoplasms
Apoptosis and Autophagy in Breast Cancer Cells following Exemestane Treatment.
Breast Neoplasms
Application of aromatase inhibitors in endocrine responsive breast cancers.
Breast Neoplasms
Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.
Breast Neoplasms
Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Breast Neoplasms
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Breast Neoplasms
Are differences in the available aromatase inhibitors and inactivators significant?
Breast Neoplasms
Are estring(®) and vagifem(®) equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?
Breast Neoplasms
Are patients with newly diagnosed breast cancer getting appropriate DEXA scans? A District General Hospital experience.
Breast Neoplasms
Are previous episodes of bacterial vaginosis a predictor for vaginal symptoms in breast cancer patients treated with aromatase inhibitors?
Breast Neoplasms
Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.
Breast Neoplasms
ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
Breast Neoplasms
AroER Tri-Screen Is a Biologically Relevant Assay for Endocrine Disrupting Chemicals Modulating the Activity of Aromatase and/or the Estrogen Receptor.
Breast Neoplasms
AroER tri-screen is a novel functional assay to estimate both estrogenic and estrogen precursor activity of chemicals or biological specimens.
Breast Neoplasms
Aromatase (CYP19) inhibition by biflavonoids obtained from the branches of Garcinia gardneriana (Clusiaceae).
Breast Neoplasms
Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition.
Breast Neoplasms
Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.
Breast Neoplasms
Aromatase activity and expression in breast cancer and benign breast tissue stromal cells.
Breast Neoplasms
Aromatase activity and interleukin-6 production by normal and malignant breast tissues.
Breast Neoplasms
Aromatase activity and the effect of estradiol and testosterone on DNA synthesis in endometrial carcinoma cell lines.
Breast Neoplasms
Aromatase activity in adipose tissue from breast quadrants: a link with tumour site.
Breast Neoplasms
Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases.
Breast Neoplasms
Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies.
Breast Neoplasms
Aromatase activity in the breast and other peripheral tissues and its therapeutic regulation.
Breast Neoplasms
Aromatase activity, serum oestradiol and their correlation with demographic indices.
Breast Neoplasms
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Breast Neoplasms
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review.
Breast Neoplasms
Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.
Breast Neoplasms
Aromatase and its inhibitors in breast cancer treatment--overview and perspective.
Breast Neoplasms
Aromatase and prostaglandin inter-relationships in breast adipose tissue: significance for breast cancer development.
Breast Neoplasms
Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor.
Breast Neoplasms
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
Breast Neoplasms
Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.
Breast Neoplasms
Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction.
Breast Neoplasms
Aromatase gene expression in adipose tissue: relationship to breast cancer.
Breast Neoplasms
Aromatase Imaging with [N-methyl-C-11]vorozole PET in Healthy Men and Women.
Breast Neoplasms
Aromatase immunoreactivity is increased in mammographically dense regions of the breast.
Breast Neoplasms
Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors.
Breast Neoplasms
Aromatase in breast cancer tissue--localization and relationship with reproductive status of patients.
Breast Neoplasms
Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations.
Breast Neoplasms
Aromatase inactivation by 2-substituted derivatives of the suicide substrate androsta-1,4-diene-3,17-dione.
Breast Neoplasms
Aromatase induction in tamoxifen-resistant breast cancer: Role of phosphoinositide 3-kinase-dependent CREB activation.
Breast Neoplasms
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Breast Neoplasms
Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.
Breast Neoplasms
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Breast Neoplasms
Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production.
Breast Neoplasms
Aromatase inhibition by 2-methyl indole hydrazone derivatives evaluated via molecular docking and in vitro activity studies.
Breast Neoplasms
Aromatase inhibition by an 11,13-dihydroderivative of a sesquiterpene lactone.
Breast Neoplasms
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Breast Neoplasms
Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
Breast Neoplasms
Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.
Breast Neoplasms
Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.
Breast Neoplasms
Aromatase inhibitor adjuvant chemotherapy of breast cancer results in cancer therapy induced bone loss.
Breast Neoplasms
Aromatase inhibitor agents in breast cancer: evolving practices in hormonal therapy treatment.
Breast Neoplasms
Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Breast Neoplasms
Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity.
Breast Neoplasms
Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors.
Breast Neoplasms
Aromatase inhibitor letrozole downregulates steroid receptor coactivator-1 in specific brain regions that primarily related to memory, neuroendocrine and integration.
Breast Neoplasms
Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
Breast Neoplasms
Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
Breast Neoplasms
Aromatase inhibitor treatment for breast cancer: short-term effect on bone health.
Breast Neoplasms
Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
Breast Neoplasms
Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients.
Breast Neoplasms
Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis.
Breast Neoplasms
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
Breast Neoplasms
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer.
Breast Neoplasms
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
Breast Neoplasms
Aromatase inhibitor-associated musculoskeletal pain: taking 'AIM' at a symptom in breast cancer survivors.
Breast Neoplasms
Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
Breast Neoplasms
Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors.
Breast Neoplasms
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
Breast Neoplasms
Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event.
Breast Neoplasms
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Breast Neoplasms
Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.
Breast Neoplasms
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Breast Neoplasms
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Breast Neoplasms
Aromatase Inhibitor-Induced Carpal Tunnel Syndrome: Results From the ATAC Trial.
Breast Neoplasms
Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.
Breast Neoplasms
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Breast Neoplasms
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Breast Neoplasms
Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis.
Breast Neoplasms
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Breast Neoplasms
Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Breast Neoplasms
Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors.
Breast Neoplasms
Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Breast Neoplasms
Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.
Breast Neoplasms
Aromatase inhibitors and bisphosphonates reduce deaths from breast cancer, studies show.
Breast Neoplasms
Aromatase inhibitors and breast cancer.
Breast Neoplasms
Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
Breast Neoplasms
Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
Breast Neoplasms
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Breast Neoplasms
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Breast Neoplasms
Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology.
Breast Neoplasms
Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis.
Breast Neoplasms
Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis.
Breast Neoplasms
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
Breast Neoplasms
Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
Breast Neoplasms
Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
Breast Neoplasms
Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis.
Breast Neoplasms
Aromatase inhibitors as adjuvant therapies in patients with breast cancer.
Breast Neoplasms
Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
Breast Neoplasms
Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer.
Breast Neoplasms
Aromatase inhibitors as solely treatment in postmenopausal breast cancer patients.
Breast Neoplasms
Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population.
Breast Neoplasms
Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer.
Breast Neoplasms
Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.
Breast Neoplasms
Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study.
Breast Neoplasms
Aromatase Inhibitors Evolution as Potential class of drugs in the treatment of Postmenopausal Breast Cancer Women.
Breast Neoplasms
Aromatase inhibitors for adjuvant treatment of postmenopausal breast cancer.
Breast Neoplasms
Aromatase inhibitors for breast cancer: different structures, same effects?
Breast Neoplasms
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Breast Neoplasms
Aromatase inhibitors for early breast cancer therapy: A choice of effective treatment strategies.
Breast Neoplasms
Aromatase Inhibitors for Ovarian Stimulation in Patients with Breast Cancer.
Breast Neoplasms
Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review.
Breast Neoplasms
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Breast Neoplasms
Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch.
Breast Neoplasms
Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Breast Neoplasms
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Breast Neoplasms
Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Breast Neoplasms
Aromatase inhibitors for treatment of postmenopausal patients with breast cancer.
Breast Neoplasms
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review.
Breast Neoplasms
Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Breast Neoplasms
Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications.
Breast Neoplasms
Aromatase inhibitors in advanced breast cancer: there are efficacy differences.
Breast Neoplasms
Aromatase inhibitors in breast cancer.
Breast Neoplasms
Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness.
Breast Neoplasms
Aromatase inhibitors in clinical practice: current status and a look to the future.
Breast Neoplasms
Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.
Breast Neoplasms
Aromatase inhibitors in early hormone receptor-positive breast cancer : what is the optimal initiation time for the maximum benefit?
Breast Neoplasms
Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.
Breast Neoplasms
Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters.
Breast Neoplasms
Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
Breast Neoplasms
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Breast Neoplasms
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.
Breast Neoplasms
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Breast Neoplasms
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Breast Neoplasms
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer.
Breast Neoplasms
Aromatase inhibitors in the breast cancer therapy and their potential using in the prevention setting.
Breast Neoplasms
Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.
Breast Neoplasms
Aromatase inhibitors in the management of early breast cancer: the TEAM trial.
Breast Neoplasms
Aromatase inhibitors in the treatment of advanced breast cancer. Introduction.
Breast Neoplasms
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.
Breast Neoplasms
Aromatase inhibitors in the treatment of early and advanced breast cancer.
Breast Neoplasms
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Breast Neoplasms
Aromatase inhibitors induce spine synapse loss in the hippocampus of ovariectomized mice.
Breast Neoplasms
Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review.
Breast Neoplasms
Aromatase inhibitors might be more effective when they are given 2-3 months later after the administration of luteinizing hormone-releasing hormone agonists in younger premenopausal breast cancer patients.
Breast Neoplasms
Aromatase inhibitors plus ovarian function suppression versus tamoxifen plus ovarian function suppression for premenopausal women with early stage breast cancer: a systematic review and meta-analysis.
Breast Neoplasms
Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients.
Breast Neoplasms
Aromatase inhibitors to augment height: continued caution and study required.
Breast Neoplasms
Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
Breast Neoplasms
Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy.
Breast Neoplasms
Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings.
Breast Neoplasms
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Breast Neoplasms
Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer.
Breast Neoplasms
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Breast Neoplasms
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Breast Neoplasms
Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
Breast Neoplasms
Aromatase Inhibitors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects.
Breast Neoplasms
Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones.
Breast Neoplasms
Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women.
Breast Neoplasms
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
Breast Neoplasms
Aromatase inhibitors: assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression.
Breast Neoplasms
Aromatase inhibitors: changing the face of endocrine therapy for breast cancer.
Breast Neoplasms
Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
Breast Neoplasms
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Breast Neoplasms
Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer.
Breast Neoplasms
Aromatase inhibitors: structural features and biochemical characterization.
Breast Neoplasms
Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells.
Breast Neoplasms
Aromatase over expression transgenic murine models for aromatase inhibitor studies.
Breast Neoplasms
Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
Breast Neoplasms
Aromatase overexpression enhances the stimulatory effects of adrenal androgens on MCF7 breast cancer cells.
Breast Neoplasms
Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer.
Breast Neoplasms
Aromatase overexpression induces malignant changes in estrogen receptor ? negative MCF-10A cells.
Breast Neoplasms
Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women.
Breast Neoplasms
Aromatase, CYP1B1 and Fatty Acid Synthase Expression in Breast Tumors of BRCA1 Mutation Carriers.
Breast Neoplasms
Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
Breast Neoplasms
Arthralgia During Aromatase Inhibitor Treatment in Early Breast Cancer Patients: Prevalence, Impact, and Recognition by Healthcare Providers.
Breast Neoplasms
Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer.
Breast Neoplasms
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Breast Neoplasms
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary.
Breast Neoplasms
Assessment of bone health in breast cancer patients starting adjuvant aromatase inhibitors: A quality improvement clinical audit.
Breast Neoplasms
Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.
Breast Neoplasms
Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors.
Breast Neoplasms
Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment.
Breast Neoplasms
Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance.
Breast Neoplasms
Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients.
Breast Neoplasms
Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.
Breast Neoplasms
Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer.
Breast Neoplasms
Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors.
Breast Neoplasms
Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women.
Breast Neoplasms
Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer.
Breast Neoplasms
Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
Breast Neoplasms
Association of aromatase inhibitors with coronary heart disease in women with early breast cancer.
Breast Neoplasms
Association of CYP19 polymorphisms with breast cancer risk: A case-control study.
Breast Neoplasms
Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Breast Neoplasms
Association of estrogen receptor alpha (ER?) gene polymorphisms with endometrial thickness and lipid profile in women with breast cancer treated with aromatase inhibitors.
Breast Neoplasms
Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
Breast Neoplasms
Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.
Breast Neoplasms
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
Breast Neoplasms
Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.
Breast Neoplasms
Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study.
Breast Neoplasms
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Breast Neoplasms
Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.
Breast Neoplasms
Attenuated peripheral endothelial function among women treated with aromatase inhibitors for breast cancer.
Breast Neoplasms
Auricular Point Acupressure to Manage Aromatase Inhibitor-Induced Arthralgia in Postmenopausal Breast Cancer Survivors: A Pilot Study.
Breast Neoplasms
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
Breast Neoplasms
Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells.
Breast Neoplasms
Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical record.
Breast Neoplasms
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Breast Neoplasms
Balanced dual acting compounds targeting aromatase and estrogen receptor ? as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer.
Breast Neoplasms
Base mediated synthesis of functionalized 2-(alkynyl)arylnitriles and their molecular docking study with aromatase receptor.
Breast Neoplasms
Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy: A descriptive study.
Breast Neoplasms
Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen resistant breast cancer; implications for treatment of advanced disease.
Breast Neoplasms
BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy.
Breast Neoplasms
BCMA (TNFRSF17) Induces APRIL and BAFF Mediated Breast Cancer Cell Stemness.
Breast Neoplasms
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Breast Neoplasms
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Breast Neoplasms
Beyond the C18 frontier: Androgen and glucocorticoid metabolism in breast cancer tissues: The role of non-typical steroid hormones in breast cancer development and progression.
Breast Neoplasms
Bicalutamide Plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer.
Breast Neoplasms
Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-bromo-4-{[(4-cyanophenyl)(4h-1,2,4-triazol-4-yl)amino]methyl}phenylsulfamate: synthesis, SAR, crystal structure, and in vitro and in vivo activities.
Breast Neoplasms
Bilateral de quervain syndrome after aromatase inhibitor administration: a case report and review of the literature.
Breast Neoplasms
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Breast Neoplasms
Bilateral Salpingo-Oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors.
Breast Neoplasms
Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Breast Neoplasms
Binding mode of triazole derivatives as aromatase inhibitors based on docking, protein ligand interaction fingerprinting, and molecular dynamics simulation studies.
Breast Neoplasms
Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway.
Breast Neoplasms
Biochemical and biological characterization of a novel anti-aromatase coumarin derivative.
Breast Neoplasms
Biochemical and pharmacological development of steroidal inhibitors of aromatase.
Breast Neoplasms
Biochemistry and pharmacology of 7alpha-substituted androstenediones as aromatase inhibitors.
Breast Neoplasms
Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast.
Breast Neoplasms
Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer.
Breast Neoplasms
Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.
Breast Neoplasms
Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Breast Neoplasms
Biological roles of estrogen and progesterone in human endometrial carcinoma--new developments in potential endocrine therapy for endometrial cancer.
Breast Neoplasms
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Breast Neoplasms
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Breast Neoplasms
Bis(4-hydroxy-2H-chromen-2-one) Coumarin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Aromatase Inhibition.
Breast Neoplasms
Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis.
Breast Neoplasms
Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis.
Breast Neoplasms
Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression.
Breast Neoplasms
Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives.
Breast Neoplasms
Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?
Breast Neoplasms
Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors.
Breast Neoplasms
Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
Breast Neoplasms
Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.
Breast Neoplasms
Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors.
Breast Neoplasms
Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
Breast Neoplasms
Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline.
Breast Neoplasms
Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors.
Breast Neoplasms
Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Breast Neoplasms
Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
Breast Neoplasms
Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer.
Breast Neoplasms
Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors.
Breast Neoplasms
Bone Mineral Density Testing Disparities Among Patients With Breast Cancer Prescribed Aromatase Inhibitors.
Breast Neoplasms
Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis.
Breast Neoplasms
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption.
Breast Neoplasms
Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.
Breast Neoplasms
Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate.
Breast Neoplasms
Bone turnover markers in postmenopausal breast cancer treated with fulvestrant--a pilot study.
Breast Neoplasms
Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer.
Breast Neoplasms
Boronic-targeted albumin-shell oily-core nanocapsules for synergistic aromatase inhibitor/herbal breast cancer therapy.
Breast Neoplasms
Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.
Breast Neoplasms
Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.
Breast Neoplasms
BRCA1 Breast Cancer Risk Is Modified by CYP19 Polymorphisms in Ashkenazi Jews.
Breast Neoplasms
BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells.
Breast Neoplasms
Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.
Breast Neoplasms
Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Breast Neoplasms
Breast Cancer Endocrine Therapy Promotes Weight Gain With Distinct Adipose Tissue Effects in Lean and Obese Female Mice.
Breast Neoplasms
Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective.
Breast Neoplasms
Breast cancer in limited-resource countries: treatment and allocation of resources.
Breast Neoplasms
Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment?
Breast Neoplasms
Breast cancer patients receiving denosumab during adjuvant aromatase inhibitors treatment: who are the "inadequate responders" patients to denosumab?
Breast Neoplasms
Breast cancer prevention with selective estrogen receptor modulators: a perspective.
Breast Neoplasms
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Breast Neoplasms
Breast cancer risk reduction: Notable achievements and remaining challenges.
Breast Neoplasms
Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Breast Neoplasms
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity.
Breast Neoplasms
Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy.
Breast Neoplasms
Breast Cancer: Abemaciclib effective in combination with aromatase inhibition.
Breast Neoplasms
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Breast Neoplasms
Breast carcinomas with immunocytochemical detection of aromatase in fine-needle aspirates: report of three cases.
Breast Neoplasms
Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.
Breast Neoplasms
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Breast Neoplasms
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Breast Neoplasms
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
Breast Neoplasms
By the way, doctor. I've had an ER-positive breast cancer tumor removed. Now I am getting ready for follow-up therapy. I've heard that the aromatase inhibitors are better than tamoxifen. What is your opinion?
Breast Neoplasms
Can aromatase inhibitors cause forgetfulness in women with breast cancer ?
Breast Neoplasms
Can Exercise Ameliorate Aromatase Inhibitor-Induced Cognitive Decline in Breast Cancer Patients?
Breast Neoplasms
Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada.
Breast Neoplasms
Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Breast Neoplasms
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Breast Neoplasms
Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer.
Breast Neoplasms
Cardiovascular Health among Black and White Breast Cancer Patients Initiating Aromatase Inhibitor Therapy.
Breast Neoplasms
Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
Breast Neoplasms
Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer.
Breast Neoplasms
Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
Breast Neoplasms
Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.
Breast Neoplasms
CC chemokine ligand 2 (CCL2) stimulates aromatase gene expression in mammary adipose tissue.
Breast Neoplasms
CCAAT/enhancer binding protein delta up-regulates aromatase promoters I.3/II in breast cancer epithelial cells.
Breast Neoplasms
CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer.
Breast Neoplasms
CDK 4/6 inhibitor induced lung injury: a case report and review of literature.
Breast Neoplasms
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Breast Neoplasms
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer.
Breast Neoplasms
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Breast Neoplasms
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.
Breast Neoplasms
Cell density is a critical determinant of aromatase expression in adipose stromal cells.
Breast Neoplasms
Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen.
Breast Neoplasms
Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole.
Breast Neoplasms
CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study.
Breast Neoplasms
Challenges in defining predictive markers for response to endocrine therapy in breast cancer.
Breast Neoplasms
Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy.
Breast Neoplasms
Change in serum oestradiol and testosterone concentrations after mastectomy for breast cancer with high aromatase activity.
Breast Neoplasms
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.
Breast Neoplasms
Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
Breast Neoplasms
Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Breast Neoplasms
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Breast Neoplasms
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
Breast Neoplasms
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
Breast Neoplasms
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.
Breast Neoplasms
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Breast Neoplasms
Changes in Cardiac Autonomic Modulation in Women with Breast Cancer Using Aromatase Inhibitors and the Relation with Biochemical Variables.
Breast Neoplasms
Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Breast Neoplasms
Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance.
Breast Neoplasms
Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
Breast Neoplasms
Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane.
Breast Neoplasms
Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
Breast Neoplasms
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Breast Neoplasms
Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.
Breast Neoplasms
Characterization of a novel silencer element in the human aromatase gene PII promoter.
Breast Neoplasms
Characterization of aromatase binding agents from the dichloromethane extract of Corydalis yanhusuo using ultrafiltration and liquid chromatography tandem mass spectrometry.
Breast Neoplasms
Chemical inhibitor anticancer drugs regulate mechanical properties and cytoskeletal structure of non-invasive and invasive breast cancer cell lines: Study of effects of Letrozole, Exemestane, and Everolimus.
Breast Neoplasms
Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Breast Neoplasms
Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.
Breast Neoplasms
Chemopreventive and Anticancer Property of Selenoproteins in Obese Breast Cancer.
Breast Neoplasms
Chemopreventive effects of anastrozole in a premenopausal breast cancer model.
Breast Neoplasms
Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model.
Breast Neoplasms
Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.
Breast Neoplasms
Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol?
Breast Neoplasms
Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting.
Breast Neoplasms
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Breast Neoplasms
Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
Breast Neoplasms
Circulating melatonin and the risk of breast and endometrial cancer in women.
Breast Neoplasms
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib.
Breast Neoplasms
Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients.
Breast Neoplasms
Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study.
Breast Neoplasms
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Breast Neoplasms
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
Breast Neoplasms
Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Breast Neoplasms
Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
Breast Neoplasms
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Breast Neoplasms
Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series.
Breast Neoplasms
Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle?
Breast Neoplasms
Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer.
Breast Neoplasms
Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study.
Breast Neoplasms
Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Breast Neoplasms
Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
Breast Neoplasms
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Breast Neoplasms
Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer.
Breast Neoplasms
Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer.
Breast Neoplasms
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Breast Neoplasms
Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
Breast Neoplasms
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Breast Neoplasms
Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.
Breast Neoplasms
Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Breast Neoplasms
Clinical significance of aromatase protein expression in axillary node negative breast cancer.
Breast Neoplasms
Clinical Significance of Female-hormones and Cytokines in Breast Cancer Patients Complicated with Aromatase Inhibitor-related Osteoarthropathy - Efficacy of Vitamin E.
Breast Neoplasms
Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer.
Breast Neoplasms
Clinical trials in cancer prevention: current results and perspectives for the future.
Breast Neoplasms
Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
Breast Neoplasms
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Breast Neoplasms
Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer.
Breast Neoplasms
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.
Breast Neoplasms
Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis.
Breast Neoplasms
Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer.
Breast Neoplasms
Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Breast Neoplasms
Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue.
Breast Neoplasms
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor treated ER-positive breast cancer.
Breast Neoplasms
Closing remarks to the conference, Aromatase: New Perspectives for Breast Cancer.
Breast Neoplasms
Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model.
Breast Neoplasms
Coadministrating luteolin minimizes the side effects of the aromatase inhibitor letrozole.
Breast Neoplasms
Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma.
Breast Neoplasms
Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors.
Breast Neoplasms
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Breast Neoplasms
Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.
Breast Neoplasms
Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality.
Breast Neoplasms
Collagen and prostaglandin E? regulate aromatase expression through the PI3K/AKT/IKK and the MAP kinase pathways in adipose stromal cells.
Breast Neoplasms
Collision tumor: invasive ductal carcinoma in association with mucosa-associated lymphoid tissue (MALT) lymphoma in the same breast.
Breast Neoplasms
Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.
Breast Neoplasms
Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
Breast Neoplasms
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Breast Neoplasms
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
Breast Neoplasms
Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
Breast Neoplasms
Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance.
Breast Neoplasms
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
Breast Neoplasms
Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
Breast Neoplasms
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
Breast Neoplasms
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Breast Neoplasms
Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
Breast Neoplasms
Combined use of vitamin D and omega-3 fatty acid in breast cancer patients might be more beneficial for reducing aromatase inhibitors-associated arthralgia.
Breast Neoplasms
Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review).
Breast Neoplasms
Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols.
Breast Neoplasms
Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.
Breast Neoplasms
Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Breast Neoplasms
CoMFA, LeapFrog and blind docking studies on sulfonanilide derivatives acting as selective aromatase expression regulators.
Breast Neoplasms
Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
Breast Neoplasms
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Breast Neoplasms
Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.
Breast Neoplasms
Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans.
Breast Neoplasms
Comparative economic analysis of aromatase inhibitors and tamoxifen in the treatment of hormone-dependent breast cancer.
Breast Neoplasms
Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Breast Neoplasms
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Breast Neoplasms
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Breast Neoplasms
Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes.
Breast Neoplasms
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Breast Neoplasms
Comparative studies of aromatase inhibitors in cultured human breast cancer cells.
Breast Neoplasms
Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis.
Breast Neoplasms
Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience.
Breast Neoplasms
Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer.
Breast Neoplasms
Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women.
Breast Neoplasms
Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment.
Breast Neoplasms
Comparison of biochemical aromatase activity with aromatase immunohistochemistry in human breast carcinomas.
Breast Neoplasms
Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.
Breast Neoplasms
Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues.
Breast Neoplasms
Comparison of in vitro and in vivo haemotoxic effects of aminoglutethimide and glutethimide.
Breast Neoplasms
Comparison of Increased Aromatase versus ER{alpha} in the Generation of Mammary Hyperplasia and Cancer.
Breast Neoplasms
Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy.
Breast Neoplasms
Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
Breast Neoplasms
Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a protocol for a systematic review and network meta-analysis.
Breast Neoplasms
Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line.
Breast Neoplasms
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Breast Neoplasms
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Breast Neoplasms
Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Breast Neoplasms
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Breast Neoplasms
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Breast Neoplasms
Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer.
Breast Neoplasms
Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study.
Breast Neoplasms
Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Breast Neoplasms
Comprehensive and Automated Linear Interaction Energy Based Binding-Affinity Prediction for Multifarious Cytochrome P450 Aromatase Inhibitors.
Breast Neoplasms
Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.
Breast Neoplasms
Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.
Breast Neoplasms
Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues.
Breast Neoplasms
Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer.
Breast Neoplasms
Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature.
Breast Neoplasms
Concomitant occurence of multiple autoantibodies against human cytochromes P450.
Breast Neoplasms
Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by these Genes.
Breast Neoplasms
Concurrent administration of aromatase inhibitors with chemotherapy might show better outcome in high risk hormone-receptor positive early-stage breast cancer patients.
Breast Neoplasms
Concurrent use of aromatase inhibitors and hypofractionated radiation therapy.
Breast Neoplasms
Conference on aromatase: new perspectives for breast cancer. Key Biscayne, Florida/Dec 6-9, 1981.
Breast Neoplasms
Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review.
Breast Neoplasms
Confounder factors masking a Leydig-cell ovarian tumor in a post-menopausal woman treated for androgen-positive receptor breast cancer.
Breast Neoplasms
Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk.
Breast Neoplasms
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
Breast Neoplasms
Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.
Breast Neoplasms
Contralateral prophylactic mastectomy for patients with unilateral breast cancer.
Breast Neoplasms
Contribution of aromatase to the deoxyribonucleic acid synthesis of MCF-7 human breast cancer cells and its suppression by aromatase inhibitors.
Breast Neoplasms
Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
Breast Neoplasms
Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry.
Breast Neoplasms
Control and expression of oestrone sulphatase activities in human breast cancer.
Breast Neoplasms
Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors.
Breast Neoplasms
Control of aromatase activity in breast tumours: the role of the immune system.
Breast Neoplasms
Control of aromatase in breast cancer cells and its importance for tumor growth.
Breast Neoplasms
Controlled ovarian hyperstimulation for fertility preservation in women with breast cancer: Practical issues.
Breast Neoplasms
Controversies of aromatase localization in human breast cancer--stromal versus parenchymal cells.
Breast Neoplasms
Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Breast Neoplasms
Correction to: Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Breast Neoplasms
Correction: Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.
Breast Neoplasms
Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial.
Breast Neoplasms
Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens.
Breast Neoplasms
Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide.
Breast Neoplasms
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Breast Neoplasms
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Breast Neoplasms
CORRIGENDUM to "Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study".
Breast Neoplasms
Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER? metastatic breast cancer.
Breast Neoplasms
Cost Effectiveness Analysis of Everolimus + Exemestane for Patients with Advanced Breast Cancer with Positive Estrogen Receptor (ER +), HER2-, Refractory to Non-Steroidal Aromatase Inhibitors (NSAIS) in Chile.
Breast Neoplasms
Cost Effectiveness of Fracture Prevention in Postmenopausal Women Who Receive Aromatase Inhibitors for Early Breast Cancer.
Breast Neoplasms
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
Breast Neoplasms
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Breast Neoplasms
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Breast Neoplasms
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Breast Neoplasms
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Breast Neoplasms
Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older.
Breast Neoplasms
Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma.
Breast Neoplasms
Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
Breast Neoplasms
Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
Breast Neoplasms
Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer.
Breast Neoplasms
Cost-effectiveness of letrozole in the treatment of advanced breast cancer.
Breast Neoplasms
Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer.
Breast Neoplasms
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Breast Neoplasms
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Breast Neoplasms
Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer.
Breast Neoplasms
Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.
Breast Neoplasms
Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
Breast Neoplasms
COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.
Breast Neoplasms
CpG dinucleotide methylation of the CYP19 I.3/II promoter modulates cAMP-stimulated aromatase activity.
Breast Neoplasms
Cross-resistance to different aromatase inhibitors in breast cancer treatment.
Breast Neoplasms
Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
Breast Neoplasms
Crown-Like Structures in Breast Adipose Tissue: Early Evidence and Current Issues in Breast Cancer.
Breast Neoplasms
Crystal engineering of exemestane to obtain a co-crystal with enhanced urease inhibition activity.
Breast Neoplasms
Crystallographic and molecular modeling studies on 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione and its butyl analogue, inhibitors of mammalian aromatase. Comparison with natural substrates: prediction of enantioselectivity for N-alkyl derivatives.
Breast Neoplasms
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Breast Neoplasms
Current comprehensive assessment and management of women at increased risk for breast cancer.
Breast Neoplasms
Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Breast Neoplasms
Current controversies in extended adjuvant endocrine therapy for early breast cancer.
Breast Neoplasms
Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players.
Breast Neoplasms
Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancer.
Breast Neoplasms
Current Opinion of Aromatase Inhibitor-induced Arthralgia in Breast Cancer in the UK.
Breast Neoplasms
Current role and safety profile of aromatase inhibitors in early breast cancer.
Breast Neoplasms
Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
Breast Neoplasms
Current Status of Aromatase Inhibitors in the Management of Breast Cancer and Critique of the NCIC MA-17 Trial.
Breast Neoplasms
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
Breast Neoplasms
Current status of hormonal treatments for metastatic breast cancer in postmenopausal women.
Breast Neoplasms
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Breast Neoplasms
Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer.
Breast Neoplasms
Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.
Breast Neoplasms
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: A case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Breast Neoplasms
Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment.
Breast Neoplasms
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Breast Neoplasms
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Breast Neoplasms
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Breast Neoplasms
Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.
Breast Neoplasms
Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.
Breast Neoplasms
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.
Breast Neoplasms
Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.
Breast Neoplasms
Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer.
Breast Neoplasms
CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.
Breast Neoplasms
CYP19A1 gene expression in the peripheral blood of Brazilian women with breast cancer relapse.
Breast Neoplasms
CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.
Breast Neoplasms
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Breast Neoplasms
CYP19A1 rs10046 pharmacogenetics in postmenopausal breast cancer patients treated with aromatase inhibitors: One-year follow-up.
Breast Neoplasms
CYP1A2 - a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
Breast Neoplasms
CYR61 contributes to poor response to letrozole in ER positive breast carcinoma.
Breast Neoplasms
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
Breast Neoplasms
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
Breast Neoplasms
Data of aromatase inhibitors alone and in combination with raloxifene on microarchitecture of lumbar vertebrae and strength test in femoral diaphysis of VCD treated ovotoxic mice.
Breast Neoplasms
David Kupfer and the metabolism connection: on aromatase inhibitors and tamoxifen.
Breast Neoplasms
DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation.
Breast Neoplasms
Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide.
Breast Neoplasms
Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.
Breast Neoplasms
Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients.
Breast Neoplasms
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Breast Neoplasms
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Breast Neoplasms
Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment.
Breast Neoplasms
Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
Breast Neoplasms
Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts.
Breast Neoplasms
Denosumab in breast cancer patients receiving aromatase inhibitors: A single-center observational study of effectiveness in adjuvant setting.
Breast Neoplasms
Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.
Breast Neoplasms
Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study.
Breast Neoplasms
Depot GnRH-agonist trigger for breast-cancer patient undergoing ovarian stimulation resulted in mature oocytes for cryopreservation: a case report.
Breast Neoplasms
Depsidones inhibit aromatase activity and tumor cell proliferation in a co-culture of human primary breast adipose fibroblasts and T47D breast tumor cells.
Breast Neoplasms
Des-acyl ghrelin inhibits the capacity of macrophages to stimulate the expression of aromatase in breast adipose stromal cells.
Breast Neoplasms
Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer.
Breast Neoplasms
Design and Synthesis of Norendoxifen Analogues with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities.
Breast Neoplasms
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Breast Neoplasms
Design, Synthesis, and Biological Evaluation of 2-(2-Bromo-3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole Derivatives as Possible Anti-Breast Cancer Agents.
Breast Neoplasms
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
Breast Neoplasms
Design, Synthesis, and Biological Evaluation of New Azole Derivatives as Potent Aromatase Inhibitors with Potential Effects against Breast Cancer.
Breast Neoplasms
Design, synthesis, antioxidant, and anti-breast cancer activities of novel diethyl(alkyl/aryl/heteroarylamino)(4-(pyridin-2-yl)phenyl)methylphosphonates.
Breast Neoplasms
Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs.
Breast Neoplasms
Design, synthesis, in vitro and in silico studies of some novel thiazole-dihydrofuran derivatives as aromatase inhibitors.
Breast Neoplasms
Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction.
Breast Neoplasms
Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation.
Breast Neoplasms
Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
Breast Neoplasms
Determination of 4-hydroxyandrostenedione in plasma and urine by extractive alkylation and electron-capture gas chromatography.
Breast Neoplasms
Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
Breast Neoplasms
Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma.
Breast Neoplasms
Development and validation of stability indicating method for the determination of exemestane by reverse phase high performance liquid chromatography.
Breast Neoplasms
Development and validation of the Penn Arthralgia Aging Scale among breast cancer survivors.
Breast Neoplasms
Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives.
Breast Neoplasms
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.
Breast Neoplasms
Development of a validated HPTLC-bioautographic method for evaluation of aromatase inhibitory activity of plant extracts and their constituents.
Breast Neoplasms
Diagnostics and Therapy for Malignant (Degenerate) Colon Endometriosis - Three Case Reports.
Breast Neoplasms
Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data.
Breast Neoplasms
Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overexpressing aromatase.
Breast Neoplasms
Dietary flavones and flavonones display differential effects on aromatase (CYP19) transcription in the breast cancer cells MCF-7.
Breast Neoplasms
Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Breast Neoplasms
Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.
Breast Neoplasms
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole - of clinical importance?
Breast Neoplasms
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Breast Neoplasms
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Breast Neoplasms
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Breast Neoplasms
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Breast Neoplasms
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Breast Neoplasms
Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
Breast Neoplasms
Differential profile of letrozole and exemestane on bone turnover markers in vinylcyclohexene diepoxide treated ovotoxic female mice.
Breast Neoplasms
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer.
Breast Neoplasms
Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.
Breast Neoplasms
Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months.
Breast Neoplasms
Discovery of a multi-target compound for estrogen receptor-positive (ER+) breast cancer: Involvement of aromatase and ERs.
Breast Neoplasms
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Breast Neoplasms
Discovery of novel aromatase inhibitors using a homogeneous time-resolved fluorescence assay.
Breast Neoplasms
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Breast Neoplasms
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
Breast Neoplasms
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Breast Neoplasms
Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors.
Breast Neoplasms
Does a higher ratio of serum calcium to magnesium increase the risk for postmenopausal breast cancer?
Breast Neoplasms
Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
Breast Neoplasms
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Breast Neoplasms
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Breast Neoplasms
Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.
Breast Neoplasms
Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Breast Neoplasms
Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
Breast Neoplasms
Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Breast Neoplasms
Down-regulation of promoter 1.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, snail (SnaH).
Breast Neoplasms
Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib.
Breast Neoplasms
Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.
Breast Neoplasms
Drug update: letrozole: A new aromatase inhibitor for metastatic breast cancer.
Breast Neoplasms
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.
Breast Neoplasms
Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
Breast Neoplasms
Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.
Breast Neoplasms
Dual Aromatase-Sulphatase Inhibitors (DASIs) for the Treatment of Hormone Dependent Breast Cancer.
Breast Neoplasms
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Breast Neoplasms
Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Breast Neoplasms
Duration of aromatase inhibitor treatment in breast cancer: the role of the 'carryover effect'.
Breast Neoplasms
DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells.
Breast Neoplasms
Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Breast Neoplasms
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Breast Neoplasms
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.
Breast Neoplasms
Early breast cancer in the elderly: assessment and management considerations.
Breast Neoplasms
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Breast Neoplasms
Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective study.
Breast Neoplasms
Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors.
Breast Neoplasms
Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy.
Breast Neoplasms
Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings.
Breast Neoplasms
Early stage breast cancer treatment and prognostic factors: Post San Antonio Breast Cancer Symposium 2016.
Breast Neoplasms
Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.
Breast Neoplasms
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore.
Breast Neoplasms
Economic evaluation of aromatase inhibitors for the treatment of breast cancer.
Breast Neoplasms
Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom.
Breast Neoplasms
Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden.
Breast Neoplasms
Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting.
Breast Neoplasms
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Breast Neoplasms
Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Breast Neoplasms
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Breast Neoplasms
Effect of a switch of aromatase inhibitors to another aromatase inhibitor or tamoxifen on musculoskeletal symptoms in breast cancer; Which is the best?
Breast Neoplasms
Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer: A meta-analysis of randomized controlled trials.
Breast Neoplasms
Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.
Breast Neoplasms
Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients.
Breast Neoplasms
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Breast Neoplasms
Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Breast Neoplasms
Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture.
Breast Neoplasms
Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Breast Neoplasms
Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor-Positive Breast Cancer and Their Relationship with Antiproliferative Response.
Breast Neoplasms
Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
Breast Neoplasms
Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
Breast Neoplasms
Effect of Aromatase Inhibitor Therapy on the Cardiovascular Health of Black and White Breast Cancer Patients.
Breast Neoplasms
Effect of Aromatase Inhibitors on Background Parenchymal Enhancement and Amount of Fibroglandular Tissue at Breast MR Imaging.
Breast Neoplasms
Effect of aromatase inhibitors on bone mineral density in Japanese breast cancer population.
Breast Neoplasms
Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Breast Neoplasms
Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma.
Breast Neoplasms
Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Breast Neoplasms
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Breast Neoplasms
Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
Breast Neoplasms
Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat.
Breast Neoplasms
Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism-A systematic review.
Breast Neoplasms
Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Breast Neoplasms
Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.
Breast Neoplasms
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
Breast Neoplasms
Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study.
Breast Neoplasms
Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Breast Neoplasms
Effect of endocrine therapy on quality of life and cognitive functions in patients with breast cancer.
Breast Neoplasms
Effect of Estrogen Depletion on Pain Sensitivity in Aromatase Inhibitor-Treated Women With Early-Stage Breast Cancer.
Breast Neoplasms
Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
Breast Neoplasms
Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Breast Neoplasms
Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.
Breast Neoplasms
Effect of Hispolon from Phellinus lonicerinus (Agaricomycetes) on Estrogen Receptors, Aromatase, and Cyclooxygenase II in MCF-7 Breast Cancer Cells.
Breast Neoplasms
Effect of Hop (Humulus lupulus L.) Flavonoids on Aromatase (Estrogen Synthase) Activity.
Breast Neoplasms
Effect of Letrozole on Plasma Lipids, Triglycerides, and Estradiol in Postmenopausal Women with Metastatic Breast Cancer.
Breast Neoplasms
Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.
Breast Neoplasms
Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer.
Breast Neoplasms
Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial.
Breast Neoplasms
Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review.
Breast Neoplasms
Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1? and Relation to Clinical Response.
Breast Neoplasms
Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.
Breast Neoplasms
Effect of sildenafil on human aromatase activity: From in vitro structural analysis to catalysis and inhibition in cells.
Breast Neoplasms
Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer.
Breast Neoplasms
Effect of Tart Cherry on Aromatase Inhibitor-Induced Arthralgia (AIA) in Nonmetastatic Hormone-Positive Breast Cancer Patients: A Randomized Double-Blind Placebo-Controlled Trial.
Breast Neoplasms
Effect of the aromatase inhibitor, MEN 11066, on growth of two different MCF-7 sublines.
Breast Neoplasms
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
Breast Neoplasms
Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells.
Breast Neoplasms
Effect of Traditional Chinese Medicine on Musculoskeletal Symptoms in Breast Cancer: A Systematic Review and Meta-Analysis.
Breast Neoplasms
Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
Breast Neoplasms
Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors.
Breast Neoplasms
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Breast Neoplasms
Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: Comparative SAR/QSAR assessment on steroidal aromatase inhibitors.
Breast Neoplasms
Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
Breast Neoplasms
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Breast Neoplasms
Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.
Breast Neoplasms
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Breast Neoplasms
Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.
Breast Neoplasms
Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation.
Breast Neoplasms
Effectiveness, safety, and economic evaluation of adjuvant moxibustion therapy for aromatase inhibitor-induced arthralgia of postmenopausal breast cancer stage I to III patients: Study protocol for a prospective, randomized, assessor-blind, usual-care controlled, parallel-group, pilot clinical trial.
Breast Neoplasms
Effects of 3-[N-(2-chlorobenzyl)amino]-6-(1H-imidazol-1-yl) pyridazine dihydrochloride on various aromatase enzyme systems and experimental breast cancer.
Breast Neoplasms
Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro.
Breast Neoplasms
Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer.
Breast Neoplasms
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Breast Neoplasms
Effects of anastrozole on Ki-67 antigen expression in the vaginal epithelium of female rats in persistent estrus.
Breast Neoplasms
Effects of anastrozole on lipid metabolism compared with tamoxifen in rats.
Breast Neoplasms
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
Breast Neoplasms
Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer.
Breast Neoplasms
Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
Breast Neoplasms
Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer.
Breast Neoplasms
Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane.
Breast Neoplasms
Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
Breast Neoplasms
Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.
Breast Neoplasms
Effects of conditioned medium from different cultured cell types on aromatase expression in adipose stromal cells.
Breast Neoplasms
Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
Breast Neoplasms
Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines.
Breast Neoplasms
Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma - an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy.
Breast Neoplasms
Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms.
Breast Neoplasms
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Breast Neoplasms
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
Breast Neoplasms
Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy.
Breast Neoplasms
Effects of exercise on physical outcomes of breast cancer survivors receiving hormone therapy - A systematic review and meta-analysis.
Breast Neoplasms
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Breast Neoplasms
Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells.
Breast Neoplasms
Effects of Neonicotinoid Pesticides on Promoter-Specific Aromatase (CYP19) Expression in Hs578t Breast Cancer Cells and the Role of the VEGF Pathway.
Breast Neoplasms
Effects of Neonicotinoids on Promoter-Specific Expression and Activity of Aromatase (CYP19) in Human Adrenocortical Carcinoma (H295R) and Primary Umbilical Vein Endothelial (HUVEC) Cells.
Breast Neoplasms
Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
Breast Neoplasms
Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Breast Neoplasms
Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells.
Breast Neoplasms
Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression.
Breast Neoplasms
Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice.
Breast Neoplasms
Effects of resistance plus aerobic training on body composition and metabolic markers in older breast cancer survivors undergoing aromatase inhibitor therapy.
Breast Neoplasms
Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.
Breast Neoplasms
Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: Aromatase inhibition and autophagy.
Breast Neoplasms
Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
Breast Neoplasms
Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action.
Breast Neoplasms
Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Breast Neoplasms
Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione in MCF-7 human mammary carcinoma cell culture.
Breast Neoplasms
Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
Breast Neoplasms
Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.
Breast Neoplasms
Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial.
Breast Neoplasms
Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer.
Breast Neoplasms
Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.
Breast Neoplasms
Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Breast Neoplasms
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Breast Neoplasms
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Breast Neoplasms
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Breast Neoplasms
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
Breast Neoplasms
Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
Breast Neoplasms
Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.
Breast Neoplasms
Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Breast Neoplasms
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil(®)) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
Breast Neoplasms
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Breast Neoplasms
Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Breast Neoplasms
Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.
Breast Neoplasms
Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review.
Breast Neoplasms
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Breast Neoplasms
Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients.
Breast Neoplasms
Efficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors.
Breast Neoplasms
Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis.
Breast Neoplasms
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
Breast Neoplasms
Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Breast Neoplasms
Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
Breast Neoplasms
Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review.
Breast Neoplasms
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Breast Neoplasms
Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Breast Neoplasms
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Breast Neoplasms
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
Breast Neoplasms
Egonol gentiobioside and egonol gentiotrioside from Styrax perkinsiae promote the biosynthesis of estrogen by aromatase.
Breast Neoplasms
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Breast Neoplasms
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Breast Neoplasms
Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.
Breast Neoplasms
Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Breast Neoplasms
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
Breast Neoplasms
Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapy.
Breast Neoplasms
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.
Breast Neoplasms
Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.
Breast Neoplasms
Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Breast Neoplasms
Emerging treatment combinations: integrating therapy into clinical practice.
Breast Neoplasms
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Breast Neoplasms
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Breast Neoplasms
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.
Breast Neoplasms
Endocrine disorders associated with inappropriately high aromatase expression.
Breast Neoplasms
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Breast Neoplasms
Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Breast Neoplasms
Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Breast Neoplasms
Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy.
Breast Neoplasms
Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies.
Breast Neoplasms
Endocrine therapy and other targeted therapies for metastatic breast cancer.
Breast Neoplasms
Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations.
Breast Neoplasms
Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement.
Breast Neoplasms
Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Breast Neoplasms
Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size.
Breast Neoplasms
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Breast Neoplasms
Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
Breast Neoplasms
Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.
Breast Neoplasms
Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
Breast Neoplasms
Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
Breast Neoplasms
Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors.
Breast Neoplasms
Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.
Breast Neoplasms
Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
Breast Neoplasms
Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Breast Neoplasms
Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors.
Breast Neoplasms
Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings.
Breast Neoplasms
Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients.
Breast Neoplasms
Endoplasmic reticulum stress and oncomir-associated chemotherapeutic drug resistance mechanisms in breast cancer tumors.
Breast Neoplasms
Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer.
Breast Neoplasms
Enhanced bioavailability of exemestane via proliposomes based transdermal delivery.
Breast Neoplasms
Enhanced expression of aromatase in p53-inactivated mammary epithelial cells.
Breast Neoplasms
Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer.
Breast Neoplasms
Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature.
Breast Neoplasms
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Breast Neoplasms
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Breast Neoplasms
Enhancing the adjuvant treatment of hormone receptor positive breast cancer.
Breast Neoplasms
Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Breast Neoplasms
EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange.
Breast Neoplasms
Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
Breast Neoplasms
Epitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activity.
Breast Neoplasms
ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.
Breast Neoplasms
ER?-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Breast Neoplasms
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Breast Neoplasms
ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.
Breast Neoplasms
Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Breast Neoplasms
Erratum to: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Breast Neoplasms
Erratum to: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
Breast Neoplasms
Erratum to: The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer.
Breast Neoplasms
Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.
Breast Neoplasms
Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.
Breast Neoplasms
Erythrocyte alpha-tocopherol in breast cancer patients treated with letrozol.
Breast Neoplasms
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Breast Neoplasms
ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer.
Breast Neoplasms
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.
Breast Neoplasms
ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
Breast Neoplasms
Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS.
Breast Neoplasms
Estradiol formation from testosterone by continuously cultured human breast cancer cells.
Breast Neoplasms
Estradiol suppresses phosphorylation of ER? serine 167 through upregulation of PP2A in breast cancer cells.
Breast Neoplasms
Estrogen biosynthesis in breast adipose tissue during menstrual cycle in women with and without breast cancer.
Breast Neoplasms
Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy.
Breast Neoplasms
Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?
Breast Neoplasms
Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review.
Breast Neoplasms
Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.
Breast Neoplasms
Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer.
Breast Neoplasms
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.
Breast Neoplasms
Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.
Breast Neoplasms
Estrogen Receptor-? Activation in Combination with Letrozole Blocks the Growth of Breast Cancer Tumors Resistant to Letrozole Therapy.
Breast Neoplasms
Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis.
Breast Neoplasms
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
Breast Neoplasms
Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Breast Neoplasms
Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
Breast Neoplasms
Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
Breast Neoplasms
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Breast Neoplasms
Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells.
Breast Neoplasms
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.
Breast Neoplasms
Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
Breast Neoplasms
Estrogen-related genes and their contribution to racial differences in breast cancer risk.
Breast Neoplasms
Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.
Breast Neoplasms
Estrogens and PTP1B Function in a Novel Pathway to Regulate Aromatase Enzymatic Activity in Breast Cancer Cells.
Breast Neoplasms
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Breast Neoplasms
Ethanol stimulates proliferation, ERalpha and aromatase expression in MCF-7 human breast cancer cells.
Breast Neoplasms
Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.
Breast Neoplasms
Etiology, assessment, and management of aromatase inhibitor-related musculoskeletal symptoms.
Breast Neoplasms
Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
Breast Neoplasms
Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.
Breast Neoplasms
Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion.
Breast Neoplasms
Evaluation of 6,7-aziridinyl steroids and related compounds as inhibitors of aromatase (P-450arom).
Breast Neoplasms
Evaluation of Active Hexose Correlated Compound (AHCC) in Combination With Anticancer Hormones in Orthotopic Breast Cancer Models.
Breast Neoplasms
Evaluation of aromatase inhibitor on radiation induced pulmonary fibrosis via TGF- ?/Smad 3 and TGF- ?/PDGF pathways in rats.
Breast Neoplasms
Evaluation of Changes in Tumor Shadows and Microcalcifications on Mammography Following KORTUC II, a New Radiosensitization Treatment without any Surgical Procedure for Elderly Patients with Stage I and II Breast Cancer.
Breast Neoplasms
Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
Breast Neoplasms
Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer.
Breast Neoplasms
Evaluation of fulvestrant in clinical practice: use of an electronic data registry.
Breast Neoplasms
Evaluation of Local CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in Postmenopausal Invasive Ductal Breast Cancer Cases.
Breast Neoplasms
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
Breast Neoplasms
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Breast Neoplasms
Evaluation of periodontal health in breast cancer patients undergoing tamoxifen or aromatase inhibitors drugs therapy: A cross-sectional study.
Breast Neoplasms
Evaluation of synthesized coumarin derivatives on aromatase inhibitory activity.
Breast Neoplasms
Evaluation of Synthesized Ester or Amide Coumarin Derivatives on Aromatase Inhibitory Activity.
Breast Neoplasms
Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.
Breast Neoplasms
Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
Breast Neoplasms
Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis.
Breast Neoplasms
Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Breast Neoplasms
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Breast Neoplasms
Everolimus plus exemestane as first-line therapy in HR?, HER2? advanced breast cancer in BOLERO-2.
Breast Neoplasms
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2.
Breast Neoplasms
Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.
Breast Neoplasms
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Breast Neoplasms
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Breast Neoplasms
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Breast Neoplasms
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.
Breast Neoplasms
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Breast Neoplasms
Everolimus-associated Acute Kidney Injury in Patients with Metastatic Breast Cancer.
Breast Neoplasms
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
Breast Neoplasms
Everolimus: side effect profile and management of toxicities in breast cancer.
Breast Neoplasms
Evidence for Enhanced Exosome Production in Aromatase Inhibitor-Resistant Breast Cancer Cells.
Breast Neoplasms
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Breast Neoplasms
Examination of the use of Exemestane in patients with metastatic breast cancer.
Breast Neoplasms
Examining factors associated with adherence to hormonal therapy in breast cancer patients.
Breast Neoplasms
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Breast Neoplasms
Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer.
Breast Neoplasms
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
Breast Neoplasms
Exemestane and aromatase inhibitors in the management of advanced breast cancer.
Breast Neoplasms
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety.
Breast Neoplasms
Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.
Breast Neoplasms
Exemestane as First-Line Therapy in Postmenopausal Women With Recurrent or Metastatic Breast Cancer.
Breast Neoplasms
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Breast Neoplasms
Exemestane Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells and Promoting the Secretion of Interleukin 10.
Breast Neoplasms
Exemestane for primary prevention of breast cancer in postmenopausal women.
Breast Neoplasms
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
Breast Neoplasms
Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure.
Breast Neoplasms
Exemestane in postmenopausal women with early or advanced breast cancer: a review.
Breast Neoplasms
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Breast Neoplasms
Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane.
Breast Neoplasms
Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
Breast Neoplasms
Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti-aromatase activity assay examining exemestane and its derivatives.
Breast Neoplasms
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial.
Breast Neoplasms
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen.
Breast Neoplasms
Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option.
Breast Neoplasms
Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
Breast Neoplasms
Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Breast Neoplasms
Exemestane: a review of its use in postmenopausal women with breast cancer.
Breast Neoplasms
Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
Breast Neoplasms
Exemestane: One part of the chemopreventive spectrum for ER-positive breast cancer.
Breast Neoplasms
Exemestane: treatment of breast cancer with selective inactivation of aromatase.
Breast Neoplasms
Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study.
Breast Neoplasms
Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study.
Breast Neoplasms
Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Breast Neoplasms
Exercise Therapies for Preventing or Treating Aromatase Inhibitor-Induced Musculoskeletal Symptoms in Early Breast Cancer.
Breast Neoplasms
Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk?
Breast Neoplasms
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Breast Neoplasms
Experience with aromatase inhibitors in the treatment of advanced breast cancer.
Breast Neoplasms
Experience with exemestane in the treatment of early and advanced breast cancer.
Breast Neoplasms
Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies.
Breast Neoplasms
Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.
Breast Neoplasms
Exploring benzcyclo derivatives as potent aromatase inhibitors using ligand-based modeling studies.
Breast Neoplasms
Exploring breast cancer therapies. Comparing aromatase inhibitors to current therapies.
Breast Neoplasms
Exploring new chemical functionalities to improve aromatase inhibition of steroids.
Breast Neoplasms
Expression and purification of a recombinant form of human aromatase from Escherichia coli.
Breast Neoplasms
Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients.
Breast Neoplasms
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Breast Neoplasms
Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer An immunocytochemical study.
Breast Neoplasms
Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
Breast Neoplasms
Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers.
Breast Neoplasms
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Breast Neoplasms
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.
Breast Neoplasms
Expression of estrogen receptors-beta and aromatase activity in primary mammary gland tumors.
Breast Neoplasms
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Breast Neoplasms
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression.
Breast Neoplasms
Expression of the forkhead transcription factor FOXL2 correlates with good prognosis in breast cancer patients treated with tamoxifen.
Breast Neoplasms
Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
Breast Neoplasms
Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis.
Breast Neoplasms
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Breast Neoplasms
Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.
Breast Neoplasms
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.
Breast Neoplasms
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Breast Neoplasms
Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials.
Breast Neoplasms
Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Breast Neoplasms
Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials.
Breast Neoplasms
Extending aromatase inhibitor sensitivity in hormone resistant breast cancer.
Breast Neoplasms
Extra five years of aromatase inhibitors increases disease-free survival in breast cancer.
Breast Neoplasms
Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells.
Breast Neoplasms
Facile synthesis of chrysin-derivatives with promising activities as aromatase inhibitors.
Breast Neoplasms
Factors Associated with Calcium Absorption in Postmenopausal Women: A Post Hoc Analysis of Dual-Isotope Studies.
Breast Neoplasms
Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial.
Breast Neoplasms
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
Breast Neoplasms
Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer.
Breast Neoplasms
Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease.
Breast Neoplasms
Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells.
Breast Neoplasms
Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors.
Breast Neoplasms
FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer.
Breast Neoplasms
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Breast Neoplasms
Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.
Breast Neoplasms
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.
Breast Neoplasms
Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors.
Breast Neoplasms
Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer.
Breast Neoplasms
Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.
Breast Neoplasms
Final 5-year results of Z-FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole.
Breast Neoplasms
First clinical experience with CDK4/6 inhibitors in breast cancer therapy.
Breast Neoplasms
First generation aromatase inhibitors--aminoglutethimide and testololactone.
Breast Neoplasms
First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
Breast Neoplasms
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.
Breast Neoplasms
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.
Breast Neoplasms
First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta.
Breast Neoplasms
Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report.
Breast Neoplasms
Flavonoids as prospective aromatase inhibitors in breast cancer prevention/therapy.
Breast Neoplasms
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Breast Neoplasms
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
Breast Neoplasms
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Breast Neoplasms
Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Breast Neoplasms
Formestane: an effective first-line endocrine treatment for advanced breast cancer.
Breast Neoplasms
Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Breast Neoplasms
Formulation and biopharmaceutical evaluation of a transdermal patch containing letrozole.
Breast Neoplasms
Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application.
Breast Neoplasms
Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells.
Breast Neoplasms
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Breast Neoplasms
FPSE-HPLC-DAD method for the quantification of anticancer drugs in human whole blood, plasma, and urine.
Breast Neoplasms
Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.
Breast Neoplasms
Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Breast Neoplasms
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Breast Neoplasms
Fractures due to Aromatase Inhibitor Therapy for Breast Cancer: A Real-World Analysis of FAERS Data in the Past 15 Years.
Breast Neoplasms
Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.
Breast Neoplasms
French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies.
Breast Neoplasms
From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures.
Breast Neoplasms
From nonsteroidal aromatase inhibitors to multifunctional drug candidates: classic and innovative strategies for the treatment of breast cancer.
Breast Neoplasms
From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target.
Breast Neoplasms
From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors.
Breast Neoplasms
Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.
Breast Neoplasms
Fulvestrant ('Faslodex'): Current and future role in breast cancer management.
Breast Neoplasms
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Breast Neoplasms
Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer.
Breast Neoplasms
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Breast Neoplasms
Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Breast Neoplasms
Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.
Breast Neoplasms
Fulvestrant in advanced breast cancer: evidence to date and place in therapy.
Breast Neoplasms
Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Breast Neoplasms
Fulvestrant in management of hormone receptor-positive metastatic breast cancer.
Breast Neoplasms
Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials.
Breast Neoplasms
Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Breast Neoplasms
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: north central cancer treatment group trial n0032.
Breast Neoplasms
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Breast Neoplasms
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Breast Neoplasms
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Breast Neoplasms
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.
Breast Neoplasms
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Breast Neoplasms
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Breast Neoplasms
Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
Breast Neoplasms
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Breast Neoplasms
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Breast Neoplasms
Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.
Breast Neoplasms
Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
Breast Neoplasms
Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
Breast Neoplasms
Functional activation of the estrogen receptor-? and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Breast Neoplasms
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Breast Neoplasms
Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer.
Breast Neoplasms
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer.
Breast Neoplasms
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Breast Neoplasms
GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Breast Neoplasms
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Breast Neoplasms
Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Breast Neoplasms
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Breast Neoplasms
Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients.
Breast Neoplasms
Gene regulation studies of aromatase expression in breast cancer and adipose stromal cells.
Breast Neoplasms
Generic entry of aromatase inhibitors and pharmaceutical access: Initiation of hormonal therapy, timeliness of initiation, and drug choice.
Breast Neoplasms
Genesis and Outcome of a Breast Cancer Trial to Develop the Aromatase Inhibitor, Anastrozole.
Breast Neoplasms
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Breast Neoplasms
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Breast Neoplasms
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Breast Neoplasms
Genetic modeling of estrogen metabolism as a risk factor of hormone-dependent disorders.
Breast Neoplasms
Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders.
Breast Neoplasms
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
Breast Neoplasms
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
Breast Neoplasms
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
Breast Neoplasms
Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India.
Breast Neoplasms
Genetic Predictors of Response to Acupuncture for Aromatase Inhibitor-Associated Arthralgia Among Breast Cancer Survivors.
Breast Neoplasms
Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis.
Breast Neoplasms
Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Breast Neoplasms
Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
Breast Neoplasms
Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.
Breast Neoplasms
Genetic variation in the androgen estrogen conversion pathway in relation to breast cancer prognosticators.
Breast Neoplasms
Genetics of androgen metabolism in women with infertility and hypoandrogenism.
Breast Neoplasms
Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model.
Breast Neoplasms
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.
Breast Neoplasms
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Breast Neoplasms
Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors.
Breast Neoplasms
Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment.
Breast Neoplasms
Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.
Breast Neoplasms
Genomic Profiling of the Steroidogenic Acute Regulatory Protein in Breast Cancer: In Silico Assessments and a Mechanistic Perspective.
Breast Neoplasms
Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.
Breast Neoplasms
Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.
Breast Neoplasms
Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.
Breast Neoplasms
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Breast Neoplasms
Ginkgo biloba extract EGb 761-mediated inhibition of aromatase for the treatment of hormone-dependent breast cancer.
Breast Neoplasms
Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.
Breast Neoplasms
GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation.
Breast Neoplasms
Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer.
Breast Neoplasms
Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.
Breast Neoplasms
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Breast Neoplasms
GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients.
Breast Neoplasms
Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression.
Breast Neoplasms
Grip Strength in Women Being Treated for Breast Cancer and Receiving Adjuvant Endocrine Therapy: Systematic Review.
Breast Neoplasms
Grover disease (transient acantholytic dermatosis) induced by anastrozole.
Breast Neoplasms
Growth factor signaling enhances aromatase activity of breast cancer cells via post-transcriptional mechanisms.
Breast Neoplasms
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
Breast Neoplasms
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Breast Neoplasms
Growth inhibitory efficacy and anti-aromatase activity of Tabebuia avellanedae in a model for post-menopausal Luminal A breast cancer.
Breast Neoplasms
Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening.
Breast Neoplasms
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Breast Neoplasms
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Breast Neoplasms
Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer: a consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians.
Breast Neoplasms
Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor.
Breast Neoplasms
Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations.
Breast Neoplasms
Hair analysis to discriminate voluntary doping vs inadvertent ingestion of the aromatase inhibitor letrozole.
Breast Neoplasms
Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.
Breast Neoplasms
Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer.
Breast Neoplasms
Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.
Breast Neoplasms
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Breast Neoplasms
Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer.
Breast Neoplasms
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Breast Neoplasms
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Breast Neoplasms
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Breast Neoplasms
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Breast Neoplasms
Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance.
Breast Neoplasms
Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
Breast Neoplasms
HER2 and hormone receptor-positive breast cancer-blocking the right target.
Breast Neoplasms
HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
Breast Neoplasms
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Breast Neoplasms
HIF-1? stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma.
Breast Neoplasms
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
Breast Neoplasms
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
Breast Neoplasms
High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
Breast Neoplasms
High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
Breast Neoplasms
High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
Breast Neoplasms
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Breast Neoplasms
High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
Breast Neoplasms
High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy.
Breast Neoplasms
High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients.
Breast Neoplasms
High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols.
Breast Neoplasms
High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study.
Breast Neoplasms
High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors.
Breast Neoplasms
High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase II study.
Breast Neoplasms
Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors.
Breast Neoplasms
Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer.
Breast Neoplasms
Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
Breast Neoplasms
Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template.
Breast Neoplasms
Histoculture drug response assay, a possible examination system for predicting the antitumor effect of aromatase inhibitors in patients with breast cancer.
Breast Neoplasms
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Breast Neoplasms
Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
Breast Neoplasms
History of Aromatase: Saga of an Important Biologic Mediator and Therapeutic Target.
Breast Neoplasms
History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response.
Breast Neoplasms
Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.
Breast Neoplasms
Hormonal enzymatic systems in normal and cancerous human breast: control, prognostic factors, and clinical applications.
Breast Neoplasms
Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
Breast Neoplasms
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Breast Neoplasms
Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women.
Breast Neoplasms
Hormonal therapy for primary breast cancer: scientific rationale and status of clinical research.
Breast Neoplasms
Hormone Receptor-Positive Breast Cancer Choroidal Infiltrates before and after Systemic Aromatase Inhibitor Therapy.
Breast Neoplasms
Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
Breast Neoplasms
Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance.
Breast Neoplasms
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
Breast Neoplasms
How we maintain bone health in early-stage breast cancer patients on aromatase inhibitors.
Breast Neoplasms
Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications.
Breast Neoplasms
Human trophoblast xenografts in athymic mice: a model for peripheral aromatization.
Breast Neoplasms
Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice.
Breast Neoplasms
Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity.
Breast Neoplasms
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Breast Neoplasms
Hydrophilic interaction liquid chromatography-tandem mass spectrometry determination of estrogen conjugates in human urine.
Breast Neoplasms
Hypovitaminosis D is a Predictor of Aromatase Inhibitor Musculoskeletal Symptoms.
Breast Neoplasms
Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Study.
Breast Neoplasms
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Breast Neoplasms
Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene.
Breast Neoplasms
Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane.
Breast Neoplasms
Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells.
Breast Neoplasms
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.
Breast Neoplasms
Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology.
Breast Neoplasms
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
Breast Neoplasms
Identification of Novel Scaffolds with Dual Role as Antiepileptic and Anti-Breast Cancer.
Breast Neoplasms
Identification of PARP-1, Histone H1 and SIRT-1 as New Regulators of Breast Cancer-Related Aromatase Promoter I.3/II.
Breast Neoplasms
Identification of the aromatase in the breast carcinoma cell lines T47D and MCF-7.
Breast Neoplasms
Identification of the aromatase inhibitor aminoglutethimide in urine by gas chromatography/mass spectrometry.
Breast Neoplasms
Identification of the aromatase inhibitor letrozole in urine by gas chromatography/mass spectrometry.
Breast Neoplasms
Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
Breast Neoplasms
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
Breast Neoplasms
Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen.
Breast Neoplasms
Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.
Breast Neoplasms
Identifying menopause in breast cancer patients: considerations and implications.
Breast Neoplasms
Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
Breast Neoplasms
IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
Breast Neoplasms
IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells.
Breast Neoplasms
IL-10 suppresses TNF-?-induced expression of human aromatase gene in mammary adipose tissue.
Breast Neoplasms
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Breast Neoplasms
Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.
Breast Neoplasms
Immunochemical specificity of placental NADPH cytochrome c (P-450) reductase in neoplastic and non-neoplastic human tissue.
Breast Neoplasms
Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer.
Breast Neoplasms
Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues.
Breast Neoplasms
Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.
Breast Neoplasms
Immunohistochemical study of KiSS1 and KiSS1R expression in human primary breast cancer: Association with breast cancer receptor status, proliferation markers and clinicopathological features.
Breast Neoplasms
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders.
Breast Neoplasms
Immunological Therapies Can Relieve Aromatase Inhibitor-Related Joint Symptoms in Breast Cancer Survivors.
Breast Neoplasms
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Breast Neoplasms
Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors.
Breast Neoplasms
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Breast Neoplasms
Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.
Breast Neoplasms
Impact of Aromatase protein variants and drug interactions in breast cancer: a molecular docking approach.
Breast Neoplasms
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
Breast Neoplasms
Impact of body mass index on breast cancer in accordance with the life-stage of women.
Breast Neoplasms
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Breast Neoplasms
Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study.
Breast Neoplasms
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Breast Neoplasms
Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
Breast Neoplasms
Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers.
Breast Neoplasms
Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
Breast Neoplasms
Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Breast Neoplasms
Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.
Breast Neoplasms
Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo.
Breast Neoplasms
Impact of hormonal therapy and other adjuvant therapies on contralateral breast volume change after implant-based breast reconstruction.
Breast Neoplasms
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Breast Neoplasms
Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.
Breast Neoplasms
Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review.
Breast Neoplasms
Impact of obesity on mammary gland inflammation and local estrogen production.
Breast Neoplasms
Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions.
Breast Neoplasms
Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer.
Breast Neoplasms
Impact of sex hormones dysregulation and adiposity on the outcome of postmenopausal breast cancer patients.
Breast Neoplasms
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Breast Neoplasms
Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-hydroexemestane in Healthy Volunteers.
Breast Neoplasms
Impact of Yoga on Functional Outcomes in Breast Cancer Survivors With Aromatase Inhibitor-Associated Arthralgias.
Breast Neoplasms
Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.
Breast Neoplasms
Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer.
Breast Neoplasms
Importance of local aromatase activity in hormone-dependent breast cancer: a review.
Breast Neoplasms
Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-? and progesterone receptor-b.
Breast Neoplasms
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
Breast Neoplasms
Improvement of treatment outcomes after implementation of comprehensive pharmaceutical care in breast cancer patients receiving everolimus and exemestane.
Breast Neoplasms
Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.
Breast Neoplasms
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Breast Neoplasms
Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: A randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
Breast Neoplasms
Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
Breast Neoplasms
In brief: An aromatase inhibitor is reported to prevent postmenopausal breast cancer.
Breast Neoplasms
In postmenopausal women with breast cancer treated with aromatase inhibitors, denosumab reduced fractures.
Breast Neoplasms
In silico analysis of nsSNPs in CYP19A1 gene affecting breast cancer associated aromatase enzyme.
Breast Neoplasms
In Silico Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer.
Breast Neoplasms
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Breast Neoplasms
In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology.
Breast Neoplasms
In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
Breast Neoplasms
In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.
Breast Neoplasms
In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells.
Breast Neoplasms
In vitro and in vivo metabolic investigation of the Palbociclib by UHPLC-Q-TOF/MS/MS and in silico toxicity studies of its metabolites.
Breast Neoplasms
In vitro evaluation of estrogenic, antiestrogenic and antitumor effects of amentoflavone.
Breast Neoplasms
In vitro screening of inhibition of PPAR-? activity as a first step in identification of potential breast carcinogens.
Breast Neoplasms
In vivo and in vitro effects of the antifungal agent miconazole on estrogen biosynthesis in human breast cancer.
Breast Neoplasms
In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6.
Breast Neoplasms
In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Breast Neoplasms
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
Breast Neoplasms
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Breast Neoplasms
In-vitro Cytotoxicity and Aromatase Inhibitory Activity of Flavonoids: Synthesis, Molecular Docking and In-silico ADME Prediction.
Breast Neoplasms
Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.
Breast Neoplasms
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Breast Neoplasms
Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Breast Neoplasms
Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
Breast Neoplasms
Incidence and Treatment Efficacy of Trigger Finger in the Breast Cancer Population on Aromatase Inhibitors.
Breast Neoplasms
Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study.
Breast Neoplasms
Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors.
Breast Neoplasms
Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
Breast Neoplasms
Increased 5?-Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation.
Breast Neoplasms
Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma.
Breast Neoplasms
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Breast Neoplasms
Increased Fracture Rate in Women With Breast Cancer: a Review of the Hidden Risk.
Breast Neoplasms
Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates.
Breast Neoplasms
Increased frequency of ESR1 mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor.
Breast Neoplasms
Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
Breast Neoplasms
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women.
Breast Neoplasms
Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors.
Breast Neoplasms
Increased use of oral chemotherapy drugs spurs increased attention to patient compliance.
Breast Neoplasms
Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
Breast Neoplasms
Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13.
Breast Neoplasms
Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical.
Breast Neoplasms
Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Breast Neoplasms
Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women.
Breast Neoplasms
Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide.
Breast Neoplasms
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer.
Breast Neoplasms
Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer.
Breast Neoplasms
Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study.
Breast Neoplasms
Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients.
Breast Neoplasms
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
Breast Neoplasms
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Breast Neoplasms
Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.
Breast Neoplasms
Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology.
Breast Neoplasms
Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
Breast Neoplasms
Influence of CYP19A1 gene expression levels in women with breast cancer: a systematic review of the literature.
Breast Neoplasms
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
Breast Neoplasms
Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
Breast Neoplasms
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Breast Neoplasms
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
Breast Neoplasms
Influence of the carbamate fungicide benomyl on the gene expression and activity of aromatase in the human breast carcinoma cell line MCF-7.
Breast Neoplasms
Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients.
Breast Neoplasms
Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.
Breast Neoplasms
Inhibition of aromatase activity in human placental microsomes by 13-retro-antiprogestins.
Breast Neoplasms
Inhibition of aromatase activity in MCF-7aro human breast cancer cells by the natural androgens testosterone and androstenedione.
Breast Neoplasms
Inhibition of Aromatase and ?-Amylase by Flavonoids and Proanthocyanidins from Sorghum bicolor Bran Extracts.
Breast Neoplasms
Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Breast Neoplasms
Inhibition of aromatase expression by a psoralen-linked triplex-forming oligonucleotide targeted to a coding sequence.
Breast Neoplasms
Inhibition of aromatase transcription via promoter II by short heterodimer partner in human preadipocytes.
Breast Neoplasms
Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
Breast Neoplasms
Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen.
Breast Neoplasms
Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Breast Neoplasms
Inhibition of estrogen synthesis in human breast tumors by testololactone and bromoandrostenedione.
Breast Neoplasms
Inhibition of estrogen-induced mammary tumor formation in MMTV-aromatase transgenic mice by 4-chlorophenylacetate.
Breast Neoplasms
Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3-sulfamates.
Breast Neoplasms
Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Breast Neoplasms
Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts.
Breast Neoplasms
Inhibition of oestrogen biosynthesis induces mild anxiety in C57BL/6J ovariectomized female mice.
Breast Neoplasms
Inhibition of oestrogen synthesis in postmenopausal women with breast cancer.
Breast Neoplasms
Inhibition of testosterone aromatization by the indole-3-carbinol derivative CTet in CYP19A1-overexpressing MCF-7 breast cancer cells.
Breast Neoplasms
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Breast Neoplasms
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Breast Neoplasms
Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol.
Breast Neoplasms
Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell.
Breast Neoplasms
Inhibitory effect of chrysin on estrogen biosynthesis by suppression of enzyme aromatase (CYP19): A systematic review.
Breast Neoplasms
Inhibitory Effect of Luteolin on Estrogen Biosynthesis in Human Ovarian Granulosa Cells by Suppression of Aromatase (CYP19).
Breast Neoplasms
Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivo.
Breast Neoplasms
Inhibitory effects of Scutellaria barbata D. Don. and Euonymus alatus Sieb. on aromatase activity of human leiomyomal cells.
Breast Neoplasms
Initial studies with [11C]vorozole positron emission tomography detect over-expression of intra-tumoral aromatase in breast cancer.
Breast Neoplasms
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Breast Neoplasms
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Breast Neoplasms
Initiation of exemestane in two warfarin-treated patients leading to elevation and variability of INR.
Breast Neoplasms
Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study.
Breast Neoplasms
Insight into the enzyme-inhibitor interactions of the first experimentally determined human aromatase.
Breast Neoplasms
Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.
Breast Neoplasms
INSIGHTS ON AROMATASE IMMUNOHISTOCHEMISTRY: VARIATIONS BETWEEN INTRINSIC MOLECULAR SUBTYPES OF BREAST CANCERS.
Breast Neoplasms
Insights on the interaction mechanism of exemestane to three digestive enzymes by multi-spectroscopy and molecular docking.
Breast Neoplasms
Insomnia caused by aromatase inhibitors; a therapeutic challenge in patients with breast cancer.
Breast Neoplasms
Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
Breast Neoplasms
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Breast Neoplasms
Integrated in silico-in vitro strategy for screening of some traditional Egyptian plants for human aromatase inhibitors.
Breast Neoplasms
Integration of ER?-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer.
Breast Neoplasms
Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Breast Neoplasms
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
Breast Neoplasms
Interaction between MUC1 and STAT1 drives IFITM1 overexpression in aromatase inhibitor-resistant breast cancer cells and mediates estrogen-induced apoptosis.
Breast Neoplasms
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.
Breast Neoplasms
Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface.
Breast Neoplasms
Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer.
Breast Neoplasms
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Breast Neoplasms
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
Breast Neoplasms
Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells.
Breast Neoplasms
Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer.
Breast Neoplasms
Interventions for the Treatment of Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: A Systematic Review and Meta-analysis.
Breast Neoplasms
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors.
Breast Neoplasms
Intracrinology of breast microenvironment: hormonal status in nipple aspirate fluid and its relationship to breast cancer.
Breast Neoplasms
Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast.
Breast Neoplasms
Intratumoral estrogen production in breast carcinoma: significance of aromatase.
Breast Neoplasms
Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer.
Breast Neoplasms
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
Breast Neoplasms
Introduction to the conference, Aromatase: New Perspectives for Breast Cancer.
Breast Neoplasms
Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole.
Breast Neoplasms
Investigation of the adolescent female breast transcriptome and the impact of obesity.
Breast Neoplasms
Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers.
Breast Neoplasms
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Breast Neoplasms
Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer.
Breast Neoplasms
Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
Breast Neoplasms
Is tamoxifen associated with an increased risk for thromboembolic complications in patients undergoing microvascular breast reconstruction?
Breast Neoplasms
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Breast Neoplasms
Is there a growing role for endocrine therapy in the treatment of breast cancer?
Breast Neoplasms
Is there a role for estrogen activity assays? Recombinant cell bioassay for estrogen: Development and applications.
Breast Neoplasms
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Breast Neoplasms
Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Breast Neoplasms
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.
Breast Neoplasms
Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
Breast Neoplasms
Joint pain and falls among women with breast cancer on aromatase inhibitors.
Breast Neoplasms
Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.
Breast Neoplasms
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Breast Neoplasms
Joint problems in breast cancer patients receiving adjuvant aromatase inhibitor.
Breast Neoplasms
JunD and JunB Integrate Prostaglandin E2 Activation of Breast Cancer-Associated Proximal Aromatase Promoters.
Breast Neoplasms
Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells.
Breast Neoplasms
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24?weeks of aromatase inhibition.
Breast Neoplasms
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Breast Neoplasms
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Breast Neoplasms
KiSS1/GPR54 and estrogen-related gene expression profiles in primary breast cancer.
Breast Neoplasms
Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?
Breast Neoplasms
Lack of genomic rearrangements involving the aromatase gene CYP19A1 in breast cancer.
Breast Neoplasms
Lack of inhibition of placental estrone sulfatase and aromatase enzymes by vitamin D3 and its analogs.
Breast Neoplasms
Lactoferrin-decorated vs PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer.
Breast Neoplasms
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Breast Neoplasms
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer.
Breast Neoplasms
Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.
Breast Neoplasms
Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Breast Neoplasms
LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format.
Breast Neoplasms
Lead optimization of 4-(thio)-chromenone 6-O-sulfamate analogs using QSAR, molecular docking and DFT - a combined approach as steroidal sulfatase inhibitors.
Breast Neoplasms
Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors.
Breast Neoplasms
Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.
Breast Neoplasms
Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line.
Breast Neoplasms
Leptin induces CREB-dependent aromatase activation through COX-2 expression in breast cancer cells.
Breast Neoplasms
Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells.
Breast Neoplasms
Leptin is overexpressed in the tumor microenvironment of obese patients with estrogen receptor positive breast cancer.
Breast Neoplasms
Leptin regulation of the p53-HIF1?/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link.
Breast Neoplasms
Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages.
Breast Neoplasms
Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.
Breast Neoplasms
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
Breast Neoplasms
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Breast Neoplasms
Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells.
Breast Neoplasms
Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells.
Breast Neoplasms
Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Breast Neoplasms
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Breast Neoplasms
Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
Breast Neoplasms
Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1.
Breast Neoplasms
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Breast Neoplasms
Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
Breast Neoplasms
Letrozole Potentiates Mitochondrial and Dendritic Spine Impairments Induced by ? Amyloid.
Breast Neoplasms
Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
Breast Neoplasms
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Breast Neoplasms
Letrozole Suppresses the Fusion of Osteoclast Precursors through Inhibition of p38-Mediated DC-STAMP Pathway.
Breast Neoplasms
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
Breast Neoplasms
Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
Breast Neoplasms
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Breast Neoplasms
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Breast Neoplasms
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Breast Neoplasms
Letrozole-induced functional changes in carcinoma-associated fibroblasts and their influence on breast cancer cell biology.
Breast Neoplasms
Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: First report of a case in the UK.
Breast Neoplasms
Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Breast Neoplasms
Letrozole: a review of its use in postmenopausal women with breast cancer.
Breast Neoplasms
Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer.
Breast Neoplasms
Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer.
Breast Neoplasms
Lichen Sclerosus in a Breast Cancer Survivor on an Aromatase Inhibitor: A Case Report.
Breast Neoplasms
Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose.
Breast Neoplasms
Liquid chromatography tandem mass spectrometry determination of free and conjugated estrogens in breast cancer patients before and after exemestane treatment.
Breast Neoplasms
Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes.
Breast Neoplasms
Local adipocytes enable estrogen-dependent breast cancer growth: Role of leptin and aromatase.
Breast Neoplasms
Local aromatase activity alterations in breast cancer tissues: A potential way of decision support for clinicians.
Breast Neoplasms
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells.
Breast Neoplasms
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Breast Neoplasms
Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Breast Neoplasms
Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor.
Breast Neoplasms
Long-term consequences of ovarian ablation for premenopausal breast cancer.
Breast Neoplasms
Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Breast Neoplasms
Long-term efficacy and safety of exemestane in the treatment of breast cancer.
Breast Neoplasms
Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review.
Breast Neoplasms
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.
Breast Neoplasms
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Breast Neoplasms
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Breast Neoplasms
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Breast Neoplasms
Long-term safety of aromatase inhibitors in the treatment of breast cancer.
Breast Neoplasms
Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study.
Breast Neoplasms
Longer Times of Receipt of Adjuvant Endocrine Therapy Correspond to Improved Functional Capacity and Lower Adiposity in Women Receiving Adjuvant Therapy.
Breast Neoplasms
Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors.
Breast Neoplasms
Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Breast Neoplasms
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.
Breast Neoplasms
Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.
Breast Neoplasms
Low-dose environmental endocrine disruptors, increase aromatase activity, estradiol biosynthesis and cell proliferation in human breast cells.
Breast Neoplasms
Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer.
Breast Neoplasms
Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
Breast Neoplasms
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
Breast Neoplasms
LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
Breast Neoplasms
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.
Breast Neoplasms
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.
Breast Neoplasms
Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta.
Breast Neoplasms
Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
Breast Neoplasms
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Breast Neoplasms
Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness.
Breast Neoplasms
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Breast Neoplasms
Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
Breast Neoplasms
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
Breast Neoplasms
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
Breast Neoplasms
Management of bone disease in patients undergoing hormonal therapy for breast cancer.
Breast Neoplasms
Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Breast Neoplasms
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Breast Neoplasms
Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview.
Breast Neoplasms
Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.
Breast Neoplasms
Managing aromatase inhibitors in breast cancer survivors: not just for oncologists.
Breast Neoplasms
Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study.
Breast Neoplasms
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Breast Neoplasms
Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Breast Neoplasms
Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition.
Breast Neoplasms
Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Breast Neoplasms
Managing menopausal symptoms and associated clinical issues in breast cancer survivors.
Breast Neoplasms
Managing the risk of osteoporosis in women with a history of early breast cancer.
Breast Neoplasms
Mandibular indexes and fractal properties on the panoramic radiographs of the patients using aromatase inhibitors.
Breast Neoplasms
Marked heterogeneity of aromatase activity in human malignant melanoma tissue.
Breast Neoplasms
Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
Breast Neoplasms
Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.
Breast Neoplasms
MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors.
Breast Neoplasms
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
Breast Neoplasms
Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo.
Breast Neoplasms
Measuring estrogens in women, men, and children: Recent advances 2012-2017.
Breast Neoplasms
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Breast Neoplasms
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
Breast Neoplasms
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
Breast Neoplasms
Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA.
Breast Neoplasms
Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation.
Breast Neoplasms
Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance.
Breast Neoplasms
Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
Breast Neoplasms
Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells.
Breast Neoplasms
Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer.
Breast Neoplasms
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Breast Neoplasms
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
Breast Neoplasms
Melatonin as an Oncostatic Molecule Based on Its Anti-Aromatase Role in Breast Cancer.
Breast Neoplasms
Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells.
Breast Neoplasms
Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells.
Breast Neoplasms
Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity.
Breast Neoplasms
Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production.
Breast Neoplasms
Melatonin modulates aromatase activity and expression in endothelial cells.
Breast Neoplasms
Melatonin modulates aromatase activity in MCF-7 human breast cancer cells.
Breast Neoplasms
Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts.
Breast Neoplasms
Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.
Breast Neoplasms
Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.
Breast Neoplasms
Menopause is a determinant of breast aromatase expression and its associations with BMI, inflammation and systemic markers.
Breast Neoplasms
Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
Breast Neoplasms
Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women.
Breast Neoplasms
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.
Breast Neoplasms
Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
Breast Neoplasms
Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer.
Breast Neoplasms
Metabolic Activity in the Insular Cortex and Hypothalamus Predicts Hot Flashes: An FDG-PET Study.
Breast Neoplasms
Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.
Breast Neoplasms
Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.
Breast Neoplasms
Metabolism and toxicological implications of commonly used chemopreventive drugs against breast cancer/carcinogenesis.
Breast Neoplasms
Metabolism of 4-hydroxyandrostenedione and 4-hydroxytestosterone: Mass spectrometric identification of urinary metabolites.
Breast Neoplasms
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Breast Neoplasms
Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase.
Breast Neoplasms
Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
Breast Neoplasms
Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making.
Breast Neoplasms
Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients.
Breast Neoplasms
Methylation of dietary flavones increases their metabolic stability and chemopreventive effects.
Breast Neoplasms
Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
Breast Neoplasms
Micellar electrokinetic chromatographic study of the separation of an aromatase inhibitor and a tryciclic antidepressant in the breast cancer treatment.
Breast Neoplasms
Microbial transformation of anti-cancer wsteroid exemestane and cytotoxicity of its metabolites against cancer cell lines.
Breast Neoplasms
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Breast Neoplasms
Microvascular breast reconstruction and thromboembolic events in patients on hormone therapy: Audit of practice from a tertiary referral centre.
Breast Neoplasms
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Breast Neoplasms
miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
Breast Neoplasms
Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
Breast Neoplasms
Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.
Breast Neoplasms
Mixed estrogenic and anti-estrogenic activities of yuehchukene--a bis-indole alkaloid.
Breast Neoplasms
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Breast Neoplasms
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Breast Neoplasms
Modeling of diarylalkyl-imidazole and diarylalkyl-triazole derivatives as potent aromatase inhibitors for treatment of hormone-dependent cancer.
Breast Neoplasms
Modification of abdominal fat distribution after aromatase inhibitor therapy in breast cancer patients visualized using 3-d computed tomography volumetry.
Breast Neoplasms
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Breast Neoplasms
Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor.
Breast Neoplasms
Modulation of breast cancer cell survival by aromatase inhibiting hop (Humulus lupulus L.) flavonoids.
Breast Neoplasms
Modulation of CYP19 expression by cabbage juices and their active components: indole-3-carbinol and 3,3'-diindolylmethene in human breast epithelial cell lines.
Breast Neoplasms
Modulation of Delta9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase.
Breast Neoplasms
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Breast Neoplasms
Modulation of oestrone sulphatase activity in breast cancer cell lines by growth factors.
Breast Neoplasms
Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype.
Breast Neoplasms
Molecular analysis of aberrant expression of aromatase in breast cancer tissues.
Breast Neoplasms
Molecular and epidemiological analyses of abnormal expression of aromatase in breast cancer.
Breast Neoplasms
Molecular Barcode Sequencing of the Whole Ligand Binding Domain of the ESR1 Gene in Cell-Free DNA from Patients with Metastatic Breast Cancer.
Breast Neoplasms
Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase.
Breast Neoplasms
Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.
Breast Neoplasms
Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Breast Neoplasms
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
Breast Neoplasms
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Breast Neoplasms
Molecular docking and 3D-QSAR based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer.
Breast Neoplasms
Molecular docking and QSAR studies of aromatase inhibitor androstenedione derivatives.
Breast Neoplasms
Molecular mechanisms of aromatase inhibition by new A, D-ring modified steroids.
Breast Neoplasms
Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer.
Breast Neoplasms
Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents.
Breast Neoplasms
Molecular profiling of aromatase inhibitor-treated post-menopausal breast tumors identifies immune-related correlates of resistance.
Breast Neoplasms
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Breast Neoplasms
Molecular simulations of aromatase reveal new insights into the mechanism of ligand binding.
Breast Neoplasms
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Breast Neoplasms
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.
Breast Neoplasms
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
Breast Neoplasms
Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
Breast Neoplasms
Multiple forms of aromatase and response of breast cancer aromatase to antiplacental aromatase II antibodies.
Breast Neoplasms
Multiple rebound-associated vertebral fractures after denosumab discontinuation: is prompt antiresorptive therapy always recommended, even when the risk of fracture seems low? A case report.
Breast Neoplasms
Musculoskeletal adverse events associated with adjuvant aromatase inhibitors.
Breast Neoplasms
Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors.
Breast Neoplasms
Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor.
Breast Neoplasms
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.
Breast Neoplasms
Nandrolone and stanozolol upregulate aromatase expression and further increase IGF-I-dependent effects on MCF-7 breast cancer cell proliferation.
Breast Neoplasms
Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
Breast Neoplasms
Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer.
Breast Neoplasms
Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study.
Breast Neoplasms
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Breast Neoplasms
Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial.
Breast Neoplasms
Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
Breast Neoplasms
Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
Breast Neoplasms
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Breast Neoplasms
Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.
Breast Neoplasms
Network-guided prediction of aromatase inhibitor response in breast cancer.
Breast Neoplasms
Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer.
Breast Neoplasms
New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation.
Breast Neoplasms
New and emerging concepts in the use of denosumab for the treatment of osteoporosis.
Breast Neoplasms
New and translational perspectives of oestrogen deprivation in breast cancer.
Breast Neoplasms
New approaches to the endocrine prevention and treatment of breast cancer.
Breast Neoplasms
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Breast Neoplasms
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Breast Neoplasms
New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
Breast Neoplasms
New azolyl-derivatives as multitargeting agents against breast cancer and fungal infections: synthesis, biological evaluation and docking study.
Breast Neoplasms
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Breast Neoplasms
New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors.
Breast Neoplasms
New developments in endocrine therapy: role of adjuvant therapy for early breast cancer.
Breast Neoplasms
New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase.
Breast Neoplasms
New generation aromatase inhibitors in breast cancer. Weighing out potential costs and benefits.
Breast Neoplasms
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
Breast Neoplasms
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.
Breast Neoplasms
New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.
Breast Neoplasms
NewsCAP: The USPSTF recommends tamoxifen, raloxifene, or aromatase inhibitors for women at high breast cancer risk.
Breast Neoplasms
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Breast Neoplasms
No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
Breast Neoplasms
No associations between aromatase gene polymorphisms and breast cancer risk in Saudi patients.
Breast Neoplasms
Nomegestrol acetate is an anti-aromatase agent in human MCF-7aro breast cancer cells.
Breast Neoplasms
Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice.
Breast Neoplasms
Non-Steroidal Aromatase Inhibitors Based on a Biphenyl Scaffold: Synthesis, in vitro SAR, and Molecular Modelling.
Breast Neoplasms
Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.
Breast Neoplasms
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Breast Neoplasms
Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study.
Breast Neoplasms
Nonsteroidal Aromatase Inhibitors for the Treatment of Breast Cancer: An Update.
Breast Neoplasms
Nordic Walking as an Exercise Intervention to Reduce Pain in Women With Aromatase Inhibitor-Associated Arthralgia: A Feasibility Study.
Breast Neoplasms
Novel aromatase inhibitors selection using induced fit docking and extra precision methods: Potential clinical use in ER-alpha-positive breast cancer.
Breast Neoplasms
Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
Breast Neoplasms
Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design.
Breast Neoplasms
Novel non-steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer?
Breast Neoplasms
Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer.
Breast Neoplasms
Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification.
Breast Neoplasms
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
Breast Neoplasms
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
Breast Neoplasms
NSABP breast cancer clinical trials: recent results and future directions.
Breast Neoplasms
NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.
Breast Neoplasms
Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.
Breast Neoplasms
Obacunone exhibits anti-proliferative and anti-aromatase activity in vitro by inhibiting the p38 MAPK signaling pathway in MCF-7 human breast adenocarcinoma cells.
Breast Neoplasms
Obesity and breast cancer - Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue.
Breast Neoplasms
Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer.
Breast Neoplasms
Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland.
Breast Neoplasms
Obesity-Altered Adipose Stem Cells Promote ER? Breast Cancer Metastasis through Estrogen Independent Pathways.
Breast Neoplasms
Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production.
Breast Neoplasms
Occult breast tumor reservoir: biological properties and clinical significance.
Breast Neoplasms
Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors.
Breast Neoplasms
Oestrone sulphatase activity in normal and malignant breast tissues: relationship with tumour location.
Breast Neoplasms
Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
Breast Neoplasms
On the significance of in situ production of oestrogens in human breast cancer tissue.
Breast Neoplasms
Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.
Breast Neoplasms
Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction.
Breast Neoplasms
Online discussion of drug side effects and discontinuation among breast cancer survivors.
Breast Neoplasms
Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen.
Breast Neoplasms
Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis.
Breast Neoplasms
Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?
Breast Neoplasms
Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Breast Neoplasms
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Breast Neoplasms
Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study.
Breast Neoplasms
Optimal treatment strategies in hormone-responsive early breast cancer: the role of aromatase inhibitors.
Breast Neoplasms
Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
Breast Neoplasms
Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
Breast Neoplasms
Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.
Breast Neoplasms
Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Breast Neoplasms
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Breast Neoplasms
Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects.
Breast Neoplasms
Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.
Breast Neoplasms
Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer.
Breast Neoplasms
Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer.
Breast Neoplasms
Oral Endocrine Therapy Nonadherence, Adverse Effects, Decisional Support, and Decisional Needs in Women With Breast Cancer.
Breast Neoplasms
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Breast Neoplasms
Oral health-related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments.
Breast Neoplasms
Organoruthenium(II) Complexes Bearing an Aromatase Inhibitor: Synthesis, Characterization, in Vitro Biological Activity and in Vivo Toxicity in Zebrafish Embryos.
Breast Neoplasms
Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer.
Breast Neoplasms
Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
Breast Neoplasms
Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review.
Breast Neoplasms
Osteoporosis management in patients with breast cancer: EMAS position statement.
Breast Neoplasms
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Breast Neoplasms
Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Breast Neoplasms
Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.
Breast Neoplasms
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
Breast Neoplasms
Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
Breast Neoplasms
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
Breast Neoplasms
Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer.
Breast Neoplasms
Ovarian suppression failure during GnRH agonist treatment: A report of three breast cancer patients.
Breast Neoplasms
Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
Breast Neoplasms
Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation.
Breast Neoplasms
Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas.
Breast Neoplasms
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Breast Neoplasms
Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
Breast Neoplasms
Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients.
Breast Neoplasms
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Breast Neoplasms
Overview of resistance to systemic therapy in patients with breast cancer.
Breast Neoplasms
P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
Breast Neoplasms
p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Breast Neoplasms
p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis.
Breast Neoplasms
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series.
Breast Neoplasms
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Breast Neoplasms
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Breast Neoplasms
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
Breast Neoplasms
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Breast Neoplasms
Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
Breast Neoplasms
Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series.
Breast Neoplasms
Paradoxal metabolic flare detected by 18F-fluorodeoxyglucose positron emission tomography in a patient with metastatic breast cancer treated with aromatase inhibitor and biphosphonate.
Breast Neoplasms
Paradoxical effect of estradiol: it can block its own bioformation in human breast cancer cells.
Breast Neoplasms
Patient and physician perceptions on continuing aromatase inhibitors beyond the 5-year mark.
Breast Neoplasms
Patient and provider determinants associated with the prescription of adjuvant hormonal therapies following a diagnosis of breast cancer in Medicaid-enrolled patients.
Breast Neoplasms
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
Breast Neoplasms
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
Breast Neoplasms
Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors.
Breast Neoplasms
Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms.
Breast Neoplasms
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).
Breast Neoplasms
Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
Breast Neoplasms
Patients' preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments.
Breast Neoplasms
Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.
Breast Neoplasms
PCP4/PEP19 upregulates aromatase gene expression via CYP19A1 promoter I.1 in human breast cancer SK-BR-3 cells.
Breast Neoplasms
PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Breast Neoplasms
Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
Breast Neoplasms
Perceptions of Racially and Ethnically Diverse Women at High Risk of Breast Cancer Regarding the Use of a Web-Based Decision Aid for Chemoprevention: Qualitative Study Nested Within a Randomized Controlled Trial.
Breast Neoplasms
Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Breast Neoplasms
Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis.
Breast Neoplasms
Periodontal Health in Women With Early Stage Postmenopausal Breast Cancer Newly on Aromatase Inhibitors: A Pilot Study.
Breast Neoplasms
Perioperative Use of Antiestrogen Therapies in Breast Reconstruction: A Systematic Review and Treatment Recommendations.
Breast Neoplasms
Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis.
Breast Neoplasms
Personalized adjuvant therapies: Lessons from the past: The opening address by the St. Gallen 2013 award recipient.
Breast Neoplasms
Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Breast Neoplasms
PET probe with Aggregation Induced Emission characteristics for the specific turn-on of aromatase.
Breast Neoplasms
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Breast Neoplasms
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Breast Neoplasms
Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.
Breast Neoplasms
Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.
Breast Neoplasms
Pharmacogenetics of aromatase inhibitors in endocrine responsive breast cancer: lessons learnt from tamoxifen and CYP2D6 genotyping.
Breast Neoplasms
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Breast Neoplasms
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Breast Neoplasms
Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence, crossover study.
Breast Neoplasms
Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
Breast Neoplasms
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.
Breast Neoplasms
Pharmacokinetics of 4-hydroxyandrostenedione in man after intramuscular injection of different formulations and the effect of this drug on plasma aromatizable androgens and 17beta-estradiol concentrations.
Breast Neoplasms
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Breast Neoplasms
Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer.
Breast Neoplasms
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Breast Neoplasms
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Breast Neoplasms
Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.
Breast Neoplasms
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Breast Neoplasms
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Breast Neoplasms
Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Breast Neoplasms
Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
Breast Neoplasms
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Breast Neoplasms
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Breast Neoplasms
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Breast Neoplasms
Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer.
Breast Neoplasms
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR).
Breast Neoplasms
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Breast Neoplasms
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
Breast Neoplasms
Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer.
Breast Neoplasms
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Breast Neoplasms
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
Breast Neoplasms
Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.
Breast Neoplasms
Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.
Breast Neoplasms
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
Breast Neoplasms
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Breast Neoplasms
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Breast Neoplasms
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Breast Neoplasms
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
Breast Neoplasms
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Breast Neoplasms
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Breast Neoplasms
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
Breast Neoplasms
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Breast Neoplasms
Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.
Breast Neoplasms
Phosphorylation processes controlling aromatase activity in breast cancer: an update.
Breast Neoplasms
Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study.
Breast Neoplasms
Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.
Breast Neoplasms
Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model.
Breast Neoplasms
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Breast Neoplasms
Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Breast Neoplasms
Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
Breast Neoplasms
Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms.
Breast Neoplasms
Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer.
Breast Neoplasms
Pioglitazone, a PPAR? Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1.
Breast Neoplasms
Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
Breast Neoplasms
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Breast Neoplasms
Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
Breast Neoplasms
Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.
Breast Neoplasms
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Breast Neoplasms
Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients.
Breast Neoplasms
Polymorphic genetic variations of Cytochrome P450 19A1 and T-cell leukemia 1A genes in the Tamil population.
Breast Neoplasms
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Breast Neoplasms
Polymorphisms in Phase I (CYP450) Genes CYP1A1 (rs4646421), CYP1B1 (rs1056836), CYP19A1 (rs749292) and CYP2C8 (rs1058930) and Their Relation to Risk of Breast Cancer: A Case-Control Study in Mazandaran Province in North of Iran.
Breast Neoplasms
Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk.
Breast Neoplasms
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Breast Neoplasms
Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.
Breast Neoplasms
Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
Breast Neoplasms
Polyphenolic natural products and natural product-inspired steroidal mimics as aromatase inhibitors.
Breast Neoplasms
Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro.
Breast Neoplasms
Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.
Breast Neoplasms
Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue.
Breast Neoplasms
Positive Association of Polymorphisms in Estrogen Biosynthesis Gene, CYP19A1, and Metabolism, GST, in Breast Cancer Susceptibility.
Breast Neoplasms
Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.
Breast Neoplasms
Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Breast Neoplasms
Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
Breast Neoplasms
Postmenopausal Breast Cancer, Aromatase Inhibitors, and Bone Health: What the Surgeon Should Know.
Breast Neoplasms
Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
Breast Neoplasms
Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
Breast Neoplasms
Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors.
Breast Neoplasms
Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
Breast Neoplasms
Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates.
Breast Neoplasms
Potent and selective aromatase inhibitor: in vitro and in vivo studies with s-triazine derivative SEF19.
Breast Neoplasms
Potential effect of Olea europea leaves, Sonchus oleraceus leaves and Mangifera indica peel extracts on aromatase activity in human placental microsomes and CYP19A1 expression in MCF-7 cell line: Comparative study.
Breast Neoplasms
Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer.
Breast Neoplasms
Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer.
Breast Neoplasms
Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.
Breast Neoplasms
Potential utility of natural products as regulators of breast cancer-associated aromatase promoters.
Breast Neoplasms
Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer.
Breast Neoplasms
Practices and Attitudes Regarding Women Undergoing Fertility Preservation: A Survey of the National Physicians Cooperative.
Breast Neoplasms
Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor.
Breast Neoplasms
Pre-clinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas.
Breast Neoplasms
Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer.
Breast Neoplasms
Pre-menopausal breast cancer and aromatase inhibitors: treating a new generation of women.
Breast Neoplasms
Preclinical and clinical development of palbociclib and future perspectives.
Breast Neoplasms
Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1.
Breast Neoplasms
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.
Breast Neoplasms
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Breast Neoplasms
Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors.
Breast Neoplasms
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Breast Neoplasms
Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory.
Breast Neoplasms
Predicting response: identifying molecular determinants of endocrine response and resistance in breast cancer.
Breast Neoplasms
Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status.
Breast Neoplasms
Prediction of aromatase inhibitory activity using the efficient linear method (ELM).
Breast Neoplasms
Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Breast Neoplasms
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial.
Breast Neoplasms
Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Breast Neoplasms
Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.
Breast Neoplasms
Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study.
Breast Neoplasms
Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.
Breast Neoplasms
Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer.
Breast Neoplasms
Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
Breast Neoplasms
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Breast Neoplasms
Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients.
Breast Neoplasms
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Breast Neoplasms
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Breast Neoplasms
Preliminary clinical application of an aromatase inhibitor and a gonadotropin-releasing hormone agonist combination for inoperable endometrial cancer patients with comorbidities: case report and literature review.
Breast Neoplasms
Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
Breast Neoplasms
Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Breast Neoplasms
Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure.
Breast Neoplasms
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Breast Neoplasms
Preparation and characterization of letrozole-loaded poly(d,l-lactide) nanoparticles for drug delivery in breast cancer therapy.
Breast Neoplasms
Preparation and pharmacological profile of 7-(alpha-azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors.
Breast Neoplasms
Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.
Breast Neoplasms
Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines.
Breast Neoplasms
Prescription pattern of aromatase inhibitors for the adjuvant therapy of breast cancer in Germany - results of the second survey among gynaecologists and medical oncologists.
Breast Neoplasms
Prescription pattern of aromatase inhibitors in the adjuvant setting in Germany--final results of a survey among german breast cancer specialists.
Breast Neoplasms
Prescription Patterns, Initiation, and 5-Year Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Patients With Breast Cancer.
Breast Neoplasms
Presence of alternatively spliced transcripts of aromatase gene in human breast cancer.
Breast Neoplasms
Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients.
Breast Neoplasms
Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors.
Breast Neoplasms
Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors.
Breast Neoplasms
Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis.
Breast Neoplasms
Prevalence of bisphosphonate therapy in women with breast cancer treated with aromatase inhibitors in Germany?.
Breast Neoplasms
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
Breast Neoplasms
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Breast Neoplasms
Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
Breast Neoplasms
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Breast Neoplasms
Prevention and treatment of bone loss in patients with nonmetastatic breast or prostate cancer who receive hormonal ablation therapy.
Breast Neoplasms
Prevention and treatment of breast cancer by suppressing aromatase activity and expression.
Breast Neoplasms
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Breast Neoplasms
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
Breast Neoplasms
Prevention of breast cancer: current state of the science and future opportunities.
Breast Neoplasms
Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of a randomized controlled trial.
Breast Neoplasms
Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease.
Breast Neoplasms
Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies.
Breast Neoplasms
Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole.
Breast Neoplasms
Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis.
Breast Neoplasms
Primarily tamoxifen-unresponsive, steroid receptor-positive breast cancer may respond to an aromatase inhibition: a pilot study.
Breast Neoplasms
Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients.
Breast Neoplasms
Probing the origins of aromatase inhibitory activity of disubstituted coumarins via QSAR and molecular docking.
Breast Neoplasms
Proceedings of the 5th Kuwait International Pharmacy Conference (5th KIPC), Faculty of Pharmacy, Health Sciences Center, Kuwait University, Kuwait, February 1-3, 2015.
Breast Neoplasms
Profile of Steroid Receptors and Increased Aromatase Immunoexpression in Canine Inflammatory Mammary Cancer as a Potential Therapeutic Target.
Breast Neoplasms
Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer.
Breast Neoplasms
Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Breast Neoplasms
Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
Breast Neoplasms
Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Breast Neoplasms
Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
Breast Neoplasms
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.
Breast Neoplasms
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
Breast Neoplasms
Prognostic and predictive value of TFF1 for adjuvant endocrine therapy in Chinese women with early ER positive breast cancer: Comparing aromatase inhibitors with tamoxifen.
Breast Neoplasms
Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Breast Neoplasms
Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Breast Neoplasms
Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor.
Breast Neoplasms
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
Breast Neoplasms
Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer.
Breast Neoplasms
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.
Breast Neoplasms
Progress in endocrine approaches to the treatment and prevention of breast cancer.
Breast Neoplasms
Progress in preventive therapy for cancer: a reminiscence and personal viewpoint.
Breast Neoplasms
Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Breast Neoplasms
Progression of endocrine therapies for breast cancer: where are we headed?
Breast Neoplasms
Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
Breast Neoplasms
Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Breast Neoplasms
Promoter-specific effects of metformin on aromatase transcript expression.
Breast Neoplasms
Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant.
Breast Neoplasms
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
Breast Neoplasms
Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Breast Neoplasms
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
Breast Neoplasms
Prostaglandin E(2) induces breast cancer related aromatase promoters via activation of p38 and c-Jun NH(2)-terminal kinase in adipose fibroblasts.
Breast Neoplasms
Prostaglandin E2 Inhibits p53 in Human Breast Adipose Stromal Cells: A Novel Mechanism for the Regulation of Aromatase in Obesity and Breast Cancer.
Breast Neoplasms
Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes.
Breast Neoplasms
Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy.
Breast Neoplasms
Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation.
Breast Neoplasms
Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells.
Breast Neoplasms
Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
Breast Neoplasms
Protocol for Exercise Program in Cancer and Cognition (EPICC): A randomized controlled trial of the effects of aerobic exercise on cognitive function in postmenopausal women with breast cancer receiving aromatase inhibitor therapy.
Breast Neoplasms
Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer.
Breast Neoplasms
Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.
Breast Neoplasms
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Breast Neoplasms
QSAR modeling of aromatase inhibitory activity of 1-substituted 1,2,3-triazole analogs of letrozole.
Breast Neoplasms
Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study.
Breast Neoplasms
Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer.
Breast Neoplasms
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Breast Neoplasms
Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer.
Breast Neoplasms
Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer.
Breast Neoplasms
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Breast Neoplasms
Quantitative assessment of mammographic breast density: relationship with breast cancer risk.
Breast Neoplasms
Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.
Breast Neoplasms
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
Breast Neoplasms
Quantitative Proteomic Profiling Identifies a Potential Novel Chaperone Marker in Resistant Breast Cancer.
Breast Neoplasms
Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.
Breast Neoplasms
Quinone-related hexacyclic by-products in the production process of exemestane.
Breast Neoplasms
Racial Differences in Depressive Symptoms and Self-Rated Health among Breast Cancer Survivors on Aromatase Inhibitor Therapy.
Breast Neoplasms
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
Breast Neoplasms
Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus.
Breast Neoplasms
Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Breast Neoplasms
Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer.
Breast Neoplasms
Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors.
Breast Neoplasms
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Breast Neoplasms
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Breast Neoplasms
Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors.
Breast Neoplasms
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
Breast Neoplasms
Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study).
Breast Neoplasms
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study.
Breast Neoplasms
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
Breast Neoplasms
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Breast Neoplasms
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Breast Neoplasms
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Breast Neoplasms
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Breast Neoplasms
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
Breast Neoplasms
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.
Breast Neoplasms
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Breast Neoplasms
Randomized Trial Of Exercise On Body Composition In Breast Cancer Survivors Taking Aromatase Inhibitors: 1285 Board #6 June 2, 8: 00 AM - 10: 00 AM.
Breast Neoplasms
Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105.
Breast Neoplasms
Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
Breast Neoplasms
Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer.
Breast Neoplasms
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
Breast Neoplasms
RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.
Breast Neoplasms
Rapid and Sensitive Liquid Chromatographic Method for Determination of Anastrozole in Different Polymer-Lipid Hybrid Nanoparticles.
Breast Neoplasms
Rapid estradiol/ERalpha signaling enhances aromatase enzymatic activity in breast cancer cells.
Breast Neoplasms
Rapid estrogen effects on aromatase phosphorylation in breast cancer cells.
Breast Neoplasms
Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer.
Breast Neoplasms
Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.
Breast Neoplasms
Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.
Breast Neoplasms
RE: Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients.
Breast Neoplasms
Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Breast Neoplasms
Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
Breast Neoplasms
Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Breast Neoplasms
Real-World Palbociclib Use in HR+/HER2- Advanced Breast Cancer in Canada: The IRIS Study.
Breast Neoplasms
Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review.
Breast Neoplasms
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
Breast Neoplasms
Receipt of psychological counseling and integrative medicine services among breast cancer survivors with anxiety.
Breast Neoplasms
Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer.
Breast Neoplasms
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Breast Neoplasms
Recent advances in oncology acupuncture and safety considerations in practice.
Breast Neoplasms
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Breast Neoplasms
Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.
Breast Neoplasms
Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer.
Breast Neoplasms
Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer.
Breast Neoplasms
Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.
Breast Neoplasms
Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Breast Neoplasms
Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.
Breast Neoplasms
Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
Breast Neoplasms
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.
Breast Neoplasms
Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer.
Breast Neoplasms
Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES).
Breast Neoplasms
Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target.
Breast Neoplasms
Recovery of reproductive function in rats treated with the aromatase inhibitor fadrozole.
Breast Neoplasms
Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
Breast Neoplasms
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Breast Neoplasms
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Breast Neoplasms
Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
Breast Neoplasms
Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Breast Neoplasms
Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
Breast Neoplasms
Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Breast Neoplasms
Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.
Breast Neoplasms
Regression of late onset choroidal metastasis from a breast carcinoma with letrozole.
Breast Neoplasms
Regulation of arachidonic acid metabolism, aromatase activity and growth in human breast cancer cells by interleukin-1beta and phorbol ester: dissociation of a mediatory role for prostaglandin E2 in the autocrine control of cell function.
Breast Neoplasms
Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues.
Breast Neoplasms
Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.
Breast Neoplasms
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Breast Neoplasms
Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment.
Breast Neoplasms
Regulation of aromatase promoter activity in human breast tissue by nuclear receptors.
Breast Neoplasms
Regulatory nodes that integrate and coordinate signaling as potential targets for breast cancer therapy.
Breast Neoplasms
Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy.
Breast Neoplasms
Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches.
Breast Neoplasms
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.
Breast Neoplasms
Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
Breast Neoplasms
Relationship between physical activity practice and metabolic profile of postmenopausal women under treatment with aromatase inhibitors for breast cancer.
Breast Neoplasms
Relationship between tumour aromatase activity, tumour characteristics and response to therapy.
Breast Neoplasms
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Breast Neoplasms
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
Breast Neoplasms
Reply to 'Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature' by Delea et al.
Breast Neoplasms
Reply to the Letter to the Editor on "Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients", by I. Cohen Ann Oncol 2005; 16: 1399.
Breast Neoplasms
Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: a pilot study.
Breast Neoplasms
Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits.
Breast Neoplasms
Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
Breast Neoplasms
Resistance of the ovary to blockade of aromatization with aminoglutethimide.
Breast Neoplasms
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Breast Neoplasms
Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.
Breast Neoplasms
Resonance Raman Spectroscopy of the Oxygenated Intermediates of Human CYP19A1 Implicates a Compound I Intermediate in the Final Lyase Step.
Breast Neoplasms
Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
Breast Neoplasms
Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
Breast Neoplasms
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Breast Neoplasms
Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase-estrogen receptor axis.
Breast Neoplasms
RETRACTED ARTICLE: Cost-effectiveness of dual energy X-ray absorptiometry (DXA) plus anti-resorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
Breast Neoplasms
Retraction: Aromatase Inhibitor-mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Breast Neoplasms
Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Breast Neoplasms
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
Breast Neoplasms
Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Breast Neoplasms
Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant.
Breast Neoplasms
Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
Breast Neoplasms
Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer.
Breast Neoplasms
Rheumatic disorders and functional disability with aromatase inhibitor therapy.
Breast Neoplasms
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
Breast Neoplasms
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
Breast Neoplasms
Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
Breast Neoplasms
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Breast Neoplasms
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Breast Neoplasms
Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.
Breast Neoplasms
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Breast Neoplasms
Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors.
Breast Neoplasms
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Breast Neoplasms
Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Breast Neoplasms
Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Breast Neoplasms
Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States.
Breast Neoplasms
Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Breast Neoplasms
Risks versus benefits in the clinical application of aromatase inhibitors.
Breast Neoplasms
Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure.
Breast Neoplasms
Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Breast Neoplasms
Role of antiestrogens and aromatase inhibitors in breast cancer treatment.
Breast Neoplasms
Role of aromatase activation on sodium arsenite-induced proliferation, migration, and invasion of MDA-MB-231 and MDA-MB-453 breast cancer cell lines.
Breast Neoplasms
Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer.
Breast Neoplasms
Role of biologic markers in patient selection and application to disease prevention.
Breast Neoplasms
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.
Breast Neoplasms
Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.
Breast Neoplasms
Role of CRE-binding protein (CREB) in aromatase expression in breast adipose.
Breast Neoplasms
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Breast Neoplasms
Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women.
Breast Neoplasms
Role of human 3?-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C3) in the extrahepatic metabolism of the steroidal aromatase inactivator Formestane.
Breast Neoplasms
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
Breast Neoplasms
Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer.
Breast Neoplasms
Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Breast Neoplasms
Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast.
Breast Neoplasms
Roles of autophagy in breast cancer treatment: Target, bystander or benefactor.
Breast Neoplasms
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
Breast Neoplasms
Ropinirole, a potential drug for systematic repositioning based on side effect profile for management and treatment of breast cancer.
Breast Neoplasms
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
Breast Neoplasms
RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Breast Neoplasms
RU54115, a tight-binding aromatase inhibitor potentially useful for the treatment of breast cancer.
Breast Neoplasms
S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
Breast Neoplasms
S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
Breast Neoplasms
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Breast Neoplasms
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Breast Neoplasms
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Breast Neoplasms
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
Breast Neoplasms
Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
Breast Neoplasms
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Breast Neoplasms
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Breast Neoplasms
Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.
Breast Neoplasms
Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer.
Breast Neoplasms
Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Breast Neoplasms
Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study.
Breast Neoplasms
Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer.
Breast Neoplasms
Saving the bones in breast cancer: aromatase inhibitor-induced osteoporosis.
Breast Neoplasms
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Breast Neoplasms
Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More?
Breast Neoplasms
Screening of potential cancer preventing chemicals as aromatase inhibitors in an in vitro assay.
Breast Neoplasms
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.
Breast Neoplasms
Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District.
Breast Neoplasms
Selective Dual Inhibitors of CYP19 and CYP11B2: Targeting Cardiovascular Diseases Hiding in the Shadow of Breast Cancer.
Breast Neoplasms
Selective estrogen receptor modulation: concept and consequences in cancer.
Breast Neoplasms
Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
Breast Neoplasms
Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention.
Breast Neoplasms
Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara.
Breast Neoplasms
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Breast Neoplasms
Selective spatial upregulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism.
Breast Neoplasms
Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells.
Breast Neoplasms
Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
Breast Neoplasms
Sequence-function correlation of aromatase and its interaction with reductase.
Breast Neoplasms
Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer.
Breast Neoplasms
Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer.
Breast Neoplasms
Sequential adjuvant hormone therapy in postmenopausal breast cancer: rationale and clinical results.
Breast Neoplasms
Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.
Breast Neoplasms
Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
Breast Neoplasms
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Breast Neoplasms
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
Breast Neoplasms
Serum apelin levels and body composition changes in breast cancer patients treated with an aromatase inhibitor.
Breast Neoplasms
Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Breast Neoplasms
Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.
Breast Neoplasms
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Breast Neoplasms
Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs).
Breast Neoplasms
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane.
Breast Neoplasms
Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
Breast Neoplasms
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Breast Neoplasms
Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A.
Breast Neoplasms
Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer.
Breast Neoplasms
Sexual Dysfunction in Survivorship; the Impact of Menopause and Endocrine Therapy.
Breast Neoplasms
Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer.
Breast Neoplasms
Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention.
Breast Neoplasms
Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.
Breast Neoplasms
Shear wave elastography detects novel imaging biomarkers of aromatase inhibitor-induced joint pain: a pilot study.
Breast Neoplasms
Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
Breast Neoplasms
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Breast Neoplasms
Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.
Breast Neoplasms
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
Breast Neoplasms
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Breast Neoplasms
Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
Breast Neoplasms
Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Breast Neoplasms
Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting?
Breast Neoplasms
Shu-Gan-Liang-Xue Decoction Simultaneously Down-regulates Expressions of Aromatase and Steroid Sulfatase in Estrogen Receptor Positive Breast Cancer Cells.
Breast Neoplasms
Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.
Breast Neoplasms
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.
Breast Neoplasms
Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women.
Breast Neoplasms
Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.
Breast Neoplasms
Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.
Breast Neoplasms
Simple tandem repeat (TTTA)n polymorphism in CYP19 (aromatase) gene and breast cancer risk in Nigerian women.
Breast Neoplasms
Simultaneous quantification of abemaciclib and letrozole in rat plasma: method development, validation and pharmacokinetic application.
Breast Neoplasms
Singapore Cancer Network (SCAN) Guidelines for Bisphosphonate Use in the Adjuvant Breast Cancer Setting.
Breast Neoplasms
Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
Breast Neoplasms
Single CpG site methylation controls estrogen receptor gene transcription and correlates with hormone therapy resistance.
Breast Neoplasms
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Breast Neoplasms
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Breast Neoplasms
Single or Multiple Access Channels to the CYP450s Active Site? An Answer from Free Energy Simulations of the Human Aromatase Enzyme.
Breast Neoplasms
Single- and Multi-Locus Association Tests Incorporating Phenotype Heterogeneity.
Breast Neoplasms
SIRT1 Positively Regulates Breast Cancer Associated Human Aromatase (CYP19A1) Expression.
Breast Neoplasms
Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Breast Neoplasms
Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance.
Breast Neoplasms
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Breast Neoplasms
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
Breast Neoplasms
Sodium/potasium ATPase (Na(+), K(+)-ATPase) and ouabain/related cardiac glycosides: a new paradigm for development of anti- breast cancer drugs?
Breast Neoplasms
Sonographic and Electrodiagnostic Evaluations in Patients With Aromatase Inhibitor-Related Arthralgia.
Breast Neoplasms
Special considerations in the evaluation and management of breast cancer in men.
Breast Neoplasms
Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
Breast Neoplasms
Starfish polysaccharides downregulate metastatic activity through the MAPK signaling pathway in MCF-7 human breast cancer cells.
Breast Neoplasms
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Breast Neoplasms
Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
Breast Neoplasms
Status of aromatase inhibitors in relation to other breast cancer treatment modalities.
Breast Neoplasms
Steroid and growth factor modulation of aromatase activity in MCF7 and T47D breast carcinoma cell lines.
Breast Neoplasms
Steroid enzyme and receptor expression and regulations in breast tumor samples - A statistical evaluation of public data.
Breast Neoplasms
Steroid modulation of aromatase activity in human cultured breast carcinoma cells.
Breast Neoplasms
Steroid sulfatase inhibitors: Promising new tools for breast cancer therapy?
Breast Neoplasms
Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
Breast Neoplasms
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
Breast Neoplasms
Steroid-metabolizing enzymes in human breast cancer cells. II. 5 alpha-Reductase, 3 alpha-hydroxysteroid oxidoreductase, and 17 beta-hydroxysteroid oxidoreductase.
Breast Neoplasms
Steroidal alkaloids efficient aromatase inhibitors with potential for the treatment of postmenopausal breast cancer.
Breast Neoplasms
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1.
Breast Neoplasms
Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study.
Breast Neoplasms
Steroidal aromatase inhibitors inhibit growth of hormone-dependent breast cancer cells by inducing cell cycle arrest and apoptosis.
Breast Neoplasms
Steroidal Metabolites Transformed by Marchantia polymorpha Cultures Block Breast Cancer Estrogen Biosynthesis.
Breast Neoplasms
Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha.
Breast Neoplasms
Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line.
Breast Neoplasms
Stimulation of human tumor xenograft growth by local estrogen biosynthesis in stromal cells.
Breast Neoplasms
Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options.
Breast Neoplasms
Strategies to prevent chemotherapy-induced bone loss in women with breast cancer.
Breast Neoplasms
Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial.
Breast Neoplasms
Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.
Breast Neoplasms
Structural basis for androgen specificity and oestrogen synthesis in human aromatase.
Breast Neoplasms
Structural insights into anticancer activity of D-ring modified estrone derivatives using their lipophilicity in estimation of SAR and molecular docking studies.
Breast Neoplasms
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Breast Neoplasms
Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design.
Breast Neoplasms
Structure-activity relationships and binding model of novel aromatase inhibitors.
Breast Neoplasms
Structure-activity relationships of 2-, 4-, or 6-substituted estrogens as aromatase inhibitors.
Breast Neoplasms
Structure-activity relationships of estrogen derivatives as aromatase inhibitors. Effects of heterocyclic substituents.
Breast Neoplasms
Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation.
Breast Neoplasms
Structure-based design of potent aromatase inhibitors by high-throughput docking.
Breast Neoplasms
Structure-function studies of aromatase and its inhibitors: a progress report.
Breast Neoplasms
Studies on aromatase inhibitors. I. Synthesis and biological evaluation of 4-amino-4H-1,2,4-triazole derivatives.
Breast Neoplasms
Studies on non-steroidal inhibitors of aromatase enzyme; 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives.
Breast Neoplasms
Study design and methods for the using exercise to relieve joint pain and improve AI adherence in older breast cancer survivors (REJOIN) trial.
Breast Neoplasms
Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention.
Breast Neoplasms
Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women.
Breast Neoplasms
Successful treatment of three synchronous primary malignant tumours-reflection on surgical, pathological and oncological aspects and decision making.
Breast Neoplasms
Successful Use of Biweekly Gemcitabine Plus Nab-Paclitaxel in Two Male Patients With Stage IV Breast Cancer: Case Reports and Review of the Literature.
Breast Neoplasms
Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer.
Breast Neoplasms
Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors.
Breast Neoplasms
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.
Breast Neoplasms
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Breast Neoplasms
Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy.
Breast Neoplasms
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
Breast Neoplasms
Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial.
Breast Neoplasms
Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition.
Breast Neoplasms
Suppression of Nuclear Factor-?B by Glucocorticoid Receptor Blocks Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells.
Breast Neoplasms
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Breast Neoplasms
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Breast Neoplasms
Surgical and oncological outcome after skin-sparing mastectomy and immediate breast reconstruction.
Breast Neoplasms
Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Fellows' Pelvic Research Network.
Breast Neoplasms
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Breast Neoplasms
Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Breast Neoplasms
Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors.
Breast Neoplasms
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Breast Neoplasms
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Breast Neoplasms
Sweet's Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer.
Breast Neoplasms
Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
Breast Neoplasms
Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.
Breast Neoplasms
Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer.
Breast Neoplasms
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
Breast Neoplasms
Symptom Clusters in Women With Breast Cancer During the First 18 Months of Adjuvant Therapy.
Breast Neoplasms
Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer.
Breast Neoplasms
Synchronous presentation of breast cancer and hepatocellular carcinoma in a postmenopausal woman: dual action of aromatase inhibitor on breast and hepatic cancer cells?
Breast Neoplasms
Synergistic effect of CGS16949A and 5-fluorouracil on a human breast cancer cell line.
Breast Neoplasms
Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines.
Breast Neoplasms
Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione).
Breast Neoplasms
Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones.
Breast Neoplasms
Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
Breast Neoplasms
Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors.
Breast Neoplasms
Synthesis and biological evaluation of (+/-)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer.
Breast Neoplasms
Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-triazoles and 1-(Diarylmethyl)-1H-imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer.
Breast Neoplasms
Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.
Breast Neoplasms
Synthesis and docking study of benzimidazole-triazolothiadiazine hybrids as aromatase inhibitors.
Breast Neoplasms
Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors.
Breast Neoplasms
Synthesis and evaluation of novel 4-amino-4,6-androstadiene-3,17-dione: an analog of formestane.
Breast Neoplasms
Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug.
Breast Neoplasms
Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer.
Breast Neoplasms
Synthesis of carbon-11-labeled casimiroin analogues as new potential PET agents for imaging of quinone reductase 2 and aromatase expression in breast cancer.
Breast Neoplasms
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.
Breast Neoplasms
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
Breast Neoplasms
Synthesis, Aromatase Inhibitory, Antiproliferative and Molecular Modeling Studies of Functionally Diverse D-Ring Pregnenolone Pyrazoles.
Breast Neoplasms
Synthesis, structure elucidation, and biochemical evaluation of 7 alpha- and 7 beta-arylaliphatic-substituted androst-4-ene-3,17-diones as inhibitors of aromatase.
Breast Neoplasms
Synthesis, structure-activity relationships and molecular docking studies of phenyldiazenyl sulfonamides as aromatase inhibitors.
Breast Neoplasms
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Breast Neoplasms
Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer.
Breast Neoplasms
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Breast Neoplasms
Systemic treatment of patients with early breast cancer: recent updates and state of the art.
Breast Neoplasms
T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients.
Breast Neoplasms
Tai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study.
Breast Neoplasms
Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.
Breast Neoplasms
Tamoxifen (selective estrogen-receptor modulators) and aromatase inhibitors as potential perioperative thrombotic risk factors in free flap breast reconstruction.
Breast Neoplasms
Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Breast Neoplasms
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection.
Breast Neoplasms
Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature.
Breast Neoplasms
Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.
Breast Neoplasms
Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
Breast Neoplasms
Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Breast Neoplasms
Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
Breast Neoplasms
Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer.
Breast Neoplasms
Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention.
Breast Neoplasms
Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer.
Breast Neoplasms
Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
Breast Neoplasms
Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis.
Breast Neoplasms
Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population.
Breast Neoplasms
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Breast Neoplasms
TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
Breast Neoplasms
TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-?B Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.
Breast Neoplasms
Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
Breast Neoplasms
Thalassosterol, a New Cytotoxic Aromatase Inhibitor Ergosterol Derivative from the Red Sea Seagrass Thalassodendron ciliatum.
Breast Neoplasms
The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer.
Breast Neoplasms
The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.
Breast Neoplasms
The Alternative Non-Coding Exons 1 of Aromatase (Cyp19) Gene Modulate Gene Expression in a Post-Transcriptional Manner.
Breast Neoplasms
The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.
Breast Neoplasms
The anti-aromatase effect of progesterone and of its natural metabolites 20alpha- and 5alpha-dihydroprogesterone in the MCF-7aro breast cancer cell line.
Breast Neoplasms
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
Breast Neoplasms
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Breast Neoplasms
The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels.
Breast Neoplasms
The aromatase inhibitor letrozole restores FADS2 function in ER+ MCF7 human breast cancer cells.
Breast Neoplasms
The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: Ready for prime time?
Breast Neoplasms
The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer.
Breast Neoplasms
The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Breast Neoplasms
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Breast Neoplasms
The association of osteoporosis knowledge and beliefs with preventive behaviors in postmenopausal breast cancer survivors.
Breast Neoplasms
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Breast Neoplasms
The beneficial androgenic action of steroidal aromatase inactivators in estrogen-dependent breast cancer after failure of nonsteroidal drugs.
Breast Neoplasms
The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
Breast Neoplasms
The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer.
Breast Neoplasms
The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Breast Neoplasms
The case for aromatase inhibitors use in Oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in Breast Cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
Breast Neoplasms
The causes and treatment of bone loss associated with carcinoma of the breast.
Breast Neoplasms
The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression.
Breast Neoplasms
The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
Breast Neoplasms
The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
Breast Neoplasms
The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice.
Breast Neoplasms
The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer.
Breast Neoplasms
The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
Breast Neoplasms
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.
Breast Neoplasms
The concurrent use of aromatase inhibitors and radiotherapy induces echocardiographic changes in patients with breast cancer.
Breast Neoplasms
The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death.
Breast Neoplasms
The control and biological importance of intratumoural aromatase in breast cancer.
Breast Neoplasms
The current status of aromatase inhibitors in the management of breast cancer.
Breast Neoplasms
The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
Breast Neoplasms
The CYP19A1 rs700519 Polymorphism and Breast Cancer Susceptibility in China: A Case-Control Study and Updated Meta-Analysis.
Breast Neoplasms
The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.
Breast Neoplasms
The direct proliferative stimulus of dehydroepiandrosterone on MCF7 breast cancer cells is potentiated by overexpression of aromatase.
Breast Neoplasms
The effect of adipocyte-macrophage cross-talk in obesity-related breast cancer.
Breast Neoplasms
The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.
Breast Neoplasms
The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer.
Breast Neoplasms
The effect of aromatase inhibition on the cognitive function of older patients with breast cancer.
Breast Neoplasms
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Breast Neoplasms
The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results.
Breast Neoplasms
The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study.
Breast Neoplasms
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Breast Neoplasms
The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Breast Neoplasms
The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Breast Neoplasms
The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors :a systematic review and meta-analysis.
Breast Neoplasms
The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors.
Breast Neoplasms
The Effect of Exercise on the Alleviation of Side Effects Induced by Aromatase Inhibitors in Postmenopausal Breast Cancer Patients.
Breast Neoplasms
The effect of grape seed extract on estrogen levels of postmenopausal women: a pilot study.
Breast Neoplasms
The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications.
Breast Neoplasms
The effect of medroxyprogesterone acetate on aromatase and DNA polymerase alpha activities in breast tumours.
Breast Neoplasms
The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.
Breast Neoplasms
The Effect of Risedronate on Hip Structural Geometry in Chemotherapy-Induced Postmenopausal Women on SERMs versus Aromatase Inhibitors: a Two Year Trial.
Breast Neoplasms
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Breast Neoplasms
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Breast Neoplasms
The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.
Breast Neoplasms
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Breast Neoplasms
The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer.
Breast Neoplasms
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Breast Neoplasms
The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.
Breast Neoplasms
The effects of Nobiletin, Hesperetin, and Letrozole in a combination on the activity and expression of aromatase in breast cancer cells.
Breast Neoplasms
The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
Breast Neoplasms
The effects of systemic aromatase inhibitors on meibomian glands and corneal structure.
Breast Neoplasms
The effects of the standardized extracts of Ginkgo biloba on steroidogenesis pathways and aromatase activity in H295R human adrenocortical carcinoma cells.
Breast Neoplasms
The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
Breast Neoplasms
The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis.
Breast Neoplasms
The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.
Breast Neoplasms
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Breast Neoplasms
The emerging role of the new aromatase inhibitors in the treatment of breast cancer.
Breast Neoplasms
The Endocrine Society Centennial: 40 years of Aromatase Inhibitors as Targeted Therapy for Breast Cancer.
Breast Neoplasms
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Breast Neoplasms
The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.
Breast Neoplasms
The Evolutionary Tale and Future Directions of Aromatase Inhibitors in Breast Carcinoma.
Breast Neoplasms
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
Breast Neoplasms
The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.
Breast Neoplasms
The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.
Breast Neoplasms
The evolving role of letrozole in the adjuvant setting: First results from the large, phase III, randomized trial BIG 1-98.
Breast Neoplasms
The expanding use of third-generation aromatase inhibitors: what the general internist needs to know.
Breast Neoplasms
The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival.
Breast Neoplasms
The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.
Breast Neoplasms
The fight against tamoxifen resistance in breast cancer therapy: a new target in the battle?
Breast Neoplasms
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
Breast Neoplasms
The human breast cancer cell line MDA-MB231 produces an aromatase stimulating activity.
Breast Neoplasms
The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters.
Breast Neoplasms
The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.
Breast Neoplasms
The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.
Breast Neoplasms
The impact of an exercise program on quality of life in older breast cancer survivors undergoing aromatase inhibitor therapy: a randomized controlled trial.
Breast Neoplasms
The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions.
Breast Neoplasms
The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers.
Breast Neoplasms
The impact of CYP19A1 variants and haplotypes on breast cancer risk, clinicopathological features and prognosis.
Breast Neoplasms
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of ARomatase Inhibitors AssessmenT In Daily practice through Educational approach (CARIATIDE) study.
Breast Neoplasms
The impact of generic aromatase inhibitors on initiation, adherence, and persistence among women with breast cancer: Applying multi-state models to understand the dynamics of adherence.
Breast Neoplasms
The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
Breast Neoplasms
The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer.
Breast Neoplasms
The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
Breast Neoplasms
The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors.
Breast Neoplasms
The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.
Breast Neoplasms
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
Breast Neoplasms
The increasing use of prophylactic mastectomy in the prevention of breast cancer.
Breast Neoplasms
The individual or combinational effects of Hesperetin and Letrozole on the activity and expression of aromatase in MCF-7 cells.
Breast Neoplasms
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
Breast Neoplasms
The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
Breast Neoplasms
The influence of endocrine treatments for breast cancer on health-related quality of life.
Breast Neoplasms
The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.
Breast Neoplasms
The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells.
Breast Neoplasms
The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
Breast Neoplasms
The inhibition of aromatase alters the mechanical and rheological properties of non-small-cell lung cancer cell lines affecting cell migration.
Breast Neoplasms
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer.
Breast Neoplasms
The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy.
Breast Neoplasms
The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer.
Breast Neoplasms
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.
Breast Neoplasms
The intracellular control of aromatase activity by 5 alpha-reduced androgens in human breast carcinoma cells in culture.
Breast Neoplasms
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Breast Neoplasms
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Breast Neoplasms
The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer.
Breast Neoplasms
The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7.
Breast Neoplasms
The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers.
Breast Neoplasms
The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial.
Breast Neoplasms
The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study.
Breast Neoplasms
The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective.
Breast Neoplasms
The orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion.
Breast Neoplasms
The overexpression of int-5/Aromatase, a novel MMTV integration locus gene, is responsible for D2 mammary tumor cell proliferation.
Breast Neoplasms
The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.
Breast Neoplasms
The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancer.
Breast Neoplasms
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer.
Breast Neoplasms
The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase.
Breast Neoplasms
The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase.
Breast Neoplasms
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.
Breast Neoplasms
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.
Breast Neoplasms
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Breast Neoplasms
The potential adverse effects of aromatase inhibitors on wound healing: in vitro and in vivo evidence.
Breast Neoplasms
The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Breast Neoplasms
The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)--a potent, selective aromatase inhibitor.
Breast Neoplasms
The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study.
Breast Neoplasms
The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors.
Breast Neoplasms
The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression.
Breast Neoplasms
The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells.
Breast Neoplasms
The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2.
Breast Neoplasms
The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease.
Breast Neoplasms
The relationship between growth and androstenedione metabolism in four cell lines of human breast carcinoma cells in culture.
Breast Neoplasms
The Relationship Between Insomnia and Cognitive Impairment in Breast Cancer Survivors.
Breast Neoplasms
The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.
Breast Neoplasms
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
Breast Neoplasms
The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Breast Neoplasms
The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
Breast Neoplasms
The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop.
Breast Neoplasms
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Breast Neoplasms
The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Breast Neoplasms
The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Breast Neoplasms
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Breast Neoplasms
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Breast Neoplasms
The role of cyclooxygenase-2-dependent signaling via cyclic AMP response element activation on aromatase up-regulation by o,p'-DDT in human breast cancer cells.
Breast Neoplasms
The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer.
Breast Neoplasms
The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer
Breast Neoplasms
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Breast Neoplasms
The role of genetic variability in drug metabolism pathways in breast cancer prognosis.
Breast Neoplasms
The role of Geriatric screening tool (G8) in predicting side effect in older patients during therapy with aromatase inhibitor.
Breast Neoplasms
The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.
Breast Neoplasms
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.
Breast Neoplasms
The role of letrozole (Femara(R)) in breast cancer therapy: A clinical review.
Breast Neoplasms
The Role of Long Noncoding RNAs in Antiestrogen Resistance in Breast Cancer: An Overview and Update.
Breast Neoplasms
The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer.
Breast Neoplasms
The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
Breast Neoplasms
The role of soybean extracts and isoflavones in hormone-dependent breast cancer: aromatase activity and biological effects.
Breast Neoplasms
The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis.
Breast Neoplasms
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
Breast Neoplasms
The significance of the expression of ERRalpha as a potential biomarker in breast cancer.
Breast Neoplasms
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Breast Neoplasms
The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.
Breast Neoplasms
The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells.
Breast Neoplasms
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
Breast Neoplasms
The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
Breast Neoplasms
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Breast Neoplasms
The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study.
Breast Neoplasms
The turnover of estrogen receptor ? by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
Breast Neoplasms
The Use and Concurrent Use of Side Effect Controlling Medications Among Women on Aromatase Inhibitors.
Breast Neoplasms
The use of aromatase inhibitors in adjuvant therapy for early breast cancer.
Breast Neoplasms
The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Breast Neoplasms
The use of concurrent hormonotherapy and radiotherapy does not deteriorate radiation-induced cardiac toxicity.
Breast Neoplasms
The use of simvastatin with aromasin in an ovariectomized rat model: effects on the skeletal system.
Breast Neoplasms
The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Breast Neoplasms
The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer.
Breast Neoplasms
The Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 Inhibits Aromatase.
Breast Neoplasms
The VES-13 and G-8 tools as predictors of toxicity associated with aromatase inhibitors in the adjuvant treatment of breast cancer in elderly patients: A single-center study.
Breast Neoplasms
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Breast Neoplasms
Theoretical Study of the Mechanism of Exemestane Hydroxylation Catalyzed by Human Aromatase Enzyme.
Breast Neoplasms
Theory-Guided Randomized Neural Networks for Decoding Medication-Taking Behavior.
Breast Neoplasms
Therapeutic approaches for protecting bone health in patients with breast cancer.
Breast Neoplasms
Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.
Breast Neoplasms
Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: A systematic review of systematic reviews, evidence mapping, and network meta-analysis.
Breast Neoplasms
Therapeutic Options in the Management of Aromatase Inhibitor-Associated Bone Loss.
Breast Neoplasms
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Breast Neoplasms
Third generation aromatase inhibitors and inactivators in the treatment and prevention of breast cancer
Breast Neoplasms
Third generation aromatase inhibitors in metastatic breast cancer patients failing tamoxifen. Randomized comparisons with megestrol acetate: a critical review.
Breast Neoplasms
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
Breast Neoplasms
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Breast Neoplasms
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO).
Breast Neoplasms
Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors.
Breast Neoplasms
Tibolone and its delta-4, 7alpha-methyl norethisterone metabolite are reversible inhibitors of human aromatase.
Breast Neoplasms
Time and geographical variations in utilisation of endocrine therapy for breast cancer in Australia.
Breast Neoplasms
Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
Breast Neoplasms
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
Breast Neoplasms
Tissue-Selective Regulation of Aromatase Expression by Calcitriol: Implications for Breast Cancer Therapy.
Breast Neoplasms
Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis.
Breast Neoplasms
Tissue-specific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts.
Breast Neoplasms
To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
Breast Neoplasms
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Breast Neoplasms
Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer: results of a national provider survey.
Breast Neoplasms
Topical Estrogen Prescription Fill Rates for Women With a History of Breast Cancer Who Are Taking Hormone Therapy.
Breast Neoplasms
Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study.
Breast Neoplasms
Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model.
Breast Neoplasms
Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
Breast Neoplasms
Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
Breast Neoplasms
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis.
Breast Neoplasms
Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis.
Breast Neoplasms
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
Breast Neoplasms
Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.
Breast Neoplasms
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
Breast Neoplasms
Transcriptional control of local estrogen formation by aromatase in the breast.
Breast Neoplasms
Transcriptional regulation of aromatase expression in human breast tissue.
Breast Neoplasms
Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells.
Breast Neoplasms
Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation.
Breast Neoplasms
Transient over-expression of estrogen receptor-alpha in breast cancer cells promotes cell survival and estrogen-independent growth.
Breast Neoplasms
Translational approaches for the prevention of estrogen receptor-negative breast cancer.
Breast Neoplasms
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
Breast Neoplasms
Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
Breast Neoplasms
Treating elderly patients with hormone sensitive breast cancer: what do the data show?
Breast Neoplasms
Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
Breast Neoplasms
Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Breast Neoplasms
Treatment algorithms for hormone receptor-positive advanced breast cancer.
Breast Neoplasms
Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.
Breast Neoplasms
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Breast Neoplasms
Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
Breast Neoplasms
Treatment of established breast cancer in post-menopausal women: role of aromatase inhibitors.
Breast Neoplasms
Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).
Breast Neoplasms
Treatment options in HR?/HER2? advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?
Breast Neoplasms
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Breast Neoplasms
Treatment persistence evaluation of tamoxifen and aromatase inhibitors in breast cancer patients in early and late stage disease.
Breast Neoplasms
Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
Breast Neoplasms
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer.
Breast Neoplasms
Treatment sequence of aromatase inhibitors and radiotherapy and long-term outcomes of breast cancer patients.
Breast Neoplasms
Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.
Breast Neoplasms
Treatment with aromatase inhibitors and markers of cardiovascular disease.
Breast Neoplasms
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Breast Neoplasms
Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
Breast Neoplasms
Treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may reduce joint pain and stiffness linked to aromatase inhibitors in women with early breast cancer: results of a pilot observational study.
Breast Neoplasms
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Breast Neoplasms
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.
Breast Neoplasms
Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.
Breast Neoplasms
Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells.
Breast Neoplasms
TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression.
Breast Neoplasms
Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.
Breast Neoplasms
Tumor biology in estrogen receptor-positive, human epidermal growth factor receptor type 2-negative breast cancer: Mind the menopausal status.
Breast Neoplasms
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors.
Breast Neoplasms
Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells.
Breast Neoplasms
Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.
Breast Neoplasms
Tumour Lysis Syndrome in Occult Breast Cancer Treated With Letrozole - A Rare Occurrence. A Case Report and Review.
Breast Neoplasms
Two cases of polycystic ovary syndrome with onset of severe ovarian hyperstimulation syndrome following controlled ovarian stimulation with aromatase inhibitors for fertility preservation before breast cancer treatment.
Breast Neoplasms
Two natural products, trans-phytol and (22E)-ergosta-6,9,22-triene-3?,5?,8?-triol, inhibit the biosynthesis of estrogen in human ovarian granulosa cells by aromatase (CYP19).
Breast Neoplasms
Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.
Breast Neoplasms
Ultrasensitive Serum Estradiol Measurement by Liquid Chromatography-Mass Spectrometry in Postmenopausal Women and Mice.
Breast Neoplasms
Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Breast Neoplasms
Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Breast Neoplasms
Unprovoked Vestibular Burning in Late Estrogen-Deprived Menopause: A Case Series.
Breast Neoplasms
Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER+ breast cancer cells: Impact on aromatase and steroid receptors.
Breast Neoplasms
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes.
Breast Neoplasms
Update on identifying and managing osteoporosis in women with breast cancer.
Breast Neoplasms
Updates on managing advanced breast cancer with palbociclib combination therapy.
Breast Neoplasms
Upfront adjuvant aromatase inhibitors in women with lobular breast cancer.
Breast Neoplasms
Upregulation of AIB1, aromatase and ER? provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.
Breast Neoplasms
Urinary lead exposure and breast cancer risk in a population-based case-control study.
Breast Neoplasms
Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer.
Breast Neoplasms
Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
Breast Neoplasms
Use of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer at German Breast Cancer Centers and University Hospitals - Results of an Enquiry (Adjuvant Endocrine Therapy Enquiry).
Breast Neoplasms
Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients.
Breast Neoplasms
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Breast Neoplasms
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Breast Neoplasms
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.
Breast Neoplasms
Use of Aromatase Inhibitors in IVF for Fertility Preservation of Non-Breast Cancer Patients: A Case Series.
Breast Neoplasms
Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density.
Breast Neoplasms
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Breast Neoplasms
Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
Breast Neoplasms
Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
Breast Neoplasms
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Breast Neoplasms
Use of MR-based trabecular bone microstructure analysis at the distal radius for osteoporosis diagnostics: a study in post-menopausal women with breast cancer and treated with aromatase inhibitor.
Breast Neoplasms
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
Breast Neoplasms
Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer.
Breast Neoplasms
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
Breast Neoplasms
Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome.
Breast Neoplasms
Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole.
Breast Neoplasms
Usefulness of 22-oxa-1,25-dihydroxyvitamin D-3 (OCT) as a single agent or combined therapy with aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Breast Neoplasms
Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.
Breast Neoplasms
Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
Breast Neoplasms
Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Breast Neoplasms
Vaginal Atrophy in Breast Cancer Survivors: Attitude and Approaches Among Oncologists.
Breast Neoplasms
Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients.
Breast Neoplasms
Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
Breast Neoplasms
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.
Breast Neoplasms
Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.
Breast Neoplasms
Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28?days.
Breast Neoplasms
Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Breast Neoplasms
Vaginal Testosterone for Management of Aromatase Inhibitor-Related Sexual Dysfunction: An Integrative Review.
Breast Neoplasms
Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia.
Breast Neoplasms
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
Breast Neoplasms
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Breast Neoplasms
Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study.
Breast Neoplasms
Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
Breast Neoplasms
Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors.
Breast Neoplasms
Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase.
Breast Neoplasms
Vitamin D Compounds PRI-2191 and PRI-2205 Enhance Anastrozole Activity in Human Breast Cancer Models.
Breast Neoplasms
Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Breast Neoplasms
Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy.
Breast Neoplasms
Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Breast Neoplasms
Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer.
Breast Neoplasms
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
Breast Neoplasms
VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats.
Breast Neoplasms
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group).
Breast Neoplasms
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Breast Neoplasms
Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
Breast Neoplasms
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Breast Neoplasms
Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors.
Breast Neoplasms
Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Breast Neoplasms
Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel.
Breast Neoplasms
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
Breast Neoplasms
White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation.
Breast Neoplasms
Whole Body Vibration Exposure on Markers of Bone Turnover, Body Composition, and Physical Functioning in Breast Cancer Patients Receiving Aromatase Inhibitor Therapy: A Randomized Controlled Trial.
Breast Neoplasms
Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
Breast Neoplasms
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Breast Neoplasms
Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1?,25-dihydroxyvitamin D3.
Breast Neoplasms
Withdrawal: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange.
Breast Neoplasms
X-ray Structure of Human Aromatase Reveals An Androgen-Specific Active Site.
Breast Neoplasms
Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity.
Breast Neoplasms
Yoga versus massage in the treatment of aromatase inhibitor-associated knee joint pain in breast cancer survivors: a randomized controlled trial.
Breast Neoplasms
Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan.
Breast Neoplasms
Zeranol stimulates proliferation and aromatase activation in human breast preadipocytes.
Breast Neoplasms
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Breast Neoplasms
Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results.
Breast Neoplasms
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Breast Neoplasms
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Breast Neoplasms
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Breast Neoplasms
Zoledronic acid inhibits aromatase activity and phosphorylation: Potential mechanism for additive zoledronic acid and letrozole drug interaction.
Breast Neoplasms
[ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
Breast Neoplasms
[A case of advanced breast cancer with multiple bone metastases responding to docetaxel and high-dose toremifene as fourth-line chemo-endocrine therapy]
Breast Neoplasms
[A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy].
Breast Neoplasms
[A Case of Cecal Cancer with Para-Aortic Lymph Node Metastasis and Peritoneum Dissemination Treated with Curative Resection after mFOLFOX6 plus Panitumumab Chemotherapy].
Breast Neoplasms
[A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy]
Breast Neoplasms
[A Case of Recurrent Breast Cancer with Drug-Induced Interstitial Pneumonia Triggered by the Switch from an Original to a Generic Aromatase Inhibitor].
Breast Neoplasms
[A Case of Simultaneous Double Cancer with Gastric Metastasis of Breast Cancer and Lung Cancer].
Breast Neoplasms
[A combined effect of fadrozole and tamoxifen in postmenopausal patients with recurrent breast cancer: a preliminary report: Japanese Cooperative Study Group of Fadrozole and Tamoxifen]
Breast Neoplasms
[A cost-effectiveness study of first-line hormone therapy in post-menopausal patients with metastatic breast cancer on neoadjuvant treatment]
Breast Neoplasms
[A meta-analysis of the effectiveness of aromatase inhibitors as adjuvant treatment for postmenopausal patients with breast cancer]
Breast Neoplasms
[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
Breast Neoplasms
[A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer].
Breast Neoplasms
[A successful case of advanced breast cancer of the elderly treated with the only breast-hormone therapy as PST]
Breast Neoplasms
[Activation of aromatase gene expression by RORalpha and GR expression in breast cancer tissue].
Breast Neoplasms
[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer]
Breast Neoplasms
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: To lead, to switch or to extend?]
Breast Neoplasms
[An immunohistochemical study of aromatase, estrogen 4-hydroxylase and fatty acid synthetase in breast cancer tissues from BRCA1 mutation carriers]
Breast Neoplasms
[Aromatase activity and its gene expression in tumor tissue of smokers and non-smokers with breast cancer]
Breast Neoplasms
[Aromatase activity in breast cancer tissue: the role of a cellular substrate]
Breast Neoplasms
[Aromatase activity in lymphocytes of cancer patients and healthy subjects]
Breast Neoplasms
[Aromatase expression in invasive and in situ ductal carcinoma present in the same breast.]
Breast Neoplasms
[Aromatase gene expression and its modifying factors in breast tumor tissue]
Breast Neoplasms
[Aromatase inhibitors and inactivators in the treatment of advanced breast cancer]
Breast Neoplasms
[Aromatase inhibitors for metastasing breast cancer in postmenopausal women. A survey of a Cochrane review]
Breast Neoplasms
[Aromatase inhibitors in risk reduction of breast cancer: potential use in premenopausal women]
Breast Neoplasms
[Aromatase inhibitors in the adjuvant treatment of early breast cancer. Is there still a place for tamoxifen?]
Breast Neoplasms
[Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?]
Breast Neoplasms
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer]
Breast Neoplasms
[Assessment of the quality of life of women with breast cancer in adjuvant treatment with tamoxifen or aromatase inhibitors--a randomized trial].
Breast Neoplasms
[Association of CYP19A1 gene rs7176005 single nucleotide polymorphism with breast cancer risk and clinicopathologic features of tumor].
Breast Neoplasms
[Bone and calcium metabolism associated with malignancy. Clinical Characteristics and Treatment of Cancer Treatment Induced Bone Loss(CTIBL)in Breast Cancer.]
Breast Neoplasms
[Bone and calcium metabolism associated with malignancy. Endocrine therapy of breast cancer.]
Breast Neoplasms
[Bone and Men's Health. Effects of aromatase inhibitors on human osteoblasts]
Breast Neoplasms
[Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)]
Breast Neoplasms
[CGS 20267 (Letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer]
Breast Neoplasms
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group]
Breast Neoplasms
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]
Breast Neoplasms
[Chemoprevention of breast cancer: a literature review and report on the current status in Germany]
Breast Neoplasms
[Chemoprevention of breast cancer: exemestane ready to be tested in study setting].
Breast Neoplasms
[Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications].
Breast Neoplasms
[Clinical study of anastrozole in the treatment of postmenopausal women with advanced breast cancer]
Breast Neoplasms
[Clinical trial on exemestane in the treatment of postmenopausal women with advanced breast cancer]
Breast Neoplasms
[Clinicopathological significance of aromatase expression in breast cancers]
Breast Neoplasms
[Combination of trastuzumab, aromatase inhibitor and anti-cancer drugs obtained a good prognosis for an inoperable stage III B breast cancer patient with giant skin ulceration].
Breast Neoplasms
[Consensus recommendations for the clinical application of CDK4/6 inhibitors in patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer].
Breast Neoplasms
[Correlation between tumor tissue aromatase, histological pattern and reproductive status in patients with breast cancer]
Breast Neoplasms
[Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer]
Breast Neoplasms
[Current status and prospectives of aromatase inhibitors in the treatment of advanced breast cancer]
Breast Neoplasms
[CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients]
Breast Neoplasms
[Determination of intratumoral estrone (E1) and estradiol (E2) in primary breast cancer tissues by sensitive HPLC-RIA]
Breast Neoplasms
[Effect of R264C polymorphism in CYP19A1 gene on BRCA1/2-negative hereditary breast cancer from Shanghai population of China.]
Breast Neoplasms
[Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].
Breast Neoplasms
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Breast Neoplasms
[Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors]
Breast Neoplasms
[Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor].
Breast Neoplasms
[Efficacy of oxycodone against anti-cancer agent-induced pain in breast cancer patients during adjuvant treatment before and after surgery].
Breast Neoplasms
[Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment]
Breast Neoplasms
[Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
Breast Neoplasms
[Endocrine therapy of causation: role of aromatase inhibitors in breast cancer]
Breast Neoplasms
[Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
Breast Neoplasms
[Evaluation of aromatase inhibitors' side effects in clinical and experimental studies]
Breast Neoplasms
[Evaluation of menopause and treatment choice of breast cancer patients before endocrine therapy].
Breast Neoplasms
[Evaluation of Patient Adherence to Anastrozole Therapy for Breast Cancer].
Breast Neoplasms
[Everolimus Plus Exemestane in Postmenopausal Patients with Estrogen-Receptor-Positive Advanced Breast Cancer - Japanese Subgroup Analysis ofBOLERO -2].
Breast Neoplasms
[Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer]
Breast Neoplasms
[Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
Breast Neoplasms
[Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients]
Breast Neoplasms
[Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer]
Breast Neoplasms
[Growth inhibition of MCF-7 human breast cancer cells by aromatase inhibitors]
Breast Neoplasms
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Breast Neoplasms
[Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor-Resistant Metastatic Breast Cancer].
Breast Neoplasms
[Indoleamine 2,3-dioxygenase activity during toremifene therapy for aromatase inhibitor-resistant metastatic breast cancer].
Breast Neoplasms
[Interrelationship between response to neoadjuvant hormone therapy and hormonal-metabolic status in breast cancer patients]
Breast Neoplasms
[Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer]
Breast Neoplasms
[Late phase II study of CGS16949A, a new aromatase inhibitor--a multicentral cooperative study (Western Japan Group)]
Breast Neoplasms
[Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents]
Breast Neoplasms
[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]
Breast Neoplasms
[Local production of estrogen via aromatase and estrone sulfatase in breast cancer tissue]
Breast Neoplasms
[Management of aromatase inhibitor-related bone health in postmenopausal patients with early breast cancer: Chinese expert consensus].
Breast Neoplasms
[Metabolic effect of tobacco smoke and "switching" the estrogen effect: mechanism of increased genotoxicity]
Breast Neoplasms
[Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes].
Breast Neoplasms
[Molecular mechanism of inhibition of sodium butyrate on activation of tumor associated aromatase promoters]
Breast Neoplasms
[Natural remedies and hormone preparations--potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment]
Breast Neoplasms
[New developments in the hormonal treatment of breast cancer in postmenopausal women]
Breast Neoplasms
[On "2015 Guidelines for Prevention and Treatment of Osteoporosis" . Osteoporosis associated with sex hormone depletion treatment].
Breast Neoplasms
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole]
Breast Neoplasms
[Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor]
Breast Neoplasms
[Phase I study of CGS16949A--a new aromatase inhibitor. Cooperative Study Group for CGS16949A]
Breast Neoplasms
[Phase II study of CGS16949A, a new aromatase inhibitor--a dose finding study]
Breast Neoplasms
[Prevention and treatment of aromatase inhibitor-associated bone loss by shugan jiangu recipe in postmenopausal women with breast cancer: a clinical study].
Breast Neoplasms
[Progress in study of the structure, catalytic mechanism and inhibitors of aromatase].
Breast Neoplasms
[Quantitative competitive RT-PCR method in analysis of aromatase expression in breast cancer]
Breast Neoplasms
[Risks associated with phytoestrogen dietary supplementation and adjuvant hormonal therapy for breast cancer].
Breast Neoplasms
[Role for aromatase inhibitors as adjuvant treatment of breast cancer in menopaused women: facts and questions in 2005]
Breast Neoplasms
[Sequential changes in hormone levels in postmenopausal breast cancer patients under long-term treatment with an aromatase inhibitor. Kanagawa AI Study Group]
Breast Neoplasms
[Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen]
Breast Neoplasms
[Synthesis and biological evaluation of indole derivatives acting as anti-inflammatory or antitumoral drugs]
Breast Neoplasms
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]
Breast Neoplasms
[Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma.]
Breast Neoplasms
[The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].
Breast Neoplasms
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile]
Breast Neoplasms
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Breast Neoplasms
[Tumor tissue aromatase and estrogen levels versus clinical course of endometrial cancer]
Breast Neoplasms
[Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition]
Breast Neoplasms
[Use of aromatase and its inhibitors in dealing with different oncological pathologies other than breast cancer]
Breast Neoplasms, Male
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Breast Neoplasms, Male
Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study.
Breast Neoplasms, Male
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
Breast Neoplasms, Male
Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations.
Breast Neoplasms, Male
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series.
Breast Neoplasms, Male
Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature.
Breast Neoplasms, Male
Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.
Breast Neoplasms, Male
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors.
Breast Neoplasms, Male
Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer.
Breast Neoplasms, Male
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Breast Neoplasms, Male
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Breast Neoplasms, Male
Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis.
Breast Neoplasms, Male
Successful Use of Biweekly Gemcitabine Plus Nab-Paclitaxel in Two Male Patients With Stage IV Breast Cancer: Case Reports and Review of the Literature.
Breast Neoplasms, Male
Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Breast Neoplasms, Male
[Biological and clinical implications of aromatase inhibitors in early male breast cancer patients].
Brenner Tumor
Brenner tumor of the ovary: immunoanalysis of steroidogenic enzymes in 23 cases.
Carcinogenesis
4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis.
Carcinogenesis
A novel nonradioactive method for measuring aromatase activity using a human ovarian granulosa-like tumor cell line and an estrone ELISA.
Carcinogenesis
Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study.
Carcinogenesis
Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.
Carcinogenesis
Aromatase inhibition by 2-methyl indole hydrazone derivatives evaluated via molecular docking and in vitro activity studies.
Carcinogenesis
Aromatase overexpression induces malignant changes in estrogen receptor ? negative MCF-10A cells.
Carcinogenesis
Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology.
Carcinogenesis
Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone.
Carcinogenesis
Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.
Carcinogenesis
Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats.
Carcinogenesis
Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications.
Carcinogenesis
Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
Carcinogenesis
Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor.
Carcinogenesis
Dietary Supplementation with Methylseleninic Acid Inhibits Mammary Tumorigenesis and Metastasis in Male MMTV-PyMT Mice.
Carcinogenesis
Differential expression of steroidogenic factor-1/adrenal 4 binding protein and liver receptor homolog-1 (LRH-1)/fetoprotein transcription factor in the rat testis: LRH-1 as a potential regulator of testicular aromatase expression.
Carcinogenesis
Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea.
Carcinogenesis
Effects of aminoglutethimide, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters.
Carcinogenesis
Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms.
Carcinogenesis
Effects of high fat diet-induced obesity on mammary tumorigenesis in the PyMT/MMTV murine model.
Carcinogenesis
Effects of tamoxifen, an antiestrogen, on rat prostate carcinogenesis by 3,2'-dimethyl-4-aminobiphenyl and testosterone do not support an estrogen role in testosterone promotion.
Carcinogenesis
Elevated aromatase expression correlates with cervical carcinoma progression.
Carcinogenesis
Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario.
Carcinogenesis
Estrogen receptor alpha is required for mammary development and the induction of mammary hyperplasia and epigenetic alterations in the aromatase transgenic mice.
Carcinogenesis
Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
Carcinogenesis
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Carcinogenesis
HER-2/neu x aromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis.
Carcinogenesis
High TGFbeta1, estrogen receptor, and aromatase gene expression in a large cell calcifying sertoli cell tumor (LCCSCT): implications for the mechanism of oncogenesis.
Carcinogenesis
Histamine H4 receptor as a novel therapeutic target for the treatment of Leydig-cell tumours in prepubertal boys.
Carcinogenesis
Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis.
Carcinogenesis
Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?
Carcinogenesis
Local adipocytes enable estrogen-dependent breast cancer growth: Role of leptin and aromatase.
Carcinogenesis
Mammary steroid metabolizing enzymes in relation to hyperplasia and tumorigenesis in the dog.
Carcinogenesis
Obacunone exhibits anti-proliferative and anti-aromatase activity in vitro by inhibiting the p38 MAPK signaling pathway in MCF-7 human breast adenocarcinoma cells.
Carcinogenesis
Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice.
Carcinogenesis
Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis.
Carcinogenesis
Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients.
Carcinogenesis
Polymorphisms in the CYP19A1 (Aromatase) gene and endometrial cancer risk in Chinese women.
Carcinogenesis
Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro.
Carcinogenesis
Preventive effects of letrozole in the model of premenopausal mammary carcinogenesis.
Carcinogenesis
Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast.
Carcinogenesis
Side effects of anastrozole in the experimental pre-menopausal mammary carcinogenesis.
Carcinogenesis
Synthesis of Resveratrol Derivatives and In Vitro Screening for Potential Cancer Chemopreventive Activities.
Carcinogenesis
The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice.
Carcinogenesis
The CYP19A1 (TTTA)n Repeat Polymorphism May Affect the Prostate Cancer Risk: Evidence from a Meta-Analysis.
Carcinogenesis
The CYP19A1 rs700519 Polymorphism and Breast Cancer Susceptibility in China: A Case-Control Study and Updated Meta-Analysis.
Carcinogenesis
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer.
Carcinogenesis
Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis.
Carcinogenesis
Zeranol stimulates proliferation and aromatase activation in human breast preadipocytes.
Carcinogenesis
[Aromatase inhibitors in risk reduction of breast cancer: potential use in premenopausal women]
Carcinogenesis
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Carcinoma
7 alpha-substituted androstenediones as effective in vitro and in vivo inhibitors of aromatase.
Carcinoma
7,8-Dihydroxycoumarin exerts antitumor potential on DMBA-induced mammary carcinogenesis by inhibiting ER?, PR, EGFR, and IGF1R: involvement of MAPK1/2-JNK1/2-Akt pathway.
Carcinoma
A comparison of human H295R and rat R2C cell lines as in vitro screening tools for effects on aromatase.
Carcinoma
A novel nonradioactive method for measuring aromatase activity using a human ovarian granulosa-like tumor cell line and an estrone ELISA.
Carcinoma
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Carcinoma
Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors.
Carcinoma
Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor.
Carcinoma
Aromatase activity in an estrogen-producing adrenocortical carcinoma in a young man.
Carcinoma
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Carcinoma
Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast.
Carcinoma
Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study.
Carcinoma
Aromatase expression in normal human oral keratinocytes and oral squamous cell carcinoma.
Carcinoma
Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations.
Carcinoma
Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies.
Carcinoma
Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures.
Carcinoma
Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report.
Carcinoma
Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Carcinoma
Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells.
Carcinoma
Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women.
Carcinoma
Biochemistry and pharmacology of 7alpha-substituted androstenediones as aromatase inhibitors.
Carcinoma
Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast.
Carcinoma
Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland.
Carcinoma
Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole.
Carcinoma
Clinicopathological Significance of Estrogen Receptor ? and Estrogen Synthesizing/Metabolizing Enzymes in Urothelial Carcinoma of Urinary Bladder.
Carcinoma
Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: Gender-dependent clinical outcome.
Carcinoma
Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma.
Carcinoma
Comparison of Increased Aromatase versus ER{alpha} in the Generation of Mammary Hyperplasia and Cancer.
Carcinoma
Controversies of aromatase localization in human breast cancer--stromal versus parenchymal cells.
Carcinoma
Correlation of aromatase activity and steroid receptors in human ovarian carcinoma.
Carcinoma
De novo expression of aromatase in gastric carcinoma. Light and electron microscopic immunohistochemical and immunoblot study.
Carcinoma
Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
Carcinoma
Effect of combined lignan phytoestrogen and melatonin treatment on secretion of steroid hormones by adrenal carcinoma cells.
Carcinoma
Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea.
Carcinoma
Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma.
Carcinoma
Effects of bisphenol A-related diphenylalkanes on vitellogenin production in male carp (Cyprinus carpio) hepatocytes and aromatase (CYP19) activity in human H295R adrenocortical carcinoma cells.
Carcinoma
Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.
Carcinoma
Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione in MCF-7 human mammary carcinoma cell culture.
Carcinoma
Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.
Carcinoma
Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors.
Carcinoma
Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review.
Carcinoma
Epitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activity.
Carcinoma
Estrogen secreting adrenal adenocarcinoma in an 18-month-old boy: aromatase activity, protein expression, mRNA and utilization of gonadal type promoter.
Carcinoma
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis.
Carcinoma
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders.
Carcinoma
Immunolocalization of aromatase in human breast disorders using different antibodies.
Carcinoma
Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival.
Carcinoma
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Carcinoma
In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology.
Carcinoma
Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation.
Carcinoma
Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.
Carcinoma
Inhibition of aromatase activity and growth suppression by 4-methoxy-4-androstene-3,17-dione in an androgen sensitive human prostatic carcinoma cell line.
Carcinoma
Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Carcinoma
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Carcinoma
Intratumoral localization and activity of 17?-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor.
Carcinoma
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
Carcinoma
Multiple parameter analyses of human ovarian cancer: morphology, immunohistochemistry, steroid hormone receptors and aromatase.
Carcinoma
Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma.
Carcinoma
Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.
Carcinoma
Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Carcinoma
Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.
Carcinoma
Sex-steroid enzymes, aromatase and 5 alpha-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue.
Carcinoma
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Carcinoma
Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells.
Carcinoma
Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma.
Carcinoma
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
Carcinoma
[Aromatase activities of endometrial carcinomas and both basic and clinical analyses of endometrial hyperplasia as a premalignant disease]
Carcinoma
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole]
Carcinoma
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Carcinoma, Adenoid Cystic
Oestrogen receptor ? in adenoid cystic carcinoma of salivary glands.
Carcinoma, Adenosquamous
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Carcinoma, Ductal
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Carcinoma, Ductal
Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer.
Carcinoma, Ductal
Breast Ductal Carcinoma In Situ: A Literature Review of Adjuvant Hormonal Therapy.
Carcinoma, Ductal
Comparison of Increased Aromatase versus ER{alpha} in the Generation of Mammary Hyperplasia and Cancer.
Carcinoma, Ductal
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Carcinoma, Ductal
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Carcinoma, Ductal
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Carcinoma, Ductal
CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma.
Carcinoma, Ductal
Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
Carcinoma, Ductal
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Carcinoma, Ductal
Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
Carcinoma, Ductal
Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
Carcinoma, Ductal
Local aromatase activity alterations in breast cancer tissues: A potential way of decision support for clinicians.
Carcinoma, Ductal
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Carcinoma, Ductal
Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.
Carcinoma, Ductal
Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer.
Carcinoma, Ductal
Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast.
Carcinoma, Ductal
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer.
Carcinoma, Ductal
The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
Carcinoma, Ductal
The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer.
Carcinoma, Ductal
[Aromatase expression in invasive and in situ ductal carcinoma present in the same breast.]
Carcinoma, Embryonal
Microsomal aromatase in testicular tumour tissue: increased activity in choriocarcinoma compared to embryonal carcinoma.
Carcinoma, Endometrioid
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer.
Carcinoma, Hepatocellular
A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype.
Carcinoma, Hepatocellular
Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma.
Carcinoma, Hepatocellular
Aromatase activity in human hepatocellular carcinoma. Relationship with the degree of histologic differentiation.
Carcinoma, Hepatocellular
Aromatase inhibitors may be effective in the management of advanced hepatocellular carcinoma.
Carcinoma, Hepatocellular
Estrogen biosynthesis in human liver--a comparison of aromatase activity for C-19 steroids in fetal liver, adult liver and hepatoma tissues of human subjects.
Carcinoma, Hepatocellular
Estrogen signalling through amphiregulin may be implicated in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child.
Carcinoma, Hepatocellular
Immunochemical specificity of placental NADPH cytochrome c (P-450) reductase in neoplastic and non-neoplastic human tissue.
Carcinoma, Hepatocellular
Local estrogen formation by nontumoral, cirrhotic, and malignant human liver tissues and cells.
Carcinoma, Hepatocellular
Merlin, the product of NF2 gene, is associated with aromatase expression and estrogen formation in human liver tissues and liver cancer cells.
Carcinoma, Hepatocellular
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma.
Carcinoma, Hepatocellular
Synchronous presentation of breast cancer and hepatocellular carcinoma in a postmenopausal woman: dual action of aromatase inhibitor on breast and hepatic cancer cells?
Carcinoma, Hepatocellular
The use of rat Leydig tumor (R2C) and human hepatoma (HEPG2) cells to evaluate potential inhibitors of rat and human steroid aromatase.
Carcinoma, Hepatocellular
Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor.
Carcinoma, Intraductal, Noninfiltrating
Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast.
Carcinoma, Intraductal, Noninfiltrating
Aromatase expression in atypical ductal hyperplasia in women.
Carcinoma, Intraductal, Noninfiltrating
Aromatase inhibitors for hormonal therapy of early-stage breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Breast Ductal Carcinoma In Situ: A Literature Review of Adjuvant Hormonal Therapy.
Carcinoma, Intraductal, Noninfiltrating
Cell polarity, epithelial-mesenchymal transition, and cell-fate decision gene expression in ductal carcinoma in situ.
Carcinoma, Intraductal, Noninfiltrating
Comparison of Increased Aromatase versus ER{alpha} in the Generation of Mammary Hyperplasia and Cancer.
Carcinoma, Intraductal, Noninfiltrating
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Carcinoma, Intraductal, Noninfiltrating
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Carcinoma, Intraductal, Noninfiltrating
Current management of ductal carcinoma in situ of the breast.
Carcinoma, Intraductal, Noninfiltrating
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Carcinoma, Intraductal, Noninfiltrating
Ductal carcinoma in situ: trends in treatment over time in the US.
Carcinoma, Intraductal, Noninfiltrating
Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.
Carcinoma, Intraductal, Noninfiltrating
Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Immunolocalization of thymidylate synthase as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Carcinoma, Intraductal, Noninfiltrating
Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
Carcinoma, Intraductal, Noninfiltrating
Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
Carcinoma, Intraductal, Noninfiltrating
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Carcinoma, Intraductal, Noninfiltrating
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Carcinoma, Intraductal, Noninfiltrating
Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
Carcinoma, Intraductal, Noninfiltrating
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Quantitative assessment of mammographic breast density: relationship with breast cancer risk.
Carcinoma, Intraductal, Noninfiltrating
Recent advances and current controversies in the management of DCIS of the breast.
Carcinoma, Intraductal, Noninfiltrating
Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast.
Carcinoma, Intraductal, Noninfiltrating
Tamoxifen Initiation After Ductal Carcinoma In Situ.
Carcinoma, Intraductal, Noninfiltrating
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer.
Carcinoma, Intraductal, Noninfiltrating
The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
Carcinoma, Intraductal, Noninfiltrating
Towards optimal management of ductal carcinoma in situ of the breast.
Carcinoma, Intraductal, Noninfiltrating
Treatment of ductal carcinoma in situ of the breast: review of recent advances and future prospects.
Carcinoma, Intraductal, Noninfiltrating
[Aromatase expression in invasive and in situ ductal carcinoma present in the same breast.]
Carcinoma, Lobular
Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.
Carcinoma, Lobular
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
Carcinoma, Lobular
Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant.
Carcinoma, Non-Small-Cell Lung
Changes in aromatase (CYP19) gene promoter usage in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression of aromatase CYP19 and its relationship with parameters in NSCLC.
Carcinoma, Non-Small-Cell Lung
Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
Carcinoma, Non-Small-Cell Lung
Prognostic relevance of estrogen receptor ?, ? and aromatase expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Targeting aromatase and estrogen signaling in human non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Carcinoma, Ovarian Epithelial
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Carcinoma, Ovarian Epithelial
Lack of evidence for aromatase expression in human ovarian epithelial carcinoma.
Carcinoma, Papillary
Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved.
Carcinoma, Squamous Cell
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Carcinosarcoma
Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report.
Cardiotoxicity
Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
Cardiotoxicity
Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.
Cardiotoxicity
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Cardiotoxicity
Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer.
Cardiotoxicity
Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.
Cardiovascular Diseases
Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner.
Cardiovascular Diseases
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Cardiovascular Diseases
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review.
Cardiovascular Diseases
Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
Cardiovascular Diseases
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
Cardiovascular Diseases
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Cardiovascular Diseases
Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition.
Cardiovascular Diseases
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Cardiovascular Diseases
Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment.
Cardiovascular Diseases
Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.
Cardiovascular Diseases
Effect of Aromatase Inhibitor Therapy on the Cardiovascular Health of Black and White Breast Cancer Patients.
Cardiovascular Diseases
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
Cardiovascular Diseases
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.
Cardiovascular Diseases
Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer.
Cardiovascular Diseases
Improving quality of life after breast cancer: prevention of other diseases.
Cardiovascular Diseases
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Cardiovascular Diseases
Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
Cardiovascular Diseases
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis.
Cardiovascular Diseases
Treatment with aromatase inhibitors and markers of cardiovascular disease.
Carney Complex
High TGFbeta1, estrogen receptor, and aromatase gene expression in a large cell calcifying sertoli cell tumor (LCCSCT): implications for the mechanism of oncogenesis.
Carotid Stenosis
Treatment with aromatase inhibitors and markers of cardiovascular disease.
Carpal Tunnel Syndrome
Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice.
Carpal Tunnel Syndrome
Aromatase Inhibitor-Induced Carpal Tunnel Syndrome: Results From the ATAC Trial.
Carpal Tunnel Syndrome
Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis.
Carpal Tunnel Syndrome
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Carpal Tunnel Syndrome
Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer.
Carpal Tunnel Syndrome
Correction to: Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice.
Carpal Tunnel Syndrome
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
Carpal Tunnel Syndrome
Rheumatic disorders and functional disability with aromatase inhibitor therapy.
Cataract
Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer.
Cecal Neoplasms
[A Case of Cecal Cancer with Para-Aortic Lymph Node Metastasis and Peritoneum Dissemination Treated with Curative Resection after mFOLFOX6 plus Panitumumab Chemotherapy].
Chickenpox
Aromatase Derived Estradiol Within the Thalamus Modulates Pain Induced by Varicella Zoster Virus.
Chickenpox
Corrigendum: Aromatase Derived Estradiol Within the Thalamus Modulates Pain Induced by Varicella Zoster Virus.
Cholangiocarcinoma
The Importance of CYP19A1 in Estrogen Receptor-Positive Cholangiocarcinoma.
Cholera
Differential effects of luteinizing hormone-releasing hormone on follicle-stimulating hormone-dependent responses in rat granulosa cells and Sertoli cells in vitro.
Cholera
Factors affecting the conversion of androstenedione to estrogens by human fetal hepatocytes in monolayer culture.
Cholera
Modulation of FSH-controlled steroidogenesis in rat granulosa cells: direct in-vitro effects of LHRH and ICI-118630.
Cholera
Progestins inhibit FSH-stimulated granulosa estrogen production at a post-cAMP site.
Cholera
Regulation of aromatase cytochrome P-450 and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels in choriocarcinoma cells.
Cholera
Site of action of androgens on follicle-stimulating hormone-induced aromatase activity in cultured rat granulosa cells.
Cholera
The role of cyclic AMP in the induction of estrogen and progestin synthesis in cultured granulosa cells.
Cholestasis, Intrahepatic
Intrahepatic cholestasis of pregnancy impairs the activities of human placental xenobiotic and steroid metabolizing enzymes in vitro.
Chondrosarcoma
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Chondrosarcoma
Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo.
Choriocarcinoma
17alpha-methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture.
Choriocarcinoma
Aromatase in the human choriocarcinoma JEG-3: inhibition by R 76 713 in cultured cells and in tumors grown in nude mice.
Choriocarcinoma
Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production.
Choriocarcinoma
Aromatase inhibition by 7-substituted steroids in human choriocarcinoma cell culture.
Choriocarcinoma
Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures.
Choriocarcinoma
Aromatase inhibition by R 83 842, the dextro isomer of R 76 713, in JEG-3 choriocarcinoma grown in ovariectomized nude mice.
Choriocarcinoma
Aromatase inhibition in JAr choriocarcinoma cells by 7alpha-arylaliphatic androgens.
Choriocarcinoma
Assessment of steroidogenic pathways that do not require testosterone as intermediate.
Choriocarcinoma
Biochemical and pharmacological development of steroidal inhibitors of aromatase.
Choriocarcinoma
Biochemistry and pharmacology of 7alpha-substituted androstenediones as aromatase inhibitors.
Choriocarcinoma
Characterization of a cis-acting regulatory element involved in human-aromatase P-450 gene expression.
Choriocarcinoma
Characterization of steroid production in cultured human choriocarcinoma cells.
Choriocarcinoma
Currently used pesticides and their mixtures affect the function of sex hormone receptors and aromatase enzyme activity.
Choriocarcinoma
Cytotoxicity and aromatase (CYP19) activity modulation by organochlorines in human placental JEG-3 and JAR choriocarcinoma cells.
Choriocarcinoma
Differential toxicity of alkylphenols in JEG-3 human placental cells: alteration of P450 aromatase and cell lipid composition.
Choriocarcinoma
Effect of triptolide on aromatase activity in human placental microsomes and human placental JEG-3 cells.
Choriocarcinoma
Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity.
Choriocarcinoma
Effects of some persistent halogenated environmental contaminants on aromatase (CYP19) activity in the human choriocarcinoma cell line JEG-3.
Choriocarcinoma
Endocrine disruption induced by organotin compounds; organotins function as a powerful agonist for nuclear receptors rather than an aromatase inhibitor.
Choriocarcinoma
Estrogen synthetase (aromatase) in cultured human term placental cells and neoplastic human trophoblast.
Choriocarcinoma
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Choriocarcinoma
Induction of aromatase gene expression in human placental choriocarcinoma (JAR) cells by phorbol esters.
Choriocarcinoma
Inhibition of cyclic AMP-triggered aromatase gene expression in human choriocarcinoma cells by antisense oligodeoxynucleotide.
Choriocarcinoma
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors.
Choriocarcinoma
Lack of aromatisation of the 3-keto-4-ene metabolite of tibolone to an estrogenic derivative.
Choriocarcinoma
Let-7g inhibits synthesis of estradiol by downregulating activity of aromatase in JEG3 cells.
Choriocarcinoma
Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
Choriocarcinoma
Microsomal aromatase in testicular tumour tissue: increased activity in choriocarcinoma compared to embryonal carcinoma.
Choriocarcinoma
Modulation of aromatase activity and mRNA by various selected pesticides in the human choriocarcinoma JEG-3 cell line.
Choriocarcinoma
Modulation of estradiol synthesis and aromatase activity in human choriocarcinoma JEG-3 cells exposed to tetrabromobisphenol A.
Choriocarcinoma
Molecular cloning of a cDNA showing alternative splicing of the 5'-untranslated sequence of mRNA for human aromatase P-450.
Choriocarcinoma
Molecular targets of organotin compounds in endocrine disruption: do organotin compounds function as aromatase inhibitors in mammals?
Choriocarcinoma
Nicotine, cotinine, and anabasine inhibit aromatase in human trophoblast in vitro.
Choriocarcinoma
Peripheral precocious puberty in a girl with an intracranial hCG-producing tumor: case report and literature review.
Choriocarcinoma
Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy.
Choriocarcinoma
Regulation of aromatase cytochrome P-450 and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels in choriocarcinoma cells.
Choriocarcinoma
Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
Choriocarcinoma
Role of protein kinase A in regulating steroid sulfate uptake for estrogen production in human placental choriocarcinoma cells.
Choriocarcinoma
Selective aromatase inhibition by pyridoglutethimide, an analogue of aminoglutethimide.
Choriocarcinoma
Stimulation of serotonergic 5-HT(2A) receptor signaling increases placental aromatase (CYP19) activity and expression in BeWo and JEG-3 human choriocarcinoma cells.
Choriocarcinoma
The Inhibitory Effects of the Standardized Extracts of Ginkgo biloba on Aromatase Activity in JEG-3 Human Choriocarcinoma Cells.
Choriocarcinoma
Tibolone and its delta-4, 7alpha-methyl norethisterone metabolite are reversible inhibitors of human aromatase.
Choriocarcinoma
Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions.
Choriocarcinoma
Trialkyltin compounds enhance human CG secretion and aromatase activity in human placental choriocarcinoma cells.
Colonic Neoplasms
CYP19A1 single nucleotide polymorphism associations with CYP19A1, NF?B1, and IL6 gene expression in human normal colon and normal liver samples.
Colonic Neoplasms
Effect of butyrate on aromatase cytochrome P450 levels in HT29, DLD-1 and LoVo colon cancer cells.
Colonic Neoplasms
Fractionation of polyphenol-enriched apple juice extracts to identify constituents with cancer chemopreventive potential.
Colonic Neoplasms
mRNA expression level of CDH2, LEP, POSTN, TIMP1 and VEGFC modulates 5-fluorouracil resistance in colon cancer cells.
Colorectal Neoplasms
Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
Colorectal Neoplasms
Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Colorectal Neoplasms
Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
Colorectal Neoplasms
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Colorectal Neoplasms
Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women.
Colorectal Neoplasms
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Colorectal Neoplasms
Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.
Colorectal Neoplasms
[Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition]
Communicable Diseases
Thrombotic risk and immobility in residents of long-term care facilities.
Congenital Abnormalities
Aromatase Inhibitors for Ovarian Stimulation in Patients with Breast Cancer.
Congenital Abnormalities
Use of aromatase inhibitors in children and adolescents: what's new?
Contracture
Immediate breast reconstruction surgery with expander/direct implant and use of acellular dermal matrix: Does hormone therapy increases the risk of infection?
Coronary Artery Disease
CYP19A1 polymorphisms associated with coronary artery disease and circulating sex hormone levels in a Chinese population.
Coronary Artery Disease
Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure.
Coronary Artery Disease
Genetic Variant in the CYP19A1 Gene Associated with Coronary Artery Disease.
Coronary Artery Disease
The discrepancy of aromatase expression in epicardial adipose tissue between CHD and non-CHD patients.
Coronary Disease
Association of aromatase inhibitors with coronary heart disease in women with early breast cancer.
Coronary Disease
Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use.
Coronary Disease
Identification of a CYP19 Gene Single-Nucleotide Polymorphism Associated with a Reduced Risk of Coronary Heart Disease.
Coronary Disease
The discrepancy of aromatase expression in epicardial adipose tissue between CHD and non-CHD patients.
Cryptococcosis
Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report.
Cryptorchidism
Altered expression of CYP17A1 and CYP19A1 in undescended testes of dogs with unilateral cryptorchidism.
Cryptorchidism
Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase.
Cryptorchidism
Expression of aromatase and oestrogen receptors in reproductive tissues of the stallion and a single cryptorchid visualised by means of immunohistochemistry.
Cushing Syndrome
Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11?-hydroxylase.
Cystadenocarcinoma, Mucinous
Lack of evidence for aromatase expression in human ovarian epithelial carcinoma.
Cystadenocarcinoma, Mucinous
Liver Receptor Homologue-1 expression in ovarian epithelial and granulosa cell tumours.
Cystadenocarcinoma, Serous
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis.
Cystadenocarcinoma, Serous
Lack of evidence for aromatase expression in human ovarian epithelial carcinoma.
Cystadenocarcinoma, Serous
Liver Receptor Homologue-1 expression in ovarian epithelial and granulosa cell tumours.
Cystadenoma, Mucinous
Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
Cysticercosis
Inhibition of p-450 aromatase prevents feminisation and induces protection during cysticercosis.
Cysticercosis
Modified expression of steroid 5 alpha-reductase as well as aromatase, but not cholesterol side-chain cleavage enzyme, in the reproductive system of male mice during (Taenia crassiceps) cysticercosis.
Cysts
An epigenetic disorder may cause aberrant expression of aromatase gene in endometriotic stromal cells.
Cysts
Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman.
Cysts
Cell-specific knockout of steroidogenic factor 1 reveals its essential roles in gonadal function.
Cysts
Demethylation of a nonpromoter cytosine-phosphate-guanine island in the aromatase gene may cause the aberrant up-regulation in endometriotic tissues.
Cysts
Effects of phytoestrogens on the ovarian and pituitary phenotypes of estrogen-deficient female aromatase knockout mice.
Cysts
Exposure to ethinyl estradiol prenatally and/or after sexual maturity induces endometriotic and precancerous lesions in uteri and ovaries of mice.
Cysts
Immunocytochemical localization of aromatase in immature rat ovaries treated with PMSG and hCG, and in pregnant rat ovaries.
Cysts
Immunolocalization of aromatase in human minor salivary glands of the lower lip with primary Sjögren's syndrome.
Cysts
Induction of ovarian cysts in progesterone-synchronized immature rats: evidence that suppression of follicular aromatase activity is not a prerequisite for the induction of cystic follicles.
Cysts
Inflammatory status influences aromatase and steroid receptor expression in endometriosis.
Cysts
Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression.
Cysts
Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function.
Cysts
Spatially heterogeneous expression of aromatase P450 through promoter II is closely correlated with the level of steroidogenic factor-1 transcript in endometrioma tissues.
Cysts
The steroid hormone environment during primordial follicle formation in perinatal mouse ovaries.
Dehydration
Dehydrogenation of indoline by cytochrome P450 enzymes: a novel "aromatase" process.
Dementia
Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.
Dementia
Correction to: Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Dementia
Long-term use of tamoxifen reduces the risk of dementia: a nationwide population-based cohort study.
Dementia
Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study.
Dementia
Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Dementia
The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Demyelinating Diseases
Aromatase expression in the cerebellum of the dog infected with canine distemper virus.
Dental Plaque
Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis.
Dermatitis
Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events.
Diabetes Complications
Use of Network Pharmacology to Explore the Mechanism of Gegen (Puerariae lobatae Radix) in the Treatment of Type 2 Diabetes Mellitus Associated with Hyperlipidemia.
Diabetes Mellitus
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Diabetes Mellitus
Association of CYP19A1 and CYP1A2 genetic polymorphisms with type 2 diabetes mellitus risk in the Chinese Han population.
Diabetes Mellitus
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Diabetes Mellitus
Betaine ameliorates impaired steroidogenesis and apoptosis in mice granulosa cells induced by high glucose concentration.
Diabetes Mellitus
Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Diabetes Mellitus
Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
Diabetes Mellitus, Type 2
Association of CYP19A1 and CYP1A2 genetic polymorphisms with type 2 diabetes mellitus risk in the Chinese Han population.
Diabetes Mellitus, Type 2
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Diabetes Mellitus, Type 2
Breast Cancer Endocrine Therapy Promotes Weight Gain With Distinct Adipose Tissue Effects in Lean and Obese Female Mice.
Diabetes Mellitus, Type 2
Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone.
Diabetes Mellitus, Type 2
Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes.
Diabetes Mellitus, Type 2
Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis.
Diabetes Mellitus, Type 2
The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women.
Diabetes Mellitus, Type 2
The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer.
Diabetes Mellitus, Type 2
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease.
Diabetic Nephropathies
Angiotensin blockade attenuates diabetic nephropathy in hypogonadal adult male rats.
Diabetic Retinopathy
Association of CYP19A1 and CYP1A2 genetic polymorphisms with type 2 diabetes mellitus risk in the Chinese Han population.
Disorder of Sex Development, 46,XY
Increased peripheral aromatase activity in prepubertal children with partial androgen insensitivity syndrome.
Disorders of Sex Development
A case of female pseudohermaphroditism caused by aromatase deficiency.
Disorders of Sex Development
Aromatase Deficiency due to a Homozygous CYP19A1 Mutation in a 46,XX Egyptian Patient with Ambiguous Genitalia.
Disorders of Sex Development
Aromatase deficiency in an Ontario Old Order Mennonite family.
Disorders of Sex Development
Aromatase Deficiency in Two Siblings with 46, XX Karyotype Raised as Different Genders: A Novel Mutation (p.R115X) in CYP19A1 Gene
Disorders of Sex Development
Aromatase deficiency: a novel compound heterozygous mutation identified in a Chinese girl with severe phenotype and obvious maternal virilization.
Disorders of Sex Development
Aromatase deficiency: a rare cause of maternal virilisation and ambiguous genitalia in neonates.
Disorders of Sex Development
Evidence of endocrine alteration in the red mullet, Mullus barbatus from the NW Mediterranean.
Disorders of Sex Development
Female pseudohermaphroditism associated with a novel homozygous G-to-A (V370-to-M) substitution in the P-450 aromatase gene.
Disorders of Sex Development
Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene.
Disorders of Sex Development
Intersex condition and molecular markers of endocrine disruption in relation with burdens of emerging pollutants in thicklip grey mullets (Chelon labrosus) from Basque estuaries (South-East Bay of Biscay).
Disorders of Sex Development
Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR: Expanding the PORD Phenotype.
Disorders of Sex Development
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Disorders of Sex Development
Sex differences in autophagy-mediated diseases: toward precision medicine.
Disorders of Sex Development
Sexual differentiation of gonads as a function of temperature in the turtle Emys orbicularis: endocrine function, intersexuality and growth.
Disorders of Sex Development
Temperature-dependent sex determination and gonadal differentiation in reptiles.
Disorders of Sex Development
The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues.
Disorders of Sex Development
Variable phenotypes associated with aromatase (CYP19) insufficiency in humans.
Disorders of Sex Development
[Efficacy and safety of letrozole in treatment of male children with disorders of sex development].
Distemper
Aromatase expression in the cerebellum of the dog infected with canine distemper virus.
Drug Eruptions
Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District.
Drug-Related Side Effects and Adverse Reactions
Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Drug-Related Side Effects and Adverse Reactions
Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Drug-Related Side Effects and Adverse Reactions
Joint symptoms, aromatase inhibitor-related adverse reactions, are indirectly associated with decreased serum estradiol.
Drug-Related Side Effects and Adverse Reactions
Tamoxifen and the risk of Parkinsonism: a case/non-case study.
Drug-Related Side Effects and Adverse Reactions
TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-?B Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.
Dry Eye Syndromes
Dry eye signs and symptoms in aromatase inhibitor treatment and the relationship with pain.
Dysgerminoma
Lack of evidence for aromatase expression in human ovarian epithelial carcinoma.
Dyslexia
The aromatase gene CYP19A1: several genetic and functional lines of evidence supporting a role in reading, speech and language.
Dyslipidemias
Aromatase deficiency in a male patient - Case report and review of the literature.
Dyslipidemias
Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection.
Dyspareunia
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Dyspareunia
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Dyspareunia
Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Dyspareunia
Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.
Dyspareunia
Sexuality and quality of life in women with a prior diagnosis of breast cancer after risk-reducing salpingo-oophorectomy.
Dyspareunia
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Dyspareunia
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Endometrial Hyperplasia
Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies.
Endometrial Hyperplasia
Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women.
Endometrial Hyperplasia
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Endometrial Hyperplasia
Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity.
Endometrial Hyperplasia
Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases.
Endometrial Hyperplasia
In situ estrogen metabolism in proliferative endometria from untreated women with polycystic ovarian syndrome with and without endometrial hyperplasia.
Endometrial Hyperplasia
Letrozole as primary therapy for endometrial hyperplasia in young women.
Endometrial Hyperplasia
Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena) treatment of endometrial hyperplasia: an immunohistochemical study.
Endometrial Hyperplasia
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Endometrial Hyperplasia
The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer.
Endometrial Hyperplasia
[Aromatase activities of endometrial carcinomas and both basic and clinical analyses of endometrial hyperplasia as a premalignant disease]
Endometrial Hyperplasia
[Expressions of aromatase protein and sex hormone receptor in endometrial lesions.]
Endometrial Neoplasms
A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.
Endometrial Neoplasms
A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors.
Endometrial Neoplasms
Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer.
Endometrial Neoplasms
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
Endometrial Neoplasms
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Endometrial Neoplasms
Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17?-estradiol biosynthesis in endometrial carcinoma microenvironment.
Endometrial Neoplasms
Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology.
Endometrial Neoplasms
Altered expression of lysophosphatidic acid receptors, in association with the synthesis of estrogens and androgens in type 1 endometrial cancer biology.
Endometrial Neoplasms
Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy.
Endometrial Neoplasms
Aromatase activity and concentrations of cortisol, progesterone and testosterone in breast and abdominal adipose tissue.
Endometrial Neoplasms
Aromatase activity and the effect of estradiol and testosterone on DNA synthesis in endometrial carcinoma cell lines.
Endometrial Neoplasms
Aromatase and comparative response to its inhibitors in two types of endometrial cancer.
Endometrial Neoplasms
Aromatase expression and regulation in breast and endometrial cancer.
Endometrial Neoplasms
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Endometrial Neoplasms
Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival.
Endometrial Neoplasms
Aromatase expression was not detected by immunohistochemistry in endometrial cancer.
Endometrial Neoplasms
Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies.
Endometrial Neoplasms
Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?
Endometrial Neoplasms
Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth.
Endometrial Neoplasms
Aromatase inhibitor use during ovarian stimulation suppresses growth of uterine endometrial cancer in xenograft mouse model.
Endometrial Neoplasms
Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study.
Endometrial Neoplasms
Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.
Endometrial Neoplasms
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Endometrial Neoplasms
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Endometrial Neoplasms
Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
Endometrial Neoplasms
Association between genetic polymorphisms and endometrial cancer risk: a systematic review.
Endometrial Neoplasms
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Endometrial Neoplasms
Biological roles of estrogen and progesterone in human endometrial carcinoma--new developments in potential endocrine therapy for endometrial cancer.
Endometrial Neoplasms
Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Endometrial Neoplasms
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Endometrial Neoplasms
Committee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice.
Endometrial Neoplasms
Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes.
Endometrial Neoplasms
Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
Endometrial Neoplasms
Cyclooxygenase inhibitors may be more effective in hormone-dependent endometrial cancers: interaction between cyclooxygenase and aromatase.
Endometrial Neoplasms
CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity.
Endometrial Neoplasms
CYP19 gene expression and aromatase activity in endometrial cancer tissue: importance of the type of the disease.
Endometrial Neoplasms
CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer.
Endometrial Neoplasms
De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor.
Endometrial Neoplasms
Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity.
Endometrial Neoplasms
Decreased risk of breast cancer associated with oral bisphosphonate therapy.
Endometrial Neoplasms
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Endometrial Neoplasms
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Endometrial Neoplasms
Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma.
Endometrial Neoplasms
Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.
Endometrial Neoplasms
Endocrine disorders associated with inappropriately high aromatase expression.
Endometrial Neoplasms
Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors.
Endometrial Neoplasms
Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders.
Endometrial Neoplasms
Estrogen formation in endometrial and cervix cancer cell lines: Involvement of aromatase, steroid sulfatase and 17beta-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12).
Endometrial Neoplasms
Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells.
Endometrial Neoplasms
Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction.
Endometrial Neoplasms
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).
Endometrial Neoplasms
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Endometrial Neoplasms
Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer.
Endometrial Neoplasms
Expression of enzyme associated with steroid hormone synthesis and local production of steroid hormone in endometrial carcinoma cells.
Endometrial Neoplasms
Expression of estrogen receptors (?, ?), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.
Endometrial Neoplasms
Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Endometrial Neoplasms
Hormone therapy for patients with advanced or recurrent endometrial cancer.
Endometrial Neoplasms
Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Study.
Endometrial Neoplasms
Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Endometrial Neoplasms
Interaction between CYP19A1 polymorphisms and body mass index in the risk of endometrial cancer in postmenopausal Japanese women.
Endometrial Neoplasms
Interaction of soy food and tea consumption with CYP19A1 genetic polymorphisms in the development of endometrial cancer.
Endometrial Neoplasms
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Endometrial Neoplasms
Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer?
Endometrial Neoplasms
Leptin promotes human endometrial carcinoma cell proliferation by enhancing aromatase (P450arom) expression and estradiol formation.
Endometrial Neoplasms
Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma.
Endometrial Neoplasms
Local biosynthesis of estrogen in human endometrial carcinoma through tumor-stromal cell interactions.
Endometrial Neoplasms
MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma.
Endometrial Neoplasms
Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.
Endometrial Neoplasms
Neoadjuvant treatment of endometrial cancer using anastrozole: A randomised pilot study.
Endometrial Neoplasms
No evidence of a role for PPARgamma Pro12Ala polymorphism in endometrial cancer susceptibility.
Endometrial Neoplasms
Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation.
Endometrial Neoplasms
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
Endometrial Neoplasms
Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or decidua.
Endometrial Neoplasms
Polymorphisms in the CYP19A1 (Aromatase) gene and endometrial cancer risk in Chinese women.
Endometrial Neoplasms
Potent enzyme-activated inhibition of aromatase by a 7 alpha-substituted C19 steroid.
Endometrial Neoplasms
Preliminary clinical application of an aromatase inhibitor and a gonadotropin-releasing hormone agonist combination for inoperable endometrial cancer patients with comorbidities: case report and literature review.
Endometrial Neoplasms
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
Endometrial Neoplasms
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Endometrial Neoplasms
Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone.
Endometrial Neoplasms
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Endometrial Neoplasms
Synthesis and biochemical studies of 7-substituted 4,6-androstadiene-3,17-diones as aromatase inhibitors.
Endometrial Neoplasms
The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?
Endometrial Neoplasms
The nuclear receptors SF1 and LRH1 are expressed in endometrial cancer cells and regulate steroidogenic gene transcription by cooperating with AP-1 factors.
Endometrial Neoplasms
The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer.
Endometrial Neoplasms
The role of tissue steroids in regulating aromatase and oestradiol 17 beta-hydroxysteroid dehydrogenase activities in breast and endometrial cancer.
Endometrial Neoplasms
The therapeutic significance of aromatase inhibitors in endometrial carcinoma.
Endometrial Neoplasms
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis.
Endometrial Neoplasms
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy.
Endometrial Neoplasms
Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.
Endometrial Neoplasms
Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study.
Endometrial Neoplasms
Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review.
Endometrial Neoplasms
Variants in hormone biosynthesis genes and risk of endometrial cancer.
Endometrial Neoplasms
Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan.
Endometrial Neoplasms
[Aromatase (P450AROM) mRNA expression in normal, hyperplastic and malignant endometrium and aromatase activity in endometrial cancer tissue culture]
Endometrial Neoplasms
[Aromatase activities of endometrial carcinomas and both basic and clinical analyses of endometrial hyperplasia as a premalignant disease]
Endometrial Neoplasms
[Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma]
Endometrial Neoplasms
[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma]
Endometrial Neoplasms
[Efficacy of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
Endometrial Neoplasms
[Evaluation of aromatase inhibitors' side effects in clinical and experimental studies]
Endometrial Neoplasms
[Hormone-associated properties and plasticity of omental fat: the relation with clinical-morphological features of endometrial cancer in patients with different obesity phenotypes].
Endometrial Neoplasms
[Inhibiting effect of letrozole combined with curcumin on xenografted endometrial carcinoma growth in nude mice]
Endometrial Neoplasms
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole]
Endometrial Neoplasms
[Prospects for using aromatase inhibitors in treating endometrial cancer patients]
Endometrial Neoplasms
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Endometrial Neoplasms
[Tumor tissue aromatase and estrogen levels versus clinical course of endometrial cancer]
Endometriosis
A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis.
Endometriosis
A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF.
Endometriosis
Aberrant DNA methylation status of endometriosis: Epigenetics as the pathogenesis, biomarker and therapeutic target.
Endometriosis
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
Endometriosis
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Endometriosis
An Analysis of ESR2 and CYP19A1 Gene Expression Levels in Women With Endometriosis.
Endometriosis
An assessment of the multifactorial profile of steroid-metabolizing enzymes and steroid receptors in the eutopic endometrium during moderate to severe ovarian endometriosis.
Endometriosis
Analysis of aromatase and 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection.
Endometriosis
Anastrozole and celecoxib for endometriosis treatment, good to keep them apart?
Endometriosis
Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial.
Endometriosis
Androstenedione up-regulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis.
Endometriosis
Aromatase and other steroidogenic genes in endometriosis: translational aspects.
Endometriosis
Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis.
Endometriosis
Aromatase expression in endometriotic tissues and its relationship to clinical and analytical findings.
Endometriosis
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Endometriosis
Aromatase inhibitor (anastrozole) affects growth of endometrioma cells in culture.
Endometriosis
Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman.
Endometriosis
Aromatase inhibitor regulates let-7 expression and let-7f-induced cell migration in endometrial cells from women with endometriosis.
Endometriosis
Aromatase inhibitor treatment limits progression of peritoneal endometriosis in baboons.
Endometriosis
Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions--old answers?
Endometriosis
Aromatase Inhibitors for Endometriosis-Associated Infertility; Do We Have Sufficient Evidence?
Endometriosis
Aromatase inhibitors for the treatment of endometriosis: a systematic review about efficacy, safety and early clinical development.
Endometriosis
Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review.
Endometriosis
Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists.
Endometriosis
Aromatase P450 messenger RNA expression in eutopic endometrium is not a specific marker for pelvic endometriosis.
Endometriosis
Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target.
Endometriosis
Association between CYP19A1, GSTM1, GSTT1, and GSTP1 genetic polymorphisms and the development of endometriosis in a Chinese population.
Endometriosis
Association between single nucleotide polymorphism of the CYP19A1 and ESR2 genes and endometriosis.
Endometriosis
Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives.
Endometriosis
c-fos gene and protein expression in pelvic endometriosis: a local marker of estrogen action.
Endometriosis
C-Jun NH2-Terminal Kinase and p38 Inhibition Suppresses Prostaglandin E2-Stimulated Aromatase and Estrogen Receptor Levels in Human Endometriosis.
Endometriosis
Clotrimazole reduces endometriosis and the estrogen concentration by downregulating aromatase.
Endometriosis
Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study.
Endometriosis
Combined Effect of the PGR +331C?>?T, CYP17A1 -34A?>?G and CYP19A1 1531G?>?A Polymorphisms on the Risk of Developing Endometriosis.
Endometriosis
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Endometriosis
Correlation between aromatase expression in the eutopic endometrium of symptomatic patients and the presence of endometriosis.
Endometriosis
CYP19 gene variant confers susceptibility to endometriosis-associated infertility in Chinese women.
Endometriosis
Danazol inhibits aromatase activity of endometriosis-derived stromal cells by a competitive mechanism.
Endometriosis
Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity.
Endometriosis
Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol.
Endometriosis
Demethylation of a nonpromoter cytosine-phosphate-guanine island in the aromatase gene may cause the aberrant up-regulation in endometriotic tissues.
Endometriosis
Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis.
Endometriosis
Detection of endometriosis using immunocytochemistry of P450 Aromatase expressions in eutopic endometrial cells obtained from menstrual sloughing: a diagnostic study.
Endometriosis
Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis.
Endometriosis
Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells.
Endometriosis
Dienogest, a synthetic progestin, inhibits prostaglandin E(2) production and aromatase expression by human endometrial epithelial cells in a spheroid culture system.
Endometriosis
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Endometriosis
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection.
Endometriosis
Down-regulation of the CYP19A1 gene in cumulus cells of infertile women with endometriosis.
Endometriosis
Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis.
Endometriosis
Effect of letrozole on estradiol production and P450 aromatase messenger RNA expression of cultured luteinized granulosa cells from women with and without endometriosis.
Endometriosis
Effect of local aromatase inhibition in endometriosis using a new chick embryo chorioallantoic membrane model.
Endometriosis
Effect of Yikun Neiyi Wan on the expression of aromatase P450, COX-2, and ER related receptor in endometrial cells in vitro from patients with endometriosis.
Endometriosis
Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis.
Endometriosis
Effects of progestins on local estradiol biosynthesis and action in the Z-12 endometriotic epithelial cell line.
Endometriosis
Endocrine disorders associated with inappropriately high aromatase expression.
Endometriosis
Endometrial and peritoneal expression of aromatase, cytokines, and adhesion factors in women with endometriosis.
Endometriosis
Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis.
Endometriosis
Endometrial seedlings. A survival instinct? Immunomodulation and its role in the pathophysiology of endometriosis.
Endometriosis
Endometriosis after menopause: physiopathology and management of an uncommon condition.
Endometriosis
Endometriosis as a detrimental condition for granulosa cell steroidogenesis and development: From molecular alterations to clinical impact.
Endometriosis
Epigenetic alterations of CYP19A1 gene in Cumulus cells and its relevance to infertility in endometriosis.
Endometriosis
Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance.
Endometriosis
Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis.
Endometriosis
Estrogen receptor-? immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis.
Endometriosis
Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis.
Endometriosis
Expression of aromatase (P450 aromatase/CYP19) in peritoneal and ovarian endometriotic tissues and deep endometriotic (adenomyotic) nodules of the rectovaginal septum.
Endometriosis
Expression of aromatase and estrogen sulfotransferase in eutopic and ectopic endometrium: evidence for unbalanced estradiol production in endometriosis.
Endometriosis
Expression of aromatase cytochrome P450 in eutopic endometrium and its application as a diagnostic test for endometriosis.
Endometriosis
Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium.
Endometriosis
Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility.
Endometriosis
Farnesoid X Receptor Agonist GW4064 Inhibits Aromatase and ER? Expression in Human Endometriotic Stromal Cells.
Endometriosis
From pathogenesis to clinical practice: Emerging medical treatments for endometriosis.
Endometriosis
Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue.
Endometriosis
Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas.
Endometriosis
Gonadotropin-Releasing Hormone Agonist Reduces Aromatase Cytochrome P450 and Cyclooxygenase-2 in Ovarian Endometrioma and Eutopic Endometrium of Patients with Endometriosis.
Endometriosis
High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome.
Endometriosis
Identification of common mechanisms between endometriosis and ovarian cancer.
Endometriosis
IGF-I stimulates ER? and aromatase expression via IGF1R/PI3K/AKT-mediated transcriptional activation in endometriosis.
Endometriosis
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis.
Endometriosis
Immunomodulators and aromatase inhibitors: are they the next generation of treatment for endometriosis?
Endometriosis
Inflammatory status influences aromatase and steroid receptor expression in endometriosis.
Endometriosis
Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy.
Endometriosis
Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis.
Endometriosis
Initial endometriosis showing direct morphologic evidence of metaplasia in the pathogenesis of ovarian endometriosis.
Endometriosis
Interleukin-4 and Prostaglandin E2 Synergistically Up-Regulate 3?-Hydroxysteroid Dehydrogenase Type 2 in Endometrioma Stromal Cells.
Endometriosis
Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression.
Endometriosis
Investigational drugs for the treatment of endometriosis, an update on recent developments.
Endometriosis
Is aromatase expression in the endometrium the cause of endometriosis and related infertility?
Endometriosis
Leptin, its receptor and aromatase expression in deep infiltrating endometriosis.
Endometriosis
Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis.
Endometriosis
Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis.
Endometriosis
Letrozole stimulates the growth of human endometrial explants cultured in three-dimensional fibrin matrix.
Endometriosis
Lipoxin A4 inhibits the development of endometriosis in a mouse model by suppressing local estradiol synthesis.
Endometriosis
Liver receptor homologue-1 and steroidogenic factor-1 expression in cultured granulosa cells from patients with endometriosis: A preliminary study.
Endometriosis
Macrophage migration inhibitory factor is involved in a positive feedback loop increasing aromatase expression in endometriosis.
Endometriosis
Management of recurrent implantation failure by gonadotropin-releasing hormone agonist and aromatase inhibitor suppression, in women without evidence of endometriosis.
Endometriosis
Medical treatment in the management of deep endometriosis infiltrating the proximal rectum and sigmoid colon: a comprehensive literature review.
Endometriosis
MicroRNA23a and MicroRNA23b Deregulation Derepresses SF-1 and Upregulates Estrogen Signaling in Ovarian Endometriosis.
Endometriosis
Mouse model for endometriosis is characterized by proliferation and inflammation but not epithelial-to-mesenchymal transition and fibrosis.
Endometriosis
New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
Endometriosis
Novel therapeutic targets to improve IVF outcomes in endometriosis patients: a review and future prospects.
Endometriosis
Patients with endometriosis and patients with poor ovarian reserve have abnormal follicle-stimulating hormone receptor signaling pathways.
Endometriosis
Peroxisome proliferator-activated receptor ? agonist suppresses human telomerase reverse transcriptase expression and aromatase activity in eutopic endometrial stromal cells from endometriosis.
Endometriosis
Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Alpha Enhances Local Estrogen Biosynthesis by Stimulating Aromatase Activity in Endometriosis.
Endometriosis
Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor.
Endometriosis
Pharmacological treatment of endometriosis: experience with aromatase inhibitors.
Endometriosis
Polymorphic variants of CYP17 and CYP19A and risk of infertility in endometriosis.
Endometriosis
Polymorphisms in ESR1, ESR2 and HSD17B1 genes are associated with fertility status in endometriosis.
Endometriosis
Polymorphisms in the 3'UTR Region of ESR2 and CYP19A1 Genes in Women With Endometriosis.
Endometriosis
Post-menopausal endometriosis with inferior vena cava invasion requiring surgical management.
Endometriosis
Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium.
Endometriosis
Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells.
Endometriosis
Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis.
Endometriosis
Providing new insights into the endometriosisassociated cancer arising in episiotomy scars.
Endometriosis
Reduced aromatase activity in granulosa cells of women with endometriosis undergoing assisted reproduction techniques.
Endometriosis
Reduced preovulatory granulosa cell steroidogenesis in women with endometriosis.
Endometriosis
Reduction in Endometrioma Size with Three Months of Aromatase Inhibition and Progestin Add-Back.
Endometriosis
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Endometriosis
Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase.
Endometriosis
Regulation of Inflammation Pathways and Inflammasome by Sex Steroid Hormones in Endometriosis.
Endometriosis
Role of inflammation and aromatase expression in the eutopic endometrium and its relationship with the development of endometriosis.
Endometriosis
Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women.
Endometriosis
Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study.
Endometriosis
Screening of a panel of steroid-related genes showed polymorphisms of aromatase genes confer susceptibility to advanced stage endometriosis in the Taiwanese Han population.
Endometriosis
Selective estrogen-receptor modulators and aromatase inhibitors: promising new medical therapies for endometriosis?
Endometriosis
Serum dioxin-like compounds and aromatase (CYP19) expression in endometriotic tissues.
Endometriosis
Seven Hormonal Biomarkers for Diagnosing Endometriosis: Meta-Analysis and Adjusted Indirect Comparison of Diagnostic Test Accuracy.
Endometriosis
Smad3/4 Binding to Promoter II of P450arom So As to Regulate Aromatase Expression in Endometriosis.
Endometriosis
Spatially heterogeneous expression of aromatase P450 through promoter II is closely correlated with the level of steroidogenic factor-1 transcript in endometrioma tissues.
Endometriosis
Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element.
Endometriosis
Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats.
Endometriosis
Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor.
Endometriosis
Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients.
Endometriosis
Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor.
Endometriosis
SULFATION PATHWAYS: Contribution of intracrine oestrogens to the aetiology of endometriosis.
Endometriosis
Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis.
Endometriosis
The effect of oral contraceptives on aromatase expression in the eutopic endometrium of patients with endometriosis.
Endometriosis
The effects of dietary phytoestrogens on aromatase activity in human endometrial stromal cells.
Endometriosis
The Genetic Background of Endometriosis: Can ESR2 and CYP19A1 Genes Be a Potential Risk Factor for Its Development?
Endometriosis
Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study.
Endometriosis
Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman.
Endometriosis
Upstream stimulatory factor-2 regulates steroidogenic factor-1 expression in endometriosis.
Endometriosis
Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review.
Endometriosis
[Aromatase inhibitors--is it a new opportunity in the treatment of infertility?]
Endometriosis
[Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis]
Endometriosis
[Comparison of steroid metabolism markers in endometrium of women with endometriosis, endometrial hyperplasia and without pathological changes of endometrium]
Endometriosis
[Correlation between polymorphism of CYP19A1, GSTM1, GSTT1 and GSTP1 gene and endometriosis].
Endometriosis
[Cytochrome P-450 aromatase expression in the ectopic and eutopic endometrium in endometriosis]
Endometriosis
[Diagnostic value of the detection of aromatase cytochrome P450 and CA125 for endometriosis]
Endometriosis
[Expressions of aromatase P450 and estrogen receptor in eutopic and ectopic endometrium in endometriosis and their correlation with endometriosis]
Endometriosis
[Inhibitory effect on estrogen production and its influence on invasive ability of human endometrial cells of endometriosis by medicated serum of SLW]
Endometriosis
[Inhibitory effects of Sanlengwan on aromatase and cyclooxygenase-2 in rats of endometriosis]
Endometriosis
[New medical treatments for painful endometriosis: CNGOF-HAS Endometriosis Guidelines].
Endometriosis
[Perspectives on endometriosis: new physiopathologic approaches and treatments]
Endometriosis
[Semiquantitative analysis of mRNA aromatase expression in eutopic endometrium as a diagnostic marker of endometriosis and estrogen dependent diseases]
Endometriosis
[Treatment of endometriosis by aromatase inhibitors: Efficacy and side effects.]
Endometritis
Defining Postpartum Uterine Disease and the Mechanisms of Infection and Immunity in the Female Reproductive Tract in Cattle.
Enophthalmos
Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma.
Epilepsy
A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism.
Epilepsy
Interactions of Aromatase and Seladin-1: A Neurosteroidogenic and Gender Perspective.
Epilepsy
Mass spectrometric assay and physiological-pharmacological activity of androgenic neurosteroids.
Epilepsy
Neuroprotection by estradiol: a role of aromatase against spine synapse loss after blockade of GABA(A) receptors.
Epilepsy
Psychoneuroendocrine aspects of temporolimbic epilepsy. Part II: Epilepsy and reproductive steroids.
Erectile Dysfunction
The association between elevated serum oestradiol levels and clinically significant erectile dysfunction in men presenting for andrological evaluation.
Erythema
Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District.
Erythema Multiforme
Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.
Erythema Nodosum
Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.
Esophageal Neoplasms
MassARRAY analysis of twelve cancer related SNPs in esophageal squamous cell carcinoma in J&K, India.
Essential Hypertension
Association study of aromatase gene (CYP19A1) in essential hypertension.
Fatty Liver
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Fatty Liver
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Fecal Incontinence
Aromatase Inhibitors Are Associated With Low Sexual Desire Causing Distress and Fecal Incontinence in Women: An Observational Study.
Fetal Growth Retardation
Altered umbilical sex steroids in preterm infants born small for gestational age.
Fetal Growth Retardation
Intrauterine growth restriction alters hippocampal expression and chromatin structure of Cyp19a1 variants.
Fetal Growth Retardation
Placental ESRRG-CYP19A1 Expressions and Circulating 17-Beta Estradiol in IUGR Pregnancies.
Fetal Macrosomia
Association between rankl [RS9594759] and IL10 [RS1800896] Genes polymorphism and deciduous tooth eruption terms in Ukrainians born macrosomic.
Fibroadenoma
Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma.
Fibroma
Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.
Fibroma
Response of estrogen receptor-positive intraabdominal fibromatosis to aromatase inhibitor therapy.
Fibroma
Testicular sex cord-stromal lesions: immunohistochemical analysis of cytokeratin, vimentin and steroidogenic enzymes.
Fibromatosis, Aggressive
Complete response to exemestane in a patient with a desmoid tumor.
Fibromatosis, Aggressive
Fertility preservation and PGT-M in women with familial adenomatous polyposis-associated desmoid tumours.
Fibrosarcoma
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Fibrous Dysplasia, Polyostotic
Anastrozole plus leuprorelin in early maturing girls with compromised growth: the "GAIL" study.
Fibrous Dysplasia, Polyostotic
Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.
Fibrous Dysplasia, Polyostotic
Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
Fibrous Dysplasia, Polyostotic
Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study.
Fibrous Dysplasia, Polyostotic
Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.
Fibrous Dysplasia, Polyostotic
Luteinizing hormone-releasing hormone (LHRH)-independent precocious puberty unresponsive to LHRH agonist therapy in two girls lacking features of the McCune-Albright syndrome.
Fibrous Dysplasia, Polyostotic
Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome.
Fibrous Dysplasia, Polyostotic
Testolactone treatment of precocious puberty in McCune-Albright syndrome.
Fibrous Dysplasia, Polyostotic
The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome.
Fibrous Dysplasia, Polyostotic
Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.
Fibrous Dysplasia, Polyostotic
[Efficacy and safety of letrozole in treatment of McCune-Albright syndrome girls with peripheral precocious puberty].
Follicular Cyst
Induction of ovarian cysts in progesterone-synchronized immature rats: evidence that suppression of follicular aromatase activity is not a prerequisite for the induction of cystic follicles.
Fractures, Spontaneous
[On "2015 Guidelines for Prevention and Treatment of Osteoporosis" . Osteoporosis associated with sex hormone depletion treatment].
Genetic Diseases, Inborn
Aromatase excess syndrome: a rare autosomal dominant disorder leading to pre- or peri-pubertal onset gynecomastia.
Genetic Diseases, Inborn
Congenital hypopituitarism as a cause of undetectable estriol levels in the maternal triple-marker screen.
Genital Diseases, Female
Correlation between bone mineral density and endometrial thickness over time in women with breast cancer history.
Gingival Overgrowth
Estrogen suppression induces papillary gingival overgrowth in pregnant baboons.
Glioblastoma
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
Glioblastoma
Aromatase, the enzyme responsible for estrogen biosynthesis, is expressed by human and rat glioblastomas.
Glioblastoma
High expression of estrogen receptor alpha and aromatase in glial tumor cells is associated with gender-independent survival benefits in glioblastoma patients.
Glioblastoma
Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells.
Glioblastoma
Pre-clinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas.
Glioma
Effects of morphine on testosterone levels in rat C6 glioma cells: modulation by anastrozole.
Glioma
Effects of vitamin D in the nervous system: Special focus on interaction with steroid hormone signalling and a possible role in the treatment of brain cancer.
Glioma
Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights.
Glioma
Inhibitory effects of melatonin on sulfatase and 17beta-hydroxysteroid dehydrogenase activity and expression in glioma cells.
Glioma
Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells.
Glioma
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Glioma
Pre-clinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas.
Glioma
Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells.
Glioma
The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis.
Glucose Intolerance
Accelerated conversion of dehydroepiandrosterone sulfate to estrogen in a patient with Crow-Fukase syndrome and diabetes mellitus.
Glucose Intolerance
Effect of Pregnancy on Paroxetine-Induced Adiposity and Glucose Intolerance in Mice.
Glucose Intolerance
Hepatic glucose intolerance precedes hepatic steatosis in the male aromatase knockout (ArKO) mouse.
Glucose Intolerance
Increased adipose tissue in male and female estrogen receptor-alpha knockout mice.
Glucose Intolerance
Serotonin transporter deficiency drives estrogen-dependent obesity and glucose intolerance.
Glucose Intolerance
The role of estrogen and estrogen receptor-alpha in male adipose tissue.
Glucose Metabolism Disorders
Maternal lipopolysaccharide exposure results in glucose metabolism disorders and sex hormone imbalance in male offspring.
Gonadal Dysgenesis
A large cohort of disorders of sex development and their genetic characteristics: 6 novel mutations in known genes.
Gonadal Dysgenesis
Fertility issues in the management of patients with disorders of sex development.
Gonadal Dysgenesis
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Gonadal Dysgenesis
Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
Granular Cell Tumor
Aromatase inhibitors prevent spontaneous granular cell tumors in the distal female reproductive tract of Sprague-Dawley rats.
Granulosa Cell Tumor
Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
Granulosa Cell Tumor
Aromatase Inhibitor Therapy As Effective Rescue in a Patient With Tamoxifen-Refractory Metastatic Granulosa Cell Tumor of the Ovary.
Granulosa Cell Tumor
Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature.
Granulosa Cell Tumor
Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.
Granulosa Cell Tumor
Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter.
Granulosa Cell Tumor
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer.
Granulosa Cell Tumor
Expression of P450 Aromatase in Granulosa Cell Tumors and Sertoli-Stromal Cell Tumors of the Ovary: Which Cells Are Responsible for Estrogenesis?
Granulosa Cell Tumor
Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.
Granulosa Cell Tumor
Liver Receptor Homologue-1 expression in ovarian epithelial and granulosa cell tumours.
Granulosa Cell Tumor
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Granulosa Cell Tumor
Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor.
Granulosa Cell Tumor
Unusual Virilization in Girls with Juvenile Granulosa Cell Tumors of the Ovary Is Related to Intratumoral Aromatase Deficiency.
Growth Hormone-Secreting Pituitary Adenoma
Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis.
Gynecomastia
An aroma of complexity: how the unique genetics of aromatase (CYP19A1) explain diverse phenotypes from hens and hyenas to human gynecomastia, and testicular and other tumors.
Gynecomastia
An open label, dose response study to determine the effect of a dietary supplement on dihydrotestosterone, testosterone and estradiol levels in healthy males.
Gynecomastia
Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study.
Gynecomastia
Aromatase excess syndrome presenting with prepubertal gynecomastia in an Egyptian child with type 1 neurofibromatosis.
Gynecomastia
Aromatase excess syndrome: a rare autosomal dominant disorder leading to pre- or peri-pubertal onset gynecomastia.
Gynecomastia
Aromatase Excess Syndrome: Identification of Cryptic Duplications and Deletions Leading to Gain of Function of CYP19A1 and Assessment of Phenotypic Determinants.
Gynecomastia
Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology.
Gynecomastia
Combined surgical and medical treatment in an adolescent with severe gynecomastia due to excessive estradiol secretion: a case report.
Gynecomastia
Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred.
Gynecomastia
Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.
Gynecomastia
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Gynecomastia
Familial gynecomastia with increased extraglandular aromatization of plasma carbon19-steroids.
Gynecomastia
Genetic variants of estrogen beta and leptin receptors may cause gynecomastia in adolescent.
Gynecomastia
Gynecomastia due to hormone therapy for advanced prostate cancer: a report of ten surgically treated cases and a review of treatment options.
Gynecomastia
High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child.
Gynecomastia
Increased aromatase activity in pubic skin fibroblasts from patients with isolated gynecomastia.
Gynecomastia
Management of prepubertal gynecomastia in two monozygotic twins with peutz-jeghers syndrome: from aromatase inhibitors to subcutaneous mastectomy.
Gynecomastia
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma.
Gynecomastia
On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production.
Gynecomastia
Overexpression of aromatase associated with loss of heterozygosity of the STK11 gene accounts for prepubertal gynecomastia in boys with Peutz Jeghers Syndrome.
Gynecomastia
Overexpression of aromatase in transgenic male mice results in the induction of gynecomastia and other biochemical changes in mammary glands.
Gynecomastia
Possible involvement of aromatase overexpression induced by cyclo-oxygenase-2 in the pathogenesis of idiopathic gynecomastia.
Gynecomastia
Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor.
Gynecomastia
Prepubertal Gynecomastia in Two Monozygotic Twins with Peutz-Jeghers Syndrome: Two Years' Treatment with Anastrozole and Genetic Study.
Gynecomastia
Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene.
Gynecomastia
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
Gynecomastia
Serum inhibin B concentration in a prepubertal boy with gynecomastia and Peutz-Jeghers syndrome.
Gynecomastia
The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription.
Gynecomastia
Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole.
Gynecomastia
Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole.
Gynecomastia
Understanding the pathological manifestations of aromatase excess syndrome: lessons for clinical diagnosis.
Gynecomastia
Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development.
Gynecomastia
Use of aromatase inhibitors in large cell calcifying sertoli cell tumors: effects on gynecomastia, growth velocity, and bone age.
Gynecomastia
Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice.
Gynecomastia
[Hormonal profile of idiopathic gynecomastia in young adults. Apropos of 488 cases]
Hallucinations
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Hamartoma
Delayed closure of epiphyseal cartilages induced by the aromatase inhibitor anastrozole. Would it help short children grow up?
Head and Neck Neoplasms
Recent advances in oncology acupuncture and safety considerations in practice.
Head Injuries, Penetrating
A Quantification of the Injury-Induced Changes in Central Aromatase, Oestrogenic Milieu and Steroid Receptor Expression in the Zebra Finch.
Head Injuries, Penetrating
Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair.
Heart Diseases
Association of aromatase inhibitors with coronary heart disease in women with early breast cancer.
Heart Failure
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
Heart Failure, Systolic
Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure.
Hemangiosarcoma
Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.
Hepatolenticular Degeneration
Endocrine studies of the ovulatory disturbances in Wilson's disease (hepatolenticular degeneration).
Herpes Zoster
Aromatase Derived Estradiol Within the Thalamus Modulates Pain Induced by Varicella Zoster Virus.
Herpes Zoster
Aromatase expression in the normal human adult adrenal and in adrenocortical tumors: biochemical, immunohistochemical, and molecular studies.
Herpes Zoster
Aromatase immunoreactivity in the rat brain: gonadectomy-sensitive hypothalamic neurons and an unresponsive "limbic ring" of the lateral septum-bed nucleus-amygdala complex.
Herpes Zoster
Corrigendum: Aromatase Derived Estradiol Within the Thalamus Modulates Pain Induced by Varicella Zoster Virus.
Herpes Zoster
Expression of the IGF and the aromatase/estrogen receptor systems in human adrenal tissues from early infancy to late puberty: Implications for the development of adrenarche.
Herpes Zoster
Gonado-histopathological changes, intersex and endocrine disruptor responses in relation to contaminant burden in Tilapia species from Ogun River, Nigeria.
Herpes Zoster
Morphometric characteristics of preantral and antral follicles and expression of factors involved in folliculogenesis in ovaries of adult baboons (Papio anubis).
Hirsutism
Aromatase Deficiency in Two Siblings with 46, XX Karyotype Raised as Different Genders: A Novel Mutation (p.R115X) in CYP19A1 Gene
Hirsutism
Idiopathic hirsutism: local and peripheral expression of aromatase (CYP19A) and 5?-reductase genes (SRD5A1 and SRD5A2).
Hirsutism
Sex steroids, adiposity and smoking in the pathogenesis of idiopathic hirsutism and polycystic ovary syndrome.
Hydatidiform Mole
Quantitative evaluation of human placental aromatase in abnormal pregnancy--anencephalus and hydatidiform mole.
Hydronephrosis
Retroperitoneal leiomyomata as a cause of bilateral hydronephrosis and lumbosciatic pain.
Hyperaldosteronism
Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?
Hyperalgesia
Aromatase inhibition exacerbates pain and reactive gliosis in the dorsal horn of the spinal cord of female rats caused by spinothalamic tract injury.
Hyperalgesia
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Hyperalgesia
Expression of aromatase in the rostral ventromedial medulla and its role in the regulation of visceral pain.
Hyperalgesia
Pharmacological Modulation of Endogenous Opioid Activity to Attenuate Neuropathic Pain in Rats.
Hyperalgesia
The relationship of bone-tumor-induced spinal cord astrocyte activation and aromatase expression to mechanical hyperalgesia and cold hypersensitivity in intact female and ovariectomized mice.
Hyperandrogenism
Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women.
Hyperandrogenism
Extra-Ovarian Gonadotropin Negative Feedback Revealed by Aromatase Inhibition in Female Marmoset Monkeys.
Hyperandrogenism
Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women.
Hyperandrogenism
Growth factor-mediated regulation of aromatase activity in human skin fibroblasts.
Hyperandrogenism
Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Hyperandrogenism
Pathophysiological mechanisms of gonadotropins- and steroid hormones-related genes in etiology of polycystic ovary syndrome.
Hyperandrogenism
Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia.
Hyperandrogenism
Serum insulin-like factor 3 levels during puberty in healthy boys and boys with Klinefelter syndrome.
Hyperandrogenism
SNP rs2470152 in CYP19 is correlated to aromatase activity in Chinese polycystic ovary syndrome patients.
Hyperandrogenism
Unusual Virilization in Girls with Juvenile Granulosa Cell Tumors of the Ovary Is Related to Intratumoral Aromatase Deficiency.
Hypercalcemia
Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Hypercalcemia
Usefulness of 22-oxa-1,25-dihydroxyvitamin D-3 (OCT) as a single agent or combined therapy with aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Hypercholesterolemia
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Hypercholesterolemia
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
Hyperinsulinism
CYP19 gene expression in subcutaneous adipose tissue is associated with blood pressure in women with polycystic ovary syndrome.
Hyperinsulinism
Hepatic glucose intolerance precedes hepatic steatosis in the male aromatase knockout (ArKO) mouse.
Hyperinsulinism
Insulin increases 17 beta-estradiol production by the dominant follicle of the first postpartum follicle wave in dairy cows.
Hyperinsulinism
The effect of insulin on aromatase activity in isolated human endometrial glands and stroma.
Hyperinsulinism
The effects of experimental hyperinsulinemia on steroid secretion, ovarian [125I]insulin binding, and ovarian [125I]insulin-like growth-factor I binding in the rat.
Hyperlipidemias
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Hyperparathyroidism
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Hyperparathyroidism, Primary
Vertebral fractures cascade: potential causes and risk factors.
Hyperprolactinemia
In vitro effects of prolactin and dexamethasone on rat Leydig cell aromatase activity.
Hyperprolactinemia
Long-term hyperprolactinaemia reduces basal but not androgen-stimulated oestradiol production in small antral follicles of the rat ovary.
Hyperprolactinemia
Menometrorrhagia, infertility, elevated serum estradiol, and hyperprolactinemia resulting from increased aromatase activity (MIEHA syndrome).
Hyperprolactinemia
Testicular response to human chorionic gonadotrophin in chronic hyperprolactinaemia.
Hyperprolactinemia
The effects of prolactin on rat testicular steroidogenic enzyme activities.
Hypersensitivity
Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways.
Hypersensitivity
Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Hypersensitivity
Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
Hypersensitivity
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Hypersensitivity
Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.
Hypersensitivity
The relationship of bone-tumor-induced spinal cord astrocyte activation and aromatase expression to mechanical hyperalgesia and cold hypersensitivity in intact female and ovariectomized mice.
Hypersensitivity, Delayed
Delayed hypersensitivity reactions to multiple aromatase inhibitors followed by successful desensitization to letrozole.
Hypertension
19-Nor-corticosteroids in genetic hypertension. Effects of inhibitors of 11 beta, 18, 19-hydroxylase activity.
Hypertension
A genetic polymorphism in the CYP19A1 gene and the risk of hypertension among midlife women.
Hypertension
Anastrozole in Pulmonary Arterial Hypertension (AIPH): A Randomized, Double-Blind Placebo-Controlled Trial.
Hypertension
Antihypertensive effects of an aromatase inhibitor in the spontaneously hypertensive rat.
Hypertension
Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).
Hypertension
Sex and body mass index specific regulation of blood pressure by CYP19A1 gene variants.
Hypertension
Sex- and Obesity-specific Association of Aromatase (CYP19A1) Gene Variant with Apolipoprotein B and Hypertension.
Hypertension, Pregnancy-Induced
Aromatase and estrogen 2-hydroxylase activities of human placental microsomes in pregnancy-induced hypertension.
Hypertension, Pulmonary
Anastrozole in Pulmonary Arterial Hypertension (AIPH): A Randomized, Double-Blind Placebo-Controlled Trial.
Hypertension, Pulmonary
Metformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition.
Hyperthyroidism
Aromatase activity of human adipose tissue stromal cells: effects of thyroid hormones and progestogens.
Hyperthyroidism
Inhibition of follicle-stimulating hormone induction of aromatase activity in porcine granulosa cells by thyroxine and triiodothyronine.
Hyperthyroidism
Thyroid hormone modulates offspring sex ratio in a turtle with temperature-dependent sex determination.
Hyperthyroidism
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Hypesthesia
A prospective study of aromatase inhibitor therapy initiation and self-reported side effects.
Hypoglycemia
Ultra-High-Performance Liquid Chromatography-Electrospray Ionization-Mass Spectrometry for High-Neuroanatomical Resolution Quantification of Brain Estradiol Concentrations.
Hypogonadism
A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom).
Hypogonadism
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Hypogonadism
Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood.
Hypogonadism
Aromatase inhibition for the treatment of idiopathic hypogonadotropic hypogonadism in men with premature ejaculation.
Hypogonadism
Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects.
Hypogonadism
Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion.
Hypogonadism
Cognition is not modified by large but temporary changes in sex hormones in men.
Hypogonadism
Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone.
Hypogonadism
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Hypogonadism
Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred.
Hypogonadism
Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.
Hypogonadism
Effect of Lifestyle Intervention on the Hormonal Profile of Frail, Obese Older Men.
Hypogonadism
Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.
Hypogonadism
High aromatase activity in hypogonadal men is associated with higher spine bone mineral density, increased truncal fat and reduced lean mass.
Hypogonadism
How does obesity affect fertility in men - and what are the treatment options?
Hypogonadism
Hypogonadism Associated with Cyp19a1 (Aromatase) Posttranscriptional Upregulation in Celf1 Knockout Mice.
Hypogonadism
Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism.
Hypogonadism
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Hypogonadism
Oxytocin mediates the estrogen-dependent contractile activity of endothelin-1 in human and rabbit epididymis.
Hypogonadism
Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone.
Hypogonadism
Sex steroids and sexual desire in a man with a novel mutation of aromatase gene and hypogonadism.
Hypogonadism
Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone.
Hypogonadism
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
Hypogonadism
Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads.
Hypospadias
A loss of estrogen signaling in the aromatase deficient mouse penis results in mild hypospadias.
Hypospadias
Dysregulated expression of androgen metabolism genes and genetic analysis in hypospadias.
Hypospadias
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Hypotension
Indinavir inhibits the expression of cytoplasmic aromatase and nuclear SREBP in the hippocampus of reperfusion injury-induced ischemic rats.
Hypotension
Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBP? in reperfusion injury-induced ischemic rat hippocampus.
Hypothyroidism
Hypothyroidism affects lipid and glycogen content and peroxisome proliferator-activated receptor ? expression in the ovary of the rabbit.
Infarction, Middle Cerebral Artery
Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection.
Infarction, Middle Cerebral Artery
Estrogen synthesis in the central nucleus of the amygdala following middle cerebral artery occlusion: role in modulating neurotransmission.
Infections
Aromatase expression in the cerebellum of the dog infected with canine distemper virus.
Infections
Endotoxin induced TLR4 signaling downregulates CYP19A1 expression through CEBPB in buffalo granulosa cells.
Infections
Immediate breast reconstruction surgery with expander/direct implant and use of acellular dermal matrix: Does hormone therapy increases the risk of infection?
Infections
Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad.
Infections
Ligula intestinalis infection is associated with alterations of both brain and gonad aromatase expression in roach ( Rutilus rutilus).
Infections
Liver receptor homolog-1 stimulates the progesterone biosynthetic pathway during follicle-stimulating hormone-induced granulosa cell differentiation.
Infections
Localization and regulation of aromatase liver receptor homologue-1 in the developing rat testis.
Infertility
A randomized comparison of ovulation induction and hormone profile between the aromatase inhibitor anastrozole and clomiphene citrate in women with infertility.
Infertility
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Infertility
A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility.
Infertility
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
Infertility
Aromatase inhibition for ovarian stimulation: future avenues for infertility management.
Infertility
Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility.
Infertility
Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation.
Infertility
Aromatase Inhibitors for Endometriosis-Associated Infertility; Do We Have Sufficient Evidence?
Infertility
Aromatase inhibitors for infertility in polycystic ovary syndrome. The beginning or the end of a new era?
Infertility
Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics.
Infertility
Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome.
Infertility
Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome.
Infertility
Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination: a prospective randomized trial.
Infertility
Comparison of clomiphene and letrozole for superovulation in patients with unexplained infertility undergoing intrauterine insemination: A systematic review and meta-analysis.
Infertility
Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphen citrate gonadotropins in controlled ovarian hyperstimulation: a prospective, simply randomized, clinical trial.
Infertility
Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial.
Infertility
Correlation between aromatase expression in the eutopic endometrium of symptomatic patients and the presence of endometriosis.
Infertility
Discovery and development of a novel class of nonsteroidal aromatase inhibitors.
Infertility
Down-regulation of the CYP19A1 gene in cumulus cells of infertile women with endometriosis.
Infertility
Editor's Note: Badawy A, Shokeir T, Allam AF and Abdelhady H. Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility. Acta Obstetricia et Gynecologica Scandinavica, 2009; 88:187-191.
Infertility
Effects of dibutylphthalate and ethynylestradiol on liver peroxisomes, reproduction, and development of zebrafish (Danio rerio).
Infertility
Endometrial thickness in women undergoing IUI with ovarian stimulation. How thick is too thin? A systematic review and meta-analysis.
Infertility
Epigenetic alterations of CYP19A1 gene in Cumulus cells and its relevance to infertility in endometriosis.
Infertility
Estimating rates of multiple gestation pregnancies: Sample size calculation from the assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial.
Infertility
Evidence-based treatments for couples with unexplained infertility: a guideline.
Infertility
Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue.
Infertility
High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome.
Infertility
Identification of NR0B1 as a novel androgen receptor co-repressor in mouse Sertoli cells.
Infertility
Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene.
Infertility
In vitro bioassay for human serum follicle-stimulating hormone (FSH) based on L cells transfected with recombinant rat FSH receptor: validation of a model system.
Infertility
Influence of intrahypothalamic implants of antioestrogen or aromatase inhibitor on development of sterility following neonatal androgenization in female rats.
Infertility
Inhibition of central nervous system aromatase activity: a mechanism for fenarimol-induced infertility in the male rat.
Infertility
Is aromatase expression in the endometrium the cause of endometriosis and related infertility?
Infertility
Leydig cell-specific expression of DAX1 improves fertility of the Dax1-deficient mouse.
Infertility
Liver receptor homologue-1 and steroidogenic factor-1 expression in cultured granulosa cells from patients with endometriosis: A preliminary study.
Infertility
Menometrorrhagia, infertility, elevated serum estradiol, and hyperprolactinemia resulting from increased aromatase activity (MIEHA syndrome).
Infertility
Misclassification in Assessment of First Trimester In-utero Exposure to Drugs Used Proximally to Conception: the Example of Letrozole Utilization for Infertility Treatment.
Infertility
Multilocus analyses of estrogen-related genes reveal involvement of the ESR1 gene in male infertility and the polygenic nature of the pathology.
Infertility
Mutation of cyp19a1b results in sterile males due to efferent duct obstruction in Nile tilapia.
Infertility
Novel therapeutic targets to improve IVF outcomes in endometriosis patients: a review and future prospects.
Infertility
Oral agents for ovulation induction - clomiphene citrate versus aromatase inhibitors.
Infertility
Ovulation induction in women with infertility: a new indication for aromatase inhibitors.
Infertility
Polymorphic variants of CYP17 and CYP19A and risk of infertility in endometriosis.
Infertility
Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility.
Infertility
Randomized controlled trial of three doses of letrozole for ovulation induction in patients with unexplained infertility.
Infertility
Recent advances in the understanding and management of polycystic ovary syndrome.
Infertility
RETRACTED: Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination: a prospective randomized trial.
Infertility
Role of aromatase inhibitor in ovulation induction in patients with poor response to clomiphene citrate.
Infertility
The case for aromatase inhibitors use in Oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in Breast Cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
Infertility
THE EFFECTS OF MATERNAL HYPOTHYROIDISM ON THE IMMUNOREACTIVITY OF CYTOCHROME P450 AROMATASE IN THE POSTNATAL RAT TESTICLES.
Infertility
The Genetic Background of Endometriosis: Can ESR2 and CYP19A1 Genes Be a Potential Risk Factor for Its Development?
Infertility
The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.
Infertility
Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover.
Infertility
Treatment of unexplained infertility with aromatase inhibitors or clomiphene citrate: a systematic review and meta-analysis.
Infertility
Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate.
Infertility
[Aromatase inhibitors--is it a new opportunity in the treatment of infertility?]
Infertility
[Diagnostic value of the detection of aromatase cytochrome P450 and CA125 for endometriosis]
Infertility
[Semiquantitative analysis of mRNA aromatase expression in eutopic endometrium as a diagnostic marker of endometriosis and estrogen dependent diseases]
Infertility, Female
Aromatase gene (CYP19A1) variants, female infertility and ovarian stimulation outcome: a preliminary report.
Infertility, Female
Aromatase inhibitors for female infertility: a systematic review of the literature.
Infertility, Male
A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility.
Infertility, Male
Big enough for an aromatase inhibitor? How adiposity affects male fertility.
Infertility, Male
Do men with normal testosterone-oestradiol ratios benefit from letrozole for the treatment of male infertility?
Infertility, Male
Effect of letrozole on spermogram parameters and hormonal profile in infertile men: A clinical trial study.
Infertility, Male
Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ?25 kg/m2.
Infertility, Male
Estrogen promotes Leydig cell engulfment by macrophages in male infertility.
Infertility, Male
Insights into the role of androgen receptor in human testicular peritubular cells.
Infertility, Male
Localization and regulation of aromatase liver receptor homologue-1 in the developing rat testis.
Infertility, Male
Mutation of cyp19a1b results in sterile males due to efferent duct obstruction in Nile tilapia.
Infertility, Male
Transgenic mice expressing p450 aromatase as a model for male infertility associated with chronic inflammation in the testis.
Infertility, Male
[A study on testicular aromatase activity--spermatogenic damage in high testicular E2 models of rat]
Inflammatory Bowel Diseases
Thrombotic risk and immobility in residents of long-term care facilities.
Inflammatory Breast Neoplasms
Profile of Steroid Receptors and Increased Aromatase Immunoexpression in Canine Inflammatory Mammary Cancer as a Potential Therapeutic Target.
Insulin Resistance
Acupuncture does not ameliorate metabolic disturbances in the P450 aromatase inhibitor-induced rat model of polycystic ovary syndrome.
Insulin Resistance
Aromatase deficiency in a male patient - Case report and review of the literature.
Insulin Resistance
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-? and GPER signalling.
Insulin Resistance
Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection.
Insulin Resistance
Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women.
Insulin Resistance
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Insulin Resistance
Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition.
Insulin Resistance
Deletion of tumor necrosis factor-alpha receptor type 1 exacerbates insulin resistance and hepatic steatosis in aromatase knockout mice.
Insulin Resistance
Deregulation of WNT2/FZD3/?-catenin pathway compromises the estrogen synthesis in cumulus cells from patients with polycystic ovary syndrome.
Insulin Resistance
Effect of polymorphisms in selected genes involved in pituitary-testicular function on reproductive hormones and phenotype in aging men.
Insulin Resistance
Endogenous hormone metabolism as an exposure marker in breast cancer chemoprevention studies.
Insulin Resistance
Estrogen and adiposity--utilizing models of aromatase deficiency to explore the relationship.
Insulin Resistance
Genetic Determinants of Circulating Estrogen Levels and Evidence of a Causal Effect of Estradiol on Bone Density in Men.
Insulin Resistance
Growth factor-mediated regulation of aromatase activity in human skin fibroblasts.
Insulin Resistance
Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors.
Insulin Resistance
Increased adipose tissue aromatase activity improves insulin sensitivity and reduces adipose tissue inflammation in male mice.
Insulin Resistance
Increased adipose tissue in male and female estrogen receptor-alpha knockout mice.
Insulin Resistance
Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Insulin Resistance
Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Insulin Resistance
Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway.
Insulin Resistance
Metformin, Estrogen Replacement Therapy and Gonadotropin Inhibition Fail to Improve Insulin Sensitivity in a Girl with Aromatase Deficiency.
Insulin Resistance
Oestradiol replacement treatment and glucose homeostasis in two men with congenital aromatase deficiency: evidence for a role of oestradiol and sex steroids imbalance on insulin sensitivity in men.
Insulin Resistance
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Insulin Resistance
Serotonin transporter deficiency drives estrogen-dependent obesity and glucose intolerance.
Insulin Resistance
Sex- and Obesity-specific Association of Aromatase (CYP19A1) Gene Variant with Apolipoprotein B and Hypertension.
Insulin Resistance
Testosterone treatment increases androgen receptor and aromatase gene expression in myotubes from patients with PCOS and controls, but does not induce insulin resistance.
Insulin Resistance
The effect of adipocyte-macrophage cross-talk in obesity-related breast cancer.
Insulin Resistance
The role of estrogen and estrogen receptor-alpha in male adipose tissue.
Insulin Resistance
Use of Network Pharmacology to Explore the Mechanism of Gegen (Puerariae lobatae Radix) in the Treatment of Type 2 Diabetes Mellitus Associated with Hyperlipidemia.
Insulin Resistance
Variants in the aromatase gene and on the Y-chromosome are not associated with adult height or insulin resistance in a UK population.
Intellectual Disability
Genetics of androgen metabolism in women with infertility and hypoandrogenism.
Ischemic Stroke
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
Ischemic Stroke
Association of Genetically Predicted Serum Estradiol With Risk of Thromboembolism in Men: A Mendelian Randomization Study.
Ischemic Stroke
Increased P450 aromatase levels in post-menopausal women after acute ischemic stroke.
Joint Instability
Transmission of relaxin and estrogens to suckling canine pups via milk and possible association with hip joint laxity.
Klinefelter Syndrome
Immunoexpression of androgen receptors and aromatase in testes of patient with Klinefelter's syndrome.
Klinefelter Syndrome
Re: successful testicular sperm retrieval in adolescents with Klinefelter syndrome treated with at least 1 year of topical testosterone and aromatase inhibitor.
Klinefelter Syndrome
Successful testicular sperm retrieval in adolescents with Klinefelter syndrome treated with at least 1 year of topical testosterone and aromatase inhibitor.
Language Disorders
The aromatase gene CYP19A1: several genetic and functional lines of evidence supporting a role in reading, speech and language.
Leiomyoma
A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole.
Leiomyoma
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Leiomyoma
Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients.
Leiomyoma
Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis.
Leiomyoma
Aromatase expression in uterine leiomyomata is regulated primarily by proximal promoters I.3/II.
Leiomyoma
Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata.
Leiomyoma
Benign leiomyoma with multiple metastases to vertebrae and calvarium: An index case with comprehensive review of endocrine targets.
Leiomyoma
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma.
Leiomyoma
Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity.
Leiomyoma
Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis.
Leiomyoma
Effect of aminoglutethimide on androstenedione aromatase activity in human uterine leiomyoma.
Leiomyoma
Effect of the aromatase inhibitor anastrozole on uterine and leiomyoma doppler blood flow in patients scheduled for hysterectomy: a pilot study.
Leiomyoma
Effects of letrozole on proliferation and apoptosis in cultured leiomyoma cells treated with prostaglandin E(2).
Leiomyoma
Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture.
Leiomyoma
Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas.
Leiomyoma
Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study.
Leiomyoma
High aromatase expression in uterine leiomyoma tissues of African-American women.
Leiomyoma
High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome.
Leiomyoma
In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism.
Leiomyoma
Inhibition of in situ expression of aromatase P450 in leiomyoma of the uterus by leuprorelin acetate.
Leiomyoma
Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.
Leiomyoma
Overexpression of aromatase P450 in leiomyoma tissue is driven primarily through promoter I.4 of the aromatase P450 gene (CYP19).
Leiomyoma
Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium.
Leiomyoma
Protein Expression of Estrogen Receptors ? and ? and Aromatase in Myometrium and Uterine Leiomyoma.
Leiomyoma
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Leiomyoma
Retroperitoneal leiomyomata as a cause of bilateral hydronephrosis and lumbosciatic pain.
Leiomyoma
Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women.
Leiomyoma
Selective aromatase inhibition by pyridoglutethimide, an analogue of aminoglutethimide.
Leiomyoma
Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor.
Leiomyoma
Suicide inactivation of aromatase in human placenta and uterine leiomyoma by 5 alpha-dihydronorethindrone, a metabolite of norethindrone, and its effect on steroid-producing enzymes.
Leiomyoma
[Effects of metformin on the expression of estrogen synthetase and ER mRNA in uterine leiomyoma tissues].
Leiomyoma
[Possibilities to use the aromatase inhibitors for the treatment of the uterine fibroids]
Leiomyomatosis
Intravenous leiomyomatosis treated with radical hysterectomy and adjuvant aromatase inhibitor therapy.
Leiomyomatosis
Long-term efficacy and safety of aromatase inhibitor use for leiomyomatosis peritonealis disseminata.
Leiomyomatosis
Successful management of a leiomyomatosis peritonealis disseminata with an aromatase inhibitor.
Leiomyosarcoma
Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis.
Leiomyosarcoma
Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
Leiomyosarcoma
Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors.
Leiomyosarcoma
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Leprosy
Influence of Genetic Ancestry on INDEL Markers of NFK?1, CASP8, PAR1, IL4 and CYP19A1 Genes in Leprosy Patients.
Leukemia
Evaluation of selected lichens from iceland for cancer chemopreventive and cytotoxic activity.
Leukemia
Expression and regulation of aromatase and 17 beta-hydroxysteroid dehydrogenase type 4 in human THP 1 leukemia cells.
Leukemia
Ontogeny of elongation and gene expression in the early developing porcine conceptus.
Leukemia
[The morphological and molecular biological signs of impaired endometrial receptivity in infertility in women suffering from external genital endometriosis].
Leukemia, Lymphocytic, Chronic, B-Cell
Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?
Leukemia, Myeloid
Expression and regulation of aromatase and 17 beta-hydroxysteroid dehydrogenase type 4 in human THP 1 leukemia cells.
Leukemia, T-Cell
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Leukopenia
The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review.
Leydig Cell Tumor
Aromatase messenger RNA is derived from the proximal promoter of the aromatase gene in Leydig, Sertoli, and germ cells of the rat testis.
Leydig Cell Tumor
Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor.
Leydig Cell Tumor
Inhibition of Leydig tumor cell steroidogenesis by 10-propargylestr-4-ene-3,17-dione, an irreversible aromatase inhibitor.
Leydig Cell Tumor
Oestrogen secreting Leydig cell tumour and GnRH agonist in-vivo and in-vitro studies.
Leydig Cell Tumor
The structure of cDNA clones encoding the aromatase P-450 isolated from a rat Leydig cell tumor line demonstrates differential processing of aromatase mRNA in rat ovary and a neoplastic cell line.
Li-Fraumeni Syndrome
Hsp90 and PKM2 Drive the Expression of Aromatase in Li-Fraumeni Syndrome Breast Adipose Stromal Cells.
Li-Fraumeni Syndrome
Withdrawal: Hsp90 and PKM2 drive the expression of aromatase in Li-Fraumeni syndrome breast adipose stromal cells.
Lichen Sclerosus et Atrophicus
Lichen Sclerosus in a Breast Cancer Survivor on an Aromatase Inhibitor: A Case Report.
Lipedema
Adipose stem cells from lipedema and control adipose tissue respond differently to adipogenic stimulation in vitro.
Lipedema
Adipose Stem Cells from Lipedema and Control Adipose Tissue Respond Differently to Adipogenic Stimulation In Vitro.
Liver Cirrhosis
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Liver Diseases
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Liver Diseases
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Liver Neoplasms
Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells.
Liver Neoplasms
Endocrine disorders associated with inappropriately high aromatase expression.
Liver Neoplasms
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Liver Neoplasms
Merlin, the product of NF2 gene, is associated with aromatase expression and estrogen formation in human liver tissues and liver cancer cells.
Liver Neoplasms
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma.
Liver Neoplasms
Synchronous presentation of breast cancer and hepatocellular carcinoma in a postmenopausal woman: dual action of aromatase inhibitor on breast and hepatic cancer cells?
Lordosis
Blockade of lordosis by androst-1,4,6-triene-3,17-dione (ATD) and tamoxifen in female hamsters primed with testosterone propionate.
Lordosis
Male rats with same-sex preference show higher immobility in the forced swim test, but similar effects of fluoxetine and desipramine than males that prefer females.
Lung Diseases
Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung.
Lung Diseases
[Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer]
Lung Diseases, Interstitial
Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung.
Lung Diseases, Interstitial
[A Case of Recurrent Breast Cancer with Drug-Induced Interstitial Pneumonia Triggered by the Switch from an Original to a Generic Aromatase Inhibitor].
Lung Neoplasms
Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study.
Lung Neoplasms
Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.
Lung Neoplasms
Aromatase Expression Predicts Survival in Women with Early-Stage Non Small Cell Lung Cancer.
Lung Neoplasms
Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models.
Lung Neoplasms
Changes in aromatase (CYP19) gene promoter usage in non-small cell lung cancer.
Lung Neoplasms
Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: Gender-dependent clinical outcome.
Lung Neoplasms
Cytochrome P450 in non-small cell lung cancer related to exogenous chemical metabolism.
Lung Neoplasms
Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer.
Lung Neoplasms
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.
Lung Neoplasms
Expression of aromatase CYP19 and its relationship with parameters in NSCLC.
Lung Neoplasms
Female reproductive factors, gene polymorphisms in the estrogen metabolism pathway, and risk of lung cancer in chinese women.
Lung Neoplasms
Flavonoids as prospective aromatase inhibitors in breast cancer prevention/therapy.
Lung Neoplasms
Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer.
Lung Neoplasms
Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.
Lung Neoplasms
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.
Lung Neoplasms
Prognostic relevance of estrogen receptor ?, ? and aromatase expression in non-small cell lung cancer.
Lung Neoplasms
Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.
Lung Neoplasms
Role of Hormone Receptor Expression in Patients With Advanced-Stage Lung Cancer Treated With Chemotherapy.
Lung Neoplasms
Targeting aromatase and estrogen signaling in human non-small cell lung cancer.
Lung Neoplasms
The inhibition of aromatase alters the mechanical and rheological properties of non-small-cell lung cancer cell lines affecting cell migration.
Lung Neoplasms
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.
Lung Neoplasms
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Lung Neoplasms
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Lung Neoplasms
[Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer]
Lupus Erythematosus, Systemic
Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer.
Lymphangioleiomyomatosis
A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lymphatic Metastasis
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Lymphatic Metastasis
Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.
Lymphatic Metastasis
Immunohistochemical study of KiSS1 and KiSS1R expression in human primary breast cancer: Association with breast cancer receptor status, proliferation markers and clinicopathological features.
Lymphedema
Exercise for secondary prevention of breast cancer: moving from evidence to changing clinical practice.
Lymphedema
The efficacy of acupoint stimulation for the management of therapy-related adverse events in patients with breast cancer: a systematic review.
Lymphoma
Effect of Letrozole, a selective aromatase inhibitor, on testicular activities in adult mice: Both in vivo and in vitro study.
Lymphoma, B-Cell
Betaine ameliorates impaired steroidogenesis and apoptosis in mice granulosa cells induced by high glucose concentration.
Lymphoma, B-Cell
Synthesis and Evaluation of Novel Cholestanoheterocyclic Steroids as Anticancer Agents.
Malnutrition
Age-related decrease in aromatase and estrogen receptor (ERalpha and ERbeta) expression in rat testes: protective effect of low caloric diets.
Malnutrition
Effects of maternal undernutrition during lactation on aromatase, estrogen, and androgen receptors expression in rat testis at weaning.
Malnutrition
Impaired hypothalamic-pituitary-gonadal axis function in men with diabetes mellitus.
Malnutrition
Maternal malnutrition during lactation affects folliculogenesis, gonadotropins, and leptin receptors in adult rats.
Mammary Neoplasms, Animal
Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor.
Mammary Neoplasms, Animal
Three-component model of oestrogen formation and regulation of intratumoural oestrogen pool in breast neoplasms.
Mania
Sex differences in behavioral and neurochemical effects of gonadectomy and aromatase inhibition in rats.
Melanoma
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Melanoma
Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients.
Memory Disorders
Adverse Effects of Aromatase Inhibition on the Brain and Behavior in a Nonhuman Primate.
Memory Disorders
Aromatase inhibition abolishes LTP generation in female but not in male mice.
Memory Disorders
Pharmacological blockade of the aromatase enzyme, but not the androgen receptor, reverses androstenedione-induced cognitive impairments in young surgically menopausal rats.
Meningioma
Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells.
Meningioma
Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study.
Menopause, Premature
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Menopause, Premature
[ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
Menopause, Premature
[Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
Menorrhagia
Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use.
Menorrhagia
Aromatase inhibitor treatment of menorrhagia and subsequent pregnancy in a patient with familial hyperparathyroidism-jaw tumor syndrome.
Menorrhagia
Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies.
Menorrhagia
The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis.
Mesothelioma
Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells.
Mesothelioma
Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
Mesothelioma
Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease.
Mesothelioma
Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities.
Mesothelioma
Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane.
Mesothelioma, Malignant
Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells.
Mesothelioma, Malignant
Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease.
Mesothelioma, Malignant
Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities.
Metabolic Syndrome
A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome.
Metabolic Syndrome
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-? and GPER signalling.
Metabolic Syndrome
Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse.
Metabolic Syndrome
Cholesterol feeding prevents adiposity in the obese female aromatase knockout (ArKO) mouse.
Metabolic Syndrome
Estrogen and adiposity--utilizing models of aromatase deficiency to explore the relationship.
Metabolic Syndrome
Generation and characterization of a mouse model of the metabolic syndrome: apolipoprotein E and aromatase double knockout mice.
Metabolic Syndrome
Hepatic glucose intolerance precedes hepatic steatosis in the male aromatase knockout (ArKO) mouse.
Metabolic Syndrome
Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis.
Metabolic Syndrome
The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals.
Metabolic Syndrome
The regulatory effect of genistein on P450 aromatase and follicle-stimulating hormone receptor in mouse experimental model of menopausal metabolic syndrome.
Migraine Disorders
Contribution of polymorphisms in ESR1, ESR2, FSHR, CYP19A1, SHBG, and NRIP1 genes to migraine susceptibility in Turkish population.
Migraine Disorders
Investigation of polymorphisms in genes involved in estrogen metabolism in menstrual migraine.
Migraine Disorders
New evidence for involvement of ESR1 gene in susceptibility to Chinese migraine.
Migraine Disorders
Potential role of aromatase over estrogen receptor gene polymorphisms in migraine susceptibility: a case control study from North India.
Multiple Myeloma
Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia.
Muscle Weakness
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Muscular Atrophy
Shift from androgen to estrogen action causes abdominal muscle fibrosis, atrophy, and inguinal hernia in a transgenic male mouse model.
Musculoskeletal Pain
A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.
Musculoskeletal Pain
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Musculoskeletal Pain
Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia.
Musculoskeletal Pain
Aromatase inhibitor-associated musculoskeletal pain: taking 'AIM' at a symptom in breast cancer survivors.
Musculoskeletal Pain
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Musculoskeletal Pain
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Musculoskeletal Pain
Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
Musculoskeletal Pain
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Musculoskeletal Pain
Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.
Musculoskeletal Pain
Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis.
Musculoskeletal Pain
Genotype, allele and haplotype frequencies of four TCL1A gene polymorphisms associated with musculoskeletal toxicity in the South Indian descent.
Musculoskeletal Pain
High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
Musculoskeletal Pain
Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
Musculoskeletal Pain
Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors.
Musculoskeletal Pain
Omega-3 Fatty Acids for Aromatase Inhibitor-Induced Musculoskeletal Pain: Anything Other Than a Placebo Effect?
Musculoskeletal Pain
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Musculoskeletal Pain
Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
Musculoskeletal Pain
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.
Musculoskeletal Pain
Rheumatic disorders and functional disability with aromatase inhibitor therapy.
Myalgia
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Myalgia
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Myalgia
The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.
Myalgia
Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy.
Myocardial Infarction
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Myocardial Infarction
Aromatase Inhibition Attenuates Desflurane-Induced Preconditioning against Acute Myocardial Infarction in Male Mouse Heart In Vivo.
Myocardial Infarction
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
Myocardial Infarction
Association of Genetically Predicted Serum Estradiol With Risk of Thromboembolism in Men: A Mendelian Randomization Study.
Myocardial Infarction
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Myocardial Infarction
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Myocardial Infarction
The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
Myocardial Ischemia
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Myoma
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Myoma
Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use.
Myoma
Comparing the effect of aromatase inhibitor (letrozole) + cabergoline (Dostinex) and letrozole alone on uterine myoma regression,a randomized clinical trial.
Myoma
Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies.
Myoma
Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study.
Myoma
Protein Expression of Estrogen Receptors ? and ? and Aromatase in Myometrium and Uterine Leiomyoma.
Myoma
Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
Myoma
The aromatase expression in myomas and myometriums of women in reproduction and perimenopausal age.
Myoma
The TRAF2 and TRAF6 expression in myomas and myometrium of women in reproduction and perimenopausal age.
Myoma
[Estrogen biosynthesis in human uterine myoma tissue. The distribution of androstenedione aromatase activity in uterine myoma tissue]
Myopia
Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors.
Myxoma
Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis.
Myxoma
Treatment of aggressive angiomyxoma with aromatase inhibitor prior to surgical resection.
nadph-hemoprotein reductase deficiency
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
nadph-hemoprotein reductase deficiency
Inhibition of placental CYP19A1 activity remains as a valid hypothesis for 46,XX virilization in P450 oxidoreductase deficiency.
Neoplasm Metastasis
A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases.
Neoplasm Metastasis
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Neoplasm Metastasis
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Neoplasm Metastasis
Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Neoplasm Metastasis
Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
Neoplasm Metastasis
Aromatase inhibitor for the treatment of primary mucinous carcinoma of the skin with distant metastasis.
Neoplasm Metastasis
Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-?/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
Neoplasm Metastasis
Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women.
Neoplasm Metastasis
Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer.
Neoplasm Metastasis
Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series.
Neoplasm Metastasis
Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Neoplasm Metastasis
Current role and safety profile of aromatase inhibitors in early breast cancer.
Neoplasm Metastasis
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Neoplasm Metastasis
CYP19A1 Amplification Promotes Acquired Resistance to Aromatase Inhibitors.
Neoplasm Metastasis
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Neoplasm Metastasis
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Neoplasm Metastasis
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Neoplasm Metastasis
Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells.
Neoplasm Metastasis
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Neoplasm Metastasis
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Neoplasm Metastasis
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Neoplasm Metastasis
Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Neoplasm Metastasis
Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.
Neoplasm Metastasis
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Neoplasm Metastasis
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Neoplasm Metastasis
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Neoplasm Metastasis
Immunohistochemical study of KiSS1 and KiSS1R expression in human primary breast cancer: Association with breast cancer receptor status, proliferation markers and clinicopathological features.
Neoplasm Metastasis
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders.
Neoplasm Metastasis
Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.
Neoplasm Metastasis
Increased frequency of ESR1 mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor.
Neoplasm Metastasis
Invasive solid papillary carcinoma with neuroendocrine differentiation of the breast: a case report and literature review.
Neoplasm Metastasis
Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.
Neoplasm Metastasis
Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only.
Neoplasm Metastasis
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Neoplasm Metastasis
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Neoplasm Metastasis
Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.
Neoplasm Metastasis
MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
Neoplasm Metastasis
Molecular Barcode Sequencing of the Whole Ligand Binding Domain of the ESR1 Gene in Cell-Free DNA from Patients with Metastatic Breast Cancer.
Neoplasm Metastasis
Obesity-Altered Adipose Stem Cells Promote ER? Breast Cancer Metastasis through Estrogen Independent Pathways.
Neoplasm Metastasis
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Neoplasm Metastasis
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Neoplasm Metastasis
Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
Neoplasm Metastasis
Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
Neoplasm Metastasis
Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Neoplasm Metastasis
Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.
Neoplasm Metastasis
Response of meningeal carcinomatosis from breast cancer to capecitabine monotherapy: a case report.
Neoplasm Metastasis
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane.
Neoplasm Metastasis
Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer.
Neoplasm Metastasis
Steroid sulfatase inhibitors: Promising new tools for breast cancer therapy?
Neoplasm Metastasis
Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone.
Neoplasm Metastasis
Targeting aromatase and estrogen signaling in human non-small cell lung cancer.
Neoplasm Metastasis
The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Neoplasm Metastasis
The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease.
Neoplasm Metastasis
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.
Neoplasm Metastasis
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.
Neoplasm Metastasis
Validity of Osteoprotegerin and Receptor Activator of NF-?B Ligand for the Detection of Bone Metastasis in Breast Cancer.
Neoplasm Metastasis
[A Case of Late Recurrence of Breast Cancer Causing Multiple Organ Metastases 27 Years Postoperatively].
Neoplasm Metastasis
[A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy]
Neoplasm Metastasis
[A Case of Recurrent Breast Cancer with Complete Response to Eribulin Monotherapy after Bevacizumab plus Paclitaxel Combination Therapy].
Neoplasm Metastasis
[Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?]
Neoplasm Metastasis
[Establishment of metastatic sub-clone from estrogen independent Ishikawa cells and its characterization in vitro and in vivo]
Neoplasm Metastasis
[Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy]
Neoplasm Metastasis
[Treatment strategy of breast carcinoma in the elderly patient-surgery, hormone therapy, and chemotherapy]
Neoplasm Micrometastasis
Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial.
Neoplasms
(Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture.
Neoplasms
1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application.
Neoplasms
2-Chloro-s-triazine herbicides induce aromatase (CYP19) activity in H295R human adrenocortical carcinoma cells: a novel mechanism for estrogenicity?
Neoplasms
3D QSAR studies, pharmacophore modeling and virtual screening on a series of steroidal aromatase inhibitors.
Neoplasms
6-Hydroximinoandrostenedione, a new specific inhibitor of estrogen biosynthesis and its effect on T47D human breast cancer cells.
Neoplasms
7,8-Dihydroxycoumarin exerts antitumor potential on DMBA-induced mammary carcinogenesis by inhibiting ER?, PR, EGFR, and IGF1R: involvement of MAPK1/2-JNK1/2-Akt pathway.
Neoplasms
9-cis retinoic acid improves developmental competence and embryo quality during in vitro maturation of bovine oocytes through the inhibition of oocyte TNF-{alpha} gene expression.
Neoplasms
A benzimidazole fungicide, benomyl, and its metabolite, carbendazim, induce aromatase activity in a human ovarian granulose-like tumor cell line (KGN).
Neoplasms
A CASE OF AN AROMATASE-PRODUCING SERTOLI CELL TUMOR PRESENTING WITH GYNECOMASTIA.
Neoplasms
A Case of Estrogen-secreting Adrenocortical Carcinoma with Subclinical Cushing's Syndrome.
Neoplasms
A case of estrogen-secreting adrenocortical carcinoma: Comprehensive immunohistochemical analysis of disorganized steroid genesis.
Neoplasms
A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype.
Neoplasms
A comparison of human H295R and rat R2C cell lines as in vitro screening tools for effects on aromatase.
Neoplasms
A Dehydrogenase Dual Hydrogen Abstraction Mechanism Promotes Estrogen Biosynthesis: Can We Expand the Functional Annotation of the Aromatase Enzyme?
Neoplasms
A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance.
Neoplasms
A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription.
Neoplasms
A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
Neoplasms
A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors.
Neoplasms
A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.
Neoplasms
A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Neoplasms
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Neoplasms
A novel nonradioactive method for measuring aromatase activity using a human ovarian granulosa-like tumor cell line and an estrone ELISA.
Neoplasms
A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Neoplasms
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
Neoplasms
A pilot study of sampling subcutaneous adipose tissue to examine biomarkers of cancer risk.
Neoplasms
A risk assessment of atrazine use in California: human health and ecological aspects.
Neoplasms
A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy.
Neoplasms
A steroidogenic factor-1-binding site and cyclic adenosine 3',5'-monophosphate response element-like elements are required for the activity of the rat aromatase promoter in rat Leydig tumor cell lines.
Neoplasms
A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer.
Neoplasms
Ability of lymphocytes infiltrating breast-cancer tissue to convert androstenedione.
Neoplasms
Absence of the K303R estrogen receptor ? mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment.
Neoplasms
Acceleration of mammary neoplasia in aromatase transgenic mice by 7,12-dimethylbenz[a]anthracene.
Neoplasms
Access to care issues adversely affect breast cancer patients in Mexico: oncologists' perspective.
Neoplasms
Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
Neoplasms
Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens.
Neoplasms
Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17?-estradiol biosynthesis in endometrial carcinoma microenvironment.
Neoplasms
Activation of peroxisome proliferator-activated receptor-gamma and retinoid X receptor inhibits aromatase transcription via nuclear factor-kappaB.
Neoplasms
Activation of Sonic hedgehog signaling in neural progenitor cells promotes glioma development in the zebrafish optic pathway.
Neoplasms
Activin signaling through type IB activin receptor stimulates aromatase activity in the ovarian granulosa cell-like human granulosa (KGN) cells.
Neoplasms
Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience Joint Pain.
Neoplasms
Adaptation of Estrogen-regulated Genes in Long-term Estradiol Deprived MCF-7 Breast Cancer Cells.
Neoplasms
Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.
Neoplasms
Adaptive changes results in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors.
Neoplasms
Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance.
Neoplasms
Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients.
Neoplasms
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Neoplasms
Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
Neoplasms
Adherence to Adjuvant Hormonal Therapy and Its Relationship to Breast Cancer Recurrence and Survival Among Low-income Women.
Neoplasms
Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives.
Neoplasms
Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?
Neoplasms
Adjuvant endocrine therapy effects on bone mineral density and microstructure in women with breast cancer.
Neoplasms
Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
Neoplasms
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Neoplasms
Adult granulosa cell tumors of the ovary: a retrospective study of 30 cases with respect to the expression of steroid synthesis enzymes.
Neoplasms
Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
Neoplasms
Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors.
Neoplasms
Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy.
Neoplasms
Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies With Different Degrees of Completeness and Scientific Confidence.
Neoplasms
AKT activation predicts outcome in breast cancer patients treated with tamoxifen.
Neoplasms
Alcohol Promotes Mammary Tumor Development via the Estrogen Pathway in Estrogen Receptor Alpha-Negative HER2/neu Mice.
Neoplasms
Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial.
Neoplasms
Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer.
Neoplasms
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
Neoplasms
Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology.
Neoplasms
Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor.
Neoplasms
Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors.
Neoplasms
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Neoplasms
Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review.
Neoplasms
Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Neoplasms
An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.
Neoplasms
An aroma of complexity: how the unique genetics of aromatase (CYP19A1) explain diverse phenotypes from hens and hyenas to human gynecomastia, and testicular and other tumors.
Neoplasms
An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells.
Neoplasms
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Neoplasms
An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor- positive early breast cancer.
Neoplasms
Analogues of aminoglutethimide: selective inhibition of cholesterol side-chain cleavage.
Neoplasms
Analysis of Obesity-Related Factors and their Association with Aromatase Expression in Canine Malignant Mammary Tumours.
Neoplasms
Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Neoplasms
Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients.
Neoplasms
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.
Neoplasms
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Neoplasms
Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
Neoplasms
Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies.
Neoplasms
Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
Neoplasms
Androgen- and estrogen-receptor mediated activities of 4-hydroxytestosterone, 4-hydroxyandrostenedione and their human metabolites in yeast based assays.
Neoplasms
Androgens inhibit aromatase expression through DAX-1: insights into the molecular link between hormone balance and Leydig cancer development.
Neoplasms
Androstenedione and androst-5-ene-3 beta,17 beta-diol stimulate DMBA-induced rat mammary tumors--role of aromatase.
Neoplasms
Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer.
Neoplasms
Anti-Estrogenic and Anti-Cell Proliferative Effect of Allyl Isothiocyanate in Chemoprevention of Chemically Induced Mammary Carcinogenesis in Rats.
Neoplasms
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
Neoplasms
Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.
Neoplasms
Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
Neoplasms
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Neoplasms
Antitumor activity of the aromatase inhibitor FCE 24928 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.
Neoplasms
Antitumor and endocrine effects of an aromatase inhibitor (CGS 16949A) on DMBA-induced rat mammary tumor.
Neoplasms
Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
Neoplasms
Antitumor effect of pyridoglutethimide, an aromatase inhibitor, on 7,12-dimethylbenz(a)anthracene-induced mammary tumors of rat.
Neoplasms
Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
Neoplasms
Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in rats.
Neoplasms
Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.
Neoplasms
Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma.
Neoplasms
Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition.
Neoplasms
Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.
Neoplasms
Aromatase activity and expression in breast cancer and benign breast tissue stromal cells.
Neoplasms
Aromatase activity and interleukin-6 production by normal and malignant breast tissues.
Neoplasms
Aromatase activity in adipose tissue from breast quadrants: a link with tumour site.
Neoplasms
Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases.
Neoplasms
Aromatase activity in human hepatocellular carcinoma. Relationship with the degree of histologic differentiation.
Neoplasms
Aromatase activity in microsomes from rat ventral prostate and Dunning R3327H rat prostatic adenocarcinoma.
Neoplasms
Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies.
Neoplasms
Aromatase and comparative response to its inhibitors in two types of endometrial cancer.
Neoplasms
Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.
Neoplasms
Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast.
Neoplasms
Aromatase and its inhibitors in breast cancer treatment--overview and perspective.
Neoplasms
Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior.
Neoplasms
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
Neoplasms
Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis.
Neoplasms
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Neoplasms
Aromatase expression in normal human oral keratinocytes and oral squamous cell carcinoma.
Neoplasms
Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival.
Neoplasms
Aromatase expression in the normal human adult adrenal and in adrenocortical tumors: biochemical, immunohistochemical, and molecular studies.
Neoplasms
Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.
Neoplasms
Aromatase Expression Predicts Survival in Women with Early-Stage Non Small Cell Lung Cancer.
Neoplasms
Aromatase expression was not detected by immunohistochemistry in endometrial cancer.
Neoplasms
Aromatase in the human choriocarcinoma JEG-3: inhibition by R 76 713 in cultured cells and in tumors grown in nude mice.
Neoplasms
Aromatase induction in tamoxifen-resistant breast cancer: Role of phosphoinositide 3-kinase-dependent CREB activation.
Neoplasms
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Neoplasms
Aromatase inhibition and experimental antitumor activity of FCE 24304, MDL 18962 and SH 489.
Neoplasms
Aromatase inhibition by R 83 842, the dextro isomer of R 76 713, in JEG-3 choriocarcinoma grown in ovariectomized nude mice.
Neoplasms
Aromatase inhibition by synthetic lactones and flavonoids in human placental microsomes and breast fibroblasts--a comparative study.
Neoplasms
Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.
Neoplasms
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers.
Neoplasms
Aromatase inhibitor adjuvant chemotherapy of breast cancer results in cancer therapy induced bone loss.
Neoplasms
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Neoplasms
Aromatase Inhibitor Therapy As Effective Rescue in a Patient With Tamoxifen-Refractory Metastatic Granulosa Cell Tumor of the Ovary.
Neoplasms
Aromatase inhibitor treatment of menorrhagia and subsequent pregnancy in a patient with familial hyperparathyroidism-jaw tumor syndrome.
Neoplasms
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Neoplasms
Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis.
Neoplasms
Aromatase inhibitors as solely treatment in postmenopausal breast cancer patients.
Neoplasms
Aromatase Inhibitors Evolution as Potential class of drugs in the treatment of Postmenopausal Breast Cancer Women.
Neoplasms
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Neoplasms
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.
Neoplasms
Aromatase inhibitors in the breast cancer therapy and their potential using in the prevention setting.
Neoplasms
Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature.
Neoplasms
Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity.
Neoplasms
Aromatase inhibitors prevent spontaneous granular cell tumors in the distal female reproductive tract of Sprague-Dawley rats.
Neoplasms
Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings.
Neoplasms
Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.
Neoplasms
Aromatase inhibitors--IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione.
Neoplasms
Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones.
Neoplasms
Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter.
Neoplasms
Aromatase messenger RNA is derived from the proximal promoter of the aromatase gene in Leydig, Sertoli, and germ cells of the rat testis.
Neoplasms
Aromatase over expression transgenic murine models for aromatase inhibitor studies.
Neoplasms
Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty.
Neoplasms
Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
Neoplasms
Aromatase, the enzyme responsible for estrogen biosynthesis, is expressed by human and rat glioblastomas.
Neoplasms
Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-?/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
Neoplasms
Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance.
Neoplasms
Arsenic-induced cancer cell phenotype in human breast epithelia is estrogen receptor-independent but involves aromatase activation.
Neoplasms
Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies.
Neoplasms
Association of Aromatase With Bladder Cancer Stage and Long-Term Survival: New Insights Into the Hormonal Paradigm in Bladder Cancer.
Neoplasms
Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women.
Neoplasms
Atrazine and breast cancer: A framework assessment of the toxicological and epidemiological evidence.
Neoplasms
Atrazine promotes RM1 prostate cancer cell proliferation by activating STAT3 signaling.
Neoplasms
Atrazine-induced aromatase expression is SF-1 dependent: implications for endocrine disruption in wildlife and reproductive cancers in humans.
Neoplasms
Atrazine-induced changes in aromatase activity in estrogen sensitive target tissues.
Neoplasms
Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells.
Neoplasms
Barriers to Acupuncture Use Among Breast Cancer Survivors: A Cross-Sectional Analysis.
Neoplasms
Basal Cells Show Increased Expression of Aromatase and Estrogen Receptor ? in Prostate Epithelial Lesions of Male Aging Rats.
Neoplasms
Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesis.
Neoplasms
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
Neoplasms
Benign leiomyoma with multiple metastases to vertebrae and calvarium: An index case with comprehensive review of endocrine targets.
Neoplasms
Benign metastasising leiomyoma: a progressive disease despite chemical and surgical castration.
Neoplasms
Betaine ameliorates impaired steroidogenesis and apoptosis in mice granulosa cells induced by high glucose concentration.
Neoplasms
Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy.
Neoplasms
Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
Neoplasms
Bioactivity of natural biflavonoids in metabolism-related disease and cancer therapies.
Neoplasms
Biochemical and molecular mechanisms for the association between obesity, chronic Inflammation, and breast cancer.
Neoplasms
Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.
Neoplasms
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Neoplasms
BRCA1/BARD1 complex interacts with steroidogenic factor 1--A potential mechanism for regulation of aromatase expression by BRCA1.
Neoplasms
Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.
Neoplasms
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Neoplasms
Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival.
Neoplasms
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Neoplasms
Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo.
Neoplasms
By the way, doctor. I've had an ER-positive breast cancer tumor removed. Now I am getting ready for follow-up therapy. I've heard that the aromatase inhibitors are better than tamoxifen. What is your opinion?
Neoplasms
C19 adrenal steroids enhance prostaglandin F2 alpha output by human endometrium in vitro.
Neoplasms
CC chemokine ligand 2 (CCL2) stimulates aromatase gene expression in mammary adipose tissue.
Neoplasms
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma.
Neoplasms
CCAAT/enhancer binding protein delta up-regulates aromatase promoters I.3/II in breast cancer epithelial cells.
Neoplasms
Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen.
Neoplasms
CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
Neoplasms
Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.
Neoplasms
Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Neoplasms
Characterization of aromatase cytochrome P-450 mRNA in rat perinatal brain, ovary and a Leydig tumor cell line: evidence for the existence of brain specific aromatase transcripts.
Neoplasms
Characterization of letrozole in human hair using LC-MS/MS and confirmation by LC-HRMS: Application to a doping case.
Neoplasms
Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Neoplasms
Chemopreventive and antioxidant activity of 6-substituted imidazo[2,1-b]thiazoles.
Neoplasms
Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats.
Neoplasms
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Neoplasms
Cholesterol import and steroidogenesis are biosignatures for gastric cancer patient survival.
Neoplasms
Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.
Neoplasms
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Neoplasms
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
Neoplasms
Clinical significance of aromatase protein expression in axillary node negative breast cancer.
Neoplasms
Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer.
Neoplasms
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor treated ER-positive breast cancer.
Neoplasms
Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model.
Neoplasms
Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: Gender-dependent clinical outcome.
Neoplasms
Collagen and prostaglandin E? regulate aromatase expression through the PI3K/AKT/IKK and the MAP kinase pathways in adipose stromal cells.
Neoplasms
Colocalization of aromatase in spinal cord astrocytes: differences in expression and relationship to mechanical and thermal hyperalgesia in murine models of a painful and a non-painful bone tumor.
Neoplasms
Combination effects of dietary soy and methylselenocysteine in a mouse model of prostate cancer.
Neoplasms
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Neoplasms
Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance.
Neoplasms
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
Neoplasms
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Neoplasms
Combined treatment with specific ligands for PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells.
Neoplasms
Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors.
Neoplasms
Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women.
Neoplasms
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer.
Neoplasms
Comparison of Increased Aromatase versus ER{alpha} in the Generation of Mammary Hyperplasia and Cancer.
Neoplasms
Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours.
Neoplasms
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Neoplasms
Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by these Genes.
Neoplasms
Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale?
Neoplasms
Concurrent or Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review.
Neoplasms
Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.
Neoplasms
Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors.
Neoplasms
Correlation between bone mineral density and endometrial thickness over time in women with breast cancer history.
Neoplasms
Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial.
Neoplasms
Correlation of aromatase activity and steroid receptors in human ovarian carcinoma.
Neoplasms
Correlation of aromatase activity with histological differentiation of breast cancer--a morphometric analysis.
Neoplasms
Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide.
Neoplasms
Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.
Neoplasms
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Neoplasms
Cosecretion of estrogen and inhibin B by a feminizing adrenocortical adenoma: impact on gonadotropin secretion.
Neoplasms
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
Neoplasms
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.
Neoplasms
Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow.
Neoplasms
Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.
Neoplasms
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.
Neoplasms
CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity.
Neoplasms
CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors.
Neoplasms
CYP19 gene expression and aromatase activity in endometrial cancer tissue: importance of the type of the disease.
Neoplasms
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Neoplasms
Cytochrome b5 expression in gonadectomy-induced adrenocortical neoplasms of the domestic ferret (Mustela putorius furo).
Neoplasms
Cytochrome P450 in non-small cell lung cancer related to exogenous chemical metabolism.
Neoplasms
Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.
Neoplasms
Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.
Neoplasms
Cytoplasmic estrogen receptor ? as a potential marker in human non-small cell lung carcinoma.
Neoplasms
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
Neoplasms
DDE-induced changes in aromatase activity in endometrial stromal cells in culture.
Neoplasms
Definition of the elements required for the activity of the rat aromatase promoter in steroidogenic cell lines.
Neoplasms
Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
Neoplasms
Deletion of tumor necrosis factor-alpha receptor type 1 exacerbates insulin resistance and hepatic steatosis in aromatase knockout mice.
Neoplasms
Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts.
Neoplasms
Depsidones inhibit aromatase activity and tumor cell proliferation in a co-culture of human primary breast adipose fibroblasts and T47D breast tumor cells.
Neoplasms
Des-acyl ghrelin inhibits the capacity of macrophages to stimulate the expression of aromatase in breast adipose stromal cells.
Neoplasms
Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer.
Neoplasms
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
Neoplasms
Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.
Neoplasms
Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor.
Neoplasms
Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation.
Neoplasms
Developmental programming: Prenatal bisphenol A treatment disrupts mediators of placental function in sheep.
Neoplasms
Diagnostics and Therapy for Malignant (Degenerate) Colon Endometriosis - Three Case Reports.
Neoplasms
Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Neoplasms
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Neoplasms
Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.
Neoplasms
Discordant cellular response to pre-surgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
Neoplasms
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer.
Neoplasms
Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast.
Neoplasms
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
Neoplasms
Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
Neoplasms
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Neoplasms
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Neoplasms
DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells.
Neoplasms
Dynamics and Mechanism of Binding of Androstenedione to Membrane-Associated Aromatase.
Neoplasms
Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in mice.
Neoplasms
Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.
Neoplasms
Early stage breast cancer treatment and prognostic factors: Post San Antonio Breast Cancer Symposium 2016.
Neoplasms
Effect of an aromatase inhibitor, 1,4,6-androstatriene-3,17-dione, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat and its mechanism of action in vivo.
Neoplasms
Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Neoplasms
Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.
Neoplasms
Effect of chronic intracerebroventricular administration of an aromatase inhibitor on the expression of socio-sexual behaviors in male Japanese quail.
Neoplasms
Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study.
Neoplasms
Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
Neoplasms
Effect of the aromatase inhibitor, MEN 11066, on growth of two different MCF-7 sublines.
Neoplasms
Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.
Neoplasms
Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
Neoplasms
Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro.
Neoplasms
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
Neoplasms
Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer.
Neoplasms
Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
Neoplasms
Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma.
Neoplasms
Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.
Neoplasms
Effects of Atrazine on Estrogen Receptor ?- and G Protein-Coupled Receptor 30-Mediated Signaling and Proliferation in Cancer Cells and Cancer-Associated Fibroblasts.
Neoplasms
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Neoplasms
Effects of in utero tributyltin chloride exposure in the rat on pregnancy outcome.
Neoplasms
Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells.
Neoplasms
Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells.
Neoplasms
Effects of matrix components on aromatase activity in breast stromal cells in culture.
Neoplasms
Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
Neoplasms
Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: Aromatase inhibition and autophagy.
Neoplasms
Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Neoplasms
Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors.
Neoplasms
Effects of the aromatase inhibitor 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione on 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.
Neoplasms
Effects of tributyltin chloride on developing mouse oocytes and preimplantation embryos.
Neoplasms
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Neoplasms
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Neoplasms
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Neoplasms
Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Neoplasms
Efficient Synthesis of Glutamate Peptide-Estradiol Conjugate for Imaging Estrogen Receptor-Positive Diseases.
Neoplasms
Eicosanoids and Adipokines in Breast Cancer: From Molecular Mechanisms to Clinical Considerations.
Neoplasms
Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.
Neoplasms
Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.
Neoplasms
Endocrine characterization of a human ovarian carcinoma (BG-1) established in nude mice.
Neoplasms
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
Neoplasms
Endocrine therapy of advanced disease: analysis and implications of the existing data.
Neoplasms
Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
Neoplasms
Endocrine Therapy-Related Symptoms and Quality of Life in Female Cancer Survivors in the Yale Fitness Intervention Trial.
Neoplasms
Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors.
Neoplasms
Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review.
Neoplasms
Endophytic fungi associated with Taxus fuana (West Himalayan Yew) of Pakistan: potential bio-resources for cancer chemopreventive agents.
Neoplasms
Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Neoplasms
Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer.
Neoplasms
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Neoplasms
ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.
Neoplasms
ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
Neoplasms
Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario.
Neoplasms
Estrogen biosynthesis in THP1 cells is regulated by promoter switching of the aromatase (CYP19) gene.
Neoplasms
Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy.
Neoplasms
Estrogen inhibits cell proliferation through in situ production in human thymoma.
Neoplasms
Estrogen metabolism and impaired spermatogenesis in germ cell tumors of the testis.
Neoplasms
Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?
Neoplasms
Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells.
Neoplasms
Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer.
Neoplasms
Estrogen receptor ? represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Neoplasms
Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer.
Neoplasms
Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling.
Neoplasms
Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice.
Neoplasms
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
Neoplasms
Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?
Neoplasms
Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Neoplasms
Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor.
Neoplasms
Estrogen secreting adrenal adenocarcinoma in an 18-month-old boy: aromatase activity, protein expression, mRNA and utilization of gonadal type promoter.
Neoplasms
Estrogen signaling in cancer microenvironment and prediction of response to hormonal therapy.
Neoplasms
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Neoplasms
Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
Neoplasms
Estrogen synthesizing rare malignant Brenner tumor of the ovary with the presence of progesterone and androgen receptors in the absence of estrogen receptors.
Neoplasms
Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
Neoplasms
Estrogen-like and tissue-selective effects of 7-methoxycoumarin from Ficus umbellata (Moraceae): an in vitro and in vivo study.
Neoplasms
Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years.
Neoplasms
Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study.
Neoplasms
Evaluation of a bioluminescent mouse model expressing aromatase PII-promoter-controlled luciferase as a tool for the study of endocrine disrupting chemicals.
Neoplasms
Evaluation of Local CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in Postmenopausal Invasive Ductal Breast Cancer Cases.
Neoplasms
Evaluation of Multifunctional Hybrid Analogs for Stilbenes, Chalcones and Flavanones.
Neoplasms
Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
Neoplasms
Evaluation of selected lichens from iceland for cancer chemopreventive and cytotoxic activity.
Neoplasms
Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion.
Neoplasms
Examining factors associated with adherence to hormonal therapy in breast cancer patients.
Neoplasms
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Neoplasms
Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane.
Neoplasms
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
Neoplasms
Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.
Neoplasms
Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients.
Neoplasms
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.
Neoplasms
Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer.
Neoplasms
Expression of aromatase cytochrome P450 in eutopic endometrium and its application as a diagnostic test for endometriosis.
Neoplasms
Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.
Neoplasms
Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats.
Neoplasms
Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers.
Neoplasms
Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer.
Neoplasms
Expression of estrogen receptors (?, ?), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.
Neoplasms
Expression of estrogen receptors-beta and aromatase activity in primary mammary gland tumors.
Neoplasms
Expression of P450 Aromatase in Granulosa Cell Tumors and Sertoli-Stromal Cell Tumors of the Ovary: Which Cells Are Responsible for Estrogenesis?
Neoplasms
Expression of the forkhead transcription factor FOXL2 correlates with good prognosis in breast cancer patients treated with tamoxifen.
Neoplasms
Expression of the insulin-like growth factor (IGF) system and steroidogenic enzymes in canine testis tumors.
Neoplasms
Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells.
Neoplasms
Extranuclear ER? is associated with regression of T47D PKC?-overexpressing, tamoxifen-resistant breast cancer.
Neoplasms
Facile synthesis of chrysin-derivatives with promising activities as aromatase inhibitors.
Neoplasms
Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
Neoplasms
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
Neoplasms
Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells.
Neoplasms
Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma.
Neoplasms
Feminization as a result of both peripheral conversion of androgens and direct estrogen production from an adrenocortical carcinoma.
Neoplasms
Fertility preservation and PGT-M in women with familial adenomatous polyposis-associated desmoid tumours.
Neoplasms
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.
Neoplasms
Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report.
Neoplasms
Flavonoids as prospective aromatase inhibitors in breast cancer prevention/therapy.
Neoplasms
Forskolin up-regulates aromatase (CYP19) activity and gene transcripts in the human adrenocortical carcinoma cell line H295R.
Neoplasms
Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.
Neoplasms
From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells.
Neoplasms
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: north central cancer treatment group trial n0032.
Neoplasms
Functional activation of the estrogen receptor-? and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Neoplasms
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
Neoplasms
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Neoplasms
G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells.
Neoplasms
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Neoplasms
Gender differences in multiple sclerosis: induction of estrogen signaling in male and progesterone signaling in female lesions.
Neoplasms
Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights.
Neoplasms
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Neoplasms
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Neoplasms
Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients.
Neoplasms
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.
Neoplasms
Genetic modeling of estrogen metabolism as a risk factor of hormone-dependent disorders.
Neoplasms
Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders.
Neoplasms
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
Neoplasms
Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers.
Neoplasms
Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model.
Neoplasms
Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?
Neoplasms
Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
Neoplasms
Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer.
Neoplasms
Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors.
Neoplasms
Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.
Neoplasms
Genomic Profiling of the Steroidogenic Acute Regulatory Protein in Breast Cancer: In Silico Assessments and a Mechanistic Perspective.
Neoplasms
Genotypic and Allelic Variability in CYP19A1 among Populations of African and European Ancestry.
Neoplasms
Ghrelin and Breast Cancer: Emerging Roles in Obesity, Estrogen Regulation, and Cancer.
Neoplasms
Ghrelin and des-acyl ghrelin inhibit aromatase expression and activity in human adipose stromal cells: suppression of cAMP as a possible mechanism.
Neoplasms
Glucocorticoid Receptor as a Potential Target to Decrease Aromatase Expression and Inhibit Leydig Tumor Growth.
Neoplasms
Gonadotropin releasing hormone-independent precocious puberty in a 5 year-old girl with suprasellar germ cell tumor secreting beta-hCG and alpha-fetoprotein.
Neoplasms
Gossypol enantiomers potently inhibit human placental 3?-hydroxysteroid dehydrogenase 1 and aromatase activities.
Neoplasms
GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients.
Neoplasms
Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression.
Neoplasms
Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats.
Neoplasms
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
Neoplasms
Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience.
Neoplasms
Growth factor-mediated regulation of aromatase activity in human skin fibroblasts.
Neoplasms
Growth-inhibition of t47d human breast-cancer cells by the new antiaromatase steroid 3-methylene-1,4-androstadien-17-one.
Neoplasms
HDAC inhibitor entinostat restores responsiveness of letrozole resistant MCF-7Ca xenografts to AIs through modulation of Her-2.
Neoplasms
Health care factors associated with survival among women with breast cancer on hormone therapy in Rio de Janeiro, Brazil, 2004 - 2010.
Neoplasms
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Neoplasms
Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance.
Neoplasms
Hedera nepalensis K. Koch: A Novel Source of Natural Cancer Chemopreventive and Anticancerous Compounds.
Neoplasms
Hetero- and isosexual pseudoprecocity associated with testicular sex-cord tumors in an 8 year-old male.
Neoplasms
Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism.
Neoplasms
High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child.
Neoplasms
High aromatase expression in uterine leiomyoma tissues of African-American women.
Neoplasms
High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
Neoplasms
High expression of estrogen receptor alpha and aromatase in glial tumor cells is associated with gender-independent survival benefits in glioblastoma patients.
Neoplasms
High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Neoplasms
High gene expression of estrogen and progesterone receptors is associated with decreased t cell infiltration in patients with NSCLC.
Neoplasms
High TGFbeta1, estrogen receptor, and aromatase gene expression in a large cell calcifying sertoli cell tumor (LCCSCT): implications for the mechanism of oncogenesis.
Neoplasms
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Neoplasms
History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response.
Neoplasms
Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.
Neoplasms
HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines.
Neoplasms
Human carcinogenic risk assessment based on hormonal effects in a carcinogenicity study in rats with the antifungal agent, fluconazole.
Neoplasms
Human trophoblast xenografts in athymic mice: a model for peripheral aromatization.
Neoplasms
Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice.
Neoplasms
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Neoplasms
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Neoplasms
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Neoplasms
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
Neoplasms
IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells.
Neoplasms
Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer.
Neoplasms
Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues.
Neoplasms
Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells.
Neoplasms
Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours.
Neoplasms
Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.
Neoplasms
Immunohistochemical study of KiSS1 and KiSS1R expression in human primary breast cancer: Association with breast cancer receptor status, proliferation markers and clinicopathological features.
Neoplasms
Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders.
Neoplasms
Immunolocalization of aromatase in human breast disorders using different antibodies.
Neoplasms
Immunolocalization of aromatase P-450 in ovarian tissue from pregnant and nonpregnant mares and in ovarian tumours.
Neoplasms
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Neoplasms
Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer.
Neoplasms
Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.
Neoplasms
Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy.
Neoplasms
Importance of local aromatase activity in hormone-dependent breast cancer: a review.
Neoplasms
Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival.
Neoplasms
Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer.
Neoplasms
In silico analysis of nsSNPs in CYP19A1 gene affecting breast cancer associated aromatase enzyme.
Neoplasms
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Neoplasms
In situ aromatization enhances breast tumor estradiol levels and cellular proliferation.
Neoplasms
In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
Neoplasms
In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione.
Neoplasms
In vitro interactions between mammary fibroblasts (Hs 578Bst) and cancer epithelial cells (MCF-7) modulate aromatase, steroid sulfatase and 17?-hydroxysteroid dehydrogenases.
Neoplasms
In vitro maturation with letrozole priming: Can it be a solution for patients with cancerophobia? A pilot study.
Neoplasms
In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6.
Neoplasms
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Neoplasms
Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study.
Neoplasms
Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
Neoplasms
Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor.
Neoplasms
Increased 5?-Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation.
Neoplasms
Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical.
Neoplasms
Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women.
Neoplasms
Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation.
Neoplasms
Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients.
Neoplasms
Inhibition of aromatase activity and of endocrine-responsive tumor growth by 10-propargylestr-4-ene-3, 17-dione and its 17-propionate derivative.
Neoplasms
Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
Neoplasms
Inhibition of cyclic AMP-triggered aromatase gene expression in human choriocarcinoma cells by antisense oligodeoxynucleotide.
Neoplasms
Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells.
Neoplasms
Inhibition of estrogen biosynthesis and regression of mammary tumors by aromatase inhibitors.
Neoplasms
Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor.
Neoplasms
Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens.
Neoplasms
Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation.
Neoplasms
Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts.
Neoplasms
Inhibition of Leydig tumor cell steroidogenesis by 10-propargylestr-4-ene-3,17-dione, an irreversible aromatase inhibitor.
Neoplasms
Inhibition of leydig tumor growth by farnesoid X receptor activation: The in vitro and in vivo basis for a novel therapeutic strategy.
Neoplasms
Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione.
Neoplasms
Inhibition of steroid sulphatase activity by steroidal methylthiophosphonates: potential therapeutic agents in breast cancer.
Neoplasms
Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol.
Neoplasms
Inhibitors of aromatase prevent degradation of the enzyme in cultured human tumour cells.
Neoplasms
Inhibitory effect of a new androstenedione derivative, 14 alpha-hydroxy-4-androstene-3,6,17-trione (14 alpha-OHAT) on aromatase activity of human uterine tumors.
Neoplasms
Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats.
Neoplasms
Inhibitory Effect of Luteolin on Estrogen Biosynthesis in Human Ovarian Granulosa Cells by Suppression of Aromatase (CYP19).
Neoplasms
Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivo.
Neoplasms
Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells.
Neoplasms
Inhibitory effects of Scutellaria barbata D. Don. and Euonymus alatus Sieb. on aromatase activity of human leiomyomal cells.
Neoplasms
Initial studies with [11C]vorozole positron emission tomography detect over-expression of intra-tumoral aromatase in breast cancer.
Neoplasms
INSIGHTS ON AROMATASE IMMUNOHISTOCHEMISTRY: VARIATIONS BETWEEN INTRINSIC MOLECULAR SUBTYPES OF BREAST CANCERS.
Neoplasms
Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis.
Neoplasms
Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
Neoplasms
Insulin-like growth factor-I, regulating aromatase expression through steroidogenic factor 1, supports estrogen-dependent tumor Leydig cell proliferation.
Neoplasms
Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer.
Neoplasms
Interstitial Leydig Cell Tumorigenesis-Leptin and Adiponectin Signaling in Relation to Aromatase Expression in the Human Testis.
Neoplasms
Interventions for the Treatment of Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: A Systematic Review and Meta-analysis.
Neoplasms
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors.
Neoplasms
Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma.
Neoplasms
Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
Neoplasms
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
Neoplasms
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.
Neoplasms
Investigation of antiaromatase activity using hepatic microsomes of Nile tilapia (Oreochromis niloticus).
Neoplasms
Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinoline and uracil derivatives.
Neoplasms
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Neoplasms
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Neoplasms
Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers.
Neoplasms
IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
Neoplasms
Isolation and evaluation of kaempferol glycosides from the fern Neocheiropteris palmatopedata.
Neoplasms
JunD and JunB Integrate Prostaglandin E2 Activation of Breast Cancer-Associated Proximal Aromatase Promoters.
Neoplasms
Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells.
Neoplasms
Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Neoplasms
Lack of genomic rearrangements involving the aromatase gene CYP19A1 in breast cancer.
Neoplasms
Lactoferrin-decorated vs PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer.
Neoplasms
Late recurrence of breast carcinoma metastasis to the hypopharynx: a case report.
Neoplasms
Leptin induces CREB-dependent aromatase activation through COX-2 expression in breast cancer cells.
Neoplasms
Leptin regulation of aromatase activity in adipose stromal cells from regularly cycling women.
Neoplasms
Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer.
Neoplasms
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
Neoplasms
Letrozole as second-line hormonal treatment for recurrent low-grade endometrial stromal sarcoma: A case report and review of the literature.
Neoplasms
Letrozole efficacy in the treatment of granulosa cell tumor of the ovary: a case report.
Neoplasms
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Neoplasms
Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma.
Neoplasms
Lichen Sclerosus in a Breast Cancer Survivor on an Aromatase Inhibitor: A Case Report.
Neoplasms
Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose.
Neoplasms
Linkage of routinely collected oncology clinical data with health insurance claims data--an example with aromatase inhibitors, tamoxifen, and all-cause mortality.
Neoplasms
Liver Receptor Homologue-1 expression in ovarian epithelial and granulosa cell tumours.
Neoplasms
Local aromatase activity alterations in breast cancer tissues: A potential way of decision support for clinicians.
Neoplasms
Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
Neoplasms
Localization of inhibin alpha-, betaA- and betaB-subunits and aromatase in ovarian follicles with granulosa theca cell tumor (GTCT) in 6 mares.
Neoplasms
Localized aberrant expression of cytochrome P450 aromatase in primary and metastatic malignant tumors of human liver.
Neoplasms
Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas.
Neoplasms
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Neoplasms
Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma.
Neoplasms
Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature.
Neoplasms
Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells.
Neoplasms
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
Neoplasms
Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Neoplasms
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
Neoplasms
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Neoplasms
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Neoplasms
Major hyperestrogenism in a feminizing adrenocortical adenoma despite a moderate overexpression of the aromatase enzyme.
Neoplasms
Malignant Brenner tumor. A histologic, morphometrical, immunohistochemical, and ultrastructural study.
Neoplasms
Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells.
Neoplasms
Mammary steroid metabolizing enzymes in relation to hyperplasia and tumorigenesis in the dog.
Neoplasms
Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
Neoplasms
Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.
Neoplasms
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Neoplasms
MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity.
Neoplasms
MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors.
Neoplasms
Mechanism-based categorization of aromatase inhibitors: a potential discovery and screening tool.
Neoplasms
Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity.
Neoplasms
Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.
Neoplasms
Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.
Neoplasms
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Neoplasms
Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1.
Neoplasms
Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
Neoplasms
Microbial transformation of anti-cancer wsteroid exemestane and cytotoxicity of its metabolites against cancer cell lines.
Neoplasms
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
Neoplasms
MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
Neoplasms
Microsomal aromatase in testicular tumour tissue: increased activity in choriocarcinoma compared to embryonal carcinoma.
Neoplasms
miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
Neoplasms
Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
Neoplasms
Modeling of diarylalkyl-imidazole and diarylalkyl-triazole derivatives as potent aromatase inhibitors for treatment of hormone-dependent cancer.
Neoplasms
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.
Neoplasms
Modulation of expression of 17-Hydroxylase/17,20 lyase (CYP17) and P450 aromatase (CYP19) by inhibition of MEK1 in a human ovarian granulosa-like tumor cell line.
Neoplasms
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Neoplasms
Molecular and epidemiological analyses of abnormal expression of aromatase in breast cancer.
Neoplasms
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma.
Neoplasms
Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Neoplasms
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Neoplasms
Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.
Neoplasms
MR 20492 and MR 20494: two indolizinone derivatives that strongly inhibit human aromatase.
Neoplasms
Mucinous carcinoma in an octogenarian: Treatment and management of breast cancer in the elderly.
Neoplasms
Multidisciplinary Clinical Considerations in the Treatment of Pediatric Epithelial Ovarian Cancer.
Neoplasms
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.
Neoplasms
Nandrolone and stanozolol induce Leydig cell tumor proliferation through an estrogen-dependent mechanism involving IGF-I system.
Neoplasms
Natural Products as Anticancerous Therapeutic Molecules with Special Reference to Enzymatic Targets Topoisomerase, COX, LOX and Aromatase.
Neoplasms
Necrotizing leukocytoclastic small vessel vasculitis associated with letrozole: A case report?.
Neoplasms
Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
Neoplasms
Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review.
Neoplasms
Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.
Neoplasms
Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.
Neoplasms
Neoflavonoids and Tetrahydroquinolones as Possible Cancer Chemopreventive Agents.
Neoplasms
Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer.
Neoplasms
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Neoplasms
New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors.
Neoplasms
New insights on the pathogenesis of endometriosis and novel non-surgical therapies
Neoplasms
New small-molecule compound Hu-17 inhibits estrogen biosynthesis by aromatase in human ovarian granulosa cancer cells.
Neoplasms
Novel aromatase inhibitors selection using induced fit docking and extra precision methods: Potential clinical use in ER-alpha-positive breast cancer.
Neoplasms
Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer.
Neoplasms
Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review.
Neoplasms
Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design.
Neoplasms
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Neoplasms
Obesity and breast cancer - Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue.
Neoplasms
Obesity-Altered Adipose Stem Cells Promote ER? Breast Cancer Metastasis through Estrogen Independent Pathways.
Neoplasms
Oestrogen producing adrenocortical adenoma: clinical, biochemical and immunohistochemical studies.
Neoplasms
Oestrogen secreting Leydig cell tumour and GnRH agonist in-vivo and in-vitro studies.
Neoplasms
Oestrone sulphatase activity in normal and malignant breast tissues: relationship with tumour location.
Neoplasms
On the significance of in situ production of oestrogens in human breast cancer tissue.
Neoplasms
Oncology Acupuncture for Chronic Pain in Cancer Survivors: A Reflection on the American Society of Clinical Oncology Chronic Pain Guideline.
Neoplasms
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Neoplasms
Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women.
Neoplasms
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
Neoplasms
Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma.
Neoplasms
Organoruthenium(II) Complexes Bearing an Aromatase Inhibitor: Synthesis, Characterization, in Vitro Biological Activity and in Vivo Toxicity in Zebrafish Embryos.
Neoplasms
Osteoporosis and musculoskeletal complications related to therapy of breast cancer.
Neoplasms
Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Neoplasms
Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions.
Neoplasms
Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer.
Neoplasms
Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes.
Neoplasms
Ovarian suppression failure during GnRH agonist treatment: A report of three breast cancer patients.
Neoplasms
Ovarian Tumors With Functioning Stroma: A Clinicopathologic Study With Special Reference to Serum Estrogen Level, Stromal Morphology, and Aromatase Expression.
Neoplasms
Over expression of aromatase protein is highly related to MMPs levels in human breast carcinomas.
Neoplasms
Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
Neoplasms
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.
Neoplasms
Overexpression of aromatase leads to development of testicular leydig cell tumors : an in vivo model for hormone-mediated TesticularCancer.
Neoplasms
Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice.
Neoplasms
Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities.
Neoplasms
Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients.
Neoplasms
PAAn-1b and PAAn-E: two phosphorothioate antisense oligodeoxynucleotides inhibit human aromatase gene expression.
Neoplasms
Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review.
Neoplasms
Passenger protein determines translocation versus retention in the endoplasmic reticulum for aromatase expression.
Neoplasms
Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
Neoplasms
PCP4/PEP19 upregulates aromatase gene expression via CYP19A1 promoter I.1 in human breast cancer SK-BR-3 cells.
Neoplasms
PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer.
Neoplasms
Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors.
Neoplasms
Peripheral precocious puberty in a girl with an intracranial hCG-producing tumor: case report and literature review.
Neoplasms
Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.
Neoplasms
Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Neoplasms
PET probe with Aggregation Induced Emission characteristics for the specific turn-on of aromatase.
Neoplasms
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Neoplasms
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Neoplasms
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Neoplasms
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Neoplasms
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
Neoplasms
Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.
Neoplasms
Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.
Neoplasms
Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients.
Neoplasms
Pneumocystis Pneumonia and Acute Kidney Injury Induced by Everolimus Treatment in a Patient with Metastatic Breast Cancer.
Neoplasms
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Neoplasms
Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients.
Neoplasms
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Neoplasms
Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue.
Neoplasms
Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Neoplasms
Potent enzyme-activated inhibition of aromatase by a 7 alpha-substituted C19 steroid.
Neoplasms
Potential alternative progestin therapy for low-grade endometrial stromal sarcoma: A case report.
Neoplasms
Potential effect of Olea europea leaves, Sonchus oleraceus leaves and Mangifera indica peel extracts on aromatase activity in human placental microsomes and CYP19A1 expression in MCF-7 cell line: Comparative study.
Neoplasms
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Neoplasms
Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer.
Neoplasms
Potential utility of natural products as regulators of breast cancer-associated aromatase promoters.
Neoplasms
Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer.
Neoplasms
Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.
Neoplasms
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Neoplasms
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Neoplasms
Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Neoplasms
Predictive modes of action of pesticides in uterine adenocarcinoma development in rats.
Neoplasms
Predictor for supraphysiologic serum estradiol elevation on hCG triggering day of controlled ovarian stimulation using letrozole and gonadotropins in women with estrogen-dependent cancers.
Neoplasms
Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.
Neoplasms
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Neoplasms
Prenatal alcohol exposure increases the susceptibility to develop aggressive prolactinomas in the pituitary gland.
Neoplasms
Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.
Neoplasms
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Neoplasms
Prevention and treatment of breast cancer by suppressing aromatase activity and expression.
Neoplasms
Prevention of breast cancer: current state of the science and future opportunities.
Neoplasms
Prevention of Recurrent Mucinous Borderline Ovarian Tumor with Aromatase Inhibitor.
Neoplasms
Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor.
Neoplasms
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.
Neoplasms
Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease.
Neoplasms
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Neoplasms
Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells.
Neoplasms
Production of androgens and estrogens by tubular adenomas which developed in ovaries of mutant mice of Sl/Slt genotype.
Neoplasms
Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer.
Neoplasms
Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
Neoplasms
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
Neoplasms
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Neoplasms
Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer.
Neoplasms
Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Neoplasms
Prospects of Wedelolactone as a Chemotherapeutic Agent in Gynecological Cancers; Clue From its In-vitro and In-silico Investigation.
Neoplasms
Prostaglandin E2 down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection.
Neoplasms
Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells.
Neoplasms
Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
Neoplasms
Protein Expression of Estrogen Receptors ? and ? and Aromatase in Myometrium and Uterine Leiomyoma.
Neoplasms
Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells.
Neoplasms
Protocol for Exercise Program in Cancer and Cognition (EPICC): A randomized controlled trial of the effects of aerobic exercise on cognitive function in postmenopausal women with breast cancer receiving aromatase inhibitor therapy.
Neoplasms
QSAR modeling of aromatase inhibitory activity of 1-substituted 1,2,3-triazole analogs of letrozole.
Neoplasms
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Neoplasms
Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer.
Neoplasms
Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer.
Neoplasms
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Neoplasms
Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.
Neoplasms
Quantitative Proteomic Profiling Identifies a Potential Novel Chaperone Marker in Resistant Breast Cancer.
Neoplasms
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
Neoplasms
Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Neoplasms
Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.
Neoplasms
Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors.
Neoplasms
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
Neoplasms
Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer.
Neoplasms
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Neoplasms
Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review.
Neoplasms
Recent advances in computational design of potent aromatase inhibitors: open-eye on endocrine-resistant breast cancers.
Neoplasms
Recent Developments in Oxazole Derivatives as Anticancer Agents: Review on Synthetic Strategies, Mechanism of Action and SAR studies.
Neoplasms
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Neoplasms
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Neoplasms
Reduction of estrogen production by interleukin-6 in a human granulosa tumor cell line may have implications for endometriosis-associated infertility.
Neoplasms
Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues.
Neoplasms
Regulation of aromatase expression by the nuclear receptor LRH-1 in adipose tissue.
Neoplasms
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Neoplasms
Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment.
Neoplasms
Regulation of aromatase gene expression in purified germ cells of adult male rats: effects of transforming growth factor beta, tumor necrosis factor alpha, and cyclic adenosine 3',5'-monosphosphate.
Neoplasms
Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
Neoplasms
Relationship between physical activity practice and metabolic profile of postmenopausal women under treatment with aromatase inhibitors for breast cancer.
Neoplasms
Relationship between tumour aromatase activity, tumour characteristics and response to therapy.
Neoplasms
Relevance of pituitary aromatase and estradiol on the maintenance of the population of prolactin-positive cells in male mice.
Neoplasms
Response of estrogen receptor-positive intraabdominal fibromatosis to aromatase inhibitor therapy.
Neoplasms
Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.
Neoplasms
Retraction. Molecular mechanism of inhibition of sodium butyrate on activation of tumor associated aromatase promoters.
Neoplasms
Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor.
Neoplasms
Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer.
Neoplasms
Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Metastatic Breast Cancer.
Neoplasms
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Neoplasms
Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Neoplasms
Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast.
Neoplasms
RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Neoplasms
RU486 is a potent inhibitor of aromatase induction in human breast adipose tissue stromal cells.
Neoplasms
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Neoplasms
Screening of potential cancer preventing chemicals as aromatase inhibitors in an in vitro assay.
Neoplasms
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Neoplasms
Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention.
Neoplasms
Selective spatial upregulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism.
Neoplasms
Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites.
Neoplasms
Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
Neoplasms
Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast.
Neoplasms
Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.
Neoplasms
Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole.
Neoplasms
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
Neoplasms
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
Neoplasms
Sertoli-Leydig cell tumor of the ovary, a rare cause of precocious puberty in a 12-month-old infant.
Neoplasms
Serum inhibin B concentration in a prepubertal boy with gynecomastia and Peutz-Jeghers syndrome.
Neoplasms
Sex Differences and Effects of Estrogenic Compounds on the Expression of Inflammatory Molecules by Astrocytes Exposed to the Insecticide Dimethoate.
Neoplasms
Sex differences in behavioral and neurochemical effects of gonadectomy and aromatase inhibition in rats.
Neoplasms
Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Neoplasms
Sex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinology.
Neoplasms
Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma.
Neoplasms
SGK3 sustains ER? signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis.
Neoplasms
Sheep gene mapping: assignment of ALDOB, CYP19, WT and SOX2 by somatic cell hybrid analysis.
Neoplasms
Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
Neoplasms
Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.
Neoplasms
Singapore Cancer Network (SCAN) Guidelines for Bisphosphonate Use in the Adjuvant Breast Cancer Setting.
Neoplasms
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Neoplasms
Single or Multiple Access Channels to the CYP450s Active Site? An Answer from Free Energy Simulations of the Human Aromatase Enzyme.
Neoplasms
SIRT1 Positively Regulates Breast Cancer Associated Human Aromatase (CYP19A1) Expression.
Neoplasms
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
Neoplasms
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
Neoplasms
Stat5 assumes distinct functions in mammary gland development and mammary tumor formation.
Neoplasms
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer.
Neoplasms
Steroidal aromatase inhibitors inhibit growth of hormone-dependent breast cancer cells by inducing cell cycle arrest and apoptosis.
Neoplasms
Steroidal pyrazolines evaluated as aromatase and quinone reductase-2 inhibitors for chemoprevention of cancer.
Neoplasms
Steroidogenesis in an estrogen-producing adrenal tumor in a young woman: comparison with steroid profiles associated with cortisol- and androgen-producing tumors.
Neoplasms
Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha.
Neoplasms
Stimulation of human tumor xenograft growth by local estrogen biosynthesis in stromal cells.
Neoplasms
Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.
Neoplasms
Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor ? Transcriptional Activity in Breast Cancer Cell Lines.
Neoplasms
Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications.
Neoplasms
Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone.
Neoplasms
Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer.
Neoplasms
Suicide inactivation of aromatase in human placenta and uterine leiomyoma by 5 alpha-dihydronorethindrone, a metabolite of norethindrone, and its effect on steroid-producing enzymes.
Neoplasms
Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy.
Neoplasms
Suppression of Tumor Necrosis Factor-?-Induced Nuclear Factor ?B Activation and Aromatase Activity by Capsaicin and Its Analog Capsazepine.
Neoplasms
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
Neoplasms
Sweet's Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer.
Neoplasms
Synthesis and Evaluation of Novel Cholestanoheterocyclic Steroids as Anticancer Agents.
Neoplasms
Synthesis of highly tritium labeled steroids for evaluation of aromatase and steroidsulfatase activities in endometrial tumors.
Neoplasms
Synthesis of Resveratrol Derivatives and In Vitro Screening for Potential Cancer Chemopreventive Activities.
Neoplasms
Systemic Estrone Production and Injury-Induced Sex Hormone Steroidogenesis after Severe Traumatic Brain Injury: A Prognostic Indicator of Traumatic Brain Injury-Related Mortality.
Neoplasms
Systemic treatment of patients with early breast cancer: recent updates and state of the art.
Neoplasms
Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case.
Neoplasms
Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention.
Neoplasms
Targeting allosteric sites of human aromatase: a comprehensive in-silico and in-vitro workflow to find potential plant-based anti-breast cancer therapeutics.
Neoplasms
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
Neoplasms
Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis.
Neoplasms
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Neoplasms
Testicular sex cord-stromal lesions: immunohistochemical analysis of cytokeratin, vimentin and steroidogenic enzymes.
Neoplasms
Testosterone Aromatization to Estradiol in Course of Ovarian Functioning Brenner Tumor Associated With Endometrial Carcinoma and Endometriosis (Roncati-Manenti Triad).
Neoplasms
TGF-?1 stimulates aromatase expression and estradiol production through SMAD2 and ERK1/2 signaling pathways in human granulosa-lutein cells.
Neoplasms
The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.
Neoplasms
The anti-cancer potential of crotoxin in estrogen receptor-positive breast cancer: Its effects and mechanism of action.
Neoplasms
The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats.
Neoplasms
The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.
Neoplasms
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Neoplasms
The association of osteoporosis knowledge and beliefs with preventive behaviors in postmenopausal breast cancer survivors.
Neoplasms
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Neoplasms
The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor ? and modulates estrogen-stimulated breast cancer cell proliferation.
Neoplasms
The case for aromatase inhibitors use in Oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in Breast Cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
Neoplasms
The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression.
Neoplasms
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.
Neoplasms
The control and biological importance of intratumoural aromatase in breast cancer.
Neoplasms
The CYP19A1 rs700519 Polymorphism and Breast Cancer Susceptibility in China: A Case-Control Study and Updated Meta-Analysis.
Neoplasms
The effect of aromatase inhibitor 4-hydroxyandrostenedione on steroid receptors in hormone-dependent tissues of the rat.
Neoplasms
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Neoplasms
The effect of insulin on aromatase activity in isolated human endometrial glands and stroma.
Neoplasms
The effect of medroxyprogesterone acetate on aromatase and DNA polymerase alpha activities in breast tumours.
Neoplasms
The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.
Neoplasms
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Neoplasms
The effect of the aromatase inhibitor, 4-(phenylthio)-4-androstene-3,17-dione, on dimethylbenz(A)anthracene-induced rat mammary tumors.
Neoplasms
The effect of tumor necrosis factor/cachectin on follicle-stimulating hormone-induced aromatase activity in cultured rat granulosa cells.
Neoplasms
The effects of aromatase overexpression on mammary growth and gene expression in the aromatase x transforming growth factor alpha double transgenic mice.
Neoplasms
The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
Neoplasms
The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker.
Neoplasms
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
Neoplasms
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
Neoplasms
The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters.
Neoplasms
The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.
Neoplasms
The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Neoplasms
The Inhibitory Properties of Ethanol Extracts of Some Culinary-Medicinal Mushrooms on the Secretion of Interleukin-8 and Vascular Endothelial Growth Factor by PC3 Cancer Cells.
Neoplasms
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer.
Neoplasms
The Orphan Nuclear Receptor LRH-1 and ER? Activate GREB1 Expression to Induce Breast Cancer Cell Proliferation.
Neoplasms
The overexpression of int-5/Aromatase, a novel MMTV integration locus gene, is responsible for D2 mammary tumor cell proliferation.
Neoplasms
The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase.
Neoplasms
The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer.
Neoplasms
The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study.
Neoplasms
The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2.
Neoplasms
The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease.
Neoplasms
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
Neoplasms
The relationship of bone-tumor-induced spinal cord astrocyte activation and aromatase expression to mechanical hyperalgesia and cold hypersensitivity in intact female and ovariectomized mice.
Neoplasms
The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Neoplasms
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Neoplasms
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.
Neoplasms
The Role of Hormonal Therapy in Gynecological Cancers-Current Status and Future Directions.
Neoplasms
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.
Neoplasms
The role of soybean extracts and isoflavones in hormone-dependent breast cancer: aromatase activity and biological effects.
Neoplasms
The structure of cDNA clones encoding the aromatase P-450 isolated from a rat Leydig cell tumor line demonstrates differential processing of aromatase mRNA in rat ovary and a neoplastic cell line.
Neoplasms
The turnover of estrogen receptor ? by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
Neoplasms
The use of rat Leydig tumor (R2C) and human hepatoma (HEPG2) cells to evaluate potential inhibitors of rat and human steroid aromatase.
Neoplasms
The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Neoplasms
The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
Neoplasms
The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer.
Neoplasms
The VES-13 and G-8 tools as predictors of toxicity associated with aromatase inhibitors in the adjuvant treatment of breast cancer in elderly patients: A single-center study.
Neoplasms
Theoretical Study of the Mechanism of Exemestane Hydroxylation Catalyzed by Human Aromatase Enzyme.
Neoplasms
Therapeutic approaches for protecting bone health in patients with breast cancer.
Neoplasms
Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer.
Neoplasms
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
Neoplasms
Tissue-specific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts.
Neoplasms
Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer: results of a national provider survey.
Neoplasms
Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model.
Neoplasms
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
Neoplasms
trans-Activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers.
Neoplasms
Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture.
Neoplasms
Transdermal patches for site-specific delivery of anastrozole: In vitro and local tissue disposition evaluation.
Neoplasms
Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis.
Neoplasms
Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention.
Neoplasms
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
Neoplasms
Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Neoplasms
Treatment of aggressive angiomyxoma with aromatase inhibitor prior to surgical resection.
Neoplasms
Treatment of established breast cancer in post-menopausal women: role of aromatase inhibitors.
Neoplasms
Treatment of Intravenous Leiomyomatosis with Cardiac Extension following Incomplete Resection.
Neoplasms
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study.
Neoplasms
Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
Neoplasms
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Neoplasms
Treg deficiency-mediated TH 1 response causes human premature ovarian insufficiency through apoptosis and steroidogenesis dysfunction of granulosa cells.
Neoplasms
Tributyltin or triphenyltin inhibits aromatase activity in the human granulosa-like tumor cell line KGN.
Neoplasms
Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.
Neoplasms
Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer.
Neoplasms
Tumor necrosis factor-alpha activates transcription of inducible repressor form of 3',5'-cyclic adenosine 5'-monophosphate-responsive element binding modulator and represses P450 aromatase and inhibin alpha-subunit expression in rat ovarian granulosa cells by a p44/42 mitogen-activated protein kinase-dependent mechanism.
Neoplasms
Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4.
Neoplasms
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors.
Neoplasms
Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells.
Neoplasms
Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.
Neoplasms
Two natural products, trans-phytol and (22E)-ergosta-6,9,22-triene-3?,5?,8?-triol, inhibit the biosynthesis of estrogen in human ovarian granulosa cells by aromatase (CYP19).
Neoplasms
Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Neoplasms
Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer.
Neoplasms
Unusual Virilization in Girls with Juvenile Granulosa Cell Tumors of the Ovary Is Related to Intratumoral Aromatase Deficiency.
Neoplasms
Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER+ breast cancer cells: Impact on aromatase and steroid receptors.
Neoplasms
Upregulation of AIB1, aromatase and ER? provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.
Neoplasms
Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review.
Neoplasms
Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
Neoplasms
Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study.
Neoplasms
Use of Aromatase Inhibitors in IVF for Fertility Preservation of Non-Breast Cancer Patients: A Case Series.
Neoplasms
Use of aromatase inhibitors in large cell calcifying sertoli cell tumors: effects on gynecomastia, growth velocity, and bone age.
Neoplasms
Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
Neoplasms
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
Neoplasms
Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads.
Neoplasms
Usefulness of 22-oxa-1,25-dihydroxyvitamin D-3 (OCT) as a single agent or combined therapy with aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Neoplasms
Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature.
Neoplasms
Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report.
Neoplasms
Virilizing oncocytic adrenocortical carcinoma: clinical and immunohistochemical studies.
Neoplasms
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Neoplasms
Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel.
Neoplasms
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Neoplasms
Women's health, breast health: a review of the gynecologic effects of breast cancer.
Neoplasms
[A cost-effectiveness study of first-line hormone therapy in post-menopausal patients with metastatic breast cancer on neoadjuvant treatment]
Neoplasms
[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]
Neoplasms
[Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations]
Neoplasms
[Aromatase activity and its gene expression in tumor tissue of smokers and non-smokers with breast cancer]
Neoplasms
[Aromatase expression in invasive and in situ ductal carcinoma present in the same breast.]
Neoplasms
[Association of CYP19A1 gene rs7176005 single nucleotide polymorphism with breast cancer risk and clinicopathologic features of tumor].
Neoplasms
[Bone Marrow Metastases of Breast Cancer Treated with Endocrine Therapy-A Case Report].
Neoplasms
[Clinical assessment of neoadjuvant endocrine chemotherapy (stage II) vis-a-vis chemotherapy of breast tumor patients]
Neoplasms
[Correlation between tumor tissue aromatase, histological pattern and reproductive status in patients with breast cancer]
Neoplasms
[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma]
Neoplasms
[Current status of adjuvant endocrine therapy for hormone responsive breast cancer]
Neoplasms
[Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies]
Neoplasms
[Estrogen biosynthesis in human uterine myoma tissue. The distribution of androstenedione aromatase activity in uterine myoma tissue]
Neoplasms
[For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard]
Neoplasms
[Inhibiting effect of letrozole combined with curcumin on xenografted endometrial carcinoma growth in nude mice]
Neoplasms
[Interrelationship between response to neoadjuvant hormone therapy and hormonal-metabolic status in breast cancer patients]
Neoplasms
[Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes].
Neoplasms
[Molecular mechanism of inhibition of sodium butyrate on activation of tumor associated aromatase promoters]
Neoplasms
[Neoadjuvant use of the aromatase inhibitor letrozole in uterine cancer: endocrine and clinical effects]
Neoplasms
[Palbociclib combinations as new therapeutic strategies in the treatment of HR+/HER2- advanced breast cancer].
Neoplasms
[Pathologic-anatomic parameters for the prognosis of invasive breast cancer following amputation or saving the breast]
Neoplasms
[Possibilities to use the aromatase inhibitors for the treatment of the uterine fibroids]
Neoplasms
[Precocious puberty in girls depending on choriogonadotropin - case reports and literature review]
Neoplasms
[Preliminary study on the expression of aromatase P450 mRNA in human lung cancer tissues.]
Neoplasms
[Progenotoxic shift in mammary adipose tissue (adipogenotoxicosis): association with clinical and biological characteristics of breast cancer]
Neoplasms
[Prognostic significance of assay of sex hormones, their receptors and enzymes involved in estrogen synthesis and metabolism in endometrial carcinoma]
Neoplasms
[Properties of mammary fat in breast cancer patients: topographic, systemic and environmental factors]
Neoplasms
[Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy]
Neoplasms
[Relationship among aromatase activity, estrogen receptor and progesterone receptor in ovarian tumors from postmenopausal women]
Neoplasms
[Relationship between level of sexual hormone in external blood and aromatase expression in cancer tissues of male patients with lung cancer]
Neoplasms
[Semiquantitative analysis of mRNA aromatase expression in eutopic endometrium as a diagnostic marker of endometriosis and estrogen dependent diseases]
Neoplasms
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Neoplasms
[Tumor tissue aromatase and estrogen levels versus clinical course of endometrial cancer]
Neoplasms, Germ Cell and Embryonal
[Precocious puberty in girls depending on choriogonadotropin - case reports and literature review]
Neoplastic Cells, Circulating
An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.
Neoplastic Cells, Circulating
Early stage breast cancer treatment and prognostic factors: Post San Antonio Breast Cancer Symposium 2016.
Neoplastic Cells, Circulating
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Nephrocalcinosis
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
Nephrotic Syndrome
Central Precocious Puberty as a Complication of Therapy with Adrenocorticotropin (ACTH) and an Aromatase Inhibitor for Refractory Nephrotic Syndrome.
Nerve Compression Syndromes
Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer.
Neuralgia
Neuronal aromatase expression in pain processing regions of the medullary and spinal cord dorsal horn.
Neuroblastoma
Aromatase/Seladin-1 Interactions in Human Neuronal Cell Culture, the Hippocampus of Healthy Rats and Transgenic Alzheimer's Disease Mice.
Neuroblastoma
Effects of vitamin D in the nervous system: Special focus on interaction with steroid hormone signalling and a possible role in the treatment of brain cancer.
Neuroblastoma
Feedback Regulation of SREBP and Aromatase in A beta(25-35)-Supplemented Human Neuroblastoma Cells.
Neuroblastoma
Feedback regulation of SREBP and aromatase in A beta(25-35)-supplemented human neuroblastoma cells.
Neuroblastoma
Selective regulation of neurosteroid biosynthesis in human neuroblastoma cells under hydrogen peroxide-induced oxidative stress condition.
Neuroblastoma
Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells.
Neurodegenerative Diseases
Aromatase Expression in the Hippocampus of AD Patients and 5xFAD Mice.
Neurodegenerative Diseases
Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.
Neurodegenerative Diseases
Impact of R264C and R264H polymorphisms in human aromatase function.
Neurodegenerative Diseases
The lack of Irs2 induces changes in the immunocytochemical expression of aromatase in the mouse retina.
Neurofibromatoses
Aromatase excess syndrome presenting with prepubertal gynecomastia in an Egyptian child with type 1 neurofibromatosis.
Neurofibromatosis 1
Aromatase excess syndrome presenting with prepubertal gynecomastia in an Egyptian child with type 1 neurofibromatosis.
Neuroinflammatory Diseases
Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus.
Neuroinflammatory Diseases
Centrally Synthesized Estradiol is a Potent Anti-Inflammatory in the Injured Zebra Finch Brain.
Neuroinflammatory Diseases
Estrogen as a Neuroprotectant in Both Sexes: Stories From the Bird Brain.
Neuroinflammatory Diseases
Neuroinflammation induces glial aromatase expression in the uninjured songbird brain.
Neuroinflammatory Diseases
Reciprocal interactions between prostaglandin E2- and estradiol-dependent signaling pathways in the injured zebra finch brain.
Neutropenia
Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
Neutropenia
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Non-alcoholic Fatty Liver Disease
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Non-alcoholic Fatty Liver Disease
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Obesity
A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Obesity
Abdominal obesity and intra-abdominal pressure: a new paradigm for the pathogenesis of the hypogonadal-obesity-BPH-LUTS connection.
Obesity
An aromatase polymorphism modulates the relationship between weight and estradiol levels in obese men.
Obesity
Analysis of Obesity-Related Factors and their Association with Aromatase Expression in Canine Malignant Mammary Tumours.
Obesity
Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
Obesity
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study.
Obesity
Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.
Obesity
Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer.
Obesity
Association of aromatase (TTTAn) repeat polymorphism length and the relationship between obesity and decreased sperm concentration.
Obesity
Breast Cancer Endocrine Therapy Promotes Weight Gain With Distinct Adipose Tissue Effects in Lean and Obese Female Mice.
Obesity
CC chemokine ligand 2 (CCL2) stimulates aromatase gene expression in mammary adipose tissue.
Obesity
Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse.
Obesity
Cholesterol feeding prevents adiposity in the obese female aromatase knockout (ArKO) mouse.
Obesity
CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women.
Obesity
Des-acyl ghrelin inhibits the capacity of macrophages to stimulate the expression of aromatase in breast adipose stromal cells.
Obesity
Dietary polyphenols suppress elevated levels of proinflammatory mediators and aromatase in the mammary gland of obese mice.
Obesity
Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer.
Obesity
Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review.
Obesity
Effects of high fat diet-induced obesity on mammary tumorigenesis in the PyMT/MMTV murine model.
Obesity
Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations.
Obesity
Exemestane: One part of the chemopreventive spectrum for ER-positive breast cancer.
Obesity
Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.
Obesity
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.
Obesity
Genetic polymorphisms and obesity influence estradiol decline during the menopause.
Obesity
Ghrelin and Breast Cancer: Emerging Roles in Obesity, Estrogen Regulation, and Cancer.
Obesity
High fat-induced obesity associated with insulin-resistance increases FGF-2 content and causes stromal hyperplasia in rat ventral prostate.
Obesity
Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors.
Obesity
HTR1B, ADIPOR1, PPARGC1A, and CYP19A1 and obesity in a cohort of Caucasians and African Americans: an evaluation of gene-environment interactions and candidate genes.
Obesity
IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells.
Obesity
IL-10 suppresses TNF-?-induced expression of human aromatase gene in mammary adipose tissue.
Obesity
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women.
Obesity
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer.
Obesity
Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity.
Obesity
Leptin regulation of the p53-HIF1?/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link.
Obesity
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Obesity
Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.
Obesity
Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase.
Obesity
Obesity and breast cancer - Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue.
Obesity
Obesity and nonadherence correlate with elevated serum estradiol levels in postmenopausal women receiving adjuvant aromatase inhibitor therapy.
Obesity
Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
Obesity
Obesity during pregnancy affects sex steroid concentrations depending on fetal gender.
Obesity
Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis.
Obesity
Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland.
Obesity
Osteopontin promotes aromatase expression and estradiol production in human adipocytes.
Obesity
Pericardial adipose and aromatase: A new translational target for aging, obesity and arrhythmogenesis?
Obesity
Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.
Obesity
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Obesity
Prostaglandin E2 Inhibits p53 in Human Breast Adipose Stromal Cells: A Novel Mechanism for the Regulation of Aromatase in Obesity and Breast Cancer.
Obesity
Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis.
Obesity
Research Progress on the Relationship between Obesity-Inflammation-Aromatase Axis and Male Infertility.
Obesity
Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women.
Obesity
Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population.
Obesity
The association between adiposity and breast cancer recurrence and survival: A review of the recent literature.
Obesity
The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome.
Obesity
The low density lipoprotein receptor modulates the effects of hypogonadism on diet-induced obesity and related metabolic perturbations.
Obesity
The role of DENND1A and CYP19A1 gene variants in individual susceptibility to obesity in Turkish population-a preliminary study.
Obesity
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease.
Obesity
Transcriptome Analysis of Testis from HFD-Induced Obese Rats (Rattus norvigicus) Indicated Predisposition for Male Infertility.
Obesity
Weight gain and inflammation regulate aromatase expression in male adipose tissue, as evidenced by reporter gene activity.
Obesity
[Hormone-associated properties and plasticity of omental fat: the relation with clinical-morphological features of endometrial cancer in patients with different obesity phenotypes].
Obesity, Abdominal
Effect of Testosterone Synthesis and Conversion on Serum Testosterone Levels in Obese Men.
Obesity, Abdominal
Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity.
Obesity, Metabolically Benign
[Hormone-associated properties and plasticity of omental fat: the relation with clinical-morphological features of endometrial cancer in patients with different obesity phenotypes].
Obesity, Morbid
The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity.
Oligospermia
Do men with normal testosterone-oestradiol ratios benefit from letrozole for the treatment of male infertility?
Oligospermia
Effect of aromatase inhibition by delta 1-testolactone on basal and luteinizing hormone-releasing hormone-stimulated pituitary and gonadal hormonal function in oligospermic men.
Oligospermia
Effect of chronic aromatase inhibition by delta 1-testolactone on pituitary-gonadal function in oligozoospermic men.
Oligospermia
Serum bioactive follicle-stimulating hormone in men with idiopathic azoospermia and oligospermia.
Oligospermia
Successful use of aromatase inhibitor letrozole in NOA with an elevated FSH level: a case report.
Oligospermia
Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover.
Oligospermia
[Long-term therapy of oligozoospermia with the aromatase inhibitor testolactone]
Osteitis Deformans
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Osteoarthritis
Effect of Buthus martensi Karsch on aromatase activity and cytokine-inducted NOS and NO production in osteoblasts and leukaemic cell line FLG 29.1.
Osteoarthritis
Rheumatic disorders and functional disability with aromatase inhibitor therapy.
Osteoarthritis
The chondroprotective effects of dehydroepiandrosterone probably exerted by its conversion to estradiol.
Osteoarthritis
[Menopausal symptoms and quality of life of hormone receptor positive breast cancer patients at different endocrine therapy time].
Osteogenesis Imperfecta
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Osteolysis
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Osteoma
Two cases of treatment with aromatase inhibitors and development of miliary osteoma cutis-Is there an association?
Osteonecrosis
An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw.
Osteonecrosis
Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals.
Osteonecrosis
Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review.
Osteoporosis
1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts.
Osteoporosis
A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women.
Osteoporosis
A novel mutation in collagen gene COL1A2 associated with transient regional osteoporosis.
Osteoporosis
A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism.
Osteoporosis
A Pooled Analysis of Fall Incidence From Placebo-controlled Trials of Denosumab.
Osteoporosis
A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Osteoporosis
A retrospective study on screening and management of osteoporosis in breast cancer women treated with aromatase inhibitors in Libya.
Osteoporosis
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
Osteoporosis
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Osteoporosis
Alleviating anastrozole induced bone toxicity by selenium nanoparticles in SD rats.
Osteoporosis
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Osteoporosis
Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density.
Osteoporosis
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Osteoporosis
Aromatase inhibitor adjuvant chemotherapy of breast cancer results in cancer therapy induced bone loss.
Osteoporosis
Aromatase inhibitor treatment for breast cancer: short-term effect on bone health.
Osteoporosis
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
Osteoporosis
Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.
Osteoporosis
Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Osteoporosis
Aromatase inhibitors and osteoporosis: Comment on the review by Felson and Cummings.
Osteoporosis
Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy: A descriptive study.
Osteoporosis
Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis.
Osteoporosis
Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.
Osteoporosis
Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
Osteoporosis
Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer.
Osteoporosis
Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors.
Osteoporosis
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption.
Osteoporosis
Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
Osteoporosis
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Osteoporosis
Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment.
Osteoporosis
Correlation of rs749292 and rs700518 polymorphisms in the aromatase gene (CYP19A1) with osteoporosis in postmenopausal Polish women.
Osteoporosis
CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.
Osteoporosis
Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts.
Osteoporosis
Disease Progression Modeling Analysis of the Change of Bone Mineral Density by Postoperative Hormone Therapies in Postmenopausal Patients With Early Breast Cancer.
Osteoporosis
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Osteoporosis
Divergence from osteoporosis screening guidelines in older breast cancer patients treated with anti-estrogen therapy: A population-based cohort study.
Osteoporosis
Effect of Buthus martensi Karsch on aromatase activity and cytokine-inducted NOS and NO production in osteoblasts and leukaemic cell line FLG 29.1.
Osteoporosis
Effect of estrogen replacement on insulin sensitivity, serum lipid and bone resorption marker in hypogonadal males.
Osteoporosis
Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation.
Osteoporosis
Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
Osteoporosis
Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.
Osteoporosis
Evaluation of a bioluminescent mouse model expressing aromatase PII-promoter-controlled luciferase as a tool for the study of endocrine disrupting chemicals.
Osteoporosis
Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
Osteoporosis
Exercise for secondary prevention of breast cancer: moving from evidence to changing clinical practice.
Osteoporosis
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Osteoporosis
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Osteoporosis
Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
Osteoporosis
Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis.
Osteoporosis
Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors.
Osteoporosis
Incidence and prevalence of medication-induced osteoporosis: evidence-based review.
Osteoporosis
Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study.
Osteoporosis
Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates.
Osteoporosis
Inhibition of estrogen-induced mammary tumor formation in MMTV-aromatase transgenic mice by 4-chlorophenylacetate.
Osteoporosis
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Osteoporosis
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.
Osteoporosis
Low Aromatase Activity and Estradiol/Sex Hormone Binding Globulin Ratio are Associated with Total Hip Bone Mineral Density and the Presence of Osteoporosis: A Study in Chinese Postmenopausal Women.
Osteoporosis
Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition.
Osteoporosis
Managing the risk of osteoporosis in women with a history of early breast cancer.
Osteoporosis
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Osteoporosis
Multilocus analysis of estrogen-related genes in Spanish postmenopausal women suggests an interactive role of ESR1, ESR2 and NRIP1 genes in the pathogenesis of osteoporosis.
Osteoporosis
New and emerging concepts in the use of denosumab for the treatment of osteoporosis.
Osteoporosis
Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Osteoporosis
Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of a randomized controlled trial.
Osteoporosis
Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease.
Osteoporosis
Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.
Osteoporosis
Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Osteoporosis
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Osteoporosis
Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More?
Osteoporosis
Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Osteoporosis
Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males.
Osteoporosis
Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.
Osteoporosis
Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy.
Osteoporosis
TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
Osteoporosis
The associations of CYP19A1 rs700518 polymorphism with bone mineral density and risk of osteoporosis: a meta-analysis.
Osteoporosis
The effects of oestrogen exposure on bone mass in male to female transsexuals.
Osteoporosis
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.
Osteoporosis
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
Osteoporosis
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
Osteoporosis
Use of MR-based trabecular bone microstructure analysis at the distal radius for osteoporosis diagnostics: a study in post-menopausal women with breast cancer and treated with aromatase inhibitor.
Osteoporosis
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Osteoporosis
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Osteoporosis
[Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
Osteoporosis
[Pharmacogenic osteoporosis beyond cortisone : Proton pump inhibitors, glitazones and diuretics.]
Osteoporosis
[Thrombophlebitis in an Elderly Japanese Woman Treated with Tamoxifen for Breast Cancer].
Osteoporosis, Postmenopausal
A Pooled Analysis of Fall Incidence From Placebo-controlled Trials of Denosumab.
Osteoporosis, Postmenopausal
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
Osteoporosis, Postmenopausal
Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation.
Osteoporosis, Postmenopausal
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Osteoporosis, Postmenopausal
Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis.
Osteoporosis, Postmenopausal
Postmenopausal osteoporosis, breast cancer, and aromatase inhibitor.
Osteoporosis, Postmenopausal
RANK ligand inhibition with denosumab for the management of osteoporosis.
Osteoporosis, Postmenopausal
Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Osteoporosis, Postmenopausal
Therapeutic approaches for protecting bone health in patients with breast cancer.
Osteosarcoma
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
Ovarian Cysts
A novel compound heterozygous variant in CYP19A1 resulting in aromatase deficiency with normal ovarian tissue.
Ovarian Cysts
Genetic and Clinical Spectrum of Aromatase Deficiency in Infancy, Childhood and Adolescence.
Ovarian Cysts
Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene.
Ovarian Cysts
Hypothyroidism affects lipid and glycogen content and peroxisome proliferator-activated receptor ? expression in the ovary of the rabbit.
Ovarian Cysts
Induction of ovarian cysts in progesterone-synchronized immature rats: evidence that suppression of follicular aromatase activity is not a prerequisite for the induction of cystic follicles.
Ovarian Cysts
No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome.
Ovarian Diseases
The effects of the aromatase inhibitor delta 1-testolactone on gonadotropin release and steroid metabolism in polycystic ovarian disease.
Ovarian Hyperstimulation Syndrome
Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome.
Ovarian Hyperstimulation Syndrome
Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
Ovarian Hyperstimulation Syndrome
High ovarian GDF-8 levels contribute to elevated estradiol production in ovarian hyperstimulation syndrome by stimulating aromatase expression.
Ovarian Hyperstimulation Syndrome
Melatonin stimulates aromatase expression and estradiol production in human granulosa-lutein cells: relevance for high serum estradiol levels in patients with ovarian hyperstimulation syndrome.
Ovarian Hyperstimulation Syndrome
Modulation of steroidogenesis by vitamin D3 in granulosa cells of the mouse model of polycystic ovarian syndrome.
Ovarian Hyperstimulation Syndrome
Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
Ovarian Hyperstimulation Syndrome
The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.
Ovarian Hyperstimulation Syndrome
Two cases of polycystic ovary syndrome with onset of severe ovarian hyperstimulation syndrome following controlled ovarian stimulation with aromatase inhibitors for fertility preservation before breast cancer treatment.
Ovarian Hyperstimulation Syndrome
[Luteal letrozole administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome].
Ovarian Neoplasms
Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive.
Ovarian Neoplasms
Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.
Ovarian Neoplasms
Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk.
Ovarian Neoplasms
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Ovarian Neoplasms
Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review.
Ovarian Neoplasms
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Ovarian Neoplasms
Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.
Ovarian Neoplasms
Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma.
Ovarian Neoplasms
Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review.
Ovarian Neoplasms
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Ovarian Neoplasms
Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study.
Ovarian Neoplasms
Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours.
Ovarian Neoplasms
Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival.
Ovarian Neoplasms
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Ovarian Neoplasms
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer.
Ovarian Neoplasms
KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
Ovarian Neoplasms
Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells.
Ovarian Neoplasms
MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
Ovarian Neoplasms
Multiple parameter analyses of human ovarian cancer: morphology, immunohistochemistry, steroid hormone receptors and aromatase.
Ovarian Neoplasms
New small-molecule compound Hu-17 inhibits estrogen biosynthesis by aromatase in human ovarian granulosa cancer cells.
Ovarian Neoplasms
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
Ovarian Neoplasms
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.
Ovarian Neoplasms
Recent advances in oncology acupuncture and safety considerations in practice.
Ovarian Neoplasms
Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama.
Ovarian Neoplasms
Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women.
Ovarian Neoplasms
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
Ovarian Neoplasms
[Rationale for the approach to the choice of hormone therapy for ovarian cancer].
Ovarian Torsion
Novel CYP19A1 Mutations Extend the Genotype-Phenotype Correlation and Reveal the Impact on Ovarian Function.
Overweight
Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer.
Overweight
Analysis of Obesity-Related Factors and their Association with Aromatase Expression in Canine Malignant Mammary Tumours.
Overweight
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.
Overweight
Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?
Overweight
Effects of Obesity and Obesity-Related Molecules on Canine Mammary Gland Tumors.
Overweight
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Overweight
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Overweight
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women.
Overweight
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer.
Overweight
Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
Overweight
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Overweight
Relationship of estrogen synthesis capacity in the brain with obesity and self-control in men and women.
Overweight
[Effect of free fatty acids on CYP19A1 (aromatase) gene expression in human adipose tissue stromal vascular fraction cells].
Ovotesticular Disorders of Sex Development
Fertility issues in the management of patients with disorders of sex development.
Ovotesticular Disorders of Sex Development
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Ovotesticular Disorders of Sex Development
Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals.
Paraneoplastic Syndromes
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
Paraproteinemias
Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
Paresthesia
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Parkinson Disease
Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?
Parkinsonian Disorders
Aromatase and its inhibition in Behaviour, Obsessive Compulsive Disorder and Parkinsonism.
Parkinsonian Disorders
Sex differences in autophagy-mediated diseases: toward precision medicine.
Periodontitis
Aromatase inhibitor anastrozole modifies cellular functions in gingival fibroblasts and endothelial cells: possible periodontal complications of aromatase inhibitor treatment.
Peripheral Nervous System Diseases
Advising Women Undergoing Treatment for Breast Cancer: A Narrative Review.
Peripheral Nervous System Diseases
Exercise for secondary prevention of breast cancer: moving from evidence to changing clinical practice.
Peripheral Nervous System Diseases
Oncology Acupuncture for Chronic Pain in Cancer Survivors: A Reflection on the American Society of Clinical Oncology Chronic Pain Guideline.
Peritonitis
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Peutz-Jeghers Syndrome
Aromatase expression in human germinomas with possible biological effects.
Peutz-Jeghers Syndrome
High TGFbeta1, estrogen receptor, and aromatase gene expression in a large cell calcifying sertoli cell tumor (LCCSCT): implications for the mechanism of oncogenesis.
Peutz-Jeghers Syndrome
Management of prepubertal gynecomastia in two monozygotic twins with peutz-jeghers syndrome: from aromatase inhibitors to subcutaneous mastectomy.
Peutz-Jeghers Syndrome
Overexpression of aromatase associated with loss of heterozygosity of the STK11 gene accounts for prepubertal gynecomastia in boys with Peutz Jeghers Syndrome.
Peutz-Jeghers Syndrome
Prepubertal gynaecomastia in a boy with Peutz-Jeghers syndrome: managing the aromatase overexpression.
Peutz-Jeghers Syndrome
Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor.
Peutz-Jeghers Syndrome
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
Peutz-Jeghers Syndrome
Serum inhibin B concentration in a prepubertal boy with gynecomastia and Peutz-Jeghers syndrome.
Pituitary ACTH Hypersecretion
Combined treatment with GH and anastrozole in a pubertal boy with Cushing's disease and postsurgical GH deficiency.
Pituitary Neoplasms
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Pituitary Neoplasms
Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats.
Pituitary Neoplasms
G-protein Coupled Estrogen Receptor Expression in Growth Hormone Secreting and Non-Functioning Adenomas.
Pituitary Neoplasms
Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas.
Pituitary Neoplasms
Opposite effects of dihydrotestosterone and estradiol on apoptosis in the anterior pituitary gland from male rats.
Pituitary Neoplasms
Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas.
Pituitary Neoplasms
Spontaneous ovarian hyperstimulation syndrome and pituitary adenoma: incidental pregnancy triggers a catastrophic event.
Placental Insufficiency
In vitro aromatization of androgens into estrogens in placental insufficiency.
Pleural Effusion
[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]
Pleural Effusion
[Anastrozole-resistant breast cancer responsive to exemestane--a case report]
Pneumonia
Patients' preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments.
POEMS Syndrome
Accelerated conversion of dehydroepiandrosterone sulfate to estrogen in a patient with Crow-Fukase syndrome and diabetes mellitus.
Polycystic Ovary Syndrome
1,25-Dihydroxyvitamin D3 increases testosterone-induced 17beta-estradiol secretion and reverses testosterone-reduced connexin 43 in rat granulosa cells.
Polycystic Ovary Syndrome
17 beta-Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals.
Polycystic Ovary Syndrome
A common polymorphism in the human aromatase gene alters the risk for polycystic ovary syndrome and modifies aromatase activity in vitro.
Polycystic Ovary Syndrome
A mechanism for the suppression of estrogen production in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Acupuncture does not ameliorate metabolic disturbances in the P450 aromatase inhibitor-induced rat model of polycystic ovary syndrome.
Polycystic Ovary Syndrome
Adding the phytoestrogen Cimicifugae Racemosae to clomiphene induction cycles with timed intercourse in polycystic ovary syndrome improves cycle outcomes and pregnancy rates - a randomized trial.
Polycystic Ovary Syndrome
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Polycystic Ovary Syndrome
Aromatase Gene Polymorphism Does Not Influence Clinical Phenotype and Response to Oral Contraceptive Pills in Polycystic Ovary Syndrome Women.
Polycystic Ovary Syndrome
Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation.
Polycystic Ovary Syndrome
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Aromatase inhibitors for infertility in polycystic ovary syndrome. The beginning or the end of a new era?
Polycystic Ovary Syndrome
Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Aromatase inhibitors for PCOS: a systematic review and meta-analysis.
Polycystic Ovary Syndrome
Aromatase inhibitors for subfertile women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Aromatase inhibitors for subfertile women with polycystic ovary syndrome: summary of a Cochrane review.
Polycystic Ovary Syndrome
Aromatase inhibitors in women with clomiphene citrate resistance: a randomized, double-blind, placebo-controlled trial.
Polycystic Ovary Syndrome
Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women.
Polycystic Ovary Syndrome
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective.
Polycystic Ovary Syndrome
Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Circulating immunoreactive and bioactive follicle stimulating hormone concentrations in anovulatory infertile women and during gonadotrophin induction of ovulation using a decremental dose regimen.
Polycystic Ovary Syndrome
Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Polycystic Ovary Syndrome
Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome.
Polycystic Ovary Syndrome
Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome.
Polycystic Ovary Syndrome
Compartmental ovarian steroidogenesis in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age.
Polycystic Ovary Syndrome
CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype.
Polycystic Ovary Syndrome
CYP19A1 Gene Expression in Patients with Polycystic Ovarian Syndrome.
Polycystic Ovary Syndrome
Depletion of exosomal circLDLR in follicle fluid derepresses miR-1294 function and inhibits estradiol production via CYP19A1 in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Polycystic Ovary Syndrome
Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women.
Polycystic Ovary Syndrome
Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases.
Polycystic Ovary Syndrome
Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Granulosa cell aromatase enzyme activity: effects of follicular fluid from patients with polycystic ovary syndrome, using aromatase conversion and [11C]vorozole-binding assays.
Polycystic Ovary Syndrome
Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Letrozole stimulation in endometrial preparation for cryopreserved-thawed embryo transfer in women with polycystic ovarian syndrome: A pilot study.
Polycystic Ovary Syndrome
Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.
Polycystic Ovary Syndrome
MiR-29a regulates the proliferation, aromatase expression, and estradiol biosynthesis of human granulosa cells in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Modulation of steroidogenesis by vitamin D3 in granulosa cells of the mouse model of polycystic ovarian syndrome.
Polycystic Ovary Syndrome
No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Ovarian stimulation drugs alter the metabolite content of the growing follicle: in vivo spectroscopic evaluation of follicle fluid
Polycystic Ovary Syndrome
Placental steroidogenesis in pregnant women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Promoter methylation of CYP19A1 gene in Chinese polycystic ovary syndrome patients.
Polycystic Ovary Syndrome
Role of epigenetic modifications in the aberrant CYP19A1 gene expression in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Sex steroids, adiposity and smoking in the pathogenesis of idiopathic hirsutism and polycystic ovary syndrome.
Polycystic Ovary Syndrome
SNP rs2470152 in CYP19 is correlated to aromatase activity in Chinese polycystic ovary syndrome patients.
Polycystic Ovary Syndrome
The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome.
Polycystic Ovary Syndrome
The CYP17 MSP AI (T-34C) and CYP19A1 (Trp39Arg) variants in polycystic ovary syndrome: A case-control study.
Polycystic Ovary Syndrome
The insulin-like growth factor system in normal and abnormal human ovarian follicle development.
Polycystic Ovary Syndrome
The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome phenotype.
Polycystic Ovary Syndrome
Two cases of polycystic ovary syndrome with onset of severe ovarian hyperstimulation syndrome following controlled ovarian stimulation with aromatase inhibitors for fertility preservation before breast cancer treatment.
Polycystic Ovary Syndrome
Upregulation of Cyp19a1 and PPAR-? in ovarian steroidogenic pathway by Ficus religiosa: A potential cure for polycystic ovary syndrome.
Polycystic Ovary Syndrome
Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial.
Polycystic Ovary Syndrome
Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome.
Polycystic Ovary Syndrome
[Effect of Transcutaneuos Acupoint Electrostimulation on Serum Sex Hormone Levels and Expression of Ovarian Steroid Hormone Metabolic Enzymes in Polycystic Ovary Syndrome Rats].
Polycythemia
A case of erythrocytosis in a patient treated with an aromatase inhibitor for breast cancer.
Polycythemia
Aromatase activity after a short-course of letrozole administration in adult men at sea level and at high altitude (with or without excessive erythrocytosis).
Polycythemia
Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer.
Polymyalgia Rheumatica
Predictors of fragility fracture and low bone mineral density in patients with a history of parental fracture.
Pre-Eclampsia
Higher estrogen levels during pregnancy in Andean than European residents of high altitude suggest differences in aromatase activity.
Pre-Eclampsia
Redox-Sensitive Transcription Factor NRF2 Enhances Trophoblast Differentiation via Induction of miR-1246 and Aromatase.
Pre-Eclampsia
Risk of Preeclampsia in Pregnancies After Assisted Reproductive Technology and Ovarian Stimulation.
Precancerous Conditions
IKKbeta mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells.
Pregnancy, Tubal
Expression of P450 aromatase and 17beta-hydroxysteroid dehydrogenase type 1 at fetal-maternal interface during tubal pregnancy.
Premature Ejaculation
Aromatase inhibition for the treatment of idiopathic hypogonadotropic hypogonadism in men with premature ejaculation.
Primary Ovarian Insufficiency
Cytotoxicity and DNA damage caused from diazinon exposure by inhibiting the PI3K-AKT pathway in porcine ovarian granulosa cells.
Primary Ovarian Insufficiency
Epistasis between CYP19A1 and ESR1 polymorphisms is associated with premature ovarian failure.
Primary Ovarian Insufficiency
Epistasis between FSHR and CYP19A1 polymorphisms is associated with premature ovarian failure.
Primary Ovarian Insufficiency
Failure of FSH to influence aromatization in human adipose tissue.
Prolactinoma
Achievement of fertility in an infertile man with resistant macroprolactinoma using high dose of bromocriptine and a combination of hCG and an aromatase inhibitor.
Prolactinoma
Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior.
Prolactinoma
Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis.
Prolactinoma
Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats.
Prolactinoma
Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women.
Prolactinoma
Relevance of pituitary aromatase and estradiol on the maintenance of the population of prolactin-positive cells in male mice.
Prolactinoma
The expression of AIB1 correlates with cellular proliferation in human prolactinomas.
Prolactinoma
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
prostaglandin-endoperoxide synthase deficiency
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
Prostatic Diseases
Estrogen Receptor-Related Receptor {alpha} Mediates Up-Regulation of Aromatase Expression by Prostaglandin E2 in Prostate Stromal Cells.
Prostatic Diseases
The potential significance of aromatase in the etiology and treatment of prostatic disease.
Prostatic Hyperplasia
Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate.
Prostatic Hyperplasia
Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer.
Prostatic Hyperplasia
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-? and GPER signalling.
Prostatic Hyperplasia
Associations of SRD5A2/CYP17/CYP19/VDR gene polymorphisms with the development and clinical progression of benign prostatic hyperplasia: a case-control study in northern Chinese population.
Prostatic Hyperplasia
Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
Prostatic Hyperplasia
Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.
Prostatic Hyperplasia
Bakuchiol suppresses oestrogen/testosterone-induced Benign Prostatic Hyperplasia development through up-regulation of epithelial estrogen receptor ? and down-regulation of stromal aromatase.
Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2.
Prostatic Hyperplasia
Cactus flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5alpha reductase activity, aromatase activity and lipid peroxidation.
Prostatic Hyperplasia
Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results.
Prostatic Hyperplasia
Differential effect of keratinocyte growth factor (KGF) on aromatase activity in cultured canine prostatic epithelial cells.
Prostatic Hyperplasia
Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy.
Prostatic Hyperplasia
Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia.
Prostatic Hyperplasia
Effects of the aromatase inhibitor testolactone on human benign prostatic hyperplasia.
Prostatic Hyperplasia
Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.
Prostatic Hyperplasia
Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
Prostatic Hyperplasia
Estrogens and benign prostatic hyperplasia: rationale for therapy with aromatase inhibitors.
Prostatic Hyperplasia
Estrogens and benign prostatic hyperplasia: the basis for aromatase inhibitor therapy.
Prostatic Hyperplasia
Expression of enzymes involved in estrogen metabolism in human prostate.
Prostatic Hyperplasia
Inhibition of 5 alpha-reductase and aromatase by the ellagitannins oenothein A and oenothein B from Epilobium species.
Prostatic Hyperplasia
Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.
Prostatic Hyperplasia
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.
Prostatic Hyperplasia
Metabolism of androgens in human benign prostatic hyperplasia: aromatase and its inhibition.
Prostatic Hyperplasia
Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia.
Prostatic Hyperplasia
Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group.
Prostatic Hyperplasia
Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
Prostatic Hyperplasia
Sex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinology.
Prostatic Hyperplasia
The androgen receptor CAG repeat length polymorphism associates with prostate volume in Finnish men with benign prostatic hyperplasia.
Prostatic Hyperplasia
The potential significance of aromatase in the etiology and treatment of prostatic disease.
Prostatic Hyperplasia
The role of Eralpha and ERbeta in the prostate: insights from genetic models and isoform-selective ligands.
Prostatic Hyperplasia
[Aromatase inhibitors in the medical treatment of benign prostatic hypertrophy]
Prostatic Neoplasms
17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
Prostatic Neoplasms
1?,25-Dihydroxyvitamin D(3) exerts tissue-specific effects on estrogen and androgen metabolism.
Prostatic Neoplasms
5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3.
Prostatic Neoplasms
A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Prostatic Neoplasms
A Pooled Analysis of Fall Incidence From Placebo-controlled Trials of Denosumab.
Prostatic Neoplasms
Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment.
Prostatic Neoplasms
AKR1C3 (type 5 17?-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Prostatic Neoplasms
Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.
Prostatic Neoplasms
Aromatase inhibition in advanced prostatic cancer: preliminary communication.
Prostatic Neoplasms
Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
Prostatic Neoplasms
Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer.
Prostatic Neoplasms
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-? and GPER signalling.
Prostatic Neoplasms
Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-?/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
Prostatic Neoplasms
Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions.
Prostatic Neoplasms
Assessment of steroidogenic pathways that do not require testosterone as intermediate.
Prostatic Neoplasms
Association of variants in estrogen-related pathway genes with prostate cancer risk.
Prostatic Neoplasms
Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Prostatic Neoplasms
Benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 induces aromatase expression in prostatic stromal cells via prostaglandin E2.
Prostatic Neoplasms
Bicalutamide Plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer.
Prostatic Neoplasms
Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway.
Prostatic Neoplasms
Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer.
Prostatic Neoplasms
Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment.
Prostatic Neoplasms
Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow.
Prostatic Neoplasms
CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.
Prostatic Neoplasms
Dietary diethylstilbestrol but not genistein adversely affects rat testicular development.
Prostatic Neoplasms
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Prostatic Neoplasms
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
Prostatic Neoplasms
Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival.
Prostatic Neoplasms
Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells.
Prostatic Neoplasms
Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases.
Prostatic Neoplasms
Estrogen receptor ? and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
Prostatic Neoplasms
Estrogen receptors ? and ? and aromatase as independent predictors for prostate cancer outcome.
Prostatic Neoplasms
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Prostatic Neoplasms
Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Prostatic Neoplasms
Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers.
Prostatic Neoplasms
Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population.
Prostatic Neoplasms
In vitro kinetic properties of the Thr201Met variant of human aromatase gene CYP19A1: functional responses to substrate and product inhibition and enzyme inhibitors.
Prostatic Neoplasms
Inhibition of aromatase (P450Arom) by some 1-(benzofuran-2-ylmethyl)imidazoles.
Prostatic Neoplasms
Inhibition of aromatase activity and growth suppression by 4-methoxy-4-androstene-3,17-dione in an androgen sensitive human prostatic carcinoma cell line.
Prostatic Neoplasms
Inhibitors of the P450 enzymes aromatase and lyase. Crystallographic and molecular modeling studies suggest structural features of pyridylacetic acid derivatives responsible for differences in enzyme inhibitory activity.
Prostatic Neoplasms
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.
Prostatic Neoplasms
Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.
Prostatic Neoplasms
Modulation of aromatase activity by growth factors in an androgen sensitive human prostate cancer cell line, LNCaP.
Prostatic Neoplasms
New and emerging concepts in the use of denosumab for the treatment of osteoporosis.
Prostatic Neoplasms
Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line.
Prostatic Neoplasms
Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men.
Prostatic Neoplasms
Predictors of fragility fracture and low bone mineral density in patients with a history of parental fracture.
Prostatic Neoplasms
Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue.
Prostatic Neoplasms
Prevention and treatment of bone loss in patients with nonmetastatic breast or prostate cancer who receive hormonal ablation therapy.
Prostatic Neoplasms
Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.
Prostatic Neoplasms
Recent advances in oncology acupuncture and safety considerations in practice.
Prostatic Neoplasms
Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells.
Prostatic Neoplasms
Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Prostatic Neoplasms
Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Prostatic Neoplasms
Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis.
Prostatic Neoplasms
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
Prostatic Neoplasms
Testosterone may speed up the growth of prostate cancer due to aromatase activity.
Prostatic Neoplasms
The CYP19A1 (TTTA)n Repeat Polymorphism May Affect the Prostate Cancer Risk: Evidence from a Meta-Analysis.
Prostatic Neoplasms
The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers.
Prostatic Neoplasms
The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men.
Prostatic Neoplasms
The potential significance of aromatase in the etiology and treatment of prostatic disease.
Prostatic Neoplasms
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease.
Prostatic Neoplasms
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
Prostatic Neoplasms
Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5alpha-reductase and steroid aromatase.
Prostatic Neoplasms
[ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
Prostatic Neoplasms
[Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
Prostatitis
Basal Cells Show Increased Expression of Aromatase and Estrogen Receptor ? in Prostate Epithelial Lesions of Male Aging Rats.
Prostatitis
The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis.
Pruritus
Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Puberty, Delayed
A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial.
Puberty, Delayed
Pharmacological management of children with short stature: the role of aromatase inhibitors.
Puberty, Delayed
[Growth rate can be manipulated. Estrogen production in pubertal boys can be blocked by an aromatase inhibitor]
Puberty, Precocious
Adult height in patients with familial male-limited precocious puberty and the role of an aromatase inhibitor in patient management.
Puberty, Precocious
Aromatase expression in human germinomas with possible biological effects.
Puberty, Precocious
Aromatase inhibitors in precocious puberty: rationale and experience to date.
Puberty, Precocious
Aromatase over expression transgenic murine models for aromatase inhibitor studies.
Puberty, Precocious
Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty.
Puberty, Precocious
Association of aromatase (TTTA)n repeat polymorphisms with central precocious puberty in girls.
Puberty, Precocious
Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.
Puberty, Precocious
Central Precocious Puberty as a Complication of Therapy with Adrenocorticotropin (ACTH) and an Aromatase Inhibitor for Refractory Nephrotic Syndrome.
Puberty, Precocious
Characterization and Management of Testicular Pathology in McCune-Albright Syndrome.
Puberty, Precocious
Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome.
Puberty, Precocious
Decreased hypothalamic aromatization in female rats of true precocious puberty.
Puberty, Precocious
Delayed closure of epiphyseal cartilages induced by the aromatase inhibitor anastrozole. Would it help short children grow up?
Puberty, Precocious
Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty.
Puberty, Precocious
Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.
Puberty, Precocious
Elevated hypothalamic aromatization at the onset of precocious puberty in transgenic female mice hypersecreting human chorionic gonadotropin: effect of androgens.
Puberty, Precocious
Is there a role for estrogen activity assays? Recombinant cell bioassay for estrogen: Development and applications.
Puberty, Precocious
Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
Puberty, Precocious
Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.
Puberty, Precocious
Luteinizing hormone-releasing hormone (LHRH)-independent precocious puberty unresponsive to LHRH agonist therapy in two girls lacking features of the McCune-Albright syndrome.
Puberty, Precocious
Reproductive endocrinology: Aromatase (TTTA)13 repeat increases risk of central precocious puberty.
Puberty, Precocious
Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome.
Puberty, Precocious
Testolactone treatment of precocious puberty in McCune-Albright syndrome.
Puberty, Precocious
The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome.
Puberty, Precocious
The role of estrogen in bone growth and maturation during childhood and adolescence.
Puberty, Precocious
Third-generation Aromatase Inhibitor Improved Adult Height in a Japanese Boy with Testotoxicosis.
Puberty, Precocious
Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin.
Puberty, Precocious
Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.
Puberty, Precocious
Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development.
Puberty, Precocious
[Efficacy and safety of letrozole in treatment of McCune-Albright syndrome girls with peripheral precocious puberty].
Puberty, Precocious
[Precocious puberty in girls depending on choriogonadotropin - case reports and literature review]
Pulmonary Arterial Hypertension
Anastrozole in Pulmonary Arterial Hypertension (AIPH): A Randomized, Double-Blind Placebo-Controlled Trial.
Pulmonary Disease, Chronic Obstructive
Increased levels of enzymes involved in local estradiol synthesis in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Thrombotic risk and immobility in residents of long-term care facilities.
Pulmonary Fibrosis
Evaluation of aromatase inhibitor on radiation induced pulmonary fibrosis via TGF- ?/Smad 3 and TGF- ?/PDGF pathways in rats.
Renal Insufficiency, Chronic
Confounder factors masking a Leydig-cell ovarian tumor in a post-menopausal woman treated for androgen-positive receptor breast cancer.
Renal Insufficiency, Chronic
Short Stature in Chronic Kidney Disease Treated with Growth Hormone and an Aromatase Inhibitor.
Renal Insufficiency, Chronic
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Reperfusion Injury
Indinavir inhibits the expression of cytoplasmic aromatase and nuclear SREBP in the hippocampus of reperfusion injury-induced ischemic rats.
Reperfusion Injury
Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBP? in reperfusion injury-induced ischemic rat hippocampus.
Respiratory Insufficiency
Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies With Different Degrees of Completeness and Scientific Confidence.
Respiratory Paralysis
Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies.
Rickets
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.
Rosacea
Social factors and aromatase gene expression during adult male-to-female sex change in captive leopard grouper Mycteroperca rosacea.
Sarcoma
Aromatase cytochrome P450 and estrogen and progesterone receptors in uterine sarcomas: correlation with clinical parameters.
Sarcoma
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Sarcoma
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Sarcoma
Aromatase inhibitor therapy for endometrial stromal sarcoma - two-centre experience.
Sarcoma
Complete remission of advanced low-grade endometrial stromal sarcoma after aromatase inhibitor therapy: a case report.
Sarcoma
Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis.
Sarcoma
Hormonal treatment with aromatase inhibitors for patients with endometrial stromal sarcoma.
Sarcoma
Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma.
Sarcoma
Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature.
Sarcoma
Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole.
Sarcoma
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Sarcoma
Polymorphism 1558 C > T in the aromatase gene (CYP19A1) in low-grade endometrial stromal sarcoma.
Sarcoma
Potential benefit of hormonal therapy for non-uterine soft tissue sarcoma (STS) - a case report and literature review.
Sarcoma
Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Sarcoma
Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review.
Sarcoma
Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature.
Sarcoma, Endometrial Stromal
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.
Sarcoma, Endometrial Stromal
Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study.
Sarcoma, Endometrial Stromal
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Sarcoma, Endometrial Stromal
Aromatase inhibitor therapy for endometrial stromal sarcoma - two-centre experience.
Sarcoma, Endometrial Stromal
Complete remission of advanced low-grade endometrial stromal sarcoma after aromatase inhibitor therapy: a case report.
Sarcoma, Endometrial Stromal
Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis.
Sarcoma, Endometrial Stromal
Hormonal treatment with aromatase inhibitors for patients with endometrial stromal sarcoma.
Sarcoma, Endometrial Stromal
Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma.
Sarcoma, Endometrial Stromal
Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature.
Sarcoma, Endometrial Stromal
Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole.
Sarcoma, Endometrial Stromal
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Sarcoma, Endometrial Stromal
Polymorphism 1558 C > T in the aromatase gene (CYP19A1) in low-grade endometrial stromal sarcoma.
Sarcoma, Endometrial Stromal
Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Sarcoma, Endometrial Stromal
Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review.
Seizures
A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism.
Seizures
Acute inhibition of neurosteroid estrogen synthesis suppresses status epilepticus in an animal model.
Seizures
Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice.
Seizures
Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis.
Seizures
Chronic levetiracetam decreases hippocampal and testicular aromatase expression in normal but not kainic acid-induced experimental model of acute seizures in rats.
Seizures
Psychoneuroendocrine aspects of temporolimbic epilepsy. Part II: Epilepsy and reproductive steroids.
Seizures
Roles of Testosterone and Estradiol in Mediation of Acute Neuroendocrine and Electroencephalographic Effects of Sevoflurane During the Sensitive Period in Rats.
Seizures
Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol.
Seizures
Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism.
Seminoma
Estrogen-induced growth inhibition of human seminoma cells expressing estrogen receptor beta and aromatase.
Seminoma
Expression of the insulin-like growth factor (IGF) system and steroidogenic enzymes in canine testis tumors.
Seminoma
Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population.
Sepsis
Aromatase Blockade Is Associated With Increased Mortality in Acute Illness in Male Mice.
Sepsis
The aromatase inhibitor, 4-hydroxyandrostenedione, restores immune responses following trauma-hemorrhage in males and decreases mortality from subsequent sepsis.
Sertoli Cell Tumor
High TGFbeta1, estrogen receptor, and aromatase gene expression in a large cell calcifying sertoli cell tumor (LCCSCT): implications for the mechanism of oncogenesis.
Sertoli Cell Tumor
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
Sertoli Cell-Only Syndrome
Overexpression of CYP19A1 aromatase in Leydig cells is associated with steroidogenic dysfunction in subjects with Sertoli cell-only syndrome.
Sertoli-Leydig Cell Tumor
Expression of P450 Aromatase in Granulosa Cell Tumors and Sertoli-Stromal Cell Tumors of the Ovary: Which Cells Are Responsible for Estrogenesis?
Sertoli-Leydig Cell Tumor
Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.
Sertoli-Leydig Cell Tumor
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Sex Cord-Gonadal Stromal Tumors
Expression of P450 Aromatase in Granulosa Cell Tumors and Sertoli-Stromal Cell Tumors of the Ovary: Which Cells Are Responsible for Estrogenesis?
Sex Cord-Gonadal Stromal Tumors
Testicular sex cord-stromal lesions: immunohistochemical analysis of cytokeratin, vimentin and steroidogenic enzymes.
Sexual Infantilism
Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene.
Sexual Infantilism
Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries.
Sexually Transmitted Diseases
Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Sialadenitis
Immunolocalization of aromatase in human minor salivary glands of the lower lip with primary Sjögren's syndrome.
Skin Diseases
Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events.
Sleep Initiation and Maintenance Disorders
Acupuncture for symptoms management in Korean breast cancer survivors: a prospective pilot study.
Sleep Initiation and Maintenance Disorders
Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
Sleep Initiation and Maintenance Disorders
Insomnia caused by aromatase inhibitors; a therapeutic challenge in patients with breast cancer.
Sleep Initiation and Maintenance Disorders
Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors.
Sleep Initiation and Maintenance Disorders
The Relationship Between Insomnia and Cognitive Impairment in Breast Cancer Survivors.
Sleep Initiation and Maintenance Disorders
When should we give aromatase inhibitors for insomnia; early in the day or after dinner?
Sleep Initiation and Maintenance Disorders
[Menopausal symptoms and quality of life of hormone receptor positive breast cancer patients at different endocrine therapy time].
Small Cell Lung Carcinoma
Aromatase Expression Predicts Survival in Women with Early-Stage Non Small Cell Lung Cancer.
Squamous Cell Carcinoma of Head and Neck
Aromatase expression in normal human oral keratinocytes and oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Oestrogens and androgen receptors in oral squamous cell carcinoma.
Status Epilepticus
Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice.
steroid 17alpha-monooxygenase deficiency
Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.
steroid 21-monooxygenase deficiency
A large cohort of disorders of sex development and their genetic characteristics: 6 novel mutations in known genes.
steroid 21-monooxygenase deficiency
Ambiguous genitalia, impaired steroidogenesis, and Antley-Bixler syndrome in a patient with P450 oxidoreductase deficiency.
steroid 21-monooxygenase deficiency
Aromatase Inhibitor Increases the Height of Patients with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.
steroid 21-monooxygenase deficiency
Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.
Stomach Neoplasms
Cholesterol import and steroidogenesis are biosignatures for gastric cancer patient survival.
Stomach Neoplasms
Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review.
Stomach Neoplasms
Expression and localization of aromatase in human gastric mucosa : Immunohistochemical study using biopsy materials.
Stomach Neoplasms
Genetic susceptibility factors on genes involved in the steroid hormone biosynthesis pathway and progesterone receptor for gastric cancer risk.
Stomach Neoplasms
Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.
Stomatitis
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
Stroke
Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.
Stroke
Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use.
Stroke
Genetic Variations of CYP19A1 Gene and Stroke Susceptibility: A Case-control Study in the Chinese Han Population.
Stroke
Increased P450 aromatase levels in post-menopausal women after acute ischemic stroke.
Stroke
[Evaluation of aromatase inhibitors' side effects in clinical and experimental studies]
Sweet Syndrome
Sweet's Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer.
Tendinopathy
Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event.
Tendinopathy
Cephalexin-associated Achilles Tendonitis: Case Report and Review of Drug-induced Tendinopathy.
Teratozoospermia
Differential expression of mRNA aromatase in ejaculated spermatozoa from infertile men in relation to either asthenozoospermia or teratozoospermia.
Testicular Neoplasms
Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology.
Testicular Neoplasms
Endocrine disorders associated with inappropriately high aromatase expression.
Testicular Neoplasms
Human testicular aromatase: immunocytochemical and biochemical studies.
Testicular Neoplasms
Microsomal aromatase in testicular tumour tissue: increased activity in choriocarcinoma compared to embryonal carcinoma.
Testicular Neoplasms
Oestrogen secreting Leydig cell tumour and GnRH agonist in-vivo and in-vitro studies.
Testicular Neoplasms
Overexpression of aromatase leads to development of testicular leydig cell tumors : an in vivo model for hormone-mediated TesticularCancer.
Testicular Neoplasms
Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: Identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
Testicular Neoplasms
Serum inhibin B concentration in a prepubertal boy with gynecomastia and Peutz-Jeghers syndrome.
Testicular Neoplasms
Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice.
Thecoma
Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.
Thecoma
Localization of inhibin alpha-, betaA- and betaB-subunits and aromatase in ovarian follicles with granulosa theca cell tumor (GTCT) in 6 mares.
Thrombocytopenia
Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia.
Thromboembolism
Association of Genetically Predicted Serum Estradiol With Risk of Thromboembolism in Men: A Mendelian Randomization Study.
Thromboembolism
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Thromboembolism
The impact of hormonal treatments on quality of life of patients with metastatic breast cancer.
Thrombosis
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
Thrombosis
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature.
Thrombosis
Aortic Thrombus Extending to Left Subclavian in a Patient With Diffuse Venous Thromboembolism on Aromatase Inhibitor Therapy.
Thrombosis
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Thrombosis
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Torsades de Pointes
Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Trigger Finger Disorder
A Case of Bilateral Trigger Thumbs Secondary to Aromatase Inhibitor.
Triple Negative Breast Neoplasms
Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor.
Triple Negative Breast Neoplasms
Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer.
Triple Negative Breast Neoplasms
Whole Transcriptomic Analysis of Apigenin on TNF? Immuno-activated MDA-MB-231 Breast Cancer Cells.
Trophoblastic Neoplasms
Biological characterization of 10-(2-propynyl) estr-4-ene-3, 17-dione (MDL 18,962), an enzyme-activated inhibitor of aromatase.
Trophoblastic Neoplasms
Human trophoblast xenografts in athymic mice: a model for peripheral aromatization.
Trophoblastic Neoplasms
Time-dependent inhibition of aromatase in trophoblastic tumor cells in tissue culture.
Tuberous Sclerosis
Obesity occurring in apolipoprotein E-knockout mice has mild effects on fertility.
Tumor Lysis Syndrome
Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report.
Turner Syndrome
Is there a role for estrogen activity assays? Recombinant cell bioassay for estrogen: Development and applications.
Unilateral Breast Neoplasms
Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer.
unspecific monooxygenase deficiency
Follicular fluid steroid and epidermal growth factor content, and in vitro estrogen release by granulosa-luteal cells from patients with polycystic ovaries in an IVF/ET program.
Ureteral Obstruction
Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor.
Urinary Bladder Neck Obstruction
Molecular mechanisms of bladder outlet obstruction in transgenic male mice overexpressing aromatase (Cyp19a1).
Urinary Bladder Neoplasms
Association of Aromatase With Bladder Cancer Stage and Long-Term Survival: New Insights Into the Hormonal Paradigm in Bladder Cancer.
Urinary Bladder Neoplasms
Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.
Urinary Bladder Neoplasms
Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis.
Urinary Incontinence
Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis.
Urinary Incontinence
Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.
Urogenital Abnormalities
Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.
Uterine Cervical Neoplasms
Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells.
Uterine Cervical Neoplasms
Elevated aromatase expression correlates with cervical carcinoma progression.
Uterine Cervical Neoplasms
Estrogen formation in endometrial and cervix cancer cell lines: Involvement of aromatase, steroid sulfatase and 17beta-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12).
Uterine Cervical Neoplasms
Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation.
Uterine Cervical Neoplasms
Natural Compound Modulates the Cervical Cancer Microenvironment-A Pharmacophore Guided Molecular Modelling Approaches.
Uterine Cervical Neoplasms
Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium.
Uterine Diseases
Event-free survival following early endometrial events in breast cancer patients treated with anti-hormonal therapy: A nationwide claims data study.
Uterine Diseases
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.
Uterine Diseases
[Expressions of aromatase protein and sex hormone receptor in endometrial lesions.]
Uterine Hemorrhage
ACOG Committee Opinion No. 738 Summary: Aromatase Inhibitors in Gynecologic Practice.
Uterine Hemorrhage
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Uterine Hemorrhage
Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata.
Uterine Hemorrhage
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma.
Uterine Hemorrhage
Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice.
Uterine Hemorrhage
Committee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice.
Uterine Hemorrhage
Resolution of Uterine Arteriovenous Malformation and Maintenance of Reproduction in 20 Women Treated With a GnRH Agonist Concomitantly With an Aromatase Inhibitor and Tranexamic Acid.
Uterine Hemorrhage
The impact of hormonal treatments on quality of life of patients with metastatic breast cancer.
Uterine Hemorrhage
Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Uterine Neoplasms
Expression of estrogen receptors (?, ?), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus.
Uterine Neoplasms
Selective degradation of the estrogen receptor in the treatment of cancers.
Uterine Neoplasms
[Neoadjuvant use of the aromatase inhibitor letrozole in uterine cancer: endocrine and clinical effects]
Vaginosis, Bacterial
Are previous episodes of bacterial vaginosis a predictor for vaginal symptoms in breast cancer patients treated with aromatase inhibitors?
Vascular Diseases
Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
Vascular Diseases
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Vascular Diseases
Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.
Vasculitis
Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis.
Vasculitis
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: A case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Vasculitis
Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment.
Vasculitis
Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: First report of a case in the UK.
Vasculitis
Necrotizing leukocytoclastic small vessel vasculitis associated with letrozole: A case report?.
Venous Thromboembolism
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature.
Venous Thromboembolism
Aortic Thrombus Extending to Left Subclavian in a Patient With Diffuse Venous Thromboembolism on Aromatase Inhibitor Therapy.
Venous Thromboembolism
Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Venous Thromboembolism
Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction?
Venous Thromboembolism
Immediate breast reconstruction surgery with expander/direct implant and use of acellular dermal matrix: Does hormone therapy increases the risk of infection?
Venous Thromboembolism
Initiation of exemestane in two warfarin-treated patients leading to elevation and variability of INR.
Venous Thromboembolism
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
Venous Thromboembolism
Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States.
Venous Thromboembolism
The aromatase inhibitors in early breast cancer: who, when, and why?
Venous Thrombosis
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis.
Vision Disorders
Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors.
Vitamin D Deficiency
Aromatase inhibitor-induced arthralgia: Is vitamin D deficiency responsible?
Vitamin D Deficiency
Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Vitamin D Deficiency
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Vitamin D Deficiency
Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Vulvodynia
Unprovoked Vestibular Burning in Late Estrogen-Deprived Menopause: A Case Series.
Whooping Cough
Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through a Galphai protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression.
Williams Syndrome
Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase.
Williams Syndrome
Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1?,25-dihydroxyvitamin D3.
Wilms Tumor
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Wilms Tumor
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Wilms Tumor
Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood.
html completed